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A B S T R A C T
Background
The inability to have children aLects 10% to 15% of couples worldwide. A male factor is estimated to account for up to half of the infertility
cases with between 25% to 87% of male subfertility considered to be due to the eLect of oxidative stress. Oral supplementation with
antioxidants is thought to improve sperm quality by reducing oxidative damage. Antioxidants are widely available and inexpensive when
compared to other fertility treatments, however most antioxidants are uncontrolled by regulation and the evidence for their eLectiveness
is uncertain. We compared the benefits and risks of diLerent antioxidants used for male subfertility. This review did not examine the use
of antioxidants in normospermic men.
Objectives
To evaluate the eLectiveness and safety of supplementary oral antioxidants in subfertile men.
Search methods
The Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and two trials registers
were searched on 1 February 2018, together with reference checking and contact with study authors and experts in the field to identify
additional trials.
Selection criteria
We included randomised controlled trials (RCTs) that compared any type, dose or combination of oral antioxidant supplement with
placebo, no treatment or treatment with another antioxidant, among subfertile men of a couple attending a reproductive clinic. We
excluded studies comparing antioxidants with fertility drugs alone and studies that included fertile men attending a fertility clinic because
of female partner infertility.
Data collection and analysis
We used standard methodological procedures recommended by Cochrane. The primary review outcome was live birth. Clinical pregnancy,
adverse events and sperm parameters were secondary outcomes.
Main results
We included 61 studies with a total population of 6264 subfertile men, aged between 18 and 65 years, part of a couple who had been referred
to a fertility clinic and some of whom were undergoing assisted reproductive techniques (ART). Investigators compared and combined 18
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diLerent oral antioxidants. The evidence was of 'low' to 'very low' quality: the main limitation was that out of the 44 included studies in
the meta-analysis only 12 studies reported on live birth or clinical pregnancy. The evidence is current up to February 2018.
Live birth: antioxidants may lead to increased live birth rates (OR 1.79, 95% CI 1.20 to 2.67, P = 0.005, 7 RCTs, 750 men, I2 = 40%, low-quality
evidence). Results suggest that if in the studies contributing to the analysis of live birth rate, the baseline chance of live birth following
placebo or no treatment is assumed to be 12%, the chance following the use of antioxidants is estimated to be between 14% and 26%.
However, this result was based on only 124 live births from 750 couples in seven relatively small studies. When studies at high risk of bias
were removed from the analysis, there was no evidence of increased live birth (Peto OR 1.38, 95% CI 0.89 to 2.16; participants = 540 men,
5 RCTs, P = 0.15, I2 = 0%).
Clinical pregnancy rate: antioxidants may lead to increased clinical pregnancy rates (OR 2.97, 95% CI 1.91 to 4.63, P < 0.0001, 11 RCTs, 786
men, I2 = 0%, low-quality evidence) compared to placebo or no treatment. This suggests that if in the studies contributing to the analysis of
clinical pregnancy, the baseline chance of clinical pregnancy following placebo or no treatment is assumed to be 7%, the chance following
the use of antioxidants is estimated to be between 12% and 26%. This result was based on 105 clinical pregnancies from 786 couples in
11 small studies.
Adverse events
Miscarriage: only three studies reported on this outcome and the event rate was very low. There was no diLerence in miscarriage rate
between the antioxidant and placebo or no treatment group (OR 1.74, 95% CI 0.40 to 7.60, P = 0.46, 3 RCTs, 247 men, I2 = 0%, very low-
quality evidence). The findings suggest that in a population of subfertile men with an expected miscarriage rate of 2%, the chance following
the use of an antioxidant would result in the risk of a miscarriage between 1% and 13%.
Gastrointestinal: antioxidants may lead to an increase in mild gastrointestinal upsets when compared to placebo or no treatment (OR 2.51,
95% CI 1.25 to 5.03, P = 0.010, 11 RCTs, 948 men, I2 = 50%, very low-quality evidence). This suggests that if the chance of gastrointestinal
upsets following placebo or no treatment is assumed to be 2%, the chance following the use of antioxidants is estimated to be between
2% and 9%. However, this result was based on a low event rate of 35 out of 948 men in 10 small or medium-sized studies, and the quality
of the evidence was rated very low and was high in heterogeneity.
We were unable to draw any conclusions from the antioxidant versus antioxidant comparison as insuLicient studies compared the same
interventions.
Authors' conclusions
In this review, there is low-quality evidence from seven small randomised controlled trials suggesting that antioxidant supplementation in
subfertile males may improve live birth rates for couples attending fertility clinics. Low-quality evidence suggests that clinical pregnancy
rates may also increase. Overall, there is no evidence of increased risk of miscarriage, however antioxidants may give more mild
gastrointestinal upsets but the evidence is of very low quality. Subfertilte couples should be advised that overall, the current evidence is
inconclusive based on serious risk of bias due to poor reporting of methods of randomisation, failure to report on the clinical outcomes live
birth rate and clinical pregnancy, oQen unclear or even high attrition, and also imprecision due to oQen low event rates and small overall
sample sizes. Further large well-designed randomised placebo-controlled trials reporting on pregnancy and live births are still required
to clarify the exact role of antioxidants.
P L A I N   L A N G U A G E   S U M M A R Y
Antioxidants for male subfertility
Review question
Do supplementary oral antioxidants compared with placebo, no treatment or another antioxidant improve fertility outcomes for subfertile
men?
Background
A couple may be considered to have fertility problems if they have been trying to conceive for over a year with no success. Many subfertile
men undergoing fertility treatment also take dietary supplements in the hope of improving their fertility. Fertility treatment can be a very
stressful time for men and their partners. It is important that these couples have access to high-quality evidence that will allow them to
make informed decisions on whether to take a supplemental antioxidant. This is especially important, as most antioxidant supplements
are uncontrolled by regulation. This review aimed to assess whether supplements with oral antioxidants, taken by the subfertile men,
would increase the chances of a couple to achieve a (clinical) pregnancy confirmed by ultrasound and ultimately the birth of a baby (live
birth). This review did not examine the use of antioxidants in men with normal sperm.
Study characteristics
Cochrane authors conducted a review including 61 randomised controlled trials comparing 18 diLerent antioxidants with placebo, no
treatment or another antioxidant in a total population of 6264 subfertile men. The age range of the participants was 18 to 65 years; they
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were part of a couple who had been referred to a fertility clinic and some were undergoing fertility treatment. The evidence is current to
February 2018.
Main results
Antioxidants may be associated with an increased live birth and clinical pregnancy rate. Based on the studied population for live birth,
we would expect that out of 100 subfertile men not taking antioxidants, 12 couples would have a baby, compared with between 14 and
26 couples per 100 who would have a baby if taking antioxidants. If studies with high risk were removed from the analysis, there was no
evidence of increased live birth. In the people who were studied for clinical pregnancy, we would expect that out of 100 subfertile men not
taking antioxidants, seven couples would have a clinical pregnancy, compared with between 12 and 26 couples per 100 who would have
a clinical pregnancy if taking antioxidants. Adverse events were poorly reported. However based on three studies, we could conclude that
miscarriage did not occur more oQen if taking antioxidants. The use of antioxidants could give more gastrointestinal upsets, meaning that
we expect that out of 100 subfertile men not taking antioxidants, two would have gastrointestinal upsets compared to between two and
nine men if taking antioxidants.
Authors' conclusion and quality of the evidence
Antioxidant supplementation taken by subfertile males of a couple attending a fertility clinic may increase the chance of a live birth,
however the overall quality of evidence was low from only seven small randomised controlled trials. Low-quality evidence also suggests
that clinical pregnancy rates may increase. Overall, there is no evidence of increased risk of miscarriage, however evidence of very low
quality suggest that antioxidants may give more mild gastrointestinal upsets. Subfertile couples should be advised that overall the current
evidence is inconclusive due to the poor reporting of methods, failure to report on the clinical outcomes live birth rate and clinical
pregnancy, and furthermore imprecision due to oQen low event rates, high number of dropouts and small study group sizes. Further large
well-designed randomised placebo-controlled trials reporting on pregnancy and live births are still required to clarify the exact role of
antioxidants.
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Summary of findings for the main comparison.   Antioxidants compared to placebo or no treatment for patients with male subfertility
Antioxidants compared to placebo or no treatment for patients with male subfertility
Patient or population: patients with male subfertility
Setting: clinic
Intervention: antioxidants
Comparison: placebo or no treatment
Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo
or no treatment
Risk with antioxidants
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Live birth rate per
couple randomised
117 per 1000 192 per 1.000
(138 to 262)
OR 1.79
(1.20 to 2.67)
750
(7 RCTs)
⊕⊕⊝⊝
LOW 1
 
Clinical pregnan-
cy rate per couple
randomised
69 per 1000 180 per 1.000
(124 to 255)
OR 2.97
(1.91 to 4.63)
786
(11 RCTs)
⊕⊕⊝⊝
LOW 1
 
Adverse events -
Miscarriage
19 per 1000 33 per 1.000
(8 to 129)
OR 1.74
(0.40 to 7.60)
247
(3 RCTs)
⊕⊝⊝⊝
VERY LOW 1 2
 
Adverse events -
Gastrointestinal
18 per 1000 45 per 1.000
(23 to 86)
OR 2.51
(1.25 to 5.03)
948
(11 RCTs)
⊕⊝⊝⊝
VERY LOW 1 3
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; OR: Peto Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels for serious risk of bias: lack of allocation concealment, lack of blinding and incomplete accounting of patients and outcome events
2 Downgraded one level for serious imprecision: crossing the line of no eLect
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B A C K G R O U N D
Description of the condition
It is believed that 48.5 to 186 million people worldwide are
aLected by the inability to have children (Boivin 2007; Inhorn
2015; Mascarenhas 2012), with delayed conception aLecting
10% to 15% of couples trying to conceive (Evers 2002). The
International Glossary on Infertility and Fertility Care (Zegers-
Hochschild 2017) defines infertility as a disease characterised
by the failure to establish a clinical pregnancy aQer 12 months
of regular, unprotected intercourse and is used interchangeably
with the term subfertility (Zegers-Hochschild 2017). Subfertility
generally describes any form of grade of reduced fertility in couples
unsuccessfully trying to conceive (Gnoth 2005).
In 2010 it was stated in a World Health Organization (WHO) report
(Mascarenhas 2012) that worldwide, measured in 190 countries,
1.9% of child-seeking women were unable to have a first live birth
(primary infertility) and 10.5% with a prior live birth were unable
to have an additional live birth (secondary infertility). However, the
distribution of male and female causes of infertility have not been
well defined. Based on a WHO multicentre study from the 1980s, it is
suggested that 20% of cases are solely attributed to the male, 38%
to the female, 27% to both, and 15% not clearly to either (Comhaire
1987). Surprisingly, the most recent studies are from the 1990s and
still more than two decades old. However, these data show similar
percentages, though mainly based on national databases (ESHRE
Guidelines 1996; Thonneau 1991).
In the literature, it is suggested that a male factor is involved in
up to 50% of infertility cases (Irvine 1998; Winters 2014). However,
the true extent of male infertility is likely to be underestimated
due to the lack of male evaluation in infertile couples and the
heterogeneity of studies (Barratt 2017; Winters 2014). In the past
decades, oxidative stress (OS) has been commonly investigated
and found to play a role in 25% to 87% of male factor subfertility
(Aitken 1987; Aitken 1989; Aitken 1992; Iwasaki 1992; Mazzilli 1994;
Shekarriz 1995; Zini 1993).
In all cells using oxygen to survive, toxins are produced as a
consequence. These toxic end-products are better known as free
radicals, atoms with unpaired electrons. Some free radicals are
characterised by having higher reactive activity than molecular
oxygen, and are therefore called reactive oxygen species (ROS).
ROS can act as mediators and regulators of cell metabolism and
apoptosis (Mirończuk-Chodakowska 2018). The three major ROS
are superoxide anion (O2-), hydroxyl radical (ºOH), and hydrogen
peroxide (H2O2). Excessive production of ROS can lead to cell
damage. Therefore, the human body has developed a defence
system in which antioxidants play an important role. Antioxidants
are capable of reducing the production of free radicals, slowing
or preventing the oxidation and repairing the damage (Mirończuk-
Chodakowska 2018).
The increased levels of ROS are thought to be due to either
exogenous or endogenous factors. Exogenous factors could be
environmental such as high temperatures, pesticides and pollution
or more due to lifestyle factors such as alcohol consumption,
smoking, poor nutrition and obesity. Endogenous factors are
infections, chronic disease, auto-immune disease and in the male
reproductive tract the occurrence of more immature spermatozoa
and varicocele (Alvarez 2003; Tremellen 2008).
In conclusion, OS occurs when ROS production overwhelms the
antioxidant defence mechanisms leading to cellular damage (Sikka
1995).
Description of the intervention
Antioxidants are substances that inhibit or delay the oxidation of
biologically relevant molecules, either by directly scavenging free
radicals or by chelation of redox metals (Valko 2006). However,
the definition is very general and does not specify how a
compound may act as an antioxidant (Huang 2018). In general,
non-enzymatic antioxidants play a substantial role in first-line
defence by preventing the formation of ROS by binding ions
and enzymatic antioxidants that regulate the gene expression of
oxidative enzymes.
The predominant supplementary antioxidants that are studied
in male subfertility clinical trials are vitamin E, vitamin C,
carotenoids, carnitines, coenzyme Q10 (ubiquinol), cysteine and
the micronutrients folate, selenium and zinc (Eskenazi 2005;
Majzoub 2017). Antioxidants can be administered orally as a
single or combined supplement. They are widely available and
inexpensive when compared to other fertility treatments. However
cost-benefit analysis is beyond the scope of this review.
In contrary to the previous versions of this review, pentoxifylline
is no longer included as it is a conventional medicine or over-the-
counter drug and not a dietary supplement.
Substances with direct antioxidant action
Arginine
Arginine, or L-arginine, is an amino acid that is required for normal
spermatogenesis. It plays a role in the inflammatory response and
directly protects against oxidative damage by being a free radical
scavenger. Arginine can be derived from meat products, dairy, nuts
and seeds. Significant adverse events have not been observed,
however contraindication for people with a history of genital or oral
herpes, asthma or cancer (Appleton 2002).
Carnitines
Carnitine is an antioxidant, with the two most important isomers
being called l-carnitine (LC) and l-acetylcarnitine (LAC). In the
male genital tract carnitines are found in the epididymis, seminal
plasma and in spermatozoa (Bøhmer 1978). Carnitines assist sperm
metabolism by positively aLecting sperm motility and maturation.
There might be an association between the concentration of LAC
and male fertility (Agarwal 2004a). Animal products like meat, fish,
poultry and dairy are the best sources for carnitines. Doses above 3
g/day can give gastrointestinal side eLects and malodorous eLects
(Annals of the New York Academy of Science 2004).
Carotenoids
Carotenoids are pigments found in plants. One of the most
important carotenoids is β-carotene (Ross 2006), a provitamin
A, which can directly scavenge ROS. Other carotenoids found in
food are lycopene, lutein, and zeaxanthin, however these are not
converted into vitamin A. Both in vivo and in vitro, β-carotene has
been shown to protect isolated lipid membranes from peroxidation
(Bendich 1989). Healthy young men with a higher carotenoid
intake have higher sperm motility, and higher lycopene intake is
associated with better sperm morphology (Zareba 2013). However,
a review by Grune and colleagues (Grune 2010) stated that there are
conflicting results whether β-carotene has antioxidant properties.
Antioxidants for male subfertility (Review)
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Carotenoids come from leafy green vegetables, fruits, and some
vegetable oils (Ross 2006). Excess intake of preformed vitamin A can
lead to toxicity (hypervitaminosis A). However, excessive ingestion
of provitamins such as carotenoids are not associated with vitamin
A toxicity, the only side eLect is carotenaemia (yellow-tinged skin).
Coenzyme Q10
Coenzyme Q10 (CoQ10) is a fat-soluble antioxidant synthesised
endogenously and an essential component of the mitochondrial
energy metabolism. In its reduced form, CoQH2, ubiquinol, it
inhibits protein and DNA oxidation and lipid peroxidation (Littarru
2007). CoQ10 seminal fluid levels are significantly correlated to
sperm count and motility, except in men with varicocele (Mancini
1994). Meat, fish, nuts and some oils are the most important
dietary sources of CoQ10 due to their relatively high level of fats
and mitochondria (Pravst 2010). Reported side eLects are mild
gastrointestinal symptoms (Bhagavan 2006).
Cysteine
Cysteine plays an important role in glutathione synthesis. N-
acetylcysteine (NAC) is a precursor of the amino acid cysteine and a
direct scavenger of ROS. Glutathione becomes depleted when there
is OS, and this can be reversed by NAC supplementation (Atkuri
2007). NAC is less toxic and less susceptible to oxidation compared
to cysteine itself. Oral administration of NAC up to 8000 mg/day is
not known to cause significant adverse events (Atkuri 2007). Less
is known about ethylcysteine, however in vivo and animal studies
have shown anti-oxidative eLects (Hsia 2016).
Micronutrients (folate, selenium, zinc)
Folate, also known as vitamin B9, is a micronutrient important for
the synthesis of DNA, transfer RNA and the amino acids cysteine and
methionine. Folic acid, the synthetic form, can scavenge oxidising
free radicals and it inhibits lipid peroxidation (Joshi 2001). Folate
is present in green-leafy vegetables, liver, bread, yeast and fruits
(Ebisch 2007). Folic acid doses of 5 mg/day and over can cause
abdominal cramps, diarrhoea and rash. Higher doses can even
cause altered sleep patterns, irritability, confusion, exacerbation of
seizures and nausea (Rogovik 2009).
Zinc is involved in DNA transcription and protein synthesis and
has extensive antioxidants properties (Ebisch 2007). Zinc has
an important role in testes development, sperm physiological
functions and decrease of zinc in seminal plasma is associated with
sperm quality (Colagar 2009a). Zinc, like selenium, is absorbed from
the soil into plants. Dietary sources rich of zinc are meat products,
wheat and seeds.
Magnesium and selenium are diLerent than other antioxidant
nutrients because they are involved in the mechanisms of cellular
antioxidant defence by increasing the activity of the antioxidant
enzyme glutathione peroxidase, and not by directly reacting with
oxidant molecules (Burk 2002; Yavuz 2013). It is suggested that both
magnesium and selenium deficiency would make humans more
susceptible to oxidative injury. Selenium is furthermore essential
for normal spermatogenesis (Boitani 2008). Selenium is derived
from fish, meat products, diary and soil absorption by plants
(Navarro-Alarcon 2008). Early indicators of excess intake are a garlic
odour in the breath and a metallic taste in the mouth. The most
common clinical signs of chronically high selenium intakes are
gastrointestinal symptoms, fatigue, hair loss, joint pain and nail
problems (MacFarquhar 2010). Magnesium is derived from green
leafy vegetables, nuts, beans, and cereals (McNeill 1985).
Vitamin E
Vitamin E, also known as the bioactive form α-tocopherol, has a
principal role by being the first defence against oxidant-induced
membrane injury (Traber 2007). Vitamin E is found in vegetable
oils and there is a given upper daily limit based on the possible
increased bleeding risk (Institute of Medicine 2000).
Vitamin C
Vitamin C, also known as ascorbic acid, is able to diminish
DNA damage directly by scavenging free radicals and decreasing
formation of lipid hydroperoxides (Padayatty 2003). Ascorbic acid
concentrations are 10-fold higher in seminal plasma compared
to blood plasma. Low levels of seminal plasma ascorbic acid are
directly related to decreased amount of normal morphology of
spermatozoa and increased sperm DNA damage (Colagar 2009).
Vitamin C is mainly found in fruits and vegetables.
Substances with antioxidant properties
Myo-inositol
Inositol is a polyalcohol, naturally occurring as nine stereoisomers
including myo-inositol (MYO). Myo-inositol, a "pseudovitamin"
and previously known as vitamin B8, plays an important roll
in cell membrane formation and lipid synthesis. The highest
concentration in the genital tract is within the seminiferous tubules,
and myo-inositol is produced by Sertoli cells in response to
follicle-stimulating hormone (FSH) (Lewin 1976). Myo-inositol is a
precursor for the phosphatidyl-inositol (PtdIns) signalling pathway
and directly involved in regulation of motility, capacitation and
acrosome reaction (Bevilacqua 2015). Myo-inositol has a role as a
possible antioxidant agent by increasing endogenous antioxidant
enzymes and directly aLecting the mitochondria leading to an
increase of the membrane potential (Colone 2010; Condorelli 2017).
Polyunsaturated fatty acids (PUFAs)
Polyunsaturated fatty acids (PUFAs) are classified into omega-3
(docosahexaenoic acid, DHA), omega-6 and omega-9. Omega-9
is synthesised by animals, but omegas-3 and -6 needs to be
supplemented in the diet. The main sources of these are vegetable
and fish oils (Wathes 2007). PUFAs increase the plasma fluidity
of the sperm membrane. However, this fluidity makes the sperm
susceptible to ROS and lipid peroxidation that can damage the
sperm. Wathes states that "It appears that PUFAs are a two
edged sword - some are essential, but too many are potentially
harmful" (Wathes 2007, page 198). It seems to be that PUFAs have
a pro-oxidant rather than a direct antioxidant eLect. Although it
is suggested that omega 3 might have a free radical-scavenging
potential (Giordano 2014; Richard 2008).
Resveratrol
Resveratrol is a natural phytoalexin with antioxidant properties.
Several in vitro studies with human cryopreserved sperm and in vivo
studies in animal models suggest that resveratrol improves sperm
motility and enhances antioxidant defences (Branco 2010; Collodel
2011; Ourique 2013). It is naturally found in our diet in the form of
grapes, berries, several nuts and wine (Ourique 2013). Worldwide,
resveratrol is better known from research on the eLect of daily
intake of red wine, "the "Mediterranean diet", in cardiovascular
disease (Bertelli 2009). Reversible gastrointestinal side eLects are
reported, however evidence on side eLects is limited (Hausenblas
2014).
Vitamin B (complex)
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Vitamin B is a water-soluble vitamin and consists of several
precursor and coenzymes such as thiamine (B1), riboflavin (B2)
and cobalamin (B12). Vitamin B plays an important role in
the homocysteine metabolism. It is suggested that total plasma
homocysteine may have a pro-oxidant eLect and a role in the
release of ROS (Hankey 1999). Increased intake of vitamin B has an
homocysteine-lowering eLect, which is the strongest for folate, but
vitamins B6, B12, and B2 have all been shown to be independently
predictive of plasma homocysteine. Vitamin B is mainly found in
meat products, other examples of food sources are beans, potatoes,
bananas and mushrooms.
Vitamin D
Vitamin D is a fat-soluble vitamin, with the natural main source
being dermal synthesis (sun light). The active form of vitamin D
is 1,25-dihydroxyvitamin D, also called vitamin D3. Halicka and
colleagues suggest that vitamin D3 has antioxidant activity, mainly
by inducing the antioxidant protein superoxide dismutase (Halicka
2012). However, there are no other studies about the antioxidant
properties of vitamin D in male fertility. Clearly, vitamin D plays
an important role in male fertility and serum levels of vitamin D
are positively associated with semen quality (de Angelis 2017).
However, most of the studies do not mention the antioxidant
properties of vitamin D, but rather relate the eLect to the synthesis
of sex steroids or the regulation of calcium.
How the intervention might work
In the second half of the 20th century it was found that semen
leukocytes (white blood cells) and, mostly immature, spermatozoa
are major sources of ROS production in the male reproductive tract
(Aitken 1987; Aitken 1990; Iwasaki 1992). Additionally, the existence
of a varicocele leads to increased scrotal temperature, reflux of
blood flow and a damaged microcirculation, all of which act to
increase both germ cell death and levels of ROS. This ultimately
decreases semen quality and sperm function (Zini 2011). However,
a low production of ROS is physiological and needed for adequate
sperm functioning by supporting capacitation, maturation and
hyperactivation (Aitken 1994).
In most body cells, ROS are directly inactivated and their
damage repaired by cytoplasmic antioxidant enzymes such
as catalase, superoxide dismutase or glutathione peroxidase
(Aitken 1994; Ebisch 2007). However, spermatozoa diLer from
other cells as a substantial proportion of their cytoplasm is
removed during the final stages of spermatogenesis. The lack of
cytoplasma and therefore enzymatic antioxidants makes them
very vulnerable. Furthermore, spermatozoal membranes are rich in
PUFA which makes them susceptible for lipid peroxidation resulting
in decreased flexibility of the sperm membrane and reduction of
tail motion (Jones 1973). For these two reasons, spermatozoa are
dependant on seminal plasma, which is rich in antioxidants (Smith
1996; Zini 1993).
In general, it can be stated that OS can cause fertility problems
in two ways; firstly by damaging the sperm membrane thus
aLecting the sperm motility and ability to break down the oocyte
membrane, and secondly by apoptosis and direct alteration of
the sperm DNA (Kodama 1997; Lewis 2013) Deceivingly, men with
sperm DNA damage can still have normal seminal parameters,
but have a poor chance of natural conception (Aktan 2013;
Intasqui 2015). Sperm DNA damage or integrity can be measured
in a number of ways, either direct or indirect (Agarwal 2017).
The most current used sperm DNA fragmentation (SDF) testS
are terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labelling (TUNEL), the COMET assay and sperm chromatin
structure assay (SCSA). Other options are measurement of the
byproduct of DNA oxidation, 8-hydroxydeoxyguanosine (8-OHdG)
or by chemoluminescence assays using luminol or lucigenin.There
are experts within the field who state that SDF testing should
be part of a standard assessment of the male partner when a
couple presents with subfertility (Agarwal 2016; Boe-Hansen 2006).
Women undergoing intrauterine insemination with a sperm DNA
fragmentation index < 30%, as measured by the SCSA, were seven
times more likely to achieve a pregnancy than those couples where
the male partner had a higher degree of sperm DNA damage
(Bungum 2004). Furthermore, multiple meta-analyses show an
association between the sperm DNA fragmentation test and live
birth or clinical pregnancy aQer in vitro fertilisation (IVF) or
intracytoplasmic sperm injection (ICSI) treatment (Collins 2008;
Evenson 2006; Li 2006; Osman 2015; Zhang 2015; Zhao 2018).
However, a recent meta-analysis showed that an association does
not imply that SDF tests have an actual predictive value (Cissen
2016). An explanation for the little predictive value of SDF testing in
assisted reproductive techniques (ART) is the heterogeneity of tests.
Most of them are expensive, complex and lack standardisation and
validation (Borini 2017; Cissen 2016).
Multiple studies in the past showed that men of a subfertile
couple have higher levels of ROS and lower antioxidant levels in
their semen compared to fertile men (Aktan 2013; Bykova 2007;
Zini 1993). Furthermore, there is evidence that sperm with high
percentages of fragmented DNA have less potential of natural
conception, with levels above 30% being mentioned as the cut-oL
value (Evenson 1999; Spanò 2000). However when fertilisation does
occur, spermatozoa releasing ROS could expose oocytes and lead
to impaired oocyte function, including its capacity to repair sperm
DNA fragmentation post fertilisation (Shimura 2002). The negative
impact of damaged paternal DNA could be manifested by impaired
embryo development and an association is reported on sperm DNA
integrity and early pregnancy loss (Robinson 2012; Simon 2014).
On the contrary, there are also some studies suggesting that sperm
DNA damage and oxidative stress do not exist in male idiopathic
infertility (Hughes 1996; Verit 2006).
If oxidative stress is at the heart of the increased sperm DNA
damage and the lowering of pregnancy and live birth rates,
then supporting the antioxidant defence system with exogenous
antioxidants would seem logical. An extra dietary intake of
antioxidants or a healthy diet in general has shown to be strongly
associated with semen quality in healthy men (Eskenazi 2005;
Irvine 1998; Lewis 1997; Mendiola 2010; Pasqualotto 2001; Salas-
Huetos 2017; Zareba 2013). In conclusion, there is a fine balance
between preventing oxidative stress by antioxidants, removing
excessive amounts of ROS, and maintaining a small amount of ROS
for their physiological eLect on sperm functions. Since "reductive
stress" as a rebound eLect has been reported, large or high doses of
antioxidants might better be avoided (Dattilo 2016; Ghyczy 2001).
Why it is important to do this review
In an eLort to enhance fertility, couples are increasingly resorting
to ART. However, these techniques are expensive and do not cure
the causes of subfertility, but rather overcome some of its barriers.
Since integrity of sperm DNA is one of the major determinants of
normal fertilisation and embryo growth in natural and assisted
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conception (Agarwal 2003; Aitken 2010; Evenson 2006), there is a
clear rationale for antioxidant therapy.
One of the other reasons for this review, apart from finding
out if antioxidant therapy can overcome some of the barriers of
subfertility, is that the global vitamin and supplement market
has grown exponentially over the last years. The market value
is expected to reach 278 billion USD by 2024 (Grand View
Research 2016). The low costs of supplements and relative risk
are appealing to both patients and healthcare providers. However,
most antioxidants are uncontrolled by regulation and the evidence
for their eLectiveness is not based on randomised clinical studies.
Vitamins and supplements are dispensed through various retail
outlets, including health food shops, online retailers, health
centres, fitness clubs, supermarkets and pharmacies (Showell
2017).
The purpose of this Cochrane Review is to assess the eLectiveness
and safety of diLerent antioxidants and dosages used by men of
subfertile couples, by means of improvement of live birth rates,
clinical pregnancy rates and adverse events. This is an update of a
review first published in 2008 (Showell 2008) and updated in 2014
(Showell 2014).
O B J E C T I V E S
To evaluate the eLectiveness and safety of supplementary oral
antioxidants compared with placebo, no treatment or another
antioxidant in subfertile men.
Search methods
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria• Randomised controlled trials (RCTs)• Cross-over trials are included: however, we only used first-phase
data in the analysis. Achieving outcomes such as pregnancy and
live birth would preclude entry of couples into the next trial
phase (Dias 2006)
Exclusion criteria• Any quasi-randomised trials
Types of participants
Inclusion criteria• Studies that included subfertile men (male factor subfertility)
part of a couple who had been referred to a fertility
clinic and might or might not be undergoing assisted
reproductive techniques (ART), such as in vitro fertilisation
(IVF) and intracytoplasmic sperm injection (ICSI), or intrauterine
insemination (IUI)
In situations where individuals were randomised again following
failed cycles, the data would not be pooled in a meta-analysis
unless individual data could be excluded.
Exclusion criteria• Studies enrolling only men attending a fertility clinic exclusively
as the result of female partner or idiopathic infertility• Studies enrolling men taking any other fertility enhancing drugs• Studies enrolling men who had chemotherapy treatment in the
past
Types of interventions
Inclusion criteria
• Any type or dose of oral antioxidant supplementation (individual
or combined) that can be obtained without prescription and is
not regulated as a pharmaceutical drug, versus placebo or no
treatment• Any type or dose of oral antioxidant supplementation (individual
or combined) versus another type or dose of oral antioxidant
(head-to-head)
Interventions were considered 'combined antioxidants' if they
included three or more antioxidants in the intervention arm.
Exclusion criteria
• Interventions that included plant extracts (for example garlic) or
herbal substances
Studies that included antioxidants plus a plant extract (for example
garlic) were included if the antioxidant agent was the main focus of
the investigation.
Definition of antioxidant in male fertility: a substance that
has the ability to protect spermatozoa against endogenous
oxidative damage by directly neutralising hydroxyl, superoxide,
and hydrogen peroxide radicals, chelation of redox metals or by
functioning as a component of an antioxidant enzyme.
Types of outcome measures
Primary outcomes• Live birth rate per couple randomised, defined as delivery of a
live fetus aQer 20 completed weeks of gestation
Secondary outcomes• Clinical pregnancy rate per couple, defined as evidence of a
gestational sac confirmed by ultrasound• Any adverse event (including miscarriage) reported by the study• Level of sperm DNA fragmentation, defined as percentage (%)
of sperm with abnormal DNA integrity estimated by either
toluidine blue (TB) staining, sperm chromatin structure assay
(SCSA) or terminal transferase dUTP nick end labelling (TUNEL)
assay)• Total sperm motility: any sperm movement in any direction
(progressive plus forward plus non progressive motility),
provided as percentage (%)• Progessive sperm motility: sperm with forward progression,
defined as WHO category A + B, provided as percentage (%)• Sperm concentration:number of sperm (106)/mL
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Search methods for identification of studies
We searched for all published and unpublished RCTs investigating
oral antioxidant supplementation for subfertile men, without
language restriction and in consultation with the Gynaecology and
Fertility Group (CGF) Information Specialist(MGS).
Electronic searches
We searched the following electronic databases for relevant trials.
• The Cochrane Gynaecology and Fertility Group's (CGF)
Specialised Register of Controlled Trials, PROCITE platform
(searched 1 February 2018) (Appendix 1)• The Cochrane Central Register of Controlled Trials; via the
Cochrane Register of Studies Online (CRSO Web platform)
( searched 1 February 2018) (Appendix 2)• MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed
Citations) Ovid platform (searched from 1946 to 1 February
2018) (Appendix 3)• Embase Ovid platform (searched from 1980 to 1 February 2018)
(Appendix 4)• CINAHL EBSCO platform (Cumulative Index to Nursing and Allied
Health Literature) (searched from 1961 to 1 February 2018)
(Appendix 5)• PsycINFO Ovid platform (searched from 1806 to 1 February 2018)
(Appendix 6)
The MEDLINE search was limited by the Cochrane highly sensitive
search strategy filter for identifying randomised trials which
appears in the Cochrane Handbook of Systematic Reviews of
Interventions (Version 5.1.0, Chapter 6, 6.4.11) (Higgins 2011). The
Embase, PsychINFO and CINAHL searches were combined with trial
filters developed by the Scottish Intercollegiate Guidelines Network
(SIGN) (www.sign.ac.uk/mehodology/filters.html#random).
Searching other resources
The following other resources were searched (last search February
2018).
• International trial registers: the ClinicalTrials database, a service
of the US National Institutes of Health (clinicaltrials.gov/
ct2/home) and the World Health Organization International
Trials Registry Platform search portal (www.who.int/trialsearch/
Default.aspx) (Appendix 7; Appendix 8)• Google scholar, using the keywords 'antioxidants male
infertility' and 'antioxidants sperm random'• Database for Abstracts of Reviews of ELects (DARE) for other
reviews on this topic• 'Grey' literature (unpublished and unindexed), through the
openGREY database (www.opengrey.eu/) (Appendix 9)• ProQuest Dissertations and Theses (http://
search.proquest.com.ezproxy.auckland.ac.nz/pqdtQ/
advanced?accountid=8424) was also searched (Appendix 10)• Web of Knowledge for conference proceedings and published
trials (Appendix 11)• Appropriate journals were handsearched for trial conference
abstracts in the year 2017 (not included in CGF search). These
journals included Human Reproduction, which contains abstract
supplements for the European Society of Human Reproduction
and Embryology (ESHRE), and Fertility and Sterility that
contains abstract supplements for the 'American Society for
Reproductive Medicine' (ASRM).
We handsearched reference lists of relevant trials and systematic
reviews retrieved by the search and contacted experts in the field
to obtain additional data.
Data collection and analysis
Selection of studies
Review authors RS and RM-P did an initial screen of titles and
abstracts retrieved by the search. The search was conducted
by MGS and RS. We retrieved the full texts of all potentially
eligible studies. Two review authors (RS and RM-P) independently
examined these full-text articles for compliance with the inclusion
criteria and selected eligible studies. We corresponded with study
investigators as required, to clarify study eligibility. Disagreements
were resolved by discussion. If any reports required translation, we
described the process used for data collection. We documented the
selection process with a “PRISMA” flow chart (see Figure 1).
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Data extraction and management
Two review authors (RS and RM-P) independently extracted data
from eligible studies using a data extraction form designed and
pilot-tested by the authors. Any disagreements were resolved
by discussion. Data extracted included study characteristics and
outcome data (see data extraction table for details, Characteristics
of included studies and Characteristics of excluded studies). Where
studies had multiple publications, the review authors collated the
multiple reports under a single study ID with multiple references.
We corresponded with study investigators for further data on
methods and/or results, as required.
Assessment of risk of bias in included studies
Two review authors (RS and RM-P) independently assessed the
included studies for risk of bias using the Cochrane 'Risk of bias'
assessment tool to assess: selection (random sequence generation
and allocation concealment); performance (blinding of participants
and personnel); detection (blinding of outcome assessors); attrition
(incomplete outcome data); reporting (selective reporting); and
other potential sources of bias (Higgins 2011). Judgements
were assigned as recommended in the Cochrane Handbook for
Systematic Reviews of Interventions Section 8.5 (Higgins 2011).
Disagreements were resolved by discussion; when needed we
consulted a third party to achieve agreement (MGS or VJ). We
described all judgements fully and present the conclusions in the
'Risk of bias' table (Characteristics of included studies), which is
incorporated in the interpretation of review findings by means of
sensitivity analyses (see below). We sought published protocols.
We took care to search for within-study selective reporting, for
example, trials failing to report outcomes such as live birth or
reporting them in insuLicient detail to allow inclusion. Where
protocols were available, we assessed studies for diLerences
between study protocols and published results.
In cases where included studies failed to identify the primary
outcome of live birth, but did report pregnancy rates, we carried
out an informal assessment to determine whether pregnancy rates
were similar to those in studies that reported live birth.
We considered that the blinding status of participants could
influence findings for the outcomes of live birth, pregnancy and
adverse events, as antioxidants are easily available and it would
be possible for participants to self-medicate. Therefore, if the
participants were not blinded or the study was not placebo-
controlled, or both, we considered the study to be at high risk of
bias.
Measures of treatment e9ect
We collected dichotomous data for live birth, pregnancy rate,
miscarriage and adverse events and for the continuous data for
sperm quality measurements we collected mean diLerences (MDs)
and the associated standard deviations (SDs).
Sperm parameter outcomes were analysed at the time points of
three, six and nine months post-randomisation. All studies were
analysed in this way regardless of whether the participants were
treated for three, six or nine months.
Unit of analysis issues
The primary analysis of the outcomes of live birth, pregnancy
and adverse events was per couple randomised, counting multiple
births as one live birth event. The sperm outcome analyses were per
man randomised. Only the first-phase data from cross-over trials
were included.
Dealing with missing data
We analysed the data on an intention-to-treat basis as far as
possible (i.e. including all randomised participants in analyses,
in the groups to which they were randomised). Attempts were
made to obtain missing data from the original trialists and the
results of author contact are reported in Characteristics of included
studies. When data were unobtainable, we undertook imputation
of individual values for live birth only: live birth was assumed
not to have occurred in participants without a reported outcome.
For other outcomes, we analysed only the available data. Any
imputation undertaken was subjected to sensitivity analysis (see
below).
If studies reported suLicient detail to calculate MDs but gave no
information on an associated SD, we assumed the outcome to have
a SD equal to the highest SD from other studies within the same
analysis.
Assessment of heterogeneity
We considered whether the clinical and methodological
characteristics of included studies were suLiciently similar for
meta-analysis to provide a clinically meaningful summary. We
assessed statistical heterogeneity by the measure of the I2. If an I2
was 50% or higher, we assumed high heterogeneity, and conducted
a sensitivity analysis. A high I2 statistic suggests that variations in
eLect estimates may be due to diLerences between trials rather
than to chance alone (Higgins 2011).
Assessment of reporting biases
In view of the diLiculty of detecting and correcting for publication
bias and other reporting biases, we aimed to minimise their
potential impact by ensuring a comprehensive search for eligible
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studies and by being alert for duplication of data. If there were 10
or more studies in an analysis, we used a funnel plot to explore the
possibility of small-study eLects (a tendency for estimates of the
intervention eLect to be more beneficial in smaller studies).
Data synthesis
We conducted statistical analysis of the data using Review Manager
5 (RevMan 2014). We expressed the dichotomous data for live
birth, pregnancy rate, miscarriage and adverse events as Peto odds
ratios (ORs) with 95% confidence intervals (CIs) and combined
them in a meta-analysis with Review Manager 5 soQware using the
Peto method and a fixed-eLect model (Higgins 2011). A random-
eLects model was used on sperm outcomes because we suspected
high heterogeneity in these outcomes based on the previous
review versions. The Peto OR has mathematically sound properties
that are consistent with benefit or harm and work well in small
samples with rare events. This eLect measure is appropriate
when considering subfertility. For continuous data (for example
sperm quality measurements) MDs between treatment groups
were calculated with associated SDs and 95% CIs. The results were
displayed on forest plots, where possible.
We considered pregnancy outcomes to be positive, and higher
pregnancy rates of benefit. We considered the outcomes of
miscarriage and adverse events to be negative eLects, and
higher numbers harmful. We combined data for the following
comparisons.
• Antioxidants versus placebo or no treatment• Antioxidants versus antioxidants (head-to-head)
Adverse events as reported in the studies were included in the two
comparisons above.
The total sperm motility, progressive sperm motility and
concentration outcomes were divided into three groups:
measurement aQer starting treatment, at three, six and nine
months or more as reported by the studies. Studies were analysed
together if they reported these outcomes at the same point in time,
for example a study that stopped treatment at three months but
measured at six or nine months was measured in the same analysis
as those that were treated for six or nine months.
We displayed increases in the odds of a particular outcome, which
may be beneficial (e.g. live birth) or detrimental (e.g. adverse
events), graphically in meta-analyses to the right of the centre line,
and decreases in the odds of a particular outcome to the leQ of the
centre line.
The aim was to define analyses that were comprehensive and
mutually exclusive, so that we could slot all eligible study results
into one stratum only. We specified comparisons so that any
studies falling within each stratum could be pooled for meta-
analysis. Stratification allowed for consideration of eLects within
each stratum, as well as or instead of an overall estimate for
comparison.
If individuals had been randomly re-assigned aQer failed cycles, we
did not pool the data in a meta-analysis.
Statistical analysis was performed using Review Manager 5.3
(RevMan 2014).
Subgroup analysis and investigation of heterogeneity
Where data were available, we conducted subgroup analyses to
determine the separate evidence within the following subgroups.
• Studies that included diLerent types of antioxidant ((for the
outcomes of live birth and clinical pregnancy)• Studies that included couples who were also receiving IVF/ICSI
treatment (for the outcomes of live birth and clinical pregnancy)• Studies using no treatment as control group compared to
placebo (for outcomes of live birth and clinical pregnancy)• As-treated analysis• Over time analysis for sperm outcomes of motility and
concentration, at three, six and nine months
If we detected substantial heterogeneity, we explored possible
explanations in subgroup analyses (e.g. diLering populations) and/
or sensitivity analyses (e.g. diLering risk of bias). We took any
statistical heterogeneity into account when interpreting the results,
especially if there was any variation in the direction of eLect.
Sensitivity analysis
We conducted sensitivity analyses (using the random-eLects model
in RevMan soQware) on the primary outcomes if we detected a high
degree of heterogeneity (I2 = 50% or more), excluding studies to
assess if there is a change in eLect:
• with a high risk of bias, or• enrolling men who are part of a couple undergoing IUI, or• enrolling men with varicocele, or• for studies that reported both live birth and clinical pregnancy
rate in order to assess any overestimation of eLect and reporting
bias, or• for studies where results had been imputed, or• for studies that reported remarkably low SDs as the review
authors considered that these data were potentially erroneous
(a post hoc sensitivity analysis).
Overall quality of the body of evidence: 'Summary of findings'
table
We prepared a 'Summary of findings; table using GRADEpro
(GRADEpro GDT 2015) and Cochrane methods (Higgins 2011). This
table evaluates the overall quality of the body of evidence for
the main review outcomes (live birth, clinical pregnancy, and
the adverse events) for the main review comparison (antioxidant
compared with placebo or no treatment). We assessed the quality
of the evidence using GRADE criteria: risk of bias, consistency of
eLect, imprecision, indirectness and publication bias). Judgements
about evidence quality (high, moderate, low or very low) were
made by two review authors (RS and RM-P) working independently,
with disagreements resolved by discussion. Judgements were
justified, documented, and incorporated into reporting of results
for each outcome.
We extracted study data, formatted our comparisons in data tables
and prepared a 'Summary of findings' table before writing the
results and conclusions of our review.
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R E S U L T S
Description of studies
Results of the search
2011 version of review
We assessed 590 abstracts for inclusion from the title and abstract
found in a search dated from inception to August 2010. The
MEDLINE search produced 406 abstracts; there were six abstracts
from CENTRAL, three from CINAHL, 62 from Embase, 107 from the
CGF database and three from PsycINFO. Two conference abstracts
were found from handsearching the conference proceedings of
the European Society for Human Reproduction and Embryology
(ESHRE) and the American Society for Reproductive Medicine
(ASRM). One title was found from reference lists in reviews. AQer
removal of inappropriate and duplicate studies, we retrieved the
full texts of 53 studies. Five non-English studies were assessed
for inclusion: two Chinese, one Bulgarian, one Japanese and one
Iranian. The two Chinese studies (Li 2005; Li 2005a), the Japanese
study (Akiyama 1999) and the Iranian study (Peivandi 2010) were
included in the analysis. The Bulgarian study (Nikolova 2007) was
excluded as it did not use random allocation (see Characteristics of
excluded studies). We excluded 15 articles and found four ongoing
studies in searches of the clinical trial registers.
A total of 34 studies were included in the 2011 version of the review
(Showell 2011).
2014 update
We assessed 483 abstracts for inclusion from the title and abstract
found in a search dated from 1 August 2010 to 30 January 2014. AQer
duplicates were removed 338 remained. We assessed 34 of these
papers in full text.
Eleven of the full-text reports assessed studies were in a language
other than English and required translation, five of these were in
Chinese, two in Persian and one each in Japanese, Russian, Italian,
and Portuguese (see Acknowledgements for those who helped with
translation). Five of the Chinese studies were excluded: three (Chen
2012; Tang 2011; Wang 2010a) due to an inappropriate intervention,
one was not randomised (Wu 2012), and one had an inappropriate
population (Lu 2010). The Portuguese study (Verzeletti 2012) was
excluded as it used a herbal intervention. Five non-English studies
were included: one in Persian (Eslamian 2013), one Japanese
(Kumamoto 1988), one Italian (Morgante 2010), one Russian (Sivkov
2011) and one Chinese (Wang 2010).
We excluded 20 articles, and included 14 articles. An updated
search was run in August 2014 where six studies (Anarte 2013;
Gopinath 2013; Iacono 2014; Nadjarzadeh 2014; Nashivochnikova
2014; Nematollahi-Mahani 2014) were placed in 'Studies awaiting
assessment'. There were six ongoing studies found in the new
searches.
We included 14 new trials in the 2014 update: Attallah 2013;
Azizollahi 2013; Dimitriadis 2010; Eslamian 2013; Kumamoto 1988;
Martinez-Soto 2010; Morgante 2010; Nadjarzadeh 2011; Poveda
2013; Pryor 1978; Safarinejad 2011; Safarinejad 2012; Sivkov 2011;
Wang 2010.
A total of 48 studies were included in the 2014 update (Showell
2014).
2018 update
We assessed 979 abstracts for inclusion from the title and abstract
found in a search dated from January 2014 until February 2018.
One extra study was found through the grey literature search. AQer
duplicates were removed, 718 articles remained. We assessed 58 of
these papers in full text. One of the full-text articles assessed studies
was in Chinese (Deng 2014) and one in Russian (Gamidov 2017);
both required translation. We excluded 22 studies (28 articles), and
included 19 studies (29 articles). See the PRISMA flow chart (Figure
1)
Of the new included studies, one was from the six studies placed in
'Awaiting classification' in the 2014 update of this review (Gopinath
2013). The remaining studies awaiting classification were all found
ineligible aQer screening of title and abstract or excluded aQer
reading the full text.
In the current update, none of the eight previously 'ongoing
studies' were included. Five of these ongoing studies were
found ineligible aQer screening of title and abstract or excluded
aQer reading the full text. Three studies remained as 'ongoing
studies' (CTRI/2013/02/003431; NCT00975115; NCT01828710) with
the status of still recruiting. We added nine new ongoing studies
(DRKS00011616; IRCT2016111830947N1; IRCT2017012432153N1;
NCT01407432; NCT01846325; NCT02310087; NCT02421887;
NCT03104998; NCT03337360). In this 2018 update, a total of
12 studies are classified as 'ongoing studies' (Characteristics of
ongoing studies).
We removed and excluded four pentoxifylline studies that
were previously included in the 2014 update and the original
review (Merino 1997; Micic 1988; Safarinejad 2011; Wang 1983).
Furthermore, we removed two previously included studies due
to the discovery that the population did not meet the inclusion
criteria: they included men with idiopathic infertility with normal
sperm parameters, and no male factor infertility. (CiQci 2009;
Keskes-Ammar 2003).
We included 19 new trials in this update: Barekat 2016; Blomberg
Jensen 2018; Boonyarangkul 2015; Busetto 2018; Cyrus 2015; Deng
2014; Ener 2016; Exposito 2016; Gamidov 2017; Gopinath 2013;
Haghighian 2015; Haje 2015; Martinez 2015; Mehni 2014; Micic 2017;
Pourmand 2014; Raigani 2014; Sharifzadeh 2016; Sofikitis 2016.
A total of 61 studies have been included in this update
(Characteristics of included studies). A total of 59 studies were
excluded (Characteristics of excluded studies).
Included studies
Study design and setting
The studies came from 28 diLerent countries. Fourteen studies
were from Iran (Azizollahi 2013; Barekat 2016; Cyrus 2015; Eslamian
2013; Haghighian 2015; Mehni 2014; Nadjarzadeh 2011; Peivandi
2010; Pourmand 2014; Raigani 2014; Safarinejad 2009; Safarinejad
2009a; Safarinejad 2012; Sharifzadeh 2016). Ten studies were based
in Italy (Balercia 2005; Balercia 2009; Biagiotti 2003; Busetto 2018;
Cavallini 2004; Galatioto 2008; Lenzi 2003; Lenzi 2004; Lombardo
2002; Morgante 2010). Four studies were from China (Deng 2014;
Li 2005; Li 2005a; Wang 2010), three from Japan (Akiyama
1999; Dimitriadis 2010; Kumamoto 1988), and three from the UK
(Kessopoulou 1995; Pryor 1978; Scott 1998). Two studies each were
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from Kuwait (Omu 1998; Omu 2008), Russia (Gamidov 2017; Sivkov
2011), Spain (Exposito 2016; Martinez-Soto 2010), and the USA
(Dawson 1990; Sigman 2006). A single study was set in each of
the following countries: Australia (Tremellen 2007), Belgium (Zalata
1998), Canada (Conquer 2000), Denmark (Blomberg Jensen 2018),
Egypt (Attallah 2013), France (Greco 2005), Germany (Rolf 1999),
Greece (Sofikitis 2016), Hungary (Zavaczki 2003), India (Gopinath
2013), Iraq (Haje 2015), Mexico (Martinez 2015), the Netherlands
(Wong 2002), Panama (Poveda 2013), Saudi Arabia (Suleiman 1996),
Serbia (Micic 2017), Thailand (Boonyarangkul 2015), Tunisia (Nozha
2001) and Turkey (Ener 2016).
All included studies were randomised. Five studies had a
randomised cross-over design (Akiyama 1999; Kessopoulou 1995;
Lenzi 2003; Peivandi 2010; Pryor 1978). In the meta-analysis only
the first phase data were used as all studies reported first and
second phase data separately. The remaining 56 studies used
a randomised parallel group design. One study (Li 2005) had a
large imbalance between the intervention and control groups at
the randomisation stage; 150 men were randomised, 90 into the
treatment group and 60 into the control group. This appeared to
be a blocked 3:2 allocation ratio. This method of randomisation
was not explained in the report. Attempts were made to contact
the author but there has been no reply. Thirteen studies (Biagiotti
2003; Cavallini 2004; Conquer 2000; Dawson 1990; Gamidov 2017;
Gopinath 2013; Kumamoto 1988; Martinez 2015; Mehni 2014;
Raigani 2014; Scott 1998; Sofikitis 2016; Zalata 1998) were three-
armed and eight (Azizollahi 2013; Balercia 2005; Boonyarangkul
2015; Haje 2015; Omu 2008; Poveda 2013; Safarinejad 2009; Wong
2002) were four-armed.
The duration of the treatment period ranged from three weeks with
a three-week follow up (Dawson 1990) to 12 months treatment
(Ener 2016). The longest follow-up periods were in the studies by
Blomberg Jensen and Safarinjad with respectively a five-month
(Blomberg Jensen 2018) and six and a half-month (Safarinejad
2009a) treatment duration and both with 14 months of follow-
up. Seven studies reporting on either live birth rate or clinical
pregnancy rate, only mentioned follow-up consultations during
their treatment, however they did not report the length of follow-
up aQer treatment (Azizollahi 2013; Attallah 2013; Barekat 2016;
Busetto 2018; Kessopoulou 1995; Omu 1998; Suleiman 1996).
Funding sources were stated by 23 studies (Barekat 2016; Blomberg
Jensen 2018; Busetto 2018; Conquer 2000; Deng 2014; Eslamian
2013; Haghighian 2015; Kessopoulou 1995; Lenzi 2003; Lombardo
2002; Martinez-Soto 2010; Mehni 2014; Micic 2017; Nadjarzadeh
2011; Omu 1998; Peivandi 2010; Poveda 2013; Raigani 2014; Rolf
1999; Safarinejad 2012; Sharifzadeh 2016; Wang 2010; Zavaczki
2003). Five of these studies stated that funding was from a
commercial source (Busetto 2018; Conquer 2000; Martinez-Soto
2010; Micic 2017; Safarinejad 2012), and the remaining 18 obtained
funding through non-commercial avenues or university grants. Five
studies reported specifically no funding (Cyrus 2015; Gopinath
2013; Haje 2015; Lombardo 2002; Pourmand 2014). Thirty-three
studies did not mention any funding sources.
Participants
The 61 studies included 6264 subfertile men, 3803 in the
intervention groups and 2461 men in the control groups. The age
range of the participants was 18 to 65 years. Studies included
couples who had attended a fertility clinic, with a fertile partner
and had been trying to conceive with regular intercourse for
over one year. Most men in the included studies had a deficient
level of spermatozoa in the seminal fluid (oligospermia) or a
low motility of sperm in the seminal fluid (asthenospermia). Two
studies also included fertile (Wong 2002) or normospermic men
(Exposito 2016) with subgroup analysis. Studies excluded men with
any inflammatory disease, antibody problems or chromosomal
problems; and most studies stated that they did not enrol men who
smoked, took any additional medication or drank alcohol.
Two studies enrolled men with varicocele (Busetto 2018; Cavallini
2004), six studies enrolled men post-varicocelectomy (Azizollahi
2013; Barekat 2016; Cyrus 2015; Ener 2016; Gamidov 2017;
Pourmand 2014), and one study enrolled men with chronic
prostatitis (Sivkov 2011). Four studies (Exposito 2016; Kessopoulou
1995; Sigman 2006; Tremellen 2007) enrolled men who, as part of a
couple, were undergoing in vitro fertilisation (IVF)/intracytoplasmic
sperm injection (ICSI), and one study (Attallah 2013) enrolled men
who were part of a couple undergoing intrauterine insemination
(IUI).
Further details of inclusion and exclusion criteria are available in
Characteristics of included studies.
Interventions
A wide variety of antioxidants were used in the included studies.
Comparisons covered antioxidants versus placebo or no treatment
and head-to-head comparisons (antioxidant versus antioxidant)
The comparison 'antioxidants versus placebo or no treatment'
included the following antioxidants: arginine, carnitines (L-
carnitine, L-acetyl carnitine, L-carnitine plus L-acetyl carnitine),
carotenoids (β-carotene), coenzyme Q10 (CoQ10), cysteines
(ethylcysteine and N-acetylcysteine (NAC)), folic acid, magnesium,
polyunsaturated fatty acids (PUFAs) (alpha-lipoic-acid and
docosahexaenoic acid (DHA)), resveratrol, selenium, vitamin B,
vitamin C, vitamin D with calcium, vitamin E and zinc. Combined
antioxidants were used in 10 studies. They were labelled as
Proxeed Plus (Busetto 2018; Micic 2017), Menevit (Tremellen
2007), Selznic (Sivkov 2011), SpermActin-forte (Gamidov 2017)
and Spermotrend (Poveda 2013). Four of these 10 studies used
combined antioxidants without any brand name or labelling; "N-
acetylcysteine (NAC) with vitamins and micronutrients" (Galatioto
2008), selenium plus vitamin A/C/E (Scott 1998), a fixed dose
combination (FDC) of coenzyme Q10, L-carnitine, lycopene and zinc
(Gopinath 2013), and "essential fatty acid (EFA) mixture combined
with α-tocopherol (vitamin E) and β-carotene, acetylcysteine and
other antioxidants" (Zalata 1998).
The second comparison, head-to-head, included seven studies. The
head-to-head comparisons were included in an attempt to assess
whether one antioxidant was more eLective than another.They
looked at eLects of ethylcysteine versus vitamin E, zinc versus folic
acid versus zinc plus folic acid, L-carnitine versus L-acetyl carnitine
versus L-carnitine plus L-acetyl carnitine, vitamin E plus selenium
versus vitamin B, L-carnitine plus acetyl-L-carnitine versus vitamin
E plus vitamin C, L-carnitine versus vitamin E plus vitamin C, vitamin
D plus calcium versus vitamin C plus vitamin E, L-carnitine plus
vitamin E versus vitamin E, acetyl-cysteine versus essential fatty
acid (EFA) plus α-tocopherol (vitamin E) plus β-carotene versus
acetylcysteine plus EFA plus antioxidants.
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In summary:
• 26/61 studies compared antioxidants with placebo;• 7/61 studies compared antioxidants with no treatment;• 7/61 studies compared one antioxidant with another
antioxidant (head-to-head);• 21/61 multi-arm studies: 16 of these compared antioxidants
versus placebo and five compared antioxidants versus no
treatment.
Outcomes
The primary outcome for this review was as follows.
• Live birth per couple. Seven studies reported data for live
birth in the antioxidant versus placebo or no treatment
comparison (Balercia 2005; Balercia 2009; Blomberg Jensen
2018; Kessopoulou 1995; Omu 1998; Suleiman 1996; Tremellen
2007). One of these studies could also be included in the head-
to-head comparison of live birth rate (Balercia 2005).
Secondary outcomes for this review were as follows.
• Clinical pregnancy rate per couple, as reported by 11 studies
in the antioxidant versus placebo or no treatment comparison
(Attallah 2013; Azizollahi 2013; Balercia 2005; Balercia 2009;
Barekat 2016; Busetto 2018; Kessopoulou 1995; Omu 1998;
Suleiman 1996; Tremellen 2007; Zavaczki 2003). One of these
studies could also be included in the head-to-head comparison
of clinical pregnancy rate (Balercia 2005); one more study in the
head-to-head comparison reported on clinical pregnancy rate
(Deng 2014). Data for biochemical and undefined pregnancy can
be seen in Table 1.
• Adverse events (miscarriage, gastrointestinal upsets, euphoria
and ectopic pregnancy) were reported by 13 studies
(Busetto 2018; Cavallini 2004; Gamidov 2017; Gopinath 2013;
Kessopoulou 1995; Omu 1998; Pourmand 2014; Safarinejad
2009a; Sharifzadeh 2016; Sigman 2006; Suleiman 1996;
Tremellen 2007; Zavaczki 2003) in the antioxidant versus
placebo or no treatment comparison. Adverse events were not
reported as an outcome in any of the studies in the head-to-
head comparisons, except that the study by Li (Li 2005) reported
that no side eLects were found in either the treatment or control
groups.• DNA fragmentation was reported by six studies (Barekat 2016;
Boonyarangkul 2015; Gamidov 2017; Greco 2005; Martinez-Soto
2010; Raigani 2014), comparing antioxidants versus placebo or
no treatment. Data from two studies were not usable because
of the use of COMET assay and DNA tail length (Boonyarangkul
2015), or use of medians with interquartile ranges (Gamidov
2017)(Analysis 1.10). This outcome was not reported in the head-
to-head comparison.• Total sperm motility at three months or less was reported by
16 studies in the antioxidants versus placebo or no treatment
comparison (Azizollahi 2013; Balercia 2005; Barekat 2016;
Conquer 2000; Dimitriadis 2010; Ener 2016; Gopinath 2013;
Greco 2005; Martinez-Soto 2010; Morgante 2010; Nadjarzadeh
2011; Omu 2008; Peivandi 2010; Scott 1998; Sigman 2006;
Zavaczki 2003), by eight studies in the head-to-head comparison
(Akiyama 1999; Azizollahi 2013; Balercia 2005; Conquer 2000;
Dawson 1990; Li 2005; Omu 2008; Scott 1998).
• Total sperm motility at six months was reported by 13 studies
in the antioxidants versus placebo or no treatment comparison
(Azizollahi 2013; Balercia 2005; Balercia 2009; Blomberg Jensen
2018; Busetto 2018; Ener 2016; Gopinath 2013; Lenzi 2004;
Safarinejad 2009; Safarinejad 2009a; Safarinejad 2012; Sigman
2006; Suleiman 1996). Three studies reported this in the head-
to-head comparison (Azizollahi 2013; Balercia 2005; Safarinejad
2009).• Total sperm motility at nine months or more was reported
by five studies in the antioxidants versus placebo or no
treatment comparison (Balercia 2005; Balercia 2009; Ener 2016;
Safarinejad 2009a; Safarinejad 2012). One study reported this in
the head-to-head comparison (Balercia 2005).• Progressive sperm motility at three months or less was
reported by 14 studies in the antioxidants versus placebo
or no treatment comparison (Attallah 2013; Azizollahi 2013;
Balercia 2005; Boonyarangkul 2015; Cyrus 2015; Dawson 1990;
Haghighian 2015; Martinez-Soto 2010; Mehni 2014; Morgante
2010; Nadjarzadeh 2011; Peivandi 2010; Rolf 1999; Sharifzadeh
2016) Five studies reported this in the head-to-head comparison
(Balercia 2005; Deng 2014; Li 2005; Li 2005a; Wang 2010).• Progressive sperm motility at six months was reported by five
studies in the antioxidants versus placebo or no treatment
comparison (Azizollahi 2013; Balercia 2005; Balercia 2009;
Blomberg Jensen 2018; Boonyarangkul 2015). One study
reported this in the head-to-head comparison (Balercia 2005).• Progressive sperm motility at nine months or more was reported
by two studies in the antioxidants versus placebo or no
treatment comparison (Balercia 2005; Balercia 2009). One study
reported this in the head-to-head comparison (Balercia 2005).• Sperm concentration at three months or less was reported
by 21 studies in the antioxidants versus placebo or no
treatment comparison (Attallah 2013; Azizollahi 2013; Balercia
2005; Barekat 2016; Boonyarangkul 2015; Conquer 2000; Cyrus
2015; Dimitriadis 2010; Ener 2016; Gopinath 2013; Greco 2005;
Haghighian 2015; Martinez-Soto 2010; Mehni 2014; Morgante
2010; Nadjarzadeh 2011; Peivandi 2010; Rolf 1999; Scott 1998;
Sharifzadeh 2016; Zavaczki 2003), and seven in the head-to-
head comparison (Akiyama 1999; Azizollahi 2013; Balercia 2005;
Conquer 2000; Li 2005a; Scott 1998; Wang 2010) .• Sperm concentration at six months was reported as an outcome
by 11 studies in the antioxidants versus placebo or no treatment
comparison (Azizollahi 2013; Balercia 2005; Balercia 2009;
Boonyarangkul 2015; Busetto 2018; Ener 2016; Gopinath 2013;
Lenzi 2004; Safarinejad 2009; Safarinejad 2009a; Safarinejad
2012), and three studies in the head-to-head comparison
(Azizollahi 2013; Balercia 2005; Safarinejad 2009) .• Sperm concentration at nine months or more was reported
by five studies in the antioxidants versus placebo or no
treatment comparison (Balercia 2005; Balercia 2009; Ener 2016;
Safarinejad 2009a; Safarinejad 2012), and one study in the head-
to-head comparison (Balercia 2005).
Data were extracted from 44 of the included studies. The 17
remaining studies either did not report any data or the continuous
data were reported in medians or ranges (Biagiotti 2003; Eslamian
2013; Exposito 2016; Galatioto 2008; Haje 2015; Kumamoto 1988;
Lenzi 2003; Lombardo 2002; Martinez 2015; Micic 2017; Nozha 2001;
Poveda 2013; Pryor 1978; Sivkov 2011; Sofikitis 2016; Wong 2002;
Zalata 1998). Another study reported data for a treatment duration
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of three to six months, but did not specify this any further and
therefore data could not be used in the meta-analysis (Haje 2015).
See Characteristics of included studies and the analyses 'data
not usable for meta-analysis'(Analysis 1.10; Analysis 1.12; Analysis
1.14; Analysis 1.18; Analysis 1.20; Analysis 1.24; Analysis 1.26;
Analysis 2.5; Analysis 2.12). Table 2 also described the outcomes
and conclusions of all included studies. Attempts were made to
contact all authors of the included studies for further details and
clarification.
Excluded studies
We retrieved the full text of studies that were identified as
potentially eligible (see Figure 1). In this update we excluded 22
studies (28 full-text articles) and two ongoing studies, in total we
excluded 59 studies. The most common reasons for exclusions were
ineligible due to use of a diLerent intervention, study design or
population. See details in Characteristics of excluded studies.
In summary:
• 21/59 ineligible based on diLerent intervention such as an
added sperm wash or herbal extract; also pentoxifylline studies
were excluded;• 13/59 ineligible based on diLerent study design, they were not
randomised;• 15/59 ineligible based on diLerent population, either
normospermic men or used the exact same population as other
already included studies; in the search of this update; three of
the studies were already included in the previous 2014 update;• 3/59 ineligible based on diLerent outcome;• 5/59 ineligible based on diLerent control group, fertile men
without treatment;• 2 previously 'ongoing studies' were placed in excluded studies
because they were terminated due to insuLicient recruiting
(NCT01075334; NCT01520584).
Ongoing studies
Eight studies were 'ongoing studies' in the 2014 update. In the
current update, only one of the eight previously ongoing studies
was included (Blomberg Jensen 2018).The former ongoing study
Righospitalet 2011 was a duplicate registration of this study.
The former ongoing study AGUNCO 2012 (NCT01560065) became
the article Gulino 2016, which was excluded because of the use
of a wrong comparator with fertile men of a subfertile couple
undergoing IVF. The former ongoing studies Sadeghi 2008 and
Sadeghi 2009 became respectively the already previously included
study Nadjarzadeh 2011 and excluded study Nadjarzadeh 2014.
Three studies remained as ongoing studies (CTRI/2013/02/003431;
NCT00975115; NCT01828710) with the status of still recruiting.
We added nine new ongoing studies (DRKS00011616;
IRCT2016111830947N1; IRCT2017012432153N1; NCT01407432;
NCT01846325; NCT02310087; NCT02421887; NCT03104998;
NCT03337360). In this 2019 update, a total of 12 studies are
classified as 'ongoing studies'.
Awaiting classification
Six studies were 'awaiting classification' in the 2014 update of
this review. One study was included in the 2018 update (Gopinath
2013). The remaining studies awaiting classification were all found
to be ineligible aQer screening of title and abstract or excluded
aQer reading the full text. The former Anarte 2013a conference
abstract was the same study as the conference abstract Anarte
2013, which was already excluded in the 2014 update. Nadjarzadeh
2014 was excluded due to using the same study population as
already included Nadjarzadeh 2011. The article of Nashivochnikova
2014 was dismissed aQer a quick translation from Russian of the
methods section due to the use of a non-randomised design.
Nematollahi-Mahani 2014 was excluded due to reporting outcomes
not of interest to our review; they reported on seminal antioxidant
levels and hormone levels but not on semen parameters or
pregnancy outcomes. Furthermore, they used the same study
population as the included Azizollahi 2013.
One article from the updated 2018 search was placed in Studies
awaiting classification, waiting for an answer from the authors aQer
requesting the full text (Goswami 2015).
Risk of bias in included studies
See Figure 2 for a summary of risk of bias in individual studies, and
Figure 3 for a summary of each risk of bias item across all included
studies.
Allocation
Sequence generation
All of the 61 included studies were randomised, six of these were
cross-over studies (Akiyama 1999; Kessopoulou 1995; Lenzi 2003;
Lombardo 2002; Peivandi 2010; Pryor 1978) and the remaining
studies were parallel design.
Only 27 studies described their methods of sequence generation
and were rated as low risk in this domain (Azizollahi 2013; Balercia
2005; Barekat 2016; Biagiotti 2003; Blomberg Jensen 2018; Busetto
2018; Cavallini 2004; Cyrus 2015; Eslamian 2013; Exposito 2016;
Galatioto 2008; Gamidov 2017; Gopinath 2013; Haghighian 2015;
Kessopoulou 1995; Martinez-Soto 2010; Micic 2017; Nadjarzadeh
2011; Rolf 1999; Safarinejad 2009; Safarinejad 2009a; Safarinejad
2012; Scott 1998; Sharifzadeh 2016; Sigman 2006; Tremellen 2007;
Wong 2002) (see Figure 2 and Figure 3).
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Figure 2.   Methodological risk of bias graph: review authors' judgements about each methodological bias item
presented as percentages across all included studies.
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Figure 3.   Methodological risk of bias summary: review authors' judgements about each methodological bias item
for each included study.
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Figure 3.   (Continued)
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The remaining 34 studies were rated as unclear risk (Akiyama 1999;
Attallah 2013; Balercia 2009; Boonyarangkul 2015; Conquer 2000;
Dawson 1990; Deng 2014; Dimitriadis 2010; Ener 2016; Greco 2005;
Haje 2015; Kumamoto 1988; Lenzi 2003; Lenzi 2004; Li 2005; Li
2005a; Lombardo 2002; Martinez 2015; Mehni 2014; Morgante 2010;
Nozha 2001; Omu 1998; Omu 2008; Peivandi 2010; Pourmand 2014;
Poveda 2013; Pryor 1978; Raigani 2014; Sivkov 2011; Sofikitis 2016;
Suleiman 1996; Wang 2010; Zalata 1998; Zavaczki 2003).
The predominant method of randomisation was by computer-
generated blocks. Tremellen 2007 reported a 2:1 ratio
randomisation schedule, Cyrus 2015 reported a 3:2 randomisation
schedule, Li 2005 appeared to have a blocked 3:2 allocation, and
Micic 2017 appeared to have a 5:2 ratio.
Allocation concealment
The methods of allocation concealment were generally quite poorly
described in the included studies. Twenty studies described both
their methods of randomisation and allocation concealment and
were rated as low risk in this domain (Azizollahi 2013; Balercia
2005; Blomberg Jensen 2018; Busetto 2018; Cavallini 2004; Cyrus
2015; Eslamian 2013; Exposito 2016; Galatioto 2008; Gopinath 2013;
Haghighian 2015; Martinez-Soto 2010; Nadjarzadeh 2011; Peivandi
2010; Safarinejad 2009; Safarinejad 2012; Sharifzadeh 2016; Sigman
2006; Tremellen 2007; Wong 2002).
There were two studies with a high risk of allocation concealment:
one due to the use of a randomisation table by the doctor
(Barekat 2016); and one due to great baseline imbalance for
sperm parameters between the intervention and control group
(Boonyarangkul 2015)
The remaining 39 studies were rated as unclear risk (Akiyama
1999; Attallah 2013; Balercia 2009; Biagiotti 2003; Conquer 2000;
Dawson 1990; Deng 2014; Dimitriadis 2010; Ener 2016; Gamidov
2017; Greco 2005; Haje 2015; Kessopoulou 1995; Kumamoto 1988;
Lenzi 2003; Lenzi 2004; Li 2005; Li 2005a; Lombardo 2002; Martinez
2015; Mehni 2014; Micic 2017; Morgante 2010; Nozha 2001; Omu
1998; Omu 2008; Pourmand 2014; Poveda 2013; Pryor 1978; Raigani
2014; Rolf 1999; Safarinejad 2009a; Scott 1998; Sivkov 2011; Sofikitis
2016; Suleiman 1996; Wang 2010; Zalata 1998; Zavaczki 2003). The
methods of allocation concealment included anonymous coloured
boxes, sealed opaque envelopes, and numbered bottles.
Blinding
Performance bias
Thirty-four studies were described as randomised, double-blind
controlled trials in which clinicians and participants were blinded
(Azizollahi 2013; Balercia 2005; Balercia 2009; Blomberg Jensen
2018; Boonyarangkul 2015; Busetto 2018; Cavallini 2004; Cyrus
2015; Dawson 1990; Exposito 2016; Gopinath 2013; Greco 2005;
Kessopoulou 1995; Kumamoto 1988; Lenzi 2003; Lenzi 2004;
Lombardo 2002; Martinez 2015; Martinez-Soto 2010; Mehni 2014;
Micic 2017; Nadjarzadeh 2011; Poveda 2013; Pryor 1978; Raigani
2014; Rolf 1999; Safarinejad 2009; Safarinejad 2009a; Safarinejad
2012; Scott 1998; Sharifzadeh 2016; Sigman 2006; Tremellen 2007;
Wong 2002). In two studies investigators, clinicians and participants
were blinded (Eslamian 2013; Haghighian 2015). A total of thirty-six
studies were rated as low risk (see Figure 2 and Figure 3). In one of
the low risk studies (Dawson 1990), it was stated that a placebo was
used as the control but only the participants were blinded.
FiQeen other studies were rated high risk (Attallah 2013; Barekat
2016; Biagiotti 2003; Deng 2014; Dimitriadis 2010; Ener 2016;
Galatioto 2008; Gamidov 2017; Morgante 2010; Nozha 2001;
Omu 1998; Omu 2008; Pourmand 2014; Sofikitis 2016; Suleiman
1996;) Of these high-risk studies, 12 studies used 'no treatment'
as their comparator. Two studies were head-to-head trials and
open-labelled (Deng 2014; Nozha 2001). The double-blinded trial
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Suleiman 1996 used a placebo, however they reported that if
a couple became pregnant then "the treatment was stopped;
otherwise it was continued for 6 months. The placebo was given
for 6 months" This does appear that they did not stop the placebo.
This could suggest that the investigators had knowledge of whether
the participants were in the placebo or antioxidant group, therefore
this study was rated as high risk.
Nine studies did not give a statement regarding blinding and were
rated as unclear risk of bias (Akiyama 1999; Conquer 2000; Haje
2015; Li 2005; Li 2005a; Sivkov 2011; Wang 2010; Zalata 1998;
Zavaczki 2003). Three of these studies used a placebo as the control
but did not discuss blinding (Conquer 2000; Zavaczki 2003; Sivkov
2011).
Detection bias
The methods of blinding outcome assessment were generally
poorly described in the included studies. Only 19 studies reported
this aspect of blinding and were therefore classified as low risk
(Azizollahi 2013; Balercia 2005; Barekat 2016; Blomberg Jensen
2018; Busetto 2018; Cavallini 2004; Cyrus 2015; Eslamian 2013;
Galatioto 2008; Gamidov 2017; Gopinath 2013; Haghighian 2015;
Martinez 2015; Micic 2017; Nadjarzadeh 2011; Peivandi 2010;
Raigani 2014; Safarinejad 2009a; Safarinejad 2012).
The other 42 studies were rated as unclear risk due to the lack of
information (Akiyama 1999; Attallah 2013; Balercia 2009; Biagiotti
2003; Boonyarangkul 2015; Conquer 2000; Dawson 1990; Deng
2014; Dimitriadis 2010; Ener 2016; Exposito 2016; Greco 2005; Haje
2015; Kessopoulou 1995; Kumamoto 1988; Lenzi 2003; Lenzi 2004;
Li 2005; Li 2005a; Lombardo 2002; Martinez-Soto 2010; Mehni 2014;
Morgante 2010; Nozha 2001; Omu 1998; Omu 2008; Pourmand
2014; Poveda 2013; Pryor 1978; Rolf 1999; Safarinejad 2009; Scott
1998; Sharifzadeh 2016; Sigman 2006; Sivkov 2011; Sofikitis 2016;
Suleiman 1996; Tremellen 2007; Wang 2010; Wong 2002; Zalata
1998; Zavaczki 2003).
Incomplete outcome data
Thirty-four studies were rated as low risk for incomplete outcome
data (Akiyama 1999; Azizollahi 2013; Balercia 2005; Balercia 2009;
Blomberg Jensen 2018; Busetto 2018; Conquer 2000; Cyrus 2015;
Dawson 1990; Eslamian 2013; Exposito 2016; Gopinath 2013;
Galatioto 2008; Gamidov 2017; Greco 2005; Haghighian 2015; Lenzi
2003; Lenzi 2004; Li 2005; Martinez 2015; Micic 2017; Nadjarzadeh
2011; Omu 2008; Pourmand 2014; Rolf 1999; Safarinejad 2009;
Safarinejad 2009a; Safarinejad 2012; Scott 1998; Sharifzadeh 2016;
Sigman 2006; Tremellen 2007; Wang 2010; Zavaczki 2003).
Twenty-four studies were rated as unclear, most of them did report
the number of drop outs, but did not provide the reasons (Attallah
2013; Biagiotti 2003; Boonyarangkul 2015; Deng 2014; Dimitriadis
2010; Ener 2016; Haje 2015; Kessopoulou 1995; Kumamoto 1988; Li
2005a; Lombardo 2002; Martinez-Soto 2010; Mehni 2014; Morgante
2010; Nozha 2001; Omu 1998; Peivandi 2010; Poveda 2013; Pryor
1978; Raigani 2014; Sivkov 2011; Sofikitis 2016; Wong 2002; Zalata
1998).
Three studies were rated as high risk of attrition bias due to lack of
compliance directly related to treatment and high drop-out rates
(20" to 42%) (Barekat 2016; Cavallini 2004; Suleiman 1996).
Only five studies (Balercia 2009; Blomberg Jensen 2018; Busetto
2018; Galatioto 2008; Pryor 1978) actually stated that they used
intention-to-treat (ITT) in their analysis. However, Pryor 1978 stated
they had used ITT but the data were not presented. Most of
the other included studies accounted for the participants that
withdrew from their studies and then analysed the groups in an ITT.
Three studies (Azizollahi 2013; Barekat 2016; Wang 2010) did not
use ITT, however the numbers of dropouts were given for each
intervention and control group and therefore we were able to
use ITT in the data analysis by making the assumption of no
event for the binary outcomes. No imputation was carried out on
the continuous outcome data these were analysed as they were
reported in the studies.
Six studies had over 20% withdrawal from their studies. Cavallini
2004 had a 30% dropout rate and reasons were provided for
only 53 out of the 55 dropouts; these reasons included refusal
due to the chance of taking a placebo and preference for
assisted reproduction techniques (ARP). There also remained some
confusion in this study on the total numbers randomised and
analysed. Azizollahi 2013 had a 30% dropout rate; Li 2005a;
Suleiman 1996, Nadjarzadeh 2011, and Barekat 2016 had slightly
over 20% withdrawal from their studies.
One study (Suleiman 1996) had a large imbalance in numbers.
There were found to be 52 in the treatment group and 35 in
the placebo once the code had been broken at the end of the
study. There was no indication of how the randomisation was
performed. The reasons given for dropout were only accounted for
broadly: many couples had leQ the region and some simply failed
to continue, no numbers were given for individual dropout reasons
(see Figure 2 and Figure 3). The numbers of participants that were
initially randomised to each group were not available, so ITT for the
dichotomous outcomes was not possible.
Selective reporting
Study protocols were only available for six out of the 61 included
studies (Azizollahi 2013; Blomberg Jensen 2018; Cyrus 2015;
Exposito 2016; Raigani 2014; Sharifzadeh 2016).
Two studies were rated at high risk of reporting bias; Kumamoto
1988 performed subgroup analysis post-treatment and Safarinejad
2012 did not pre-specify outcomes. Six studies were rated as
unclear risk as they were conference abstracts (Attallah 2013;
Biagiotti 2003; Lombardo 2002; Micic 2017; Sofikitis 2016; Zalata
1998), and two studies were rated as unclear as it was possible that
these were two publications of the same study that were reporting
on diLerent intervention arms (Li 2005; Li 2005a). Obtaining help
with Chinese translation did not clarify this and attempts to contact
the authors were unsuccessful. The remaining 45 studies were rated
as unclear risk in this domain because there were no published
study protocols available.
Other potential sources of bias
One study reported great baseline imbalance for sperm parameters
between the intervention and control group (Boonyarangkul 2015).
E9ects of interventions
See: Summary of findings for the main comparison Antioxidants
compared to placebo or no treatment for patients with male
subfertility
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1 Antioxidants versus placebo or no treatment (natural
conception and undergoing fertility treatment)
1.1 Live birth; type of antioxidant
See Analysis 1.1 and Figure 4.
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Figure 4.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type
of antioxidant.
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Only seven studies reported on live birth; four of these had
methodological inadequacies as they did not describe their
methods of randomisation or allocation concealment. Three
studies reported that all clinical pregnancies led to a live birth
(Balercia 2005; Balercia 2009; Kessopoulou 1995). The meta-
analysis of the seven studies showed that antioxidants were
associated with an increased live birth rate compared with placebo
or no treatment (Peto odds ratio (OR) 1.79, 95% confidence interval
(CI) 1.20 to 2.67, 750 men, 7 RCTs, P = 0.005, I2 = 40%, low-
quality evidence). This meant that within this studied population
of subfertile men with a baseline expected live birth rate of 12%,
use of an antioxidant increased this rate to between 14% and 26%
(Summary of findings for the main comparison).
1.1.1 One study reported on this outcome comparing carnitines
versus placebo (Balercia 2005). There was no evidence of increased
live birth rate (Peto OR 1.00, 95% CI 0.24 to 4.25; 60 men, P = 1.00,
I2 = not applicable).
1.1.2 One study reported on this outcome comparing coenzyme
Q10 versus placebo (Balercia 2009). There was no evidence of
increased live birth rate (Peto OR 2.16, 95% CI 0.53 to 8.82; 60 men,
P = 0.28, I2 = not applicable).
1.1.3 One study reported on this outcome comparing vitamin D
plus calcium versus placebo (Blomberg Jensen 2018). There was no
evidence of increased live birth rate (Peto OR 1.03, 95% CI 0.59 to
1.80, 330 men, P = 0.93, I2 = not applicable).
1.1.4 Two studies reported on this outcome comparing vitamin
E versus placebo (Kessopoulou 1995; Suleiman 1996). There was
evidence of increased live birth rate (Peto OR 8.51, 95% CI 2.36 to
30.70, 140 men, 2 RCTs, P = 0.001, I2 = 0%).
1.1.5 One study reported on this outcome comparing zinc versus
no treatment (Omu 1998). There was no evidence of increased live
birth rate (Peto OR 3.74, 95% CI 1.02 to 13.74, 100 men, P = 0.05, I2
= not applicable).
1.1.6 One study reported on this outcome comparing combined
antioxidants versus placebo (Tremellen 2007). There was evidence
of increased live birth rate (Peto OR 3.42, 95% CI 1.15 to 10.13, 60
men, P = 0.03 I2 = not applicable). The results from this study also
included three sets of twins in the combined antioxidant group and
nil in the placebo group. Each twin birth was counted as one event
as stated in the methods section in the review protocol.
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences Chi2 = 12.72, P = 0.03).
1.2 Live birth; placebo or no treatment
Only one study (Omu 1998) used 'no treatment' as the control.
When this study was removed from the analysis, evidence of
increased live birth remained when compared with placebo only
(Peto OR 1.65, 95% CI 1.08 to 2.52, 650 men, 6 RCTs, P = 0.02, I2 =
41%).
There was no evidence that diLerent antioxidants had diLering
eLects (test for subgroup diLerences: Chi2 = 1.05, P = 0.31).
1.3 Live birth; in vitro fertilisation (IVF)/intracytoplasmic sperm
injection (ICSI)
See Analysis 1.3.
There were only two studies in women undergoing IVF/ICSI
which reported on live birth (Kessopoulou 1995; Tremellen 2007).
There was evidence of increased live birth rate, in those couples
undergoing IVF/ICSI, with antioxidant use when compared with
placebo (Peto OR 3.61, 95% CI 1.27 to 10.29, 2 RCTs, 90 men, P = 0.02,
I2 = 0%).
Sensitivity analysis for studies reporting live birth and clinical
pregnancy
The seven studies that reported live birth had an OR for live birth of
1.79, and in these same studies the OR for clinical pregnancy was
2.96. When we pooled all 11 studies reporting the clinical pregnancy
rate there was a comparable OR 2.97. This suggest that there is no
overestimation of live birth. However, the true eLect is unknown
unless all studies reporting on clinical pregnancy rate also reported
on live birth rate.
Sensitivity analysis for studies rated as high risk of bias
When the two studies (Omu 1998; Suleiman 1996) rated with a high
risk of bias were removed from the analysis, there was no evidence
of association between antioxidants and an increased live birth rate
when compared with placebo (Peto OR 1.38, 95% CI 0.89 to 2.16;
participants = 540 men, 5 RCTs, P = 0.15, I2 = 0%).
1.4 Live birth; as-treated analysis
See Analysis 1.4.
When an as-treated analysis was done, there was evidence of
increased live birth rate when antioxidants were compared with
placebo (Peto OR 1.71, 95% CI 1.13 to 2.58, 649 men, 7 RCTs, P = 0.01,
I2 = 26%).
1.5 Clinical pregnancy; type of antioxidant
See Analysis 1.5 and Figure 5 and Figure 6.
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Figure 5.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Clinical
pregnancy; type of antioxidant.
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Figure 5.   (Continued)
 
 
Figure 6.   Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Clinical
pregnancy; type of antioxidant.
 
Only 11 studies (with 15 treatment arms) reported on clinical
pregnancy rate; four of these had methodological inadequacies
with high risk of bias for methods of randomisation, allocation
concealment or blinding. The meta-analysis of these studies
showed that antioxidants were associated with an increased
clinical pregnancy rate when compared to placebo or no treatment
(Peto OR 2.97, 95% CI 1.91 to 4.63, 786 men, 15 RCTs, P < 0.001, I2 =
0%, low-quality evidence). This meant that within this population
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of subfertile men with the expected clinical pregnancy rate of 7%,
use of an antioxidant increased this rate to between 12% and 26%
(Summary of findings for the main comparison).
1.5.1 One study reported on this outcome comparing carnitines
versus placebo (Balercia 2005). There was no evidence of increased
clinical pregnancy rate (Peto OR 1.00, 95% CI 0.24 to 4.25, 60 men,
3 RCTs, P = 0.76, I2 = not applicable).
1.5.2 One study reported on this outcome comparing coenzyme
Q10 versus placebo (Balercia 2009). There was no evidence of
increased clinical pregnancy rate (Peto OR 2.16, 95% CI 0.53 to 8.82,
60 men, 1 RCT, P = 0.28, I2 = not applicable).
1.5.3 One study reported on this outcome comparing folic acid
versus placebo (Azizollahi 2013). There was no OR estimable due to
the occurrence of zero pregnancies in both groups.
1.5.4 One study reported on this outcome comparing magnesium
versus placebo (Zavaczki 2003). There was no evidence of increased
clinical pregnancy rate (Peto OR 8.73, 95% CI 0.17 to 445.08, 1 RCT,
26 men, P = 0.28, I2 = not applicable).
1.5.5 Two studies reported on this outcome comparing N-
acetylcysteine versus placebo or no treatment (Attallah 2013;
Barekat 2016). There was no evidence of increased clinical
pregnancy rate (Peto OR 2.00, 95% CI 0.71 to 5.63, 100 men, 2 RCTs,
P = 0.19, I2 = 0%).
1.5.6 Two studies reported on this outcome comparing vitamin E
versus placebo (Kessopoulou 1995; Suleiman 1996). There was an
increased clinical pregnancy rate (Peto OR 6.71, 95% CI 1.98 to
22.69, 2 RCTs, 117 men, P = 0.002, I2 = 0%).
1.5.7 Two studies reported on this outcome comparing zinc versus
placebo or no treatment (Azizollahi 2013; Omu 1998). There was
an increased clinical pregnancy rate (Peto OR 4.43, 95% CI 1.39 to
14.14, 2 RCTs, 153 men, P = 0.01, I2 = 0%).
1.5.8 One study reported on this outcome comparing zinc with
folic acid versus placebo (Azizollahi 2013). There was no evidence
of increased clinical pregnancy rate (Peto OR 3.86, 95% CI 0.15 to
99.84, 53 men, 1 RCT, P = 0.42, I2 = not applicable).
1.5.9 Two studies reported on this outcome comparing combined
antioxidants versus placebo (Busetto 2018; Tremellen 2007). There
was an increased clinical pregnancy rate (Peto OR 3.19, 95% CI 1.44
to 7.08, 164 men, 2 RCTs, P = 0.004, I2 = 0%).
There was no evidence that diLerent antioxidants had diLering
eLects (test for subgroup diLerences: Chi2 = 5.45, P = 0.61).
Sensitivity analysis for studies rated as high risk of bias
When the four studies rated with a high risk of bias, were
removed from the analysis there remained an association between
antioxidants and an increased clinical pregnancy rate (Peto OR 2.57,
95% CI 1.42 to 4.67, 499 men, 7 RCTs, P = 0.002, I2 = 0%) (Attallah
2013; Barekat 2016; Omu 1998; Suleiman 1996).
Sensitivity analysis for studies enrolling men with varicocele
When the studies that enrolled men with varicocele or aQer
varicocelectomy were removed from the analysis, antioxidants
remained associated with increased clinical pregnancy rate when
compared to placebo or no treatment (Peto OR 2.76, 95% CI 1.65 to
4.59, 483 men, 15 RCTs, P < 0.0001, I2 = 0%) (Azizollahi 2013; Barekat
2016; Busetto 2018).
Sensitivity analysis for studies enrolling men in couples undergoing
intrauterine insemination (IUI)
Only one study Attallah 2013 reported on men in couples
undergoing IUI. When this study was removed from the analysis
there remained an association between the use of antioxidants and
increased clinical pregnancy rate when compared to no treatment
(OR 3.20, 95% CI 2.00 to 5.13, 726 men, 15 RCTs, P < 0.0001, I2 = 0%).
1.6 Clinical pregnancy: placebo or no treatment
See Analysis 1.6.
Antioxidants were associated with an increase in clinical pregnancy
rate in the studies that compared antioxidants with placebo (Peto
OR 3.01, 95% CI 1.81 to 5.03, 626 men, 9 RCTs, 13 intervention arms,
P < 0.001, I2 = 0%) (Azizollahi 2013; Balercia 2005; Balercia 2009;
Barekat 2016; Busetto 2018; Kessopoulou 1995; Suleiman 1996;
Tremellen 2007; Zavaczki 2003). Antioxidants were also associated
with an increase in clinical pregnancy rate in those studies that
compared antioxidants versus no treatment (Peto OR 2.84, 95% CI
1.16 to 6.96, 160 men, 2 RCTs, P = 0.02, I2 = 20%) (Attallah 2013; Omu
1998).
There was no evidence that diLerent antioxidants had diLering
eLects (test for subgroup diLerences: Chi2 = 0.01, P = 0.91).
1.7 Clinical pregnancy; IVF/ICSI
See Analysis 1.7.
There were only two studies in women undergoing IVF/ICSI which
reported on clinical pregnancy rate (Kessopoulou 1995;Tremellen
2007). There was no evidence of an increase in clinical pregnancy
in those couples undergoing IVF/ICSI, when antioxidant use was
compared with placebo (Peto OR 2.64, 95% CI 0.94 to 7.41, 90 men,
2 RCTs,P = 0.07, I2 = 0%).
1.8 Adverse events
See Analysis 1.8 and Figure 7.
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Figure 7.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.8 Adverse events.
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The only adverse events reported in the studies were miscarriage,
gastrointestinal disorders, euphoria and ectopic pregnancy.
1.8.1 Miscarriage. Only three studies reported on miscarriage and
the event rate was very low (eight miscarriages from 247 couples)
(Omu 1998; Suleiman 1996; Tremellen 2007). The analysis of
these three studies showed no evidence of increased miscarriage
between the use of antioxidants when compared to placebo or no
treatment (Peto OR 1.74, 95% CI 0.40 to 7.60, 3 RCTs, 247 men, P =
0.46, I2 = 0%, very low-quality evidence). This meant that within this
population of subfertile men, with an expected miscarriage rate of
2%, the chances of having a miscarriage lay between 1% and 13%
with the use of an antioxidant (Summary of findings for the main
comparison).
1.8.2 Gastrointestinal. The analysis of 11 studies showed an
increase between the use of antioxidants and gastrointestinal
upsets when compared to placebo or no treatment (Peto OR 2.51,
95% CI 1.25 to 5.03, 948 men, 11 RCTs, P =0.010, I2 = 50%, very
low-quality evidence) (Busetto 2018; Cavallini 2004; Gamidov 2017;
Gopinath 2013; Kessopoulou 1995; Pourmand 2014; Safarinejad
2009a; Sharifzadeh 2016; Sigman 2006; Tremellen 2007; Zavaczki
2003). However, the event rate was very low so we could not be
sure of these results. Three of these 11 studies reported no events,
therefore a Peto OR could not be estimated and a funnel plot was
not created.
1.8.3 Euphoria. Only one study (Cavallini 2004) reported on this
adverse event and there was no evidence of increased occurrence
of euphoria when antioxidants were compared to placebo (Peto OR
1.21, 95% CI 0.16 to 9.01,1 RCT, 86 men, P = 0.85, I2 = not applicable).
1.8.4 Ectopic pregnancy. Only one study (Tremellen 2007) reported
on this adverse event and there was no evidence of increase of
ectopic pregnancy when antioxidants were compared to placebo
(Peto OR 4.48, 95% CI 0.07 to 286.49,1 RCT, 60 men, P = 0.48, I2 = not
applicable).
It was unlikely that these last two adverse events, euphoria
and ectopic pregnancy, were related to intake of antioxidants
especially with the reported extreme low event rate. Therefore
these outcomes were not included in the 'Summary of findings'
table.
1.9 Sperm DNA fragmentation; type of antioxidant
See Analysis 1.9, Analysis 1.10 and Figure 8
 
Figure 8.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.9 Sperm DNA
fragmentation; type of antioxidant.
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Four studies reported on DNA fragmentation and found that there
was a lower DNA fragmentation rate when antioxidants were
compared with placebo or no treatment (mean diLerence (MD)
-5.00, 95% CI -12.61 to 2.61, 254 men, 4 RCTs, six intervention arms,
P < 0.0001, I2 = 89%) (Barekat 2016; Greco 2005; Martinez-Soto 2010;
Raigani 2014).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 43.69, P < 0.00001).
Sensitivity analysis for studies enrolling men with varicocele
In the literature it is reported that men with varicocele have higher
levels of DNA fragmentation. Only one study reported on men
with varicocele. When this study was removed from the analysis
there remained an association between the use of antioxidants and
lower DNA fragmentation rate when compared to no treatment (MD
-10.05, 95% CI -12.86 to -7.25, 219 men, 6 RCTs, P < 0.001, I2 = 74%)
(Barekat 2016).
1.10 Data not usable for meta-analysis
Two studies reported on DNA fragmentation, but could not be
included in the forest plots of the meta-analysis. Boonyarangkul
2015 because of the use of Comet assay, and Gamidov 2017 only
reported medians and interquartile ranges (Analysis 1.10). Both
studies showed an improvement (decrease) in DNA fragmentation
aQer the use of antioxidants. However, in Boonyarangkul 2015 this
was only in the (excluded) arm tamoxifen plus folate.
1.11 Total sperm motility at three months or less; type of
antioxidant
See Analysis 1.11 and Figure 9
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Figure 9.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.11 Total sperm
motility at 3 months or less; type of antioxidant.
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Figure 9.   (Continued)
 
We analysed this outcome using a random-eLects model and used
subtotals as pooling was not possible.
1.11.1 Five studies (seven intervention arms) comparing carnitines
with placebo or no treatment did not show an increase in
total sperm motility (Balercia 2005; Dimitriadis 2010; Lenzi 2003;
Peivandi 2010; Sigman 2006) (MD 11.91, 95% CI -0.85 to 24.66,
244 men, 5 RCTs, 7 intervention arms, P = 0.07, I2 = 97%). One
study (Lenzi 2003) did not report standard deviations (SDs); we
assumed the outcome to have an SD equal to the highest SD
from other studies within this analysis. The heterogeneity was
extremely high due to the fact that one study (Peivandi 2010) had
very small SDs when compared to data in the other studies but the
authors confirmed, when contacted, that they are indeed SDs and
not standard errors (SEs). When these two studies were removed
from the analysis carnitines did show an increase in total sperm
motility when compared with placebo or no treatment, with low
heterogeneity (MD 11.83, 95% CI 7.78 to 15.87, 128 men, 3 RCTs, 5
intervention arms, P < 0.00001, I2 = 0%).
1.11.2 Coenzyme Q10 did not show evidence of an increase in
total sperm motility compared with placebo (Nadjarzadeh 2011)
(MD 3.61, 95% CI -6.13 to 13.35, 47 men, 1 RCT, P = 0.47, I2 = not
applicable).
1.11.3 Folic acid did not show evidence of an increase in total sperm
motility compared with placebo (Azizollahi 2013) (MD 8.40, 95% CI
-5.81 to 22.61, 51 men, 1 RCT, P = 0.25, I2 = not applicable).
1.11.4 Magnesium did not show evidence of an increase in total
sperm motility compared with placebo (Zavaczki 2003) (MD 14.50,
95% CI -6.01 to 35.01, 20 men, 1 RCT, P = 0.17, I2 = not applicable).
1.11.5 N-acetylcysteine (NAC) did not show evidence of an increase
in total sperm motility compared with placebo (Barekat 2016) (MD
14.60, 95% CI 0.32 to 28.88, 35 men, P = 0.05, I2 = not applicable).
1.11.6 Two studies (three intervention arms) compared
polyunsaturated fatty acids (PUFAs) with placebo and did not show
evidence of an increase in total sperm motility (Conquer 2000;
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Martinez-Soto 2010) (MD -8.35, 95% CI -17.40 to 0.69, 64 men, 3 RCT,
P = 0.07, I2 = 0%).
1.11.7 Selenium did show an increase in total sperm motility
compared with placebo (Scott 1998) (MD 14.90, 95% CI 1.14 to 28.66,
34 men, 1 RCT, P = 0.03, I2 = not applicable).
1.11.8 Vitamin C plus Vitamin E did not show evidence of an increase
in total sperm motility compared with placebo (Greco 2005) (MD
2.90, 95% CI -7.76 to 13.56, 64 men, 1 RCT, P = 0.59, I2 = not
applicable).
1.11.9 Vitamin E did show an increase in total sperm motility
compared with no treatment (Ener 2016) (MD 18.90, 95% CI 4.90 to
32.90, 45 men, 1 RCT, P = 0.08, I2 = not applicable).
1.11.10 Two studies compared zinc with placebo or no treatment
and did not show evidence of an increase in total sperm motility
(Azizollahi 2013; Omu 2008). As the heterogeneity was high (78%)
we have not reported the pooled analysis; individually their results
were:
• Azizollahi 2013 showed did not show evidence of an increase in
total sperm motility at three months when compared to placebo
(MD 4.00, 95% CI -12.11 to 20.11, 57 men);• Omu 2008 showed an increase in total sperm motility at three
months when compared to no treatment (MD 25.00, 95% CI 14.07
to 35.93, 19 men).
1.11.11 Zinc plus folic acid did not show evidence of an increase
in total sperm motility compared with placebo (Azizollahi 2013)
(MD 6.80, 95% CI -7.57 to 21.17, 54 men,1 RCT, P = 0.93, I2 = not
applicable).
1.11.12 Zinc plus vitamin E did show an increase in total sperm
motility compared with no treatment (Omu 2008) (MD 26.00, 95%
CI 12.85 to 39.15, 20 men, 1 RCT, P = 0.0001 I2 = not applicable)
1.11.13 Zinc plus vitamin E plus vitamin C did show an increase in
total sperm motility compared with no treatment (Omu 2008) (MD
26.00, 95% CI 12.62 to 39.38, 22 men, 1 RCT, P - 0.0001, I2 = not
applicable).
1.11.14 Four studies (five intervention arms) compared combined
antioxidants with placebo or no treatment (Gopinath 2013;
Morgante 2010; Scott 1998; Sivkov 2011). There was an increase in
total sperm motility (MD 12.43, 95% CI 8.39 to 16.46, 383 men, 4
RCTs, P < 0.00001, I2 = 55%). However, there was high heterogeneity
of 55%. One study (Morgante 2010) had not described the method
of randomisation and carried 40.8% of the weight in this analysis;
a sensitivity analysis for this risk of bias still showed an increase
in total sperm motility, however now with low heterogeneity (MD
10.02, 95% CI 6.20 to 13.84, 203 men, 3 RCTs, P < 0.00001, I2 = 0%).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 853.44, P < 0.00001).
1.12 Data not usable for meta-analysis
Analysis 1.12
Four studies (Cavallini 2004; Galatioto 2008; Kessopoulou 1995;
Raigani 2014) provided data as medians or percentages, and
therefore they could not be used in the forest plot. Three of these
studies (Galatioto 2008; Kessopoulou 1995; Raigani 2014) found no
diLerence between the intervention and control or no treatment
for this outcome. Two studies (Cavallini 2004; Lenzi 2003) indicated
that there might be some improvement in sperm motility in the
intervention group when measured at three months, however
these data were not rigorous and no conclusions could be made.
1.13 Total sperm motility at six months or less; type of
antioxidant
See Analysis 1.13.
We analysed this outcome using a random-eLects model and used
subtotals as pooling was not possible.
1.13.1 Three studies compared carnitines with placebo (Balercia
2005; Lenzi 2004; Sigman 2006) . As the heterogeneity was high
(78%) we have not reported the pooled analysis for these studies;
individually their results were:
• Balercia 2005 (three arms) showed an increased total sperm
motility at six months when compared to placebo (MD 21.13,
95% CI 14.58 to 27.68, 30 men, P < 0.00001);• Lenzi 2004 showed no evidence of increased total sperm motility
at six months when compared to placebo (MD 1.50, 95% CI-4.56
to 7.56, 56 men, P = 0.63);• Sigman 2006 showed no evidence of increased total sperm
motility at six months when compared to placebo (MD -7.70, 95%
CI -33.24 to 17.84, 21 men, P = 0.55).
1.13.2 Three studies compared coenzyme Q10 with placebo
(Balercia 2009; Safarinejad 2009a; Safarinejad 2012). As the
heterogeneity was extremely high (99%) we we have not reported
the pooled analysis; individually their results were:
• Balercia 2009 did show an increased total sperm motility when
compared to placebo ( MD 4.50, 95% 0.74 to 8.26, 60 men, P =
0.02);• Safarinejad 2009a did show an increased total sperm motility
when compared to placebo (MD 4.50, 95% CI 3.89 to 5.11, 194
men, P < 0.000001);• Safarinejad 2012 did show an increased total sperm motility
when compared to placebo (MD 10.40, 95% CI 9.77 to 11.03, 225
men, P < 0.000001).
1.13.3 Folic acid did not show evidence of increased total sperm
motility when compared to placebo (MD 1.70, 95% CI -8.49 to 11.89,
51 men, P = 0.74, I2 = not applicable) (Azizollahi 2013).
1.13.4 N-acetylcysteine (NAC) did show increased total sperm
motility when compared to placebo (MD 1.90, 95% CI 1.20 to 2.60,
211 men, P ≤ 0.0001, I2 = not applicable) (Safarinejad 2009).
1.13.5 Selenium did show increased total sperm motility when
compared to placebo (MD 3.20, 95% CI 2.50 to 3.90, 211 men, P ≤
0.00001, I2 = not applicable) (Safarinejad 2009).
1.13.6 Selenium plus N-acetylcysteine did show increased total
sperm motility when compared to placebo (MD 6.30, 95% CI 5.60 to
7.00, 210 men, P ≤ 0.00001, I2 = not applicable) (Safarinejad 2009).
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1.13.7 Vitamin D plus calcium did not show evidence of increased
total sperm motility when compared to placebo (MD -4.00, 95%
CI -9.57 to 1.57, 260 men, P = 0.16, I2 = not applicable) (Blomberg
Jensen 2018).
1.13.8 Vitamin E did show increased total sperm motility when
compared to placebo or no treatment (MD 11.20, 95% CI 4.70 to
17.70, 132 men, 2 RCTs, P = 0.0007, I2 = 16%) (Ener 2016; Suleiman
1996).
1.13.9 Zinc did not show evidence of increased total sperm motility
when compared to placebo (MD 0.00, 95% CI -10.19 to 10.19, 57
men, P = 1.00, I2 = not applicable) (Azizollahi 2013).
1.13.10 Zinc plus folic acid did not show evidence of increased total
sperm motility when compared to placebo (MD 2.60, 95% CI -8.82
to 14.02, 54 men, P = 0.66, I2 = not applicable) (Azizollahi 2013).
1.13.11 Combined antioxidants did not show evidence of increased
total sperm motility when compared to placebo or no treatment
(Busetto 2018; Gopinath 2013). As the heterogeneity was high (80%)
we we have not reported the pooled analysis; individually their
results were:
• Busetto 2018 did show increased total sperm motility when
compared to placebo (MD 4.40, 95% CI 1.49 to 7.31, 104 men, P
= 0.003);• Gopinath 2013 with three arms, did show increased total sperm
motility when compared to placebo(MD 12.44, 95% CI 8.29 to
16.59, 125 men, P < 0.00001).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 239.07, P < 0.00001).
1.14 Data not usable for meta-analysis
See Analysis 1.14.
Three studies (Cavallini 2004; Micic 2017; Wong 2002) provided data
as medians, no SDs or percentages, and therefore could not be
used in the forest plot. All studies indicated that there might be
some increase in sperm motility in the intervention group when
measured at six months, however these data are not rigorous and
no conclusions could be made.
1.15 Total sperm motility at nine months or more; type of
antioxidant
See Analysis 1.15.
We analysed this outcome using a random-eLects model and used
subtotals as pooling was not possible.
1.15.1 One study reported on carnitines, and did show increased
total sperm motility when compared to placebo (Balercia 2005):
• L-carnitine did show increased total sperm motility when
compared to placebo (MD 11.54, 95% CI 1.66 to 21.42, 19 men,
P = 0.02);• L-acetyl carnitine did not show evidence of increased total
sperm motility when compared to placebo (MD 7.84, 95% CI
-1.41 to 17.09, 20 men, P = 0.10);
• L-carnitine + L-acetyl carnitine did not show evidence of
increased total sperm motility when compared to placebo (MD
6.27, 95% CI -3.36 to 15.90, 20 men, P = 0.20).
1.15.2 Three studies reported on coenzyme Q10 (Balercia 2009;
Safarinejad 2009a; Safarinejad 2012). As the heterogeneity was
extremely high (98%) we we have not reported the pooled analysis;
individually their results were:
• Balercia 2009 did not show evidence of increased total sperm
motility when compared to placebo (MD -2.30, 95% CI -5.94 to
1.34, 60 men, P = 0.22);• Safarinejad 2009a did show increased total sperm motility when
compared to placebo (MD 1.40, 95% CI 0.79 to 2.01, 194 men, P
< 0.00001);• Safarinejad 2012 did show increased total sperm motility when
compared to placebo (MD 5.40, 95% CI 4.80 to 6.00, 225 men, P
< 0.00001).
1.15.4 Vitamin E did not show evidence of increased total sperm
motility when compared to no treatment (Ener 2016) (MD 2.20, 95%
CI -8.48 to 12.88, 45 men, 1 RCT, P = 0.69, I2 = not applicable).
There was no evidence that diLerent antioxidants had diLering
eLects (test for subgroup diLerences: Chi2 = 3.42, P = 0.18).
1.16 Total sperm motility over time
See Analysis 1.16.
This analysis was only useful in directly comparing the same studies
reporting at the three time points and not in comparing results of
meta-analyses that included diLerent subsets of studies.
1.16.1 Total sperm motility at three months or less. We analysed this
outcome using a random-eLects model (MD 10.19, 95% CI 4.35 to
16.04, 1105 men, 18 RCTs, 27 intervention arms, P = 0.006, I2 = 97%)
and used subtotals (Attallah 2013; Azizollahi 2013; Balercia 2005;
Barekat 2016; Conquer 2000; Dimitriadis 2010; Ener 2016; Gopinath
2013; Greco 2005; Lenzi 2003; Martinez-Soto 2010; Morgante 2010;
Nadjarzadeh 2011; Omu 2008; Peivandi 2010; Scott 1998; Sigman
2006; Zavaczki 2003).
1.16.2 Total sperm motility at six months. We analysed this outcome
using a random-eLects model (MD 6.00, 95% CI 3.92 to 8.09, 1768
men,13 RCTs, 20 intervention arms, P < 0.000001, I2 = 95%) and used
subtotals (Azizollahi 2013; Balercia 2005; Balercia 2009; Blomberg
Jensen 2018; Busetto 2018; Ener 2016; Gopinath 2013; Lenzi 2004;
Safarinejad 2009; Safarinejad 2009a; Safarinejad 2012; Sigman
2006; Suleiman 1996).
1.16.3 Total sperm motility at nine months or more. We analysed
this outcome using a random-eLects model (MD 3.29, 95% CI 0.36
to 6.23, 583 men, 5 RCTs, seven intervention arms, P = 0.03 I2 =
94%) and used subtotals (Balercia 2005; Balercia 2009; Ener 2016;
Safarinejad 2009a; Safarinejad 2012).
Two of the studies included in the analysis of the semen parameter
outcomes (Safarinejad 2009; Safarinejad 2009a) had consistently
reported SDs very much smaller than those reported by most of the
other included studies. The review authors considered that these
were potentially erroneous, but an attempt to check with the study
authors was unsuccessful. One other study (Peivandi 2010) also had
very small SDs when compared to data in the other studies, but the
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authors confirmed, when contacted, that they are indeed SDs and
not SEs. We tried to manage these analyses in two diLerent ways:
firstly we assumed the outcome to have a SD equal to the highest
SD from other studies within the same analysis and secondly by
treating the data as SEs and converting back to SDs, however
heterogeneity remained high in both situations so for the final
analyses we reverted to the SDs as reported in the studies. The low
SDs may have been due to the strict inclusion and exclusion criteria
indicating that the study was homogenous in nature, however we
were unable to carry out a sensitivity analysis on these studies as
pooling was not possible due to high heterogeneity.
1.17 Progressive sperm motility at three months or less; type of
antioxidant
See Analysis 1.17 and Figure 10.
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Figure 10.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.17 Progressive
sperm motility at 3 months or less; type of antioxidant.
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Figure 10.   (Continued)
 
We analysed this outcome using a random-eLects model and used
subtotals as pooling was not possible.
1.17.1 Three studies with carnitines reported an increase in
progressive sperm motility when compared to placebo (Balercia
2005; Mehni 2014; Peivandi 2010). As the heterogeneity was
moderately high (63%), we have not reported the pooled analysis;
individually their results were:
• Balercia 2005 showed an increase in progressive sperm motility
when compared to placebo (MD 13.72, 95% CI 9.08 to 18.35, 59
men, P < 0.00001);• Mehni 2014 showed an increase in progressive sperm motility
when compared to placebo (MD 21.30, 95% CI 20.50 to 22.10, 110
men, P < 0.00001);• Peivandi 2010 showed an increase in progressive sperm motility
when compared to placebo (MD 21.00, 95% CI 20.53 to 21.47, 30
men, P < 0.00001).
1.17.2 Coenzyme Q10 did not show evidence of increased
progressive sperm motility when compared to placebo
(Nadjarzadeh 2011) (MD 4.60, 95% CI -3.54 to 12.74, 47 men, 1 RCT,
P = 0.27, I2 = not applicable).
1.17.3 Docosahexaenoic (DHA) did show an increase in progressive
sperm motility when compared to placebo (Martinez-Soto 2010)
(MD -6.60, 95% CI -8.57 to -4.63, 36 men, 1 RCT, P< 0.00001, I2 = not
applicable).
1.17.4 Two studied with folic acid did not show evidence of
increased progressive sperm motility when compared to placebo
(Azizollahi 2013; Boonyarangkul 2015) (MD 5.68, 95% CI -5.02 to
16.38, 81 men, 2 RCTs, P = 0.3, I2 = 18%).
1.17.5 N-acetylcysteine (NAC) did not show evidence of increased
progressive sperm motility when compared to no treatment
(Attallah 2013) (MD 3.80, 95% CI -1.03 to 8.63, 60 men, 1 RCT, P =
0.12, I2 = not applicable).
1.17.6 PUFAs did not show evidence of increased progressive sperm
motility when compared to placebo (Haghighian 2015) (MD 6.40,
95% CI 4.83 to 7.97, 44 men,1 RCT, P < 0.00001, I2 = not applicable).
1.17.7 Two studies with vitamin C did show an increase in
progressive sperm motility when compared to placebo (Cyrus 2015;
Dawson 1990). As the heterogeneity was high (64%) we have not
reported the pooled analysis; individually their results were:
• Cyrus 2015 showed an increase in progressive sperm motility
when compared to placebo (MD 9.60, 95% CI 2.29 to 16.91, 115
men, P = 0.01);• Dawson 1990 showed an increase in progressive sperm motility
when vitamin C 1000 mg was compared to placebo (MD 45.00,
95% CI 15.25 to 74.75,15 men, P = 0.03);• Dawson 1990 did not show evidence of increased progressive
sperm motility when vitamin C 200 mg was compared to placebo
(MD 2.00, 95% CI -24.07 to 28.07, 15 men, P = 0.88).
1.17.8 Vitamin C plus vitamin E did not show evidence of increased
progressive sperm motility when compared to placebo (Rolf 1999)
(MD 0.20, 95% CI -9.77 to 10.17, 31 men, 1 RCT, P = 0.97, I2 = not
applicable).
1.17.9 Two studies with zinc did not show evidence of increased
progressive sperm motility when compared to placebo (Azizollahi
2013; Sharifzadeh 2016) (MD 1.14, 95% CI -3.37 to 5.64, 157 men, 2
RCTs, P = 0.62, I2 = 0%).
1.17.10 Zinc plus folic acid did not show evidence of increased
progressive sperm motility when compared to placebo (Azizollahi
2013) (MD 3.80, 95% CI -13.66 to 21.26, 54 men, 1 RCT, P = 0.67, I2 =
not applicable).
1.17.11 Combined antioxidants did not show evidence of increased
progressive sperm motility when compared to placebo (Morgante
2010) (MD 15.20, 95% CI 13.62 to 16.78, 180 men, 1 RCT, P < 0.00001,
I2 = not applicable).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 1152.65, P < 0.00001).
1.18 Data not usable for meta-analysis
See Analysis 1.18.
Two studies provided data as medians with interquartile ranges
and therefore could not be used in the forest plot (Gamidov 2017;
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Micic 2017). These data are not rigorous and no conclusions could
be made.
1.19 Progressive sperm motility at six months; type of
antioxidant
See Analysis 1.19.
We analysed this outcome using a random-eLects model and used
subtotals as pooling was not possible.
1.19.1 Carnitines did show an increase in progressive sperm motility
when compared with placebo (Balercia 2005) (MD 15.94, 95% CI
11.01 to 20.87, 59 men, 1 RCT, 3 intervention arms, P < 0.00001, I2
= not applicable).
1.19.2 Coenzyme Q10 did show an increase in progressive sperm
motility when compared to placebo (Balercia 2009) (MD 5.00, 95%
CI 2.13 to 7.87, 60 men,1 RCT, P = 0.0006, I2 = not applicable).
1.19.3 Two studies with folic acid did not show evidence of
increased progressive sperm motility when compared to placebo
(Azizollahi 2013; Boonyarangkul 2015) (MD -1.77, 95% CI -10.21 to
6.67, 81 men, 2 RCTs, P = 0.68, I2 = 0%).
1.19.4 Vitamin D with calcium did not show evidence of increased
progressive sperm motility when compared to placebo (Blomberg
Jensen 2018) (MD -4.00, 95% CI -9.59 to 1.59, 260 men, P = 0.16, I2
= not applicable).
1.19.5 Zinc did not show evidence of increased progressive sperm
motility when compared to placebo (Azizollahi 2013) (MD 2.00, 95%
CI -13.56 to 17.56, 57 men, 1 RCT, P = 0.80, I2 = not applicable).
1.19.6 Zinc plus folic acid did not show evidence of increased
progressive sperm motility when compared to placebo (Azizollahi
2013) (MD 2.70, 95% CI -14.58 to 19.98, 54 men, 1 RCT, P = 0.76, I2 =
not applicable).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 31.49, P < 0.000001).
1.20 Data not usable for meta-analysis
See Analysis 1.20.
One study provided data as medians with interquartile range and
therefore could not be used in the forest plot (Micic 2017). Results
indicated that there might be increased progressive sperm motility
in the intervention group when measured at six months, however
these data are not rigorous and no conclusions could be made.
1.21 Progressive sperm motility at nine months or more; type of
antioxidant
See Analysis 1.21.
We analysed this outcome using a random-eLects model and used
subtotals as pooling was not possible.
1.21.1 Carnitines did show an increase in progressive sperm motility
when compared to placebo (Balercia 2005) (MD 7.77, 95% CI 2.68
to 12.87, 59 men, 1 RCT, 3 intervention arms, P = 0.003, I2 = not
applicable).
1.21.2 Coenzyme Q10 did not show evidence of increased
progressive sperm motility when compared to placebo (Balercia
2009) (MD -0.90, 95% CI -2.68 to 0.88, 60 men, 1 RCT, P = 0.32, I2 =
not applicable).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 9.93, P = 0.002).
1.22 Progressive sperm motility over time
See Analysis 1.22.
This analysis was only useful in directly comparing the same studies
reporting at the three time points and not in comparing results of
meta-analyses that included diLerent subsets of studies.
1.22.1 Progressive sperm motility at three months or less. We
analysed this outcome using a random-eLects model and used
subtotals (Attallah 2013; Azizollahi 2013; Balercia 2005; Balercia
2009; Boonyarangkul 2015; Cyrus 2015; Dawson 1990; Haghighian
2015; Martinez-Soto 2010; Mehni 2014; Morgante 2010; Nadjarzadeh
2011; Peivandi 2010; Rolf 1999).
1.22.2 Progressive sperm motility at six months. We analysed this
outcome using a random-eLects model (MD 6.11, 95% CI 0.57 to
11.66, 521 men, 5 RCTs, 9 intervention arms, P = 0.03, I2 = 76%)
and used subtotals (Azizollahi 2013; Balercia 2005; Balercia 2009;
Blomberg Jensen 2018; Boonyarangkul 2015).
1.22.3 Progressive sperm motility at nine months or more. We
analysed this outcome using a random-eLects model (MD 4.64, 95%
CI -1.67 to 10.95, 119 men, 2 RCTs, 4 intervention arms, P = 0.15) and
used subtotals (Balercia 2005; Balercia 2009).
1.23 Sperm concentration at three months or less; type of
antioxidant
See Analysis 1.23 and Figure 11.
 
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
39
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 11.   Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.23 Sperm
concentration at 3 months or less; type of antioxidant.
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Figure 11.   (Continued)
 
We analysed this outcome using a random-eLects model. We used
only subtotals in this analysis.
1.23.1 Four studies (six intervention arms) compared carnitines
with placebo or no treatment and showed an increase in
sperm concentration (Balercia 2005; Dimitriadis 2010; Mehni 2014;
Peivandi 2010). As the heterogeneity was extremely high (96%) we
have not reported the pooled analysis; individually their results
were:
• Balercia 2005 did not show evidence of increased sperm
concentration when compared to placebo (MD 7.76, 95% CI -0.73
to 16.25, 59 men, P = 0.07);• Dimitriadis 2010 did not show evidence of increased sperm
concentration when compared to no treatment (MD -0.90, 95%
CI -4.80 to 3.00, 48 men, P = 0.65);• Mehni 2014 showed an increase in sperm concentration when
compared to placebo (MD 8.50, 95% CI 7.85 to 9.15, 110 men, P
< 0.00001);• Peivandi 2010 showed an increase in sperm concentration when
compared to placebo (MD 29.50, 95% CI 25.39 to 33.61, 30 men,
P < 0.00001).
1.23.2 Coenzyme Q10 did not show evidence of increased sperm
concentration when compared to placebo (Nadjarzadeh 2011) (MD
-0.10, 95% CI -12.37 to 12.17, 47 men, 1 RCT, P = 0.99, I2 = not
applicable).
1.23.3 Two studies compared folic acid with placebo and did not
show evidence of increased sperm concentration (Azizollahi 2013;
Boonyarangkul 2015). As the heterogeneity was high (68%) we have
not reported the pooled analysis; individually their results were:
• Azizollahi 2013 showed an increase in sperm concentration
when compared to placebo (MD 22.20, 95% CI 3.80 to 40.60, 51
men, P = 0.02);• Boonyarangkul 2015 did not show evidence of increased sperm
concentration when compared to placebo (MD -9.60, 95% CI
-39.36 to 20.16, 30 men, P = 0.53). However, in this study there
was great baseline imbalance for sperm parameters between
the intervention and control group.
1.23.4 Magnesium did not show evidence of increased sperm
concentration when compared to placebo (Zavaczki 2003) (MD 5.20,
95% CI -2.61 to 13.01, 20 men, 1 RCT, P = 0.19, I2 = not applicable).
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1.23.5 Two studies did not show evidence of increased sperm
concentration when N-acetylcysteine (NAC) was compared with
placebo or no treatment (Attallah 2013; Barekat 2016) (MD 4.59,
95% CI -0.27 to 9.46, 95 men, 2 RCTs, P = 0.06, I2 = 0%).
1.23.6 Three studies showed an increase in sperm concentration
when PUFAs were compared to placebo or no treatment (Conquer
2000; Haghighian 2015; Martinez-Soto 2010) (MD 3.44, 95% CI 1.70
to 5.17, 108 men, P = 0.0001, I2 = 0%).
1.23.7 Selenium did not show evidence of increased sperm
concentration when compared to placebo (Scott 1998) (MD 21.20,
95% CI -11.43 to 53.83, 25 men, 1 RCT,P = 0.20, I2 = not applicable).
1.23.8 Vitamin C did not show evidence of increased sperm
concentration when compared to placebo (Cyrus 2015) (MD 9.70,
95% CI 0.09 to 19.31, 115 men, 1 RCT,P = 0.05, I2 = not applicable).
1.23.9 Two studies did not show evidence of increased sperm
concentration when Vitamin C plus vitamin E was compared to
placebo (Greco 2005; Rolf 1999). As the heterogeneity was high
(52%) we have not reported the pooled analysis; individually their
results were:
• Greco 2005 did not show evidence of increased sperm
concentration when compared to placebo (MD 7.20, 95% CI -4.05
to 18.45, 64 men, P = 0.21);• Rolf 1999 did not show evidence of increased sperm
concentration when compared to placebo (MD -4.40, 95% CI
-15.48 to 6.68, 31 men, P = 0.44).
1.23.10 Vitamin E showed an increase in sperm concentration when
compared to no treatment (Ener 2016) (MD 18.90, 95% CI 3.92 to
33.88, 45 men, 1 RCT, P = 0.01, I2 = not applicable).
1.23.11 Two studies showed an increase in sperm concentration
when zinc was compared to placebo (Azizollahi 2013; Sharifzadeh
2016) (MD 8.75, 95% CI 2.25 to 15.24, 157 men, 2 RCTs, P = 0.008, I2
= 17%).
1.23.12 Zinc plus folic acid showed an increase in sperm
concentration when compared to placebo (Azizollahi 2013) (MD
18.00, 95% CI 1.11 to 34.89, 54 men, 1 RCT, P = 0.04, I2 = not
applicable).
1.23.13 Three studies (four intervention arms) showed an
increase in sperm concentration when combined antioxidants were
compared to placebo or no treatment (Gopinath 2013; Morgante
2010; Scott 1998). As the heterogeneity was extremely high (96%)
we have not reported the pooled analysis; individually their results
were:
• Gopinath 2013 showed an increase in sperm concentration
when compared to placebo (MD 10.69, 95% CI 8.15 to 13.22, 125
men, P < 0.00001);• Morgante 2010 showed an increase in sperm concentration
when compared to no treatment (MD -0.90, 95% CI -1.85 to 0.05,
180 men, P = 0.06);• Scott 1998 did not show evidence of increased sperm
concentration when compared to placebo (MD 6.50, 95% CI
-16.66 to 29.66, 39 men, P = 0.58).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 236.53, P < 0.00001).
Data not usable for meta-analysis
See Analysis 1.24.
Four studies (Cavallini 2004; Gamidov 2017; Kessopoulou 1995;
Raigani 2014) provided data as medians and interquartile ranges
or percentiles and therefore could not be used in the forest
plot. These studies might indicate some improvement in sperm
concentration in the intervention group when measured at three
months, however these data were not rigorous and no conclusions
could be made. One study (Lenzi 2003) provided data as the mean
with no SD, the P value was 0.03 indicating that there may have
been an association between L-carnitine and improved sperm
concentration at three months.
1.25 Sperm concentration at six months; type of antioxidant
See Analysis 1.25.
We analysed this outcome using a random-eLects model. We used
only subtotals in this analysis.
1.25.1 Two studies (four intervention arms) did not show evidence
of increased sperm concentration when carnitines were compared
with placebo (Balercia 2005; Lenzi 2004) (MD 2.60, 95% CI -3.13 to
8.33, 115 men, 2 RCTs, 4 intervention arms, P = 0.37, I2 = 0%).
1.25.2 Three studies showed an increase in sperm concentration
when coenzyme Q10 was compared with placebo (Balercia 2009;
Safarinejad 2009a; Safarinejad 2012). As the heterogeneity was
extremely high (96%) we have not reported the pooled analysis;
individually their results were:
• Balercia 2009 did not show evidence of increased sperm
concentration when compared to placebo (MD -1.50, 95% CI
-11.39 to 8.39, 60 men, P = 0.77);• Safarinejad 2009a showed an increase in sperm concentration
when compared to placebo (MD 5.60, 95% CI 4.38 to 6.82, 194
men, P < 0.00001);• Safarinejad 2012 showed an increase in sperm concentration
when compared to placebo (MD 11.90, 95% CI 10.72 to 13.08, 225
men, P < 0.00001).
1.25.3 Two studies compared folic acid with placebo did not
show evidence of increased sperm concentration (Azizollahi 2013;
Boonyarangkul 2015). As the heterogeneity was high (78%) we have
not reported the pooled analysis; individually their results were:
• Azizollahi 2013 showed an increase in sperm concentration
when compared to placebo(MD 19.20, 95% CI 12.24 to 26.16, 51
men, P < 0.00001);• Boonyarangkul 2015 did not show evidence of increased sperm
concentration when compared to placebo (MD -22.80, 95% CI
-60.44 to 14.84, 30 men, P = 0.24). However, in this study there
was great baseline imbalance for sperm parameters between
the intervention and control group.
1.25.4 N-acetylcysteine (NAC) showed an increase in sperm
concentration when compared to placebo (Safarinejad 2009) (MD
3.30, 95% CI 1.80 to 4.80, 211 men, 1 RCT, P < 0.0001, I2 = not
applicable).
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1.25.5 Selenium showed an increase in sperm concentration when
compared to placebo (Safarinejad 2009) (MD 4.10, 95% CI 2.45 to
5.75, 211 men, 1 RCT, P < 0.0001, I2 = not applicable).
1.25.6 Selenium plus N-acetylcysteine (NAC) showed an increase in
sperm concentration when compared to placebo (Safarinejad 2009)
(MD 8.60, 95% CI 6.89 to 10.31, 210 men, 1 RCT, P < 0.0001 I2 = not
applicable).
1.25.7 Vitamin E did not show evidence of increased sperm
concentration when compared to no treatment (Ener 2016) (MD
5.90, 95% CI -10.83 to 22.63, 45 men, 1 RCT, P = 0.49, I2 = not
applicable).
1.25.8 Zinc did not show evidence of increased sperm
concentration when compared to placebo (Azizollahi 2013) (MD
9.70, 95% CI -7.00 to 26.40, 57 men, 1 RCT, P = 0.26, I2 = not
applicable).
1.25.9 Zinc plus folic acid did not show evidence of increased sperm
concentration when compared to placebo (Azizollahi 2013) (MD
17.70, 95% CI -1.88 to 37.28, 54 men, 1 RCT< P = 0.08, I2 = not
applicable).
1.25.10 Two studies (three intervention arms) did not show
evidence of increased in sperm concentration when combined
antioxidants were compared to placebo (Busetto 2018; Gopinath
2013). As the heterogeneity was high (74%) we have not reported
the pooled analysis; individually their results were:
• Busetto 2018 showed an increase in sperm concentration when
compared to placebo (MD 7.70, 95% CI 2.41 to 12.99, 104 men,
P = 0.004);• Gopinath 2013 showed an increase in sperm concentration
when compared to placebo (MD 16.48, 95% CI 13.08 to 19.87, 125
men, P < 0.00001).
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 82.87, P < 0.00001)
Data not usable for meta-analysis
Analysis 1.26
Three studies (Blomberg Jensen 2018; Cavallini 2004; Wong 2002)
provided data as medians with interquartile ranges or percentages
with no SDs, and therefore could not be used in the forest plot.
The last two mentioned of these studies indicated that there might
be some improvement in sperm concentration in the intervention
group when measured at six months.
1.27 Sperm concentration at nine months; type of antioxidant
See Analysis 1.27.
We analysed this outcome using a random-eLects model. We used
only subtotals in this analysis.
1.27.1 Carnitines (three intervention arms) did not show evidence
of increased sperm concentration when compared to placebo
(Balercia 2005) (MD 4.17, 95% CI -1.71 to 10.06, 59 men, 1 RCT, 3
intervention arms, P = 0.16, I2 = not applicable).
1.27.2 Three studies showed an increase in sperm concentration
when coenzyme Q10 was compared to placebo (Balercia 2009;
Safarinejad 2009a; Safarinejad 2012). As the heterogeneity was
extremely high (95%) we have not reported the pooled analysis;
individually their results were:
• Balercia 2009 did not show evidence of increased sperm
concentration when compared to placebo (MD -5.40, 95% CI
-15.75 to 4.95, 60 men, P = 0.31);• Safarinejad 2009a showed an increase in sperm concentration
when compared to placebo (MD 1.60, 95% CI 0.53 to 2.67, 194
men, P = 0.003);• Safarinejad 2012 showed an increase in sperm concentration
when compared to placebo (MD 6.20, 95% CI 5.17 to 7.23, 225
men, P < 0.00001).
1.27.3 Vitamin E did not show evidence of increased sperm
concentration when compared to no treatment (Ener 2016) (MD
11.40, 95% CI -2.56 to 25.36, 45 men, 1 RCT, P = 0.11, I2 = not
applicable).
There was no evidence that diLerent antioxidants had diLering
eLects (test for subgroup diLerences: Chi2 = 1.10, P = 0.58).
1.28 Sperm concentration over time
See Analysis 1.28.
This analysis was only useful in directly comparing the same studies
reporting at the three time points and not in comparing results of
meta analyses that included diLerent subsets of studies.
1.28.1 Total sperm concentration at three months or less. We
analysed this outcome using a random-eLects model (MD 7.51,
95% CI 4.23 to 10.79, 1244 men, 20 RCTs, P < 0.000001, I2 = 95%)
and used subtotals (Attallah 2013; Azizollahi 2013; Balercia 2005;
Balercia 2009; Barekat 2016; Boonyarangkul 2015; Conquer 2000;
Cyrus 2015; Dimitriadis 2010; Ener 2016; Gopinath 2013; Greco 2005;
Haghighian 2015; Martinez-Soto 2010; Mehni 2014; Morgante 2010;
Nadjarzadeh 2011; Peivandi 2010; Rolf 1999; Scott 1998; Zavaczki
2003).
1.28.2 Total sperm concentration at six months. We analysed this
outcome using a random-eLects model (MD 7.49, 95% CI 4.76
to 10.23, 1430 men, 11 RCTs, P < 0.0001, I2 = 87%) and used
subtotals (Azizollahi 2013; Balercia 2005; Balercia 2009; Busetto
2018; Boonyarangkul 2015; Ener 2016; Gopinath 2013; Lenzi 2004;
Safarinejad 2009; Safarinejad 2009a; Safarinejad 2012).
1.28.3 Total sperm concentration at nine months or more. We
analysed this outcome using a random-eLects model (MD 3.61, 95%
CI 0.17 to 7.06, 583 men, 5 RCTs, seven intervention arms, P = 0.04, I2
= 86%) and used subtotals (Balercia 2005; Balercia 2009; Ener 2016;
Safarinejad 2009a; Safarinejad 2012).
2 Head-to-head antioxidants (natural conception and
undergoing fertility treatment)
The studies included in this comparison did not report on adverse
events or sperm DNA fragmentation.
2.1 Live birth; type of antioxidant
See Analysis 2.1.
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Totals were not used in this analysis as there were data for one study
only per subgroup, and therefore pooling was not possible.
2.1.1 L-carnitine versus L-acetyl carnitine. There was no evidence of
the use of L-carnitine and increased live birth rate when compared
to L-acetyl carnitine (Balercia 2005) (Peto OR 1.00, 95% CI 0.13 to
7.92, 30 men, 1 RCT, P = 1.00).
2.1.2 L-carnitine versus L-carnitine plus L-acetyl carnitine.There was
evidence of the use of L-carnitine and increased live birth rate when
compared to L-carnitine plus L-acetyl carnitine (Balercia 2005) (Peto
OR 0.34, 95% CI 0.06 to 1.79, 30 men, 1 RCT, P = 0.20).
2.1.3 L-acetyl carnitine versus L-carnitine plus L-acetyl
carnitine.There was no evidence of the use of L-acetyl carnitine and
increased live birth rate when compared to L-carnitine plus L-acetyl
carnitine (Balercia 2005) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30 men,
1 RCT, P = 0.20).
There was no evidence that diLerent antioxidants had diLering
eLects (test for subgroup diLerences: Chi2 = 0.79, P = 0.67)
2.2 Clinical pregnancy; type of antioxidant
See Analysis 2.2.
Totals were not used in this analysis as there were data for one study
only per subgroup, and therefore pooling was not possible.
2.2.1. L-carnitine versus L-acetyl carnitine. There was no evidence
of the use of L-carnitine and increased clinical pregnancy rate when
compared to L-acetyl carnitine (Balercia 2005) (Peto OR 1.00, 95%
CI 0.13 to 7.92, 30 men, 1 RCT, P = 1.00).
2.2.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased clinical
pregnancy rate when compared to L-carnitine plus L-acetyl
carnitine (Balercia 2005) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30
men,1 RCT, P = 0.20).
2.2.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
clinical pregnancy rate when compared to L-carnitine plus L-acetyl
carnitine (Balercia 2005) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30
men,1 RCT, P = 0.20).
2.2.4 Vitamin D plus calcium versus vitamin E plus vitamin C. There
was an association between the use of vitamin D plus calcium and
increased clinical pregnancy rate when compared to vitamin E plus
vitamin C (Deng 2014) (Peto OR 5.13, 95% CI 1.21 to 21.79, 86 men,
P = 0.03)
There was evidence that diLerent antioxidants had diLering eLects
(test for subgroup diLerences: Chi2 = 8.15, P = 0.04)
2.3 Total sperm motility at three months or less; type of
antioxidant
See Analysis 2.3.
Totals were not used in this analysis as, of the eight studies
included, there were data for one study only per subgroup, and
therefore pooling was not possible.
2.3.1 Docosahexaenoic acid (DHA) 400 mg versus DHA 800 mg.
There was no evidence of the use of DHA 400 g/day and increased
sperm motility when compared to DHA800 mg/day (Conquer 2000)
(MD 7.40, 95% CI -11.35 to 26.15, 19 men, P = 0.44).
2.3.2 Ethylcysteine versus vitamin E. There was no evidence of the
use of ethyl cysteine and increased sperm motility when compared
to vitamin E (Akiyama 1999) (MD -1.90, 95% CI -41.97 to 38.17, 10
men, P = 0.93).
2.3.3 L acetyl carnitine plus L carnitine versus vitamin E plus vitamin
C. There was an association between the use of L acetyl carnitine + L
carnitine and increased sperm motility when compared to vitamin
E + vitamin C (Li 2005) (MD 23.10, 95% CI 20.14 to 26.06, 138 men,
P < 0.00001).
2.3.4 L-carnitine versus L-acetyl carnitine. There was no evidence of
the use of L-carnitine and increased sperm motility when compared
to L-acetyl carnitine (Balercia 2005) (MD 3.40, 95% CI -3.73 to 10.53,
30 men, P = 0.35).
2.3.5 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased sperm
motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 4.80, 95% CI -1.76 to 11.36, 30 men, P = 0.15).
2.3.6 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
sperm motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 1.40, 95% CI -6.42 to 9.22, 30 men, P = 0.73).
2.3.7 Selenium versus combined antioxidants. There was no
evidence of the use of selenium and increased sperm motility when
compared to combined antioxidants (Scott 1998) (MD 3.20, 95% CI
-10.13 to 16.53, 46 men, P = 0.64).
2.3.8 Vitamin C 200 mg/day versus vitamin C 1000 mg/day. There
was an association between the use of ascorbic acid 200 mg/day
and decreased sperm motility when compared to ascorbic acid
1000 mg/day (Dawson 1990) (MD -43.00, 95% CI -67.10 to -18.90, 20
men, P = 0.0005).
2.3.9 Zinc versus folic acid. There was no evidence of the use of
zinc and increased sperm motility when compared to folic acid
(Azizollahi 2013) (MD -4.40, 95% CI -14.21 to 5.41, 80 men, P = 0.38).
2.3.10 Zinc versus zinc plus folic acid. There was no evidence of the
use of zinc and increased sperm motility when compared to zinc
plus folic acid (Azizollahi 2013) (MD -2.80, 95% CI -12.91 to 7.31, 80
men, P = 0.59).
2.3.11 Zinc plus folic acid versus folic acid. There was no evidence
of the use of zinc plus folic acid and increased sperm motility when
compared to folic acid alone (Azizollahi 2013) (MD -0.60, 95% CI
-7.74 to 6.54, 80 men, P = 0.87).
2.3.12 Zinc versus zinc plus vitamin E. There was no evidence of the
use of zinc and increased sperm motility when compared to zinc
plus vitamin E (Omu 2008) (MD -1.00, 95% CI -15.00 to 13.00, 18 men,
P = 0.89).
2.3.13 Zinc versus zinc plus vitamin E plus vitamin C. There was
no evidence of the use of zinc and increased sperm motility when
compared to zinc plus vitamin E plus vitamin C (Omu 2008) (MD
-1.00, 95% CI -19.66 to 17.66, 12 men, P = 0.89).
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2.3.14 Zinc plus vitamin E versus zinc plus vitamin E plus vitamin
C. There was no evidence of the use of zinc plus vitamin E and
increased sperm motility when compared to zinc plus vitamin E
plus vitamin C (Omu 2008) (MD -0.00, 95% CI -18.97 to 18.97, 18 men,
P = 1.00).
2.4 Total sperm motility at six months or less; type of
antioxidant
See Analysis 2.4.
Pooling was not possible in this analysis as of the four studies
included in this analysis there were data for one study per
subgroup.
2.4.1 L-carnitine versus L-acetyl carnitine. There was no evidence of
the use of L-carnitine and increased sperm motility when compared
to L-acetyl carnitine (Balercia 2005) (MD 4.10, 95% CI -2.70 to 10.90,
30 men, P = 0.2).
2.4.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased sperm
motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 3.40, 95% CI -2.87 to 9.67, 30 men, P = 0.29).
2.4.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
sperm motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD -0.70, 95% CI -7.73 to 6.33, 30 men, P = 0.85).
2.4.4 N-acetylcysteine versus selenium plus NAC. There was an
association between the use of NAC and decreased sperm motility
when compared to selenium plus NAC (Safarinejad 2009) (MD -4.40,
95% CI -5.14 to -3.66, 234 men, P < 0.00001).
2.4.5 Selenium versus N-acetylcysteine (NAC). There was an
association between the use of selenium and increased sperm
motility when compared to NAC (Safarinejad 2009) (MD 1.30, 95%
CI 0.56 to 2.04, 234 men, P = 0.0006).
2.4.6 Selenium versus selenium plus N-acetylcysteine (NAC). There
was an association between the use of selenium and decreased
sperm motility when compared to selenium plus NAC (Safarinejad
2009) (MD -3.10, 95% CI -3.85 to -2.35, 232 men, P < 0.00001).
2.4.7 Zinc versus folic acid. There was no evidence of the use of
zinc and increased sperm motility when compared to folic acid
(Azizollahi 2013) (MD -1.70, 95% CI -6.42 to 3.02, 80 men, P = 0.48).
2.4.8 Zinc plus folic acid versus folic acid. There was no evidence of
the use of zinc plus folic acid and increased sperm motility when
compared to folic acid (Azizollahi 2013) (MD 0.90, 95% CI -5.45 to
7.25, 80 men, P = 0.78).
2.4.9 Zinc versus zinc plus folic acid. There was no evidence of the
use of zinc and increased sperm motility when compared to zinc
plus folic acid (Azizollahi 2013) (MD -2.60, 95% CI -9.13 to 3.93, 80
men, P = 0.44).
Data not usable for meta-analysis
See Analysis 2.5.
Zinc versus folic acid, zinc versus zinc plus folic acid, folic acid
versus zinc plus folic acid. One study Wong 2002 reported data
as medians and ranges for these three subgroups. There was no
indication of any diLerence in eLect for total sperm motility at
six months between the intervention and control groups, however
these data were not rigorous and no conclusions could be made.
2.6 Total sperm motility at nine months or more; type of
antioxidant
See Analysis 2.6.
Pooling was not possible in this analysis as it included only one
study.
2.6.1 L-carnitine versus L-acetyl carnitine. There was no evidence of
the use of L-carnitine and increased sperm motility when compared
to L-acetyl carnitine (Balercia 2005) (MD 3.70, 95% CI -1.69 to 9.09,
30 men, P = 0.18).
2.6.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased sperm
motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 5.30, 95% CI -0.73 to 11.33,30 men, P = 0.08).
2.6.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
sperm motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 1.60, 95% CI -3.29 to 6.49, 30 men, P = 0.52).
2.7 Progressive sperm motility at three months or less; type of
antioxidant
See Analysis 2.7.
Pooling was not possible in this analysis as of the four studies
included in this analysis there were data for one study per
subgroup.
2.7.1 L-carnitine versus L-acetyl carnitine. There was no evidence
of the use of L-carnitine and increased progressive sperm motility
when compared to L-acetyl carnitine (Balercia 2005) (MD 4.00, 95%
CI -1.88 to 9.88, 30 men, P = 0.18).
2.7.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased progressive
sperm motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 5.00, 95% CI -0.68 to 10.68, 29 men, P = 0.08)
2.7.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
progressive sperm motility when compared to L-carnitine plus L-
acetyl carnitine (Balercia 2005) (MD 1.00, 95% CI -5.41 to 7.41, 29
men, P = 0.76).
2.7.4 L-acetyl carnitine versus L-carnitine plus vitamin E plus
vitamin C. There was an association between the use of L-acetyl
carnitine and increased progressive sperm motility when compared
to L-carnitine plus vitamin E plus vitamin C (Li 2005) (MD 13.30, 95%
CI 11.21 to 15.39, 138 men, P < 0.00001).
2.7.5 L-carnitine versus vitamin E plus vitamin C. There was
an association between the use of L-carnitine and increased
progressive sperm motility when compared to vitamin E plus
vitamin C (Li 2005a) (MD 30.50, 95% CI 27.70 to 33.30, 63 men, P <
0.00001).
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2.7.6 L-carnitine plus vitamin E versus vitamin E. There was an
association between the use of L-carnitine plus vitamin E and
increased progressive sperm motility when compared to vitamin E
(Wang 2010) (MD 14.10, 95% CI 10.11 to 18.09, 113 men, P < 0.00001).
2.7.7 Vitamin D plus calcium versus vitamin E plus vitamin C. There
was an association between the use of vitamin D plus calcium and
increased progressive sperm motility when compared to vitamin E
plus vitamin C (Deng 2014) (MD 6.90, 95% CI 5.38 to 8.42, 86 men,
P < 0.000001).
2.8 Progressive sperm motility at six months; type of
antioxidant
See Analysis 2.8.
Pooling was not possible in this analysis as it included only one
study.
2.8.1 L-carnitine versus L-acetyl carnitine. There was an association
between the use of L-carnitine and increased progressive sperm
motility when compared to L-acetyl carnitine (Balercia 2005) (MD
6.30, 95% CI 0.42 to 12.18, 30 men, P = 0.04).
2.8.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was an association between the use of L-carnitine and increased
progressive sperm motility when compared to L-carnitine plus L-
acetyl carnitine (Balercia 2005) (MD 5.70, 95% CI 0.10 to 11.30, 29
men, P = 0.05).
2.8.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
progressive sperm motility when compared to L-carnitine plus L-
acetyl carnitine (Balercia 2005) (MD -0.60, 95% CI -6.93 to 5.73, 29
men, P = 0.85).
2.9 Progressive sperm motility at nine months or more; type of
antioxidant
See Analysis 2.9.
Pooling was not possible in this analysis as it included only one
study.
2.9.1 L-carnitine versus L-acetyl carnitine. There was no evidence
of the use of L-carnitine and increased progressive sperm motility
when compared to L-acetyl carnitine (Balercia 2005) (MD 3.80, 95%
CI -1.50 to 9.10, 30 men, P = 0.16).
2.9.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased progressive
sperm motility when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 5.50, 95% CI -0.11 to 11.11,29 men, P = 0.05).
2.9.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
progressive sperm motility when compared to L-carnitine plus L-
acetyl carnitine (Balercia 2005) (MD 1.70, 95% CI -4.17 to 7.57, 29
men, P = 0.57).
2.10 Sperm concentration at three months or less; type of
antioxidant
See Analysis 2.10.
Pooling was not possible in this analysis as the six studies included
in this analysis reported on single subgroups.
2.10.1 Docosahexaenoic acid (DHA) 400 mg versus DHA 800 mg.
There was no evidence of the use of DHA 400 mg and increased
sperm concentration when compared to DHA 800 mg (Conquer
2000) (MD -6.80, 95% CI -41.87 to 28.27, 19 men, P = 0.70).
2.10.2 Ethyl cysteine versus vitamin E. There was no evidence of
the use of ethyl cysteine and increased sperm concentration when
compared to vitamin E (Akiyama 1999) (MD 2.20, 95% CI -16.65 to
21.05, 10 men, P = 0.82).
2.10.3 L-carnitine versus vitamin E plus vitamin C. There was an
association between the use of L-carnitine and increased sperm
concentration when compared to vitamin E plus vitamin C (Li
2005a) (MD 15.50, 95% CI 12.49 to 18.51, 63 men, P < 0.00001).
2.10.4 L-carnitine plus vitamin E versus vitamin E. There was no
evidence of the use of L-carnitine plus vitamin E and increased
sperm concentration when compared to vitamin E (Wang 2010) (MD
1.90, 95% CI -10.52 to 14.32, 113 men, P = 0.76).
2.10.5 L-carnitine versus L-acetyl carnitine. There was no evidence
of the use of L-carnitine and increased sperm concentration when
compared to L-acetyl carnitine (Balercia 2005) (MD 1.70, 95% CI
-10.97 to 14.37, 30 men, P = 0.79).
2.11.6 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased sperm
concentration when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 4.10, 95% CI -9.17 to 17.37, 30 men, P = 0.54).
2.10.7 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
sperm concentration when compared to L-carnitine plus L-acetyl
carnitine (Balercia 2005) (MD 2.40, 95% CI -11.14 to 15.94, 30 men,
P = 0.73).
2.10.8 Selenium versus combined antioxidants. There was no
evidence of the use of selenium and increased sperm concentration
when compared to combined antioxidants (Scott 1998) (MD 14.70,
95% CI -6.51 to 35.91, 46 men, P = 0.17).
2.10.9 Zinc versus folic acid. There was no evidence of the use of zinc
and increased sperm concentration when compared to folic acid
(Azizollahi 2013) (MD -5.30, 95% CI -23.38 to 12.78, 80 men, P = 0.57).
2.10.10 Zinc plus folic acid versus folic acid. There was no evidence
of the use of zinc plus folic acid and increased sperm concentration
when compared to folic acid alone (Azizollahi 2013) (MD -4.20, 95%
CI -22.21 to 13.81, 80 men, P = 0.65).
2.10.11 Zinc versus zinc plus folic acid. There was no evidence of
the use of zinc and increased sperm concentration when compared
to zinc plus folic acid (Azizollahi 2013) (MD -1.10, 95% CI -18.63 to
16.43, 80 men, P = 0.90)
2.11 Sperm concentration at six months or less; type of
antioxidant
See Analysis 2.11.
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Pooling was not possible in this analysis as of the three studies
included in this analysis there were data for only one study per
subgroup.
2.11.1 L-carnitine versus L-acetyl carnitine. There was no evidence
of the use of L-carnitine and increased sperm concentration when
compared to L-acetyl carnitine (Balercia 2005) (MD 5.90, 95% CI
-8.92 to 20.72, 30 men, P = 0.44).
2.11.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased sperm
concentration when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 8.10, 95% CI -5.54 to 21.74, 30 men, P = 0.24).
2.11.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
sperm concentration when compared to L-carnitine plus L-acetyl
carnitine (Balercia 2005) (MD 2.20, 95% CI -10.89 to 15.29, 30 men,
P = 0.74).
2.11.4 N-acetylcysteine (NAC) versus selenium plus NAC. There
was an association between the use of NAC and decreased sperm
concentration when compared to selenium plus NAC (Safarinejad
2009) (MD -5.30, 95% CI -6.86 to -3.74, 234 men, P < 0.00001).
2.11.5 Selenium versus N-acetylcysteine (NAC). There was no
evidence of the use of selenium and increased sperm concentration
when compared to NAC (Safarinejad 2009) (MD 0.80, 95% CI -0.71 to
2.31, 234 men, P = 0.30).
2.11.6 Selenium versus selenium plus N-acetylcysteine (NAC).
There was an association between the use of selenium and
decreased sperm concentration when compared to selenium plus
NAC (Safarinejad 2009) (MD -4.50, 95% CI -6.20 to -2.80, 232 men, P
< 0.00001).
2.11.7 Zinc versus folic acid. There was no evidence of the use of zinc
and increased sperm concentration when compared to folic acid
(Azizollahi 2013) (MD -9.50, 95% CI -20.31 to 1.31, 80 men, P = 0.08).
2.11.8 Zinc plus folic acid versus folic acid. There was no evidence
of the use of zinc plus folic acid and increased sperm concentration
when compared to folic acid (Azizollahi 2013) (MD -1.50, 95% CI
-15.06 to 12.06, 80 men, P = 0.83).
2.11.9 Zinc versus zinc plus folic acid. There was no evidence of the
use of zinc and increased sperm concentration when compared to
zinc plus folic acid (Azizollahi 2013) (MD -8.00, 95% CI -23.69 to 7.69,
80 men, P = 0.32).
Data not usable for meta-analysis
See Analysis 2.12.
One study Wong 2002 reported data as medians and ranges for
these three subgroups. There may have been an association with
improved sperm concentration at six months for the intervention
groups when compared to the control groups, however these data
were not rigorous and no conclusions could be made.
2.13 Sperm concentration at nine months or more; type of
antioxidant
See Analysis 2.13.
Pooling was not possible in this analysis as only one study reported
on two subgroups.
2.13.1 L-carnitine versus L-acetyl carnitine. There was no evidence
of the use of L-carnitine and increased sperm concentration when
compared to L-acetyl carnitine (Balercia 2005) (MD 8.20, 95% CI
-0.07 to 16.47, 30 men, P = 0.05).
2.13.2 L-carnitine versus L-carnitine plus L-acetyl carnitine. There
was no evidence of the use of L-carnitine and increased sperm
concentration when compared to L-carnitine plus L-acetyl carnitine
(Balercia 2005) (MD 6.10, 95% CI -3.74 to 15.94, 30 men, P = 0.22).
2.13.3 L-acetyl carnitine versus L-carnitine plus L-acetyl carnitine.
There was no evidence of the use of L-acetyl carnitine and increased
sperm concentration when compared to L-carnitine plus L-acetyl
carnitine (Balercia 2005) (MD -2.10, 95% CI -10.24 to 6.04, 30 men,
P = 0.61).
Funnel plot
We assessed publication bias by using a funnel plot. Only the
outcome of clinical pregnancies included 10 studies. There was
no clear evidence of publication bias. We did not have enough
studies to look at each of the subgroups for publication bias
(Figure 6). However, the majority of the other studies (33) included
in this review reported only on sperm parameters. Only 30 of
the 61 studies reported on pregnancy. Only six studies reported
live birth (Balercia 2005; Blomberg Jensen 2018; Kessopoulou
1995; Omu 1998; Suleiman 1996; Tremellen 2007). The author
of Balercia 2005 provided live birth data for this update. No
new studies in the update reported on live birth. Twelve studies
reported on clinical pregnancy (Attallah 2013; Azizollahi 2013;
Balercia 2005; Barekat 2016; Busetto 2018; Deng 2014; Haje
2015; Kessopoulou 1995; Omu 1998; Suleiman 1996; Tremellen
2007; Zavaczki 2003). Seventeen studies reported on biochemical
pregnancy or undefined pregnancy (Balercia 2009; Cavallini 2004;
Ener 2016; Exposito 2016; Galatioto 2008; Gopinath 2013; Lenzi
2003; Lenzi 2004; Li 2005; Nadjarzadeh 2011; Peivandi 2010; Pryor
1978; Rolf 1999; Safarinejad 2009a; Scott 1998; Sigman 2006;
Wang 2010) (Table 1). Six of these studies reported on pregnancy
rates even though this was not stated a priori in the methods
sections of the papers (Balercia 2005; Balercia 2009; Barekat 2016;
Kessopoulou 1995; Lenzi 2004; Omu 1998) (Table 2). Six studies
were included in both the clinical pregnancy and the live birth
analyses (Balercia 2005; Balercia 2009; Kessopoulou 1995; Omu
1998; Suleiman 1996; Tremellen 2007). Failure to report live birth
or pregnancy is common and of great loss as ultimately for couples
these are the most meaningful outcomes.
D I S C U S S I O N
Summary of main results
ELectiveness of antioxidants versus placebo or no treatment
Live birth
The findings of this review suggest that for subfertile men, the use
of antioxidants may be eLective in increasing a couple's chances of
having a live birth when compared to placebo or no treatment. It
was found that within the studies that contributed to the analysis
of live birth rate, the population of subfertile men had a baseline
or expected live birth rate of 12% and with the use of antioxidant
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this would increase to between 14% and 26%. However, there were
only seven studies with a total of 750 couples reporting on live birth
and the quality of this evidence was considered to be low (Summary
of findings for the main comparison). The methods were not well
explained in two out of seven of these studies, Suleiman 1996 had
a significant number of participants who dropped out of the study
and Omu 1998 used 'no treatment' as control which introduced
a degree of performance bias. We were unaware of how many of
the dropouts were from the treatment or control groups. When
these high-risk studies were removed from the analysis, there was
no evidence of association between the use of antioxidants and
increased live birth.
The apparent benefit from antioxidants persisted when analyses
were restricted to placebo-controlled studies and studies enrolling
men undergoing assisted reproductive techniques (ART) (in vitro
fertilisation (IVF)/intracytoplasmic sperm injection(ICSI)).
Clinical pregnancy
The findings of this review also suggest that for subfertile men
the use of antioxidants may be eLective in increasing a couple's
chances of clinical pregnancy rate when compared to placebo or no
treatment. It was found that within the studies that contributed to
the analysis of clinical pregnancy, the population of subfertile men
had a baseline or expected clinical pregnancy rate of 7%,and with
the use of antioxidants this would increase to between 12% and
26%. However there were only 11 studies with a total of 786 men
reporting on clinical pregnancy and the quality of this evidence
was considered to be low (Summary of findings for the main
comparison). The methods were not well explained in four of the
11 studies, with two of these studies having a significant number of
participants who dropped out of the study (Barekat 2016; Suleiman
1996). Furthermore, four of the 15  analyses (one trial had three
arms) crossed the line of no eLect with wide confidence intervals.
The apparent benefit from antioxidants persisted when analyses
were restricted to studies at lower risk of bias, studies of men not
undergoing ART, and studies of men post-varicocelectomy. This
benefit was not seen in the men undergoing IVF/ICSI.
Adverse events
There is no evidence that antioxidants used by the subfertile male
lead to an increased miscarriage risk when compared to placebo or
no treatment. It was found that within this population of subfertile
men with an expected miscarriage rate of 2%, the use of an
antioxidant would increase the chances of having a miscarriage to
between 1% and 13%. However, there were only three studies with
a total of 247 men reporting on miscarriage and the quality of this
evidence was very low quality (Summary of findings for the main
comparison). The event rate in this analysis was very low with only
eight miscarriages reported in three studies, furthermore there was
a high risk of bias within these studies.
The use of antioxidants by subfertile men may increase the
occurrence of mild gastrointestinal complaints when compared to
placebo or no treatment. It was found that within this population
of subfertile men with an expected gastrointestinal event rate of
2%, the use of an antioxidant would increase the chances of having
gastrointestinal complaints to between 2% and 9%. However,
there were only 11 studies with a total of 948 men reporting on
gastrointestinal complaints and the quality of this evidence was
very low (Summary of findings for the main comparison). The
event rate in this analysis was low with only 35 events reported;
furthermore there was a high risk of bias within these studies.
There was no evidence that the risk of other adverse events, such
as euphoria and ectopic pregnancy diLered between antioxidant or
control group.
Sperm DNA fragmentation
Only four studies (254 men) reported on sperm DNA fragmentation.
Antioxidant use showed a lowered sperm DNA fragmentation
when compared to placebo. One study reported substantial higher
DNA fragmentation rates (> 80%), which could be explained by
enrolment of post-varicocelectomy participants (Barekat 2016).
Sperm parameters
The findings for total sperm motility, progressive sperm motility
and concentration at three, six and nine months were unreliable
as heterogeneity was extremely high in each analysis. The only
subgroups within the analyses with low heterogeneity reported the
following.
• Carnitines (three studies, five intervention arms, 128 men)
showed evidence of increased total sperm motility at three
months when compared to placebo or no treatment• PUFAs (two studies, three intervention arms, 64 men) did not
show evidence of increased total sperm motility at three months
when compared to placebo• Combined antioxidants (three studies, four intervention arms,
203 men) showed evidence of increased total sperm motility at
three months when compared to placebo or no treatment• Zinc (two studies, 157 men) did not show evidence of increased
progressive sperm motility at three months when compared to
placebo• Folic acid (two studies, 81 men) did not show evidence
of increased progressive sperm motility when compared to
placebo• N-acetylcysteine (two studies, 95 men) did not show evidence of
increased sperm concentration at three months when compared
to placebo or no treatment• PUFAs (three studies, 108 men) showed evidence of increased
sperm concentration at three months when compared to
placebo or no treatment• Zinc (two studies, 157 men) showed evidence of increased
sperm concentration at three months when compared to
placebo• Carnitines (two studies, four intervention arms, 115 men) did not
show evidence of increased sperm concentration at six months
when compared to placebo
Comparisons for each parameter over time showed an
improvement aQer the use of antioxidants, especially aQer three
and six months of use. The slight decrease of this positive eLect
aQer nine months of use could be explained by a possible decrease
in therapy compliance or less living up to influencing lifestyle
factors such as smoking and alcohol use.
ELectiveness of antioxidants versus antioxidants ( head-to-head)
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In the head-to-head studies only two studies reported on live
birth and/or clinical pregnancy, one study with diLerent types
of carnitines in multiple arms (versus placebo) and one study
comparing vitamin D plus calcium with vitamin E plus vitamin C.
Only vitamin D plus calcium showed an association. However, due
to the small study size no direct conclusions can be drawn. The
head-to-head studies did not report adverse events.
Overall completeness and applicability of evidence
Of the 61 studies included in this review only seven reported
on the primary outcome of live birth, and only 12 reported on
clinical pregnancy rate. Live birth and clinical pregnancy rate are
the outcomes of most interest to subfertile couples and until these
are robustly reported by all subfertility studies we will not be able
to draw clear conclusions for the use of antioxidants for subfertile
men. We believe that the lower baseline rate for clinical pregnancy
than the baseline rate for live birth could be due to the diLerence in
included populations. In the clinical pregnancy analysis (11 studies)
there were three studies including men with varicocele; those
studies did not report live birth and were therefore not included
in the live birth rate analysis (seven studies). Adverse events such
as miscarriage, ectopic pregnancy, euphoria and gastrointestinal
side eLects appear to be poorly reported. The high heterogeneity
may be an artefact caused by some of the studies reporting very
small and potentially erroneous standard deviations (SDs). This
undermines the credibility of the data.
Two of the trials included in the analysis of the semen parameter
outcomes (Safarinejad 2009; Safarinejad 2009a) had consistently
reported SDs very much smaller than those reported by most
of the other included trials. The review authors considered that
these were potentially erroneous, but an attempt to check with the
study authors was unsuccessful. One other trial (Peivandi 2010),
also had very small SDs when compared to data in the other
trials but the authors confirmed, when contacted, that they are
indeed SDs and not standard errors (SEs). We tried to manage
these analyses in two diLerent ways: firstly by imputing SDs from
studies of a similar size and secondly by treating the data as SEs
and converting back to SDs, however heterogeneity remained high
in both situations so for the final analyses we reverted to the SDs
as reported in the studies. The low SDs may have been due to the
strict inclusion and exclusion criteria indicating that the trial was
homogenous in nature, however we were unable to carry out a
sensitivity analysis on these trials as pooling was not possible due
to high heterogeneity.
Sixteen of the 61 included trials were very small in size (randomising
< 50 men), 25 of 61 included trials were small in size (randomising
between 50 to 100 men) and only 20 of 61 included trials included
more then 100 men. The estimates of the intervention eLect tend to
be more beneficial in smaller studies. Smaller studies also may not
be as rigorous as the larger studies in their methodology (Higgins
2011).
We tried to assess which type of antioxidant might have a beneficial
eLect on the outcomes of interest in this review, however only
three studies at the most could be pooled in any antioxidant
subgrouping. Five studies (Busetto 2018; Gopinath 2013; Morgante
2010; Scott 1998; Tremellen 2007) used combined antioxidants
versus placebo or no treatment but only Tremellen 2007 reported
on live birth and clinical pregnancy rate. The other studies reported
on total or progressive sperm motility and concentration.
The head-to-head comparison does not provide constructive
information as we could not pool direct comparisons. Subgrouping
of antioxidants, or diLerent doses of antioxidants, was unable to
be performed in the treatment versus treatment groups as there
were only single studies analysing these diLerences. Therefore,
this review was unable to show any diLerence in eLect between
diLerent antioxidants or diLerent doses of the same antioxidant.
There were 24 studies that contained data that were unusable
in the analysis, with either some or all of their data (Biagiotti
2003; Boonyarangkul 2015; Cavallini 2004; Eslamian 2013; Exposito
2016; Gamidov 2017; Galatioto 2008; Haje 2015; Kessopoulou 1995;
Kumamoto 1988; Lenzi 2003; Lombardo 2002; Martinez 2015; Micic
2017; Nozha 2001; Omu 1998; Pourmand 2014; Poveda 2013; Pryor
1978; Raigani 2014; Sivkov 2011; Sofikitis 2016; Wong 2002; Zalata
1998). The reasons for this were baseline imbalance, presentation
of medians, percentages or ranges, and in some cases no SDs or SEs
were given (Analysis 1.10; Analysis 1.12; Analysis 1.14; Analysis 1.18;
Analysis 1.20; Analysis 1.24; Analysis 1.26; Analysis 2.5; Analysis
2.12). Attempts were made to contact these authors regarding the
data. There was no clear evidence of publication bias
Quality of the evidence
The evidence was graded as low to very low quality. The main
limitation of this review was that out of the 44 included studies
in the meta-analysis, only 13 studies reported on live birth or
clinical pregnancy. Other limitations included poor reporting of
study methods, imprecision, the number of small studies, reporting
bias and lack of data about adverse events.There was no clear
evidence of publication bias.
Figure 2 shows the review authors' judgements about the risk of
bias of the studies included in this review. All included studies
were described as randomised, however only less than 50% gave
information on how the randomisation was achieved. Allocation
concealment was described in only 31% of the studies. Blinding was
better described with over 56% of the studies being double-blinded
or occasionally single-blinded; 8% of studies stated that there was
no blinding and 21% of included studies used no treatment as
a control. Dropout rates were high in some studies and dropout
rates tended to be higher in the control groups, which created a
potential for diLerential follow-up with better reporting of clinical
pregnancies in the intervention groups. Reporting bias was unclear
in 87% of studies.
Potential biases in the review process
There may have been some potential for bias in the review process,
as there were some changes compared to the protocol. These
included additions and deletions to exclusion criteria such as the
removal of pentoxifylline, and adding the new outcome progressive
sperm motility. Some bias in the review process may have arisen
due to the inclusion of studies that have had a dropout of
participants of > 20%, with subsequent imbalances in the number
of participants between the treatment and control groups.
Agreements and disagreements with other studies or
reviews
The results of our review are in agreement with those of other
published systematic reviews. Two other reviews described the
eLects of L-carnitine and L-acetylcarnitine on subfertile men. The
systematic review and meta-analysis by Zhou and colleagues (Zhou
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
49
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
2007) compared L-carnitine and L-acetylcarnitine therapy versus
placebo treatment and found improvements in pregnancy rate
and total sperm motility. Our review was unable to pool the
results of the carnitine studies due to inconsistencies between
the studies. The descriptive review by Patel and Sigman (Patel
2008) discusses the improvement in pregnancy rates with oral
intake of antioxidants, however Patel states that randomised
controlled trials (RCTs) have not shown an eLect on sperm
motility and that there is a need for more RCTs in men with
oxidative stress. Furthermore, Garg 2016 discusses in a review the
eLect of antioxidants in men with varicocele. They conclude that
antioxidant therapy is a potential option as primary treatment or
adjunct aQer surgical repair of varicocele.
Agarwal and colleagues discussed in both an overview of the
literature (Agarwal 2004) and systematic review (Majzoub 2018),
the eLectiveness of antioxidants. In the 2004 overview Agarwal
notes that vitamin E and a combination of vitamin E with other
antioxidants such as N-acetylcysteine, vitamin A and fatty acids
appears to improve pregnancy rates in asthenozoospermic men.
This is in agreement with our review. However, their conclusion that
carnitines also appear to have an eLect on pregnancy rates could
not be confirmed. In the systematic review Majzoub 2018 included
29 studies, of which there were 19 RCTs and 10 prospective studies.
In 26 studies they found a significant positive eLect on basic semen
parameters, advanced sperm function tests, ART outcomes or live
birth rate. Specifically, a positive eLect was seen on live birth rate
and fertilisation rate when using vitamin E, vitamin C, carnitines,
coenzyme Q10 and zinc. A diLerence between diLering antioxidants
was not seen in our study.
Another review (Ross 2010) showed improvement in pregnancy rate
and sperm quality aQer antioxidant therapy. This is in agreement
with our review, although we are uncertain of the sperm parameter
outcomes due to the extreme heterogeneity. A systematic review
(Lafuente 2013) looking at the eLect of coenzyme Q10 and male
subfertility found an association between this antioxidant and
improved pregnancy rate, sperm concentration and motility. We
did agree on the eLect of coenzyme Q10 on sperm motility
and concentration at six months, however we could not draw
clear conclusions due to the heterogeneity in these analyses. A
more recent systematic review with meta-analysis studied the
eLectiveness of folate and folate plus zinc on sperm parameters in
subfertile men (Irani 2017). They concluded that folate alone was
only eLective on sperm concentration, and folate plus zinc only on
sperm concentration and morphology. Both interventions did not
have any eLect on sperm motility. This eLect of zinc plus folate or
folate alone could be confirmed with our review.
The above-mentioned systematic reviews mainly reported on
overall pregnancy rates, whereas this updated Cochrane Review
reported specifically on clinical pregnancy rates (as confirmed by
the identification of a gestational sac on ultrasound) so fewer
studies were available for analysis.
A Cochrane Review of antioxidants for female subfertility has been
published (Showell 2017) showing that there is limited evidence
for a beneficial eLect of antioxidants for subfertile women.
Furthermore, a recent systematic review and meta-analysis looking
at the eLect of micronutrient supplementation, in both male
and females, on IVF outcomes showed a positive influence on
clinical outcomes in terms of pregnancy rate and/or live birth
rate (Kofi Arhin 2017). However, only five RCTs could be included,
with significant heterogeneity among the interventions and study
designs.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In this review, there is low-quality evidence from seven
small randomised controlled trials suggesting that antioxidant
supplementation in subfertile males may improve live birth
rates for couples attending fertility clinics. Low-quality evidence
suggests that clinical pregnancy rates may also increase. Overall,
there is no evidence of increased risk of miscarriage, however
antioxidants may give more mild gastrointestinal upsets but the
evidence is of very low quality. Subfertilte couples should be
advised that overall the current evidence is inconclusive based
on serious risk of bias due to poor reporting of methods of
randomisation, failure to report on the clinical outcomes live birth
rate and clinical pregnancy, oQen unclear or even high attrition,
and also imprecision due to oQen low event rates and small overall
sample sizes. Further large well-designed randomised placebo-
controlled trials reporting on pregnancy and live births are still
required to clarify the exact role of antioxidants.
Implications for research
In this review there were only seven small studies reporting on
live birth, the most important outcome from the perspective of the
couple experiencing diLiculty with conception, and the number of
events was very small. Strangely, most of the trials in our meta-
analysis reporting on live birth are from before 2008. Despite our
recommendations in the original review and 2014 update on this
topic, principal investigators of clinical trials seem not to have taken
clinical outcomes into consideration, which leads to a great gap in
evidence. Only four studies reported on DNA fragmentation. A low
degree of DNA fragmentation is thought to increase the likelihood
of achieving a pregnancy. Further large well-designed placebo-
controlled randomised trials with live birth as primary outcome are
needed.
Five studies (Busetto 2018; Gopinath 2013; Morgante 2010; Scott
1998; Tremellen 2007) used combined antioxidants (three or more
antioxidants) versus control but reported on diLerent outcomes.
The results were generally in favour of the antioxidant over the
control. However, there is a need for more randomised controlled
trials in order to make any conclusions on whether a combination
of antioxidants would have a statistically significant benefit over a
single antioxidant versus placebo.
If evidence emerges from placebo-controlled randomised trials
which shows that antioxidant supplements improve clinical
outcomes (pregnancy and live birth) then randomised head-to-
head trials will be needed to assess whether one antioxidant is
more eLective than another in terms of size of benefit. A network
meta-analysis could be of interest.
There is also a gap in the evidence as to whether diLerent doses
of an antioxidant have diLerent eLects. This review was only able
to include single studies measuring diLerent doses and therefore
meta-analysis of this comparison was not possible.
Evidence to date shows that few studies reported side eLects.
According to the studies that did report, the side-eLect profile of
antioxidants was low and mild. However, more data are required to
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evaluate fully any adverse events and the side eLect profile of these
supplements.
A C K N O W L E D G E M E N T S
Cochrane Gynaecology and Fertility group. I would like to make
special mention of the editors who were very thorough and helpful
in editing this review.
Many thanks to the translators of the non-English studies: Ichiro
Omori, Shaofu Li, Ivan Sola, Pawel Kanturski, Dr Peviandi, Shaofu
Li, Farhad Shokraneh, Taixiang Wu, Juliane Reid, Roberto D'Amico,
Vasily Vlassov, Liu Qin, Jianping Liu, Guoyan Yang, Gustavo Porfi,
Valter Silva, Maíra Parra, Dr Tomoko Kumaga, Tan Wantao and
Andrew Dubovyi. A special thank you to Juliane Reid and Helen
Nagels for putting us in touch with many of our translators.
Thanks also to Stephan Bontekoe who kindly helped with some of
the text in the original review.
We acknowledge comments sent by Tina Kold Jensen, Niels Erik
Skakkebaek, Niels Jørgensen, Martin Blomberg Jensen, Anders
Juul, Peter Gøtzsche, Department of Growth and Reproduction, and
The Nordic Cochrane Centre, Rigshospitalet, Denmark. Our formal
response was published in December 2011 and the points made
have been addressed.
The authors of the 2018 review thank Professor Roger Hart for his
contributions to all previous version of this review.
Further information for the studies was received from:
Dr N Adel (Adel 2015)
Dr Ovchinnikov (Gamidov 2017)
Dr Zavari (Gopinath 2013)
Dr Kabir (Cyrus 2015)
Professor Matorras (Exposito 2016)
Dr Balercia (Balercia 2005; Balercia 2009)
Dr Busetto (Busetto 2018)
Dr Nasr-Esfahani (Barekat 2016)
Dr Irge (NCT01520584)
Dr Dimitriadis (Sofikitis 2016)
Dr Agarwal and ms. Micic (Micic 2017)
Dr Norouzi (Sharifzadeh 2016)
Dr Hekmatdoost (NCT01846325)
Dr Mathieu-d'Argent (NCT01407432)
Dr Kamath (CTRI/2013/02/003431)
Dr Pinter (NCT02310087)
Dr Nematollahi-mahani (Azizollahi 2013),
Associate Professor Kelton Tremellen (Tremellen 2007).
Dr Kamath (CTRI/2013/02/003431)
Dr Peivandi (Peivandi 2010)
Dr El Gindy (Elgindy 2008)
Dr M Sigman (Sigman 2006)
Professor Niewchlag (Rolf 1999)
Dr Cavallini (Cavallini 2004)
Dr Wang (Wang 1983)
Dr Martinez-Soto (Martinez-Soto 2010)
Dr Morgante (Morgante 2010)
Dr Nadjarzadeh (Nadjarzadeh 2011)
Dr Safarinejad (Safarinejad 2009; Safarinejad 2009a).
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
51
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
R E F E R E N C E S
 
References to studies included in this review
Akiyama 1999 {published data only}
Akiyama M. In vivo scavenging eLect of ethylcysteine on
reactive oxygen species in human semen. Japanese Journal of
Urology 1999;90(3):421-8.
Attallah 2013 {published data only}
Attallah D, El Nashar IH, Mahmoud R, Shaaban OM, Salman SA.
N-acytelcysteine prior to intrauterine insemination in couples
with isolated athenozospermia: a randomized controlled trial.
Fertility and Sterility 2013;100(3 Suppl):S462.
Azizollahi 2013 {published data only}
*  Azizollahi G, Azizollahi S, Babaei H, Kianinejad M, Baneshi MR,
Nematollahi-mahani SN. ELects of supplement therapy on
sperm parameters, protamine content and acrosomal integrity
of varicocelectomized subjects. Journal of Assisted Reproduction
and Genetics 2013;30(4):593-9.
Azizollahi G, Azizollahi S, Babaei H, Kianinejad MA, Baneshi MR,
Nematollahi-Mahani SN. ELects of zinc sulfate and folic acid
coadministration on sperm parameters, protamine content
and acrosomal integrity of varicocelectomized patients. Iranian
Journal of Reproductive Medicine 2013;1):37.
Azizollahi S, Azizollahi G, Nematollahi SN, Babaei H, Rastegari A,
Maghsudi S. The eLect of folic acid administration on protamine
deficiency, acrosomal activity and semen parameters in
varicocelectomized patients. Human Reproduction 2011;26
Suppl 1 Abstract no: P-57:i340.
Azizollahi S, Nematollahi-Mahani SN, Azizollahi G, Baneshi MR,
Safari Z. The eLect of folic acid and zinc sulfate on endocrine
parameters and seminal antioxidant level, aQer variocelectomy.
Iranian Journal of Reproductive Medicine 2013;1):36.
Balercia 2005 {published data only}
Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M.
Placebo-controlled double-blind randomized trial on the use
of L-carnitine, L-acetylcarnitine, or combined L-carnitine and
L-acetylcarnitine in men with idiopathic asthenozoospermia.
Fertility and Sterility 2005;84(3):662-71.
Balercia 2009 {published data only}
Balercia G, Buldreghini E, Vignini A, Tiano L, Paggi F, Amoroso S,
et al. Coenzyme Q10 treatment in infertile men with idiopathic
asthenozoospermia: a placebo-controlled, double-blind
randomized trial. Fertility and Sterility 2009;91(5):1785-92.
Barekat 2016 {published data only}
Barekat F, Tavalaee M, Deemeh MR, Bahreinian M, Azadi L,
Abbasi H, et al. A Preliminary Study: N-acetyl-L-cysteine
Improves Semen Quality following Varicocelectomy.
International Journal of Fertility & Sterility 2016;10(1):120-6.
Biagiotti 2003 {published data only}
Biagiotti G, Cavallini G, Modenini F, Vitali G, Magli C, Ferraretti A.
Prostaglanadins pulsed down-regulation enhances carnitine
therapy performance in severe idiopathic oligoasthenospermia.
Human Reproduction 2003;18 Suppl 1:202.
Blomberg Jensen 2018 {published data only}
*  Blomberg Jensen M, Gerner Lawaetz J, Andersson A,
Petersen JH, Nordkap L, Bang AK, et al. Vitamin D deficiency
and low ionized calcium are linked with semen quality and
sex steroid levels in infertile men. Human Reproduction
2016;31(8):1875-85.
*  Blomberg Jensen M, Lawaetz JG, Petersen JH, Juul A,
Jorgensen N. ELects of vitamin D supplementation on
semen quality, reproductive hormones, and live birth rate: a
randomized clinical trial. Journal of Clinical Endocrinology &
Metabolism 2018;103(3):870-81.
Boonyarangkul 2015 {published data only}
Boonyarangkul A, Vinayanuvattikhun N, Chiamchanya C,
Visutakul P. Comparative study of the eLects of tamoxifen
citrate and folate on semen quality of the infertile male with
semen abnormality. Journal of the Medical Association of
Thailand 2015;98(11):1057-63.
Busetto 2018 {published data only}
Busetto G, Virmani A, Del Giudice F, Micic S, Agarwal A,
De Berardinis E. Varicocele and oligoasthenoteratozoo-spermia:
Evaluation of antioxidant supplementation eLect on pregnancy
rate and sperm quality. Fertility and Sterility 2017;108 (3
Supplement 1):e133.
Busetto G, Virmani MA, Antonini G, Ragonesi G, De Berardinis E,
Agarwal A, et al. ELect of antioxidant supplementation on
sperm parameters in oligoasthenoteratozoospermia, with and
without varicocele: A DBPC study. Fertility and Sterility 2016;106
(Supplement 3):e46.
*  Busetto GM, Agarwal A, Virmani A, Antonini G, Ragonesi G,
Del Giudice F, et al. ELect of metabolic and antioxidant
supplementation on sperm parameters in oligo-astheno-
teratozoospermia, with and without varicocele: a double-blind
placebo-controlled study. Andrologia 2018;07:07.
Busetto GM, Virmani A, Antonini G, Ragonesi G, Del Giudice F,
Agarwal A, et al. ELect of antioxidant supplementation on
sperm parameters in oligo-astheno-teratozoospermia, with
and without varicocele: A double blind place controlled (DBPC)
study. Human Reproduction 2017;32 (Supplement 1):i142-3.
Cavallini 2004 {published data only}
*  Cavallini G, Ferraretti AP, Gianaroli L, Biagiotti G, Vitali G.
Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for
idiopathic and varicocoele associated oligoasthenospermia [see
comment]. Journal of Andrology 2004; Vol. 25, issue 5:761-70.
Cavallini G, Ferraretti AP, Gianaroli L, Magli MC, Biagiotti G,
Vitali G. Cinnoxicam + carnitines for idiopathic dyspermia.
The 20th Annual Meeting of the European Society of Human
Reproduction and Embryology. Human Reproduction
2004:i23-4.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
52
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Conquer 2000 {published data only}
Conquer JA, Martin JB, Tummon I, Watson L, Tekpetey F. ELect
of DHA supplementation on DHA status and sperm motility in
asthenozoospermic males. Lipids 2000;35(2):149-54.
Cyrus 2015 {published data only}
Cyrus A, Kabir A, Goodarzi D, Moghimi M. The eLect of adjuvant
vitamin C aQer varicocele surgery on sperm quality and quantity
in infertile men: a double blind placebo controlled clinical trial.
International Brazilian Journal of Urology 2015; Vol. 41, issue
2:230-8.
Dawson 1990 {published data only}
Dawson EB, Harris WA, Powell LC. Relationship between
ascorbic acid and male fertility. World Review of Nutrition and
Dietetics 1990; Vol. 62:1-26.
Deng 2014 {published data only}
*  Deng XL, Li YM, Yang XY, Huang JR, Guo SL, Song LM.
ELicacy and safety of vitamin D in the treatment of idiopathic
oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue =
National Journal of Andrology 2014; Vol. 20, issue 12:1082-5.
Deng XL, Li YM, Yang XY, Huang JR, Guo SL, Song LM. [ELicacy
and safety of vitamin D in the treatment of idiopathic
oligoasthenozoospermia]. Zhong Hua Nan Ke Xue 2014; Vol. 20,
issue 12:1082-5.
Dimitriadis 2010 {published data only}
Dimitriadis F, Tsambalas S, Tsounapi P, Kawamura H,
Vlachopoulou E, Haliasos N, et al. ELects of
phosphodiesterase-5 inhibitors on Leydig cell secretory
function in oligoasthenospermic infertile men: A randomized
trial. BJU International 2010;106(8):1181-5.
Ener 2016 {published data only}
Ener K, Aldemir M, Isik E, Okulu E, Ozcan MF, Ugurlu M, et al. The
impact of vitamin E supplementation on semen parameters and
pregnancy rates aQer varicocelectomy: A randomised controlled
study. Andrologia 2016;48(7):829-34.
Eslamian 2013 {published data only}
*  Eslamian G, Amirjannati N, Sadeghi MR, Rashidkhani B,
Pahlavan S, Hooshangi A, et al. The eLects of combined
supplementation of docosahexaenoic acid and vitamin E on
fatty acid changes in sperm membrane in asthenozoospermic
men. Iranian Journal of Nutrition Sciences & Food Technology
2013;8(1):23-37.
Hekmatdoost A. The eLects of administration of combined
docosahexaenoic acid and vitamin E supplements on
spermatogram and seminal plasma oxidative stress in
infertile men with asthenozoospermia. www.clinicaltrials.gov.
[ClinicalTrials.gov: NCT01846325]
Exposito 2016 {published data only}
*  Exposito A, Perez-Sanz J, Crisol L, Aspichueta F, Quevedo S,
Diaz-Nunez M, et al. A prospective double-blind randomized
placebo-controlled study of the eLect of vitamin E on semen
parameters in infertile men. Human Reproduction 2016; Vol. 31
(Supplement 1):i137-8.
Exposito A, Perez-Sanz J, Crisol L, Aspichueta F, Quevedo S,
Diaz-Nunez M, et al. A prospective double-blind randomized
placebo-controlled study of the eLect of vitamin E on semen
parameters in infetile men. Human Reproduction 2016; Vol. 31
(Supp1):i137-i138 Abstract no: P-018.
Galatioto 2008 {published data only}
Galatioto GP, Gravina GL, Angelozzi G, Sacchetti A,
Innominato PF, Pace G, et al. May antioxidant therapy improve
sperm parameters of men with persistent oligospermia aQer
retrograde embolization for varicocele?. World Journal of
Urology 2008; Vol. 26, issue 1:97-102.
Gamidov 2017 {published data only}
*  Gamidov SI, Ovchinnikov RI, Popova AY, Avakyan AY,
Sukhikh GT. Adjuvant antioxidant therapy in varicocele
infertility. [Russian]. Urologiia 2017; Vol. 2:64-72.
Gamidov SI, Ovchinnikov RI, Popova AY, Avakyan AY, Sukhikh GT.
[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia
(Moscow, Russia) 2017, issue 2 (supplement):64-72.
Gopinath 2013 {published data only}
Gopinath PM, Kalra B, Saxena A, Malik S, Kochhar K, Kalra S, et
al. Fixed dose combination therapy of antioxidants in treatment
of idiopathic oligoasthenozoospermia: Results of a randomized,
double-blind, placebo-controlled clinical trial. International
Journal of Infertility and Fetal Medicine 2013; Vol. 4, issue
1:6-13.
Greco 2005 {published data only}
Greco E, Iacobelli M, Rienzi L, Ubaldi F, Ferrero S, Tesarik J.
Reduction of the incidence of sperm DNA fragmentation by oral
antioxidant treatment. Journal of Andrology 2005; Vol. 26, issue
3:349-53.
Haghighian 2015 {published data only}
Haghighian HK, Haidari F, Mohammadi-Asl J, Dadfar M.
Randomized, triple-blind, placebo-controlled clinical trial
examining the eLects of alpha-lipoic acid supplement on the
spermatogram and seminal oxidative stress in infertile men.
Fertility & Sterility 2015; Vol. 104, issue 2:318-24.
Haje 2015 {published data only}
Haje M, Naoom K. Combined tamoxifen and L-carnitine
therapies for the treatment of idiopathic male infertility
attending intracytoplasmic sperm injection: A randomized
controlled trial. International Journal of Infertility and Fetal
Medicine 2015; Vol. 6, issue 1:20-4.
Kessopoulou 1995 {published data only}
Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell JM,
Cooke ID, et al. A double-blind randomized placebo cross-over
controlled trial using the antioxidant vitamin E to treat reactive
oxygen species associated male infertility. Fertility and Sterility
1995; Vol. 64, issue 4:825-31.
Kumamoto 1988 {published data only}
Kumamoto Y, Maruta H, Ishigami J, Kamidono S, Orikasa S,
Kimura M, et al. Clinical eLicacy of mecobalamin in the
treatment of oligozoospermia--results of double-blind
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
53
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
comparative clinical study. Hinyokika Kiyo. Acta Urologica
Japonica 1988;34:1109-32.
Lenzi 2003 {published data only}
Lenzi A, Lombardo F, Sgro P, Salacone P, Caponecchia L,
Dondero F, et al. Use of carnitine therapy in selected cases
of male factor infertility: a double-blind crossover trial [see
comment]. Fertility and Sterility 2003; Vol. 79, issue 2:292-300.
Lenzi 2004 {published data only}
Lenzi A, Sgro P, Salacone P, Paoli D, Gilio B, Lombardo F, et al. A
placebo-controlled double-blind randomized trial of the use of
combined l-carnitine and l-acetyl-carnitine treatment in men
with asthenozoospermia [see comment]. Fertility and Sterility
2004; Vol. 81, issue 6:1578-84.
Li 2005 {published data only}
Li Z, Chen GW, Shang XJ, Bai WJ, Han YF, Chen B, et al.
A controlled randomized trial of the use of combined L-
carnitine and acetyl-L-carnitine treatment in men with
oligoasthenozoospermia. Zhong Hua Nan Ke Xue 2005; Vol. 11,
issue 10:761-4.
Li 2005a {published data only}
Li Z, Gu R, Liu Y, Xiang Z, Cao X, Han Y, et al. Curative eLect of L-
carnitine supplementation in the treatment of male infertility.
Academic Journal of Shanghai Second Medical University 2005;
Vol. 25, issue 3:292-4.
Lombardo 2002 {published data only}
Lombardo F, Gandini L, Agarwal A, Sgro P, Dondero F, Lenzi A. A
prospective double blind placebo controlled cross over trial of
carnitine therapy in selected cases of male infertility. Fertility
and Sterility 2002; Vol. 78 Suppl 1:68-9.
Martinez 2015 {published data only}
Martinez AM, Sordia-Hernandez LH, Morales JA, Merino M,
Vidal O, Garcia Garza MR, et al. A randomized clinical
study assessing the eLects of the antioxidants, resveratrol
or SC1002, a hydrogen sulfide prodrug, on idiopathic
oligoasthenozoospermia. Asian Pacific Journal of Reproduction
2015; Vol. 4, issue 2:106-11.
Martinez-Soto 2010 {published data only}
Martinez-Soto JC, Domingo JC, Cardobilla LP, Pellicer A,
Landeras J. ELect of dietary DHA supplementation on
sperm DNA integrity. Fertility and Sterility September
2010;94(4):S235-6.
Mehni 2014 {published data only}
Mehni NM, Ketabchi AA, Hosseini E. Combination
eLect of pentoxifylline and L-carnitine on idiopathic
oligoasthenoteratozoospermia. Iranian Journal of Reproductive
Medicine 2014; Vol. 12, issue 12:817-24.
Micic 2017 {published data only}
Micic S, Lalic N, Bojanic N, Djordjevic D, Virmani A, Agarwal A.
Assessment of sperm motility in oligoasthenospermic
men, treated with metabolic and essential nutrients, in a
randomized, double blind, placebo study. Human Reproduction
2016; Vol. 31 (Supplement 1):i151-2.
Micic S, Lalic N, Bojanic N, Djordjevic D, Virmani A, Agarwal A.
DBPC study in oligoasthenospermic men treated with metabolic
and essential nutrients showed that progressive sperm motility
was correlated to seminal carnitine levels. Andrology 2016; Vol.
4 (Supplement 2):56.
*  Micic S, Lalic N, Bojanic N, Djordjevic D, Virmani A, Agarwal A.
DBPC study showed significant correlation of DNA fragmetation
index (DFI) and seminal carnitine with progressive sperm
motility in oligospermic men treated with metabolic and
essential nutrients. Fertility and Sterility 2017; Vol. 108 (3
Supplement 1):e307-8.
Micic S, Lalic N, Bojanic N, Djordjevic D, Virmani A, Agarwal A.
Oligoastenospermic men treated with proxeed plus showed
correlation between sperm motility and seminal carnitine.
Fertility and Sterility 2016; Vol. 106 (Supplement 3):e298-9.
Micic S, Lalic N, Djordjevic D, Bogavac-Stanojevic N, Virmani A,
Agarwal A. Seminal carnitine and DNA fragmentation index (DFI)
impact progressive sperm motility in oligoasthenospermic men
treated with metabolic and essential nutrients, with moderate
accuracy. Human Reproduction 2017; Vol. 32 (Supplement
1):i132.
Morgante 2010 {published data only}
Morgante G, Scolaro V, Tosti C, Di Sabatino A, Piomboni P,
De Leo V. Treatment with carnitine, acetyl carnitine, L-arginine
and ginseng improves sperm motility and sexual health in
men with asthenopermia. Minerva Urologica e Nefrologica
2010;62(3):213-8.
Nadjarzadeh 2011 {published data only}
Nadjarzadeh A, Shidfar F, Amirjannati N, Vafa MR, Motevalian SA,
Gohari MR, et al. Coenzyme Q10 improves seminal oxidative
defense but does not aLect on seman in idiopathic
oligoasthenoteratozoospermia: A randomized double-
blind placebo controlled trial. Journal of Endocrinological
Investigation 2011;34:e224-8.
Nozha 2001 {published data only}
Nozha CF, Leila AK, Zouhir S, Hanen G, Khled Z, Tarek R.
Oxidative stress and male infertility: comparative study of
combined vitamin E/selenium treatment versus vitamin B.
Human Reproduction 2001; Vol. 17, issue Abstract book 1:111-2.
Omu 1998 {published data only}
Omu AE, Dashti H, Al-Othman S. Treatment of
asthenozoospermia with zinc sulphate: andrological,
immunological and obstetric outcome. European Journal of
Obstetrics, Gynecology, and Reproductive Biology 1998; Vol. 79,
issue 2:179-84.
Omu 2008 {published data only}
Omu AE, Al-Azemi MK, Kehinde EO, Anim JT, Oriowo MA,
Mathew TC. Indications of the mechanisms involved in
improved sperm parameters by zinc therapy. Medical Principles
and Practice 2008; Vol. 17, issue 2:108-16.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Peivandi 2010 {published data only}
Peivandi S, Abasali K, Narges M. ELects of L-carnitine on infertile
men's spermogram; a randomised clinical trial. Journal of
Reproduction and Infertility 2010;10(4):331.
Pourmand 2014 {published data only}
*  Pourmand G, Movahedin M, Dehghani S, Mehrsai A, Ahmadi A,
Pourhosein M, et al. Does L-carnitine therapy add any extra
benefit to standard inguinal varicocelectomy in terms of
deoxyribonucleic acid damage or sperm quality factor indices: a
randomized study. Urology 2014; Vol. 84, issue 4:821-5.
Pourmand GH, Movahedin M, Dehghan S, Mehrsai A, Ahmadi A,
Pourhosein M. Does L-carnitine therapy add any extra benefit to
standard inguinal varicocelectomy in terms of deoxyribonucleic
acid damage or sperm quality factor indices: a randomized
study. Iranian Journal of Reproductive Medicine. 2015, issue 4
suppl. 1:67.
Poveda 2013 {published data only}
Poveda C, Rodriguez R, Chu EE, Aparicio LE, Gonzales IG,
Moreno CJ. A placebo-controlled double-blind randomized trial
of the eLect of oral supplementation with spermotrend, maca
extract (lepidium meyenii) or L-carnitine in semen parameters
of infertile men. Fertility and Sterility 2013; Vol. 100, issue 3
Suppl:S440.
Pryor 1978 {published data only}
Pryor JP, Blandy JP, Evans P, Chaput de Saintonge DM,
Usherwood M. Controlled clinical trial of arginine for infertile
men with oligozoospermia. British Journal of Urology
1978;50:47-50.
Raigani 2014 {published data only}
Raigani M, Yaghmaei B, Amirjannti N, Lakpour N, Akhondi MM,
Zeraati H, et al. The micronutrient supplements, zinc sulphate
and folic acid, did not ameliorate sperm functional parameters
in oligoasthenoteratozoospermic men. Andrologia 2014; Vol. 46,
issue 9:956-62.
Rolf 1999 {published data only}
*  Rolf C, Cooper TG, Yeung CH, Nieschlag E. Antioxidant
treatment of patients with asthenozoospermia or moderate
oligoasthenozoospermia with high-dose vitamin C and vitamin
E: a randomized, placebo-controlled, double-blind study.
Human Reproduction 1999;14(4):1028-33.
Rolf C, Cooper TG, Yeung CH, Nieschlag E. Antioxidant
treatment of patients with asthenozoospermia or moderate
oligoasthenozoospermia with high-dose vitamin C and vitamin
E: a randomized, placebo-controlled, double-blind study [see
comment]. Human Reproduction 1999;14(4):1028-33.
Safarinejad 2009 {published data only}
Safarinejad MR, Safarinejad S. ELicacy of selenium and/or N-
acetyl-cysteine for improving semen parameters in infertile
men: a double-blind, placebo controlled, randomized study.
Journal of Urology 2009;181(2):741-51.
Safarinejad 2009a {published data only}
Safarinejad ME. ELicacy of coenzyme Q10 on semen
parameters, sperm function and reproductive hormones in
infertile men. Journal of Urology 2009;182(1):237-48.
Safarinejad 2012 {published data only}
Safarinejad MR, Shafiei N, Safarinejad S. ELects of the reduced
form of coenzyme Q10 (ubiquinol) on semen parameters in men
with idiopathic infertility: A double-blind, placebo controlled,
randomized study. Journal of Urology 2012;188(2):526-31.
Scott 1998 {published data only}
Scott R, MacPherson A, Yates RW, Hussain B, Dixon J. The eLect
of oral selenium supplementation on human sperm motility.
British Journal of Urology 1998; Vol. 82, issue 1:76-80.
Sharifzadeh 2016 {published data only}
Sharifzadeh F, Norouzi S, Ashrafi M, Aminimoghaddam S,
Koohpayezadeh J. ELects of zinc sulfate on subfertility related
to male factors: a prospective double-blind, randomized,
placebo-controlled clinical trial. Journal of Obstetrics,
Gynecology and Cancer Research 2016; Vol. 1, issue 2:e7242.
[2476-5848]
Sigman 2006 {published data only}
Pryor JL, Stacy L, Glass S, Campagnone J, Sigman M.
Randomized double blind placebo controlled trial of carnitine
for the treatment of idiopathic asthenospermia. Fertility and
Sterility 2003;80 Suppl 3:48.
*  Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for
the treatment of idiopathic asthenospermia: a randomized,
double-blind, placebo-controlled trial. Fertility and Sterility
2006;85(5):1409-14.
Sivkov 2011 {published data only}
Sivkov AV, Oshchepkov VN, Evdokimov VV, Keshishev NG,
Skabko OV. Selzink plus study in patients with chronic non-
infectious prostatitis and abnormal fertility. [Russian]. Urologii
2011; Vol. 5:27-33.
Sofikitis 2016 {published data only}
Sofikitis N, Dimitriadis F, Skouros S, Stavrou S, Seminis G,
Giannakis I, et al. ELects of avanafil on semen quality and
sperm cytoskeleton in oligoasthenospermic infertile men: A
randomized controlled trial. Journal of Sexual Medicine 2016;
Vol. 2:S164-5.
Suleiman 1996 {published data only}
Suleiman SA, Ali ME, Zaki ZM, el-Malik EM, Nasr MA. Lipid
peroxidation and human sperm motility: protective role of
vitamin E. Journal of Andrology 1996; Vol. 17, issue 5:530-7.
Tremellen 2007 {published data only}
Tremellen K, Froiland D, Miari G, Thompson J. A randomised
control trial examining the eLect of an antioxidant on sperm
function pregnancy outcome during IVF treatment. The Fertility
Society of Australia 25th Annual scientific meeting. Australian &
New Zealand Journal of Obstetrics & Gynaecology 2006;46 Suppl
2:A.2.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
55
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
*  Tremellen K, Miari G, Froiland D, Thompson J. A randomised
control trial examining the eLect of an antioxidant (Menevit) on
pregnancy outcome during IVF-ICSI treatment. Australian & New
Zealand Journal of Obstetrics & Gynaecology 2007;47:216-21.
Wang 2010 {published data only}
Wang YX, Yang SW, Qu CB, Huo HX, Li W, Li JD, et al. L-carnitine:
safe and eLective for asthenozoospermia. Zhonghua nan ke xue
- National Journal of Andrology 2010;16(5):420-2.
Wong 2002 {published data only}
Ebisch IM, Pierik FH, De Jong FH, Thomas CM, Steegers-
Theunissen RP. Does folic acid and zinc sulphate intervention
aLect endocrine parameters and sperm characteristics in men?.
International Journal of Andrology 2006;29(2):339-45.
*  Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA,
Steegers-Theunissen RP. ELects of folic acid and zinc sulfate on
male factor subfertility: a double-blind, randomized, placebo-
controlled trial. Fertility and Sterility 2002; Vol. 77, issue 3:491-8.
Zalata 1998 {published data only}
*  Zalata A, Christophe A, Horrbin D, Dhooge W, Comhaire F.
Protection of sperm function and DNA by essential fatty acids
and antioxidants dietary supplementation. Fertility and Sterility
1998;70:287.
Zalata A, Christophe A, Horrobin D, Dhooge W, Comhaire F.
ELect of essential fatty acids and antioxidants dietary
supplementation on the oxidative DNA damage of the
human spermatozoa. ESHRE 14th annual meeting. Goteborg,
1998:270-1.
Zavaczki 2003 {published data only}
Zavaczki Z, Szollosi J, Kiss S, Koloszar S, Fejes I, Kovacs L, Pal A.
Magnesium-orotate supplementation for idiopathic infertile
male patients: a randomized, placebo-controlled clinical pilot
study. Magnesium Research 2003;16(2):131-6.
 
References to studies excluded from this review
Adel 2015 {published data only}
Adel N, El Maghraby H, Ghareeb D, Elmahdy M. Vitamin e and
berberine counteract the adverse eLects of ros on sperm and
seminal parameters. Human Reproduction 2015;30 Suppl 1:i171
Abstract no: P-113.
Alahmar 2017 {published data only}
Alahmar AT. ELect of vitamin C, vitamin E, zinc, selenium,
and coenzyme Q10 in infertile men with idiopathic
oligoasthenozoospermia. International Journal of Infertility and
Fetal Medicine 2017;8(2):45-9.
Alizadeh 2018 {published data only}
Alizadeh F, Javadi M, Karami AA, Gholaminejad F, Kavianpour M,
Haghighian HK. Curcumin nanomicelle improves semen
parameters, oxidative stress, inflammatory biomarkers, and
reproductive hormones in infertile men: A randomized clinical
trial. Phytotherapy Research 2018;32(3):514-21.
Alsalman 2018 {published data only}
Alsalman AR, Almashhedy LA, Hadwan MH. ELect of oral zinc
supplementation on the thiol oxido-reductive index and thiol-
related enzymes in seminal plasma and spermatozoa of Iraqi
asthenospermic patients. Biological Trace Element Research
2018;184(2):340-9.
Anarte 2012 {published data only}
Anarte C, Calvo I, Domingo A, Presilla N, Aleman M, Bou R, et
al. ELect of DHA supplementation on fatty acid composition of
sperm and its relation to semen quality. Human Reproduction
- Abstract book of the 28th ESHRE Annual Meeting, Turkey 1-4
July 2012. 2012; Vol. 27, issue 2:ii121-ii50.
Anarte 2013 {published data only}
Anarte C, Domingo A, Agirregoikoa JA, De Pablo J,
Barrenetxea G. Regular consumption of docosahexaenoic acid
(DHA) improves semen quality. Fertility and Sterility 2013;100
Suppl 3:S443.
Azizollahi 2013a {published data only}
Azizollahi S, Nematollahi-Mahani SN, Azizollahi G, Baneshi MR,
Safari Z. The eLect of folic acid and zinc sulfate on endocrine
parameters and seminal antioxidant level, aQer variocelectomy.
Iranian Journal of Reproductive Medicine 2013;1):36.
Cai 2012 {published data only}
Cai T, Wagenlehner F, Mazzoli S, Meacci F, Mondaini N,
Nesi G, et al. Semen quality in patients with Chlamydia
trachomatis genital infection treated concurrently with
prulifloxacin and a phytotherapeutic agent. Journal of
Andrology 2012;33(4):615-23.
Calogero 2015 {published data only}
Calogero AE, Gullo G, La Vignera S, Condorelli RA, Vaiarelli A.
Myoinositol improves sperm parameters and serum
reproductive hormones in patients with idiopathic infertility: a
prospective double-blind randomized placebo-controlled study.
Andrology 2015;3(3):491-5.
Capece 2017 {published data only}
*  Capece M, Romeo G, RuLo A, Romis L, Mordente S,
Di Lauro G. A phytotherapic approach to reduce sperm DNA
fragmentation in patients with male infertility. Urologia (Treviso)
2017;84(2):79-82.
Capece M, Romeo G, RuLo A, Romis L, Mordente S, Di Lauro G.
Alga Ecklonia Bicyclis, tribulus terrestris, myoinositol and
biovistm reduce sperm DNA fragmentation in patients with
oligo-asthenoterato-zoospermia (OAT) syndrome. Journal of
Sexual Medicine 2015;12 (Supplement 5):365.
Chattopadhyay 2016 {published data only}
Chattopadhyay R, Yasmin S, Chakravarty BN. ELect of
continuous 6 months oral antioxidant combination with
universally recommended dosage in idiopathic male
infertility. International Journal of Infertility and Fetal Medicine
2016;7(1):1-6.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
56
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Chen 2012 {published data only}
Chen XF, Li Z, Ping P, Dai JC, Zhang FB, Shang XJ, et al. ELicacy
of natural vitamin E on oligospermia and asthenospermia: a
prospective multi-centered randomized controlled study of 106
cases. Zhong Hua Nan Ke Xue 2012;18(5):428-31.
CiNci 2009 {published data only}
CiQci H, Verit A, Savas M, Yeni E, Erel O. ELects of N-
acetylcysteine on semen parameters and oxidative/antioxidant
status. Urology 2009;74(1):73-6.
Comhaire 2005 {published data only}
Comhaire FH, El Garem Y, Mahmoud A, Eertmans F,
Schoonjans F. Combined conventional/antioxidant
"Astaxanthin" treatment for male infertility: a double blind,
randomized trial. Asian Journal of Andrology 2005;7(3):257-62.
Ebisch 2003 {published data only}
Ebisch IM, van Heerde WL, Thomas CM, van der Put N, Wong WY,
Steegers-Theunissen RP. C677T methylenetetrahydrofolate
reductase polymorphism interferes with the eLects of folic acid
and zinc sulfate on sperm concentration. Fertility and Sterility
2003;80(5):1190-4.
Elgindy 2008 {published data only}
Elgindy EA, El-Huseiny AM, Mostafa MI, Gaballah AM, Amed TA.
N-Acetylcysteine: Could it be an eLective adjuvant therapy in
ICSI cycles. Fertility and Sterility 2008;90 Suppl 1(American
Society for Reproductive Medicine 64th Annual Meeting. 8-12
November 2008, San Francisco, CA):356 Abstract no: P738.
Ghafarizadeh 2018 {published data only}
Ghafarizadeh AA, Vaezi G, Shariatzadeh MA, Malekirad AA.
ELect of in vitro selenium supplementation on sperm quality in
asthenoteratozoospermic men. Andrologia 2018;50(2):e12869.
Ghanem 2010 {published data only}
Ghanem H, Shaeer O, El-Segini A. Combination clomiphene
citrate and antioxidant therapy for idiopathic male
infertility: a randomized controlled trial. Fertility and Sterility
2010;93(7):2232-5.
Gulati 2015 {published data only}
Gulati S, Chattopadhyay R, Ghosh B, Yasmin S, Ghosh S, Bose G,
et al. Treatment with combined antioxidant formulation before
ICSI improves pregnancy rate in couples with obstructive
azoospermia. Fertility and Sterility 2015;1):e241.
Gulino 2016 {unpublished data only}
AGUNCO Obstetrics and Gynecology Centre (PI unknown). ELect
of treatment with myo-inositol on human semen parameters
in patients undergoing in vitro fertilization cycles. https://
clinicaltrials.gov.
*  Gulino FA, Leonardi E, Marilli I, Musmeci G, Vitale SG,
Leanza V, et al. ELect of treatment with myo-inositol on semen
parameters of patients undergoing an IVF cycle: in vivo study.
Gynecological Endocrinology 2016;32(1):65-8.
Hafeez 2011 {published data only}
Hafeez M, Ahmed A, Usmanghani K, Mohiuddin E, Asif HM,
Akram M, et al. Clinical evaluation of herbal medicine for
oligospermia. Pakistan Journal of Nutrition 2011;10(3):238-40.
Iacono 2014 {published data only}
Iacono F, RuLo A, Prezioso D, Illiano E, Romeo G, Romis L,
et al. Combination therapy with antiestrogen and a natural
composite containing tribulus terrestris, alga ecklonia bicyclis,
biovis and myo-inositol in the treatment of male idiopathic
infertility. Journal of Sexual Medicine 2014;1:92.
Jawad 2013 {published data only}
Jawad HM. Zinc sulfate treatment of secondary male infertility
associated with positive serum and seminal plasma anti-
sperm antibody test. Middle East Fertility Society Journal
2013;18(1):24-30.
Kanta Goswami 2017 {published data only}
Kanta Goswami S, Chattopadhyay R, Ghosh S, Ghosh B,
Yasmin S, Goswami M, et al. Exogenous oral combination
antioxidants in idiopathic infertile males, having higher DNA
fragmentation index, before ICSI cycle may improve live birth
rate. Human Reproduction 2017;32 (Supplement 1):i160.
Keskes-Ammar 2003 {published data only}
Keskes-Ammar L, Feki-Chakroun N, Rebai T, Sahnoun Z,
Ghozzi H, Hammami S, et al. Sperm oxidative stress and the
eLect of an oral vitamin E and selenium supplement on semen
quality in infertile men. Archives of Andrology 2003;49(2):83-94.
Kim 2010 {published data only}
Kim C-H, Yoon J-W, Ahn J-W, Kang H-J, Lee J-W, Kang B-M. The
eLect of supplementation with omega-3-polyunsaturated fatty
acids in intracytoplasmic sperm injection cycles for infertile
patients with a history of unexplained total fertilization failure.
Fertility and Sterility 2010;94(4 Suppl 1):S242.
Korosi 2017 {published data only}
Korosi T, Barta C, Rokob K, Torok T. Physiological Intra-
Cytoplasmic Sperm Injection (PICSI) outcomes aQer oral
pretreatment and semen incubation with myo-inositol in
oligoasthenoteratozoospermic men: results from a prospective,
randomized controlled trial. European Review for Medical &
Pharmacological Sciences 2017;21(2 Suppl):66-72.
Kumar 2011 {published data only}
Kumar R, Saxena V, Shamsi M, Venkatesh S, Dada R.
Herbo-mineral supplementation in men with idiopathic
oligoasthenoteratospermia: A double blind randomized
placebo-controlled trial. Indian Journal of Urolology
2011;27(3):357–62.
Lenzi 1993 {published data only}
Lenzi A, Culasso F, Gandini L, Lombardo F, Dondero F. Placebo-
controlled, double-blind, cross-over trial of glutathione therapy
in male infertility. Human Reproduction 1993;8(10):1657-62.
Lu 2010 {published data only}
Lu SM, Li X, Zhang HB, Hu JM, Yan JH, Liu JL, et al. [Use
of L-carnitine before percutaneous epididymal sperm
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
57
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
aspiration-intracytoplasmic sperm injection for obstructive
azoospermia]. Zhonghua nan ke xue - National Journal of
Andrology 2010;16(10):919-21.
Martinez-Soto 2016 {published data only}
Martinez-Soto JC, Domingo JC, Cordobilla B, Nicolas M,
Fernandez L, Albero P, et al. Dietary supplementation with
docosahexaenoic acid (DHA) improves seminal antioxidant
status and decreases sperm DNA fragmentation. Systems
Biology in Reproductive Medicine 2016;62(6):387-95.
Merino 1997 {published data only}
Merino G, Martinez Chequer JC, Barahona E, Bermudez JA,
Moran C, Carranza-Lira S. ELects of pentoxifylline on sperm
motility in normogonadotropic asthenozoospermic men.
Archives of Andrology 1997;39(1):65-9.
Micic 1988 {published data only}
Micic S, Hadzi-Djokic J, Dotlic R, Tulic C. Pentoxifyllin treatment
of oligoasthenospermic men. Acta Europaea Fertilitatis
1988;19(3):135-7.
Micic 2001 {published data only}
Micic S, Lalic N, Bojanic N, Nale DJ. Oligospermic men treated
by carnitine. 17th World Congress on Fertility and Sterility.
Melbourne, 2001:38.
Movahedin 2014 {published data only}
Movahedin M, Mehrsai A, Noori M, Dehghani S, Pourmand G,
Ahmadi A, et al. Does anti-oxidant therapy add any extra benefit
to standard inguinal varicocelectomy in terms of DNA damage
or sperm quality factor indices: a randomized study. Urology
2014;4(suppl. 1):S252.
Nadjarzadeh 2014 {published data only}
Nadjarzadeh A, Shidfar F, Amirjannati N, Vafa MR, Motevalian SA,
Gohari MR, et al. ELect of Coenzyme Q10 supplementation on
antioxidant enzymes activity and oxidative stress of seminal
plasma: a double-blind randomised clinical trial. Andrologia
2014;46(2):177-83.
Nashivochnikova 2014 {published data only}
Nashivochnikova NA, Krupin VN, Selivanova SA. [ELiciency of
spematon in male infertility]. Urologiia (Moscow, Russia: 1999)
2014;2:52-4. [PUBMED: 24956674]
NCT01075334 {unpublished data only}
Tsafrir A. Is a carnitine based food supplement (PorimoreTM)
for infertile men superior to folate and zinc with regard to
pregnancy rates in intrauterine insemination cycles?. https://
clinicaltrials.gov.
NCT01520584 {unpublished data only}
Irge D. Supplement intake in infertile men; the eLect on sperm
parameters, fertilization rate and embryo quality. https://
clinicaltrials.gov.
Nematollahi-Mahani 2014 {published data only}
Nematollahi-Mahani SN, Azizollahi GH, Baneshi MR, Safari Z,
Azizollahi S. ELect of folic acid and zinc sulphate on endocrine
parameters and seminal antioxidant level aQer varicocelectomy.
Andrologia 2014;46(3):240-5.
Niederberger 2011 {published data only}
Niederberger C. Combination clomiphene citrate and
antioxidant therapy for idiopathic male infertility: a randomized
controlled trial. Journal of Urology 2011;185(1):252.
Nikolova 2007 {published data only}
Nikolova V, Stanislavov R, Vatev I, Nalbanski B, Punevska M.
Sperm parameters in male idiopathic infertility aQer treatment
with prelox. Akusherstvo i Ginekologiia 2007;46(5):7-12.
Pawlowicz 2001 {published data only}
Pawlowicz P, Stachowiak G, Bielak A, Wilczynski J.
Administration of natural anthocyanins derived from
chokeberry (aronia melanocarpa) extract in the treatment
of oligospermia in males with enhanced autoantibodies
to oxidized low density lipoproteins (oLAB). The impact on
fructose levels. Ginekologia Polska 2001;72(12):983-8.
Polak 2013 {published data only}
Polak de Fried E, Bossi NM, Notrica JA, Vazquez Levin MH.
Vitamin-d treatment does not improve pregnancy rates in
patients undergoing art: a prospective, randomized, double-
blind placebo-controlled trial. Fertility and Sterility 2013;100
Suppl 3:S493-4.
Raigani 2010 {published data only}
Raigani M, Sadeghi MR, Akhondi MA, Amir Jannati N, Soleimani
Badia M. Impacts of MTHFR polymorphism on the eLects of folic
acid and zinc sulfate supplementations in OAT men. Iranian
Journal of Reproductive Medicine 2010;1):46.
Safarinejad 2011 {published data only}
Safarinejad MR. ELect of pentoxifylline on semen parameters,
reproductive hormones and seminal plasma antioxidant
capacity in men with idiopathic infertility: a randomized
double-blind placebo-controlled study. International Urology
and Nephrology 2011;43:315-28.
Safarinejad 2011a {published data only}
Safarinejad MR, Shafiei N, Safarinejad S. A prospective double-
blind randomized placebo-controlled study of the eLect of
saLron (Crocus sativus Linn.) on semen parameters and seminal
plasma antioxidant capacity in infertile men with idiopathic
oligoasthenoteratozoospermia. Phytotherapy research: PTR
2011;25(4):508-16.
Singh 2016 {published data only}
Singh AK, Deshpande SB. Role of nutraceuticals in treatment
of azoospermia due to maturation arrest. Indian Journal of
Physiology and Pharmacology 2016;60 (5 Supplement 1):6-7.
Soylemez 2012 {published data only}
Soylemez H, Kilic S, Atar M, Penbegul N, Sancaktutar AA,
Bozkurt Y. ELects of micronised purified flavonoid fraction on
pain, semen analysis and scrotal color Doppler parameters
in patients with painful varicocele; results of a randomized
placebo-controlled study. International Urology and Nephrology
2012;44(2):401-8.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
58
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Stanislavov 2009 {published data only}
Stanislavov R, Nikolova V, Rohdewald P. Improvement of
seminal parameters with Prelox®: a randomized, double-blind,
placebo controlled, cross over trial. Phytotherapy Research
2009;23:297-302. [DOI: 10.1002]
Stanislavov 2014 {published data only}
Stanislavov R, Rohdewald P. Sperm quality in men is improved
by supplementation with a combination of L-arginine, L-
citrullin, roburins and Pycnogenol. Minerva Urologica e
Nefrologica 2014;66(4):217-23.
Stanislavov R, Rohdewald P. Sperm quality in men is improved
by supplementation with a combination of L-arginine, L-
citrulline, roburins and Pycnogenol. Minerva Urologica e
Nefrologica 2014;66(4):217-23.
*  Stanislavov R, Rohdewald P. Sperm quality in men is
improved by supplementation with a combination of L-arginine,
L-citrulline, roburins and Pycnogenol. Minerva Urologica e
Nefrologica 2014;66(4):217-23.
Tang 2011 {published data only}
Tang KF, Xing Y, Wu CY, Liu RZ, Wang XY, Xing JP.
[Tamoxifen combined with coenzyme Q10 for idiopathic
oligoasthenospermia]. Zhong Hua Nan Ke Xue 2011;17(7):615-8.
Verzeletti 2012 {published data only}
Verzeletti FB, Poletto RS, Bertolin TE, Fornari F. Evaluation
of sperm quality in adults aQer use spirulina platensis
and resveratrol. Jornal Brasileiro de Reproducao Assistida
2012;16(5):271-7.
Vicari 2001 {published data only}
Vicari E, Calogero AE. ELects of treatment with carnitines
in infertile patients with prostatovesiculoepididymitis and
elevated sperm oxidative stress. ESHRE 17th Annual Meeting.
Lausanne: Human Reproduction, 2001; Vol. 16 Suppl 1:106-7.
Vicari 2001a {published data only}
Vicari E, Rubino C, De Palma A, Longo G, Lauretta M, Consoli S,
et al. Antioxidant therapeutic eLiciency aQer the use of
carnitine in infertile patients with bacterial or non bacterial
prostato-vesiculo-epididymitis. Archivio Italiano di Urologia,
Andrologia 2001;73(1):15-25.
Vicari 2002 {published data only}
Vicari E, La Vignera S, Calogero AE. Antioxidant treatment
with carnitines is eLective in infertile patients with
prostatovesiculoepididymitis and elevated seminal
leukocyte concentrations aQer treatment with nonsteroidal
anti-inflammatory compounds. Fertility and Sterility
2002;78(6):1203-8.
Wang 1983 {published data only}
Wang C, Chan CW, Wong KK, Yeung KK. Comparison of the
eLectiveness of placebo, clomiphene citrate, mesterolone,
pentoxifylline, and testosterone rebound therapy for the
treatment of idiopathic oligospermia. Fertility and Sterility
1983;40(3):358-65.
Wang 2010a {published data only}
Wang Y, Yang S, Cai W, Qu C, Li J, Chang X, et al. [Clinical
eLicacy of L-carnitine combined with tamoxifen in treatment
of oligoasthenozoospermia] LA: Chi. Zhonghua nan ke xue -
National Journal of Andrology 2010;16(5):420-2.
Wu 2012 {published data only}
Wu ZM, Lu X, Wang YW, Sun J, Tao JW, Yin FH, et al. Short-
term medication of L-carnitine before intracytoplasmic sperm
injection for infertile men with oligoasthenozoospermia. Zhong
Hua Nan Ke Xue 2012;18(3):253-6.
 
References to studies awaiting assessment
Goswami 2015 {published data only}
Goswami SK, Yasmin S, Chakraborty P, Chattopadhyay R,
Ghosh S, Goswami M, et al. Role of dietary antioxidant
supplementation in treatment of idiopathic male infertility:
Promising evidence from a sub-continental study. Fertility and
Sterility 2015;1):e288.
 
References to ongoing studies
CTRI/2013/02/003431 {unpublished data only}
Kamath MS. To compare the eLectiveness of antioxidants
versus no treatment for male partner for improving pregnancy
rates in couples undergoing In vitro fertilization (IVF) for
abnormal semen analysis. www.who.int/trialsearch.
DRKS00011616 {unpublished data only}
Baumgraß H. Randomized, placebo-controlled, double-blind,
multi-centre pilot study to investigate the eLect of AM019016
on male spermatogenesis in subjects with diagnosed unspecific
(idiopathic) subfertility. www.who.int/trialsearch.
IRCT2016111830947N1 {unpublished data only}
Talebi A, Amini L. The eLect of oral vitamin D3 supplementation
on spermogram quantitative and qualitative indicators in
infertile male. www.who.int/trialsearch.
IRCT2017012432153N1 {unpublished data only}
Azima S. The eLects of folic acid, vitamin E, selenium on semen
parameters in infertile men [ELect of folic acid, vitamin E,
selenium on semen parameters]. www.who.int/trialsearch.
NCT00975115 {unpublished data only}
Aguilar MM. Assessment of the eLicacy of dietary
supplement spermotrend in the treatment of male infertility.
ClinicalTrials.gov.
NCT01407432 {unpublished data only}
Mathieu-d’Argent E. Impact of folates in the care of the male
infertility (FOLFIV). https://clinicaltrials.gov.
NCT01828710 {unpublished data only}
Palumbo M. Myo-inositol on human semen parameters [ELect
of of treatment with Myo-inositol on human semen parameters
in patients undergoing IVF cycles]. https://clinicaltrials.gov.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
59
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
NCT01846325 {unpublished data only}
Hekmatdoost A. The eLects of administration of combined
docosahexaenoic acid and vitamin e supplements on
spermatogram and seminal plasma oxidative stress in infertile
men with asthenozoospermia. https://clinicaltrials.gov.
NCT02310087 {unpublished data only}
Pinter B, Imamovic Kumalic S. Oral Astaxanthin and semen
quality, fertilization and embryo development in Assisted
Reproduction Techniques procedures. https://clinicaltrials.gov.
NCT02421887 {unpublished data only}
Eisenberg E, Steiner AZ. Males, antioxidants, and infertility trial
(MOXI). https://clinicaltrials.gov.
NCT03104998 {unpublished data only}
Jawaid M. Neotililty trial: ELect of coenzyme Q10 on semen
parameters in men with idiopathic infertility (neotility). https://
clinicaltrials.gov.
NCT03337360 {unpublished data only}
Smits RM, Fleischer K, Braat DDM. The impact of a nutritional
supplement (Impryl®) on male fertility. https://clinicaltrials.gov.
 
Additional references
Agarwal 2003
Agarwal A, Said T. Role of sperm chromatin abnormalities and
DNA damage in male infertility. Human Reproduction Update
2003;9(4):331-45.
Agarwal 2004
Agarwal A, Nallella KP, Allamaneni S, Said TM. Role of
antioxidants in treatment of male infertility: an overview of the
literature. Reproductive Biomedicine Online 2004;8(6):616-27.
Agarwal 2004a
Agarwal A, Said TM. Carnitines and male infertility.
Reproductive BioMedicine Online (Reproductive Healthcare
Limited). Reproductive Healthcare Limited, 2004; Vol. 8, issue
4:376-84.
Agarwal 2016
Agarwal A, Majzoub A, Esteves SC, Ko EY, Ramasamy R, Zini A.
Clinical utility of sperm DNA fragmentation testing: practice
recommendations based on clinical scenarios. Translational
Andrology and Urology 2016;5(6):935-50.
Agarwal 2017
Agarwal A, Majzoub A. Laboratory tests for oxidative stress.
Indian Journal of Urology 2017;33(3):199-206. [0970-1591:
(Print)]
Aitken 1987
Aitken RJ, Clarkson JS. Cellular basis of defective sperm
function and its association with the genesis of reactive oxygen
species by human spermatozoa. Journal of Reproduction and
Fertility 1987;81(2):459-69. [0022-4251: (Print)]
Aitken 1989
Aitken RJ, Clarkson JS, Hargreave TB, Irvine DS, Wu FC.
Analysis of the relationship between defective sperm function
and the generation of reactive oxygen species in cases of
oligozoospermia. Journal of Andrology 1989;10(3):214-20.
[0196-3635: (Print)]
Aitken 1990
Aitken RJ, West KM. Analysis of the relationship between
reactive oxygen species production and leucocyte infiltration
in fractions of human semen separated on Percoll gradients.
International Journal of Andrology. Blackwell Publishing Ltd,
1990; Vol. 13, issue 6:433-51.
Aitken 1992
Aitken RJ, Buckingham D, West K, Wu FC, Zikopoulos K,
Richardson DW. DiLerential contribution of leucocytes and
spermatozoa to the generation of reactive oxygen species
in the ejaculates of oligozoospermic patients and fertile
donors. Journal of Reproduction and Fertility 1992;94(2):451-62.
[0022-4251: (Print)]
Aitken 1994
Aitken J, Fisher H. Reactive oxygen species generation and
human spermatozoa: the balance of benefit and risk. Bioessays
1994;16(4):259-67. [0265-9247: (Print)]
Aitken 2010
Aitken RJ, De Iuliis GN, Finnie JM, Hedges A, McLachlan RI.
Analysis of the relationships between oxidative stress,
DNA damage and sperm vitality in a patient population:
development of diagnostic criteria. Human Reproduction
2010;25(10):2415-26.
Aktan 2013
Aktan G, Dogru-Abbasoglu S, Kucukgergin C, Kadioglu A,
Ozdemirler-Erata G, Kocak-Toker N. Mystery of idiopathic male
infertility: is oxidative stress an actual risk?. Fertility and Sterility
2013;99(5):1211-5.
Alvarez 2003
Alvarez 2003. Nuture vs nature: How can we optimise sperm
quality?. Journal of Andrology 2003;24(5):640-8.
Annals of the New York Academy of Science 2004
Annals of the New York Academy of Science. Preface: Carnitine:
Lessons from One Hundred Years of Research. Annals of the
New York Academy of Science. Blackwell Publishing Ltd, 2004;
Vol. 1033, issue 1:ix-xi.
Appleton 2002
Appleton J. Arginine: clinical potential of a semi-essential amino
acid. Alternative Medicine Review 2002;7(6):512-22. [10895159]
Atkuri 2007
Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-
Acetylcysteine—a safe antidote for cysteine/glutathione
deficiency. Cancer/Immunomodulation 2007;7(4):355-9.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
60
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Barratt 2017
Barratt CLR, Bjorndahl L, De Jonge CJ, Lamb DJ, Osorio
Martini F, McLachlan R, et al. The diagnosis of male infertility: an
analysis of the evidence to support the development of global
WHO guidance-challenges and future research opportunities.
Human Reproduction Update 2017;23(6):660-80. [1460-2369:
(Electronic)]
Bendich 1989
Bendich A, Olson JA. Biological actions of carotenoids. The
FASEB Journal 1989;3(8):1927-32.
Bertelli 2009
Bertelli AA, Das DK. Grapes, wines, resveratrol, and heart health.
Journal of Cardiovascular Pharmacology 2009;54(6):468-76.
Bevilacqua 2015
Bevilacqua A, Carlomagno G, Gerli S, Montanino Oliva M,
Devroey P, Lanzone A, et al. Results from the International
Consensus Conference on myo-inositol and D-chiro-inositol in
Obstetrics and Gynecology – assisted reproduction technology.
Gynecological Endocrinology 2015;31(6):441-6.
Bhagavan 2006
Bhagavan HN, Chopra RK. Coenzyme Q10: Absorption, tissue
uptake, metabolism and pharmacokinetics. Free Radical
Research 2006;40(5):445-53.
Boe-Hansen 2006
Boe-Hansen GB, Fedder J, Ersboll AK, Christensen P. The sperm
chromatin structure assay as a diagnostic tool in the human
fertility clinic. Human Reproduction 2006;21(6):1576-82.
Boitani 2008
Boitani C, Puglisi R. Selenium, a key element in
spermatogenesis and male fertility. Molecular Mechanisms in
Spermatogenesis. New York, NY: Springer New York, 2008:65-73.
Boivin 2007
Boivin J, Bunting L, Collins JA, Nygren KG. International
estimates of infertility prevalence and treatment-seeking:
potential need and demand for infertility medical care. Human
Reproduction 2007;22(6):1506-12. [0268-1161]
Borini 2017
Borini A, Tarozzi N, Nadalini M. Sperm DNA fragmentation
testing in male infertility work-up: are we ready?. Translational
Andrology and Urology 2017;6(Suppl 4):S580-2.
Branco 2010
Branco CS, Garcez ME, Pasqualotto FF, Erdtman B, Salvador M.
Resveratrol and ascorbic acid prevent DNA damage
induced by cryopreservation in human semen. Cryobiology
2010;60(2):235-7.
Bungum 2004
Bungum M, Humaidan P, Spano M, Jepson K, Bungum L,
Giwercman A. The predictive value of sperm chromatin
structure assay (SCSA) parameters for the outcome of
intrauterine insemination, IVF and ICSI. Human Reproduction
2004;19(6):1401-8.
Burk 2002
Burk RF. Selenium, an antioxidant nutrient. Nutrition in Clinical
Care 2002;5(2):75-9.
Bykova 2007
Bykova M, Athayde K, Sharma R, Jha R, Sabanegh E, Agarwal A.
Defining the reference value of seminal reactive oxygen species
in a population of infertile men and normal healthy volunteers.
Fertility and Sterility 2007;88 Suppl 1(P-597):305.
Bøhmer 1978
Bøhmer T, Hoel P, Purvis K, Hansson V. Carnitine levels
in human accessory sex organs. Archives of Andrology
1978;1(1):53-9.
Cissen 2016
Cissen M, Wely M, Scholten I, Mansell S, Bruin JP, Mol BW, et al.
Measuring sperm DNA fragmentation and clinical outcomes of
medically assisted reproduction: a systematic review and meta-
analysis. PLOS One 2016;11(11):e0165125.
Colagar 2009
Colagar AH, Marzony ET. Ascorbic acid in human seminal
plasma: determination and its relationship to sperm quality.
Journal of Clinical Biochemistry and Nutrition 2009;45(2):144-9.
Colagar 2009a
Colagar AH, Marzony ET, Chaichi MJ. Zinc levels in seminal
plasma are associated with sperm quality in fertile and infertile
men. Nutrition Research 2009; Vol. 29, issue 2:82-8.
Collins 2008
Collins JA, Barnhart KT, Schlegel PN. Do sperm DNA integrity
tests predict pregnancy with in vitro fertilization?. Fertility and
Sterility 2008;89(4):823-31.
Collodel 2011
Collodel G, Federico MG, Geminiani M, Martini S, Bonechi C,
Rossi C, et al. ELect of trans-resveratrol on induced oxidative
stress in human sperm and in rat germinal cells. Reproductive
Toxicology 2011;31(2):239-46.
Colone 2010
Colone M, Marelli G, Unfer V, Bozzuto G, Molinari A, Stringaro A.
Inositol activity in oligoasthenoteratospermia--an in vitro study.
European Review for Medical and Pharmacological Sciences
2010;14(10):891-6. [1128-3602: (Print)]
Comhaire 1987
Comhaire FH. Towards more objectivity in diagnosis and
management of male infertility. International Journal of
Andrology. Supplement. Oxford; Melbourne: Blackwell
Scientific, 1987; Vol. 7.
Condorelli 2017
Condorelli RA, La Vignera S, Mongioi LM, Vitale SG, Lagana AS,
Cimino L, et al. Myo-inositol as a male fertility molecule: speed
them up!. European Review for Medical and Pharmacological
Sciences 2017;21(2 Suppl):30-5. [2284-0729: (Electronic)]
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
61
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Dattilo 2016
Dattilo M, Giuseppe D, Ettore C, Ménézo Y. Improvement of
gamete quality by stimulating and feeding the endogenous
antioxidant system: mechanisms, clinical results, insights on
gene-environment interactions and the role of diet. Journal of
Assisted Reproduction and Genetics 2016;33(12):1633-48.
de Angelis 2017
de Angelis C, Galdiero M, Pivonello C, Garifalos F, Menafra D,
Cariati F, et al. The role of vitamin D in male fertility: A focus
on the testis. Reviews in Endocrine and Metabolic Disorders
2017;18(3):285-305.
Dias 2006
Dias S, McNamee R, Vail A. Evidence of improving quality of
reporting of randomised controlled trials in subfertility. Human
Reproduction 2006;21(10):2617-27.
Ebisch 2007
Ebisch IM, Thomas CM Peters WH, Braat DD, Steegers-
Theunissen RP. The importance of folate, zinc and antioxidants
in the pathogenesis and prevention of subfertility. Human
Reproduction Update 2007;13(2):163-74.
El-Taieb 2009
El-Taieb MA, Herwig R, Nada EA, Greilberger J, Marberger M.
Oxidative stress and epididymal sperm transport, motility
and morphological defects. European Journal of Obstetrics,
Gynecology, and Reproductive Biology 2009;144 Suppl
1:199-203.
ESHRE Guidelines 1996
The European Society of Human Reproduction and Embryology
(ESHRE). Guidelines to the prevalence, diagnosis, treatment
and management of infertility, 1996. Human Reproduction
1996;11(8):1775.
Eskenazi 2005
Eskanazi B, Kidd SA, Marks AR, Sloter E, Block G, Wyrobeck AJ.
Antioxidant intake is associated with semen quality in healthy
men. Human Reproduction 2005;20(4):1006-12.
Evenson 1999
Evenson DP, Jost LK, Marshall D, Zinaman MJ, Clegg E, Purvis K,
et al. Utility of the sperm chromatin structure assay as a
diagnostic and prognostic tool in the human fertility clinic.
Human Reproduction 1999;14(4):1039-49.
Evenson 2006
Evenson D, Wixon R. Meta-analysis of sperm DNA fragmentation
using the sperm chromatin structure assay. Reproductive
Biomedicine Online 2006;12(4):466-72.
Evers 2002
Evers JL. Female subfertility. Lancet 2002;360(9327):151-9.
[0140-6736: (Print)]
Garg 2016
Garg H, Kumar R. An update on the role of medical treatment
including antioxidant therapy in varicocele. Asian Journal of
Andrology 2016;18(2):222-8.
Ghyczy 2001
Ghyczy M, Boros M. Electrophilic methyl groups present in
the diet ameliorate pathological states induced by reductive
and oxidative stress: a hypothesis. British Journal of Nutrition
2001;85(4):409-14.
Giordano 2014
Giordano E, Visioli F. Long-chain omega 3 fatty acids: Molecular
bases of potential antioxidant actions. Prostaglandins
Leukotrienes and Essential Fatty Acids 2014;90(1):1-4.
Gnoth 2005
Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J,
Freundl G. Definition and prevalence of subfertility and
infertility. Human Reproduction 2005;20(5):1144-7.
GRADEpro GDT 2015 [Computer program]
GRADEpro. GRADEpro Guideline Development Tool. McMaster
University: developed by Evidence Prime, Inc., 2015.
Grand View Research 2016
Grand View Research. Dietary Supplements Market Analysis
By Ingredient (Botanicals, Vitamins, Minerals, Amino Acids,
Enzymes), By Product (Tablets, Capsules, Powder, Liquids,
SoQ Gels, Gel Caps), By Application (Additional Supplement,
Medicinal Supplement, Sports Nutrition), By End-Use (Infant,
Children, Adults, Pregnant Women, Old-Aged) And Segment
Forecasts To 2024. https://www.grandviewresearch.com
2016:0-200.
Grune 2010
Grune T, Lietz G, Palou A, Ross AC, Stahl W, Tang G, et al. β-
Carotene Is an Important Vitamin A Source for Humans1–3.
Journal of Nutrition 2010;140(12):2268S-85S.
Halicka 2012
Halicka HD, Zhao H, Li J, Traganos F, Studzinski GP,
Darzynkiewicz Z. Attenuation of constitutive DNA damage
signaling by 1,25-dihydroxyvitamin D3. Aging. Impact Journals,
LLC, 2012; Vol. 4, issue 4:270-8.
Hankey 1999
Hankey GJ, Eikelboom JW. Homocysteine and vascular disease.
Lancet 1999; Vol. 354, issue 9176:407-13.
Hausenblas 2014
Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol
treatment as an adjunct to pharmacological management in
type 2 diabetes mellitus—systematic review and meta-analysis.
Molecular Nutrition & Food Research 2014;59(1):147-59.
Higgins 2011
Higgins JP, Green S, editors. Cochrane Handbook for Systematic
Reviews of Interventions 5.1.0 (updated March 2011). The
Cochrane Collaboration 2011. Available from www.cochrane-
handbook.org. Chichester UK: John Wiley and Sons Ltd.
Hsia 2016
Hsia T, Yin M. Post-intake of S-Ethyl Cysteine and S-Methyl
Cysteine improved LPS-induced acute lung injury in mice.
Nutrients 2016;8(8):507.
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
62
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Huang 2018
Huang D, Tocmo R. Assays based on competitive measurement
of the scavenging ability of reactive oxygen/nitrogen species.
In: Apak R, Capanoglu E, Shahidi F editor(s). Measurement
of Antioxidant Activity and Capacity: Recent Trends and
Applications. Chichester, West Sussex, UK: John Wiley & Sons
Ltd, 2018.
Hughes 1996
Hughes CM, Lewis SE, McKelvey-Martin VJ, Thompson W. A
comparison of baseline and induced DNA damage in human
spermatozoa from fertile and infertile men, using a modified
comet assay. Molecular Human Reproduction 1996;2(8):613-9.
[1360-9947: (Print)]
Inhorn 2015
Inhorn MC, Patrizio P. Infertility around the globe: new
thinking on gender, reproductive technologies and global
movements in the 21st century. Human Reproduction Update
2015;21(4):411-26. [1460-2369: (Electronic)]
Institute of Medicine 2000
Institute of Medicine. Vitamin E. Dietary Reference Intakes for
Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington,
DC: The National Academies Press, 2000.
Intasqui 2015
Intasqui P, Antoniassi M, Camargo M, Nichi M, Carvalho VM,
Cardozo KHM, et al. DiLerences in the seminal plasma proteome
are associated with oxidative stress levels in men with normal
semen parameters. Fertility and Sterility 2015;104(2):292-301.
Irani 2017
Irani M, Amirian M, Sadeghi R, Lez JL, Latifnejad Roudsari R.
The eLect of folate and folate plus zinc supplementation on
endocrine parameters and sperm characteristics in sub-fertile
men: a systematic review and meta-analysis. Urology Journal
August 29 2017;14(5):4069-78.
Irvine 1998
Irvine DS. Epidemiology and aetiology of male infertility.
Human Reproduction 1998;13 Suppl 1:33-44. [0268-1161:
(Print)]
Iwasaki 1992
Iwasaki A, Gagnon C. Formation of reactive oxygen species
in spermatozoa of infertile patients. Fertility and Sterility
1992;57(2):409-16. [0015-0282: (Print)]
Jones 1973
Jones R, Mann T. Lipid peroxidation in spermatozoa.
Proceedings of the Royal Society Series B-Biological Sciences
1973;184(1074):103-7. [0080-4649]
Joshi 2001
Joshi R, Adhikari S, Patro BS, Chattopadhyay S, Mukherjee T.
Free radical scavenging behavior of folic acid: evidence for
possible antioxidant activity. Free Radical Biology & Medicine
2001;30(12):1390-9.
Kodama 1997
Kodama H, Yamaguchi R, Fukuda J, Kasai H, Tanaka T. Increased
oxidative deoxyribonucleic acid damage in the spermatozoa of
infertile male patients. Fertilty and Sterility 1997;68(3):519-24.
[0015-0282: (Print)]
Kofi Arhin 2017
Kofi Arhin S, Zhao Y, Lu XS, Chetry M, Lu JQ. ELect of
micronutrient supplementation on IVF outcomes: a systematic
review of the literature. Reproductive BioMedicine Online
2017;35(6):715-22.
Lafuente 2013
Lafuente R, Gonzalez-Comadran M, Sola I, Lopez G, Brassesco M,
Carreras R, et al. Coenzyme Q10 and male infertility: a meta-
analysis. Journal of Assisted Reproduction and Genetics.
2013;30(9):1147-56.
Lewin 1976
Lewin LM, Yannai Y, Sulimovici S, Kraicer PF. Studies on the
metabolic role of myo-inositol. Distribution of radioactive myo-
inositol in the male rat. Biochemical Journal 1976;156(2):375-80.
Lewis 1997
Lewis SE, Sterling ES, Young IS, Thompson W. Comparison of
individual antioxidants of sperm and seminal plasma in fertile
and infertile men. Fertility and Sterility 1997;67(1):142-7.
Lewis 2013
Lewis SEM, Aitken RJ, Conner SJ, Iuliis GD, Evenson DP,
Henkel R, et al. The impact of sperm DNA damage in assisted
conception and beyond: recent advances in diagnosis and
treatment. Reproductive BioMedicine Online 2013; Vol. 27, issue
4:325-37.
Li 2006
Li Z, Wang L, Cai J, Huang H. Correlation of sperm DNA damage
with IVF and ICSI outcomes: a systematic review and meta-
analysis. Journal of Assisted Reproduction and Genetics
2006;23(9-10):367-76.
Littarru 2007
Littarru GP, Tiano L. Bioenergetic and antioxidant properties of
coenzyme Q10: recent developments. Molecular Biotechnology
2007;37(1):31-7.
MacFarquhar 2010
MacFarquhar JK, Broussard DL, Melstrom P, Hutchinson R,
Wolkin A, Martin C, et al. Acute selenium toxicity associated
with a dietary supplement. Archives of Internal Medicine
2010;170(3):256-61.
Majzoub 2017
Majzoub A, Agarwal A. Antioxidant therapy in idiopathic
oligoasthenoteratozoospermia. Indian Journal of Urology
2017;33(3):207-14.
Majzoub 2018
Majzoub A, Agarwal A. Systematic review of antioxidant types
and doses in male infertility: Benefits on semen parameters,
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
63
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
advanced sperm function, assisted reproduction and live-birth
rate. Arab Journal of Urology 2 January 2018;16(1):113-24.
Mascarenhas 2012
Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S,
Stevens GA. National, regional, and global trends in infertility
prevalence since 1990: a systematic analysis of 277 health
surveys. PLOS Medicine 2012;9(12):e1001356. [1549-1676:
(Electronic)]
Mazzilli 1994
Mazzilli F, Rossi T, Marchesini M, Ronconi C, Dondero F.
Superoxide anion in human semen related to seminal
parameters and clinical aspects. Fertility and Sterility
1994;62(4):862-8. [0015-0282: (Print)]
McNeill 1985
McNeill DA, Ali PS, Song YS. Mineral analyses of vegetarian,
health, and conventional foods: magnesium, zinc, copper, and
manganese content. Journal of the American Dietetic Association
1985;85(5):569-72. [0002-8223: (Print)]
Mendiola 2010
Mendiola J, Torres-Cantero AM, Vioque J, Moreno-Grau JM,
Ten J, Roca M, et al. A low intake of antioxidant nutrients is
associated with poor semen quality in patients attending
fertility clinics. Fertility and Sterility 2010;93(4):1128-33.
Mirończuk-Chodakowska 2018
Mirończuk-Chodakowska I, Witkowska AM, Zujko ME.
Endogenous non-enzymatic antioxidants in the human body.
Advances in Medical Sciences 2018;63(1):68-78.
Navarro-Alarcon 2008
Navarro-Alarcon M, Cabrera-Vique C. Selenium in food and
the human body: A review. Science of The Total Environment
2008;400(1):115-41.
Osman 2015
Osman A, Alsomait H, Seshadri S, El-Toukhy T, Khalaf Y. The
eLect of sperm DNA fragmentation on live birth rate aQer IVF
or ICSI: a systematic review and meta-analysis. Reproductive
Biomedicine Online 2015;30(2):120-7.
Ourique 2013
Ourique GM, Finamor IA, Saccol EM, RiLel AP, Pês TS,
Gutierrez K, et al. Resveratrol improves sperm motility, prevents
lipid peroxidation and enhances antioxidant defences in
the testes of hyperthyroid rats. Reproductive Toxicology
2013;37:31-9.
Padayatty 2003
Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee J, et al. Vitamin
C as an antioxidant: evaluation of Its role in disease prevention.
Journal of the American College of Nutrition 2003;22(1):18-35.
Pasqualotto 2001
Pasqualotto FF, Sharma RK, Kobayashi H, Nelson DR, Jr AJT,
Agarwal A. Oxidative stress in normospermic men undergoing
infertility evaluation. Journal of Andrology 2001;22(2):316-22.
Patel 2008
Patel SR, Sigman M. Antioxidant therapy in male infertility.
Urologic Clinics of North America. 2008;35(2):319-30. [MEDLINE:
18423251]
Pravst 2010
Pravst I, Žmitek K, Žmitek J. Coenzyme Q10 contents in foods
and fortification strategies. Critical Reviews in Food Science and
Nutrition 2010;50(4):269-80.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration. Review
Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Richard 2008
Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated
fatty acids as antioxidants. Pharmacological Research
2008;57(6):451-5.
Robinson 2012
Robinson L, Gallos ID, Conner SJ, Rajkhowa M, Miller D, Lewis S,
et al. The eLect of sperm DNA fragmentation on miscarriage
rates: a systematic review and meta-analysis. [Review]. Human
Reproduction 2012;27(10):2908-17.
Rogovik 2009
Rogovik AL, Vohra S, Goldman RD. Safety considerations
and potential interactions of vitamins: should vitamins
be considered drugs?. Annals of Pharmacotherapy
2009;44(2):311-24.
Ross 2006
Ross AC. Vitamin A and Carotenoids. In: Shils ME SM, Ross AC,
Caballero B, Cousins R editor(s). Modern Nutrition in Health
and Disease. Vol. 10th edition, Lippincott Williams & Wilkins,
2006:351-75.
Ross 2010
Ross C, Morriss A, Khairy M, Khalaf Y, Braude P, Coomarasamy A,
El-Toukhy T. A systematic review of the eLect of oral
antioxidants on male infertility. Reproductive Biomedicine
Online 2010;20(6):711-23. [PUBMED: 20378409]
Salas-Huetos 2017
Salas-Huetos A, Bulló M, Salas-Salvadó J. Dietary patterns,
foods and nutrients in male fertility parameters and
fecundability: a systematic review of observational studies.
Human Reproduction Update 1 July 2017;23(4):371–89.
Shekarriz 1995
Shekarriz M, Thomas AJ Jr, Agarwal A. Incidence and level
of seminal reactive oxygen species in normal men. Urology
1995;45(1):103-7. [0090-4295: (Print)]
Shimura 2002
Shimura T, Toyoshima M, Taga M, Shiraishi K, Uematsu N,
Inoue M, et al. The novel surveillance mechanism of the Trp53-
dependent s-phase checkpoint ensures chromosome damage
repair and preimplantation-stage development of mouse
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
64
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
embryos fertilized with x-irradiated sperm. Radiation Research
2002;158(6):735-42.
Showell 2017
Showell MG, Mackenzie-Proctor R, Jordan V, Hart RJ.
Antioxidants for female subfertility. Cochrane
Database of Systematic Reviews 2017, Issue 7. [DOI:
10.1002/14651858.CD007807.pub3]
Sikka 1995
Sikka S, Rajasekaran M, Hellstrom W. Role of oxidative stress
and antioxidants in male infertility. Journal of Andrology
1995;16(6):464-8.
Simon 2014
Simon L, Murphy K, Shamsi MB, Liu L, Emery B, Aston KI, et al.
Paternal influence of sperm DNA integrity on early embryonic
development. Human Reproduction 2014;29(11):2402-12.
Smith 1996
Smith R, Vantman D, Ponce J, Escobar J, Lissi E. Total
antioxidant capacity of human seminal plasma. Human
Reproduction 1996;11(8):1655-60.
Spanò 2000
Spanò M, Bonde JP, Hjøllund HI, Kolstad HA, Cordelli E, Leter G.
Sperm chromatin damage impairs human fertility. The Danish
First Pregnancy Planner Study Team. Fertility and Sterility
2000;73(1):43-50.
Thonneau 1991
Thonneau P, Marchand S, Tallec A, Ferial M, Ducot B, Lansac J,
et al. Incidence and main causes of infertility in a resident
population (1 850 000) of three French regions (1988–1989)*.
Human Reproduction 1991;6(6):811-6.
Traber 2007
Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more.
Free Radical Biology and Medicine 2007;43(1):4-15.
Tremellen 2008
Tremellen K. Oxidative stress and male infertility - a clinical
perspective. Human Reproduction Update 2008;14(3):243-58.
Valko 2006
Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free
radicals, metals and antioxidants in oxidative stress-induced
cancer. Chemico-Biological Interactions 2006;160(1):1-40.
Verit 2006
Verit FF, Verit A, Kocyigit A, CiQci H, Celik H, Koksal M. No
increase in sperm DNA damage and seminal oxidative stress in
patients with idiopathic infertility. Archives of Gynecology and
Obstetrics 2006;274(6):339-44.
Wathes 2007
Wathes DC, Abayasekara DR, Aitken RJ. Polyunsaturated fatty
acids in male and female reproduction. Biology of Reproduction
2007;77(2):190-201.
Winters 2014
Winters BR, Walsh TJ. The epidemiology of male infertility.
Urologic Clinics of North America 2014;41(1):195-204.
[1558-318X: (Electronic)]
Yavuz 2013
Yavuz Y, Mollaoglu H, Yurumez Y, Ucok K, Duran L, Tunay K, et al.
Therapeutic eLect of magnesium sulphate on carbon monoxide
toxicity-mediated brain lipid peroxidation. European Review for
Medical and Pharmacological Sciences 2013;17 Suppl 1:28-33.
[1128-3602: (Print)]
Zareba 2013
Zareba P, Colaci DS, Afeiche M, Gaskins AJ, Jorgensen N,
Mendiola J, et al. Semen quality in relation to antioxidant
intake in a healthy male population. Fertility and Sterility
2013;100(6):1572-9.
Zegers-Hochschild 2017
Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C,
de Mouzon J, Sokol R, et al. The International Glossary on
Infertility and Fertility Care, 2017. Human Reproduction
2017;32(9):1786-1801. [1556-5653: (Electronic)]
Zhang 2015
Zhang Z, Zhu L, Jiang H, Chen H, Chen Y, Dai Y. Sperm DNA
fragmentation index and pregnancy outcome aQer IVF or ICSI:
a meta-analysis. Journal of Assisted Reproduction and Genetics
2015;32(1):17-26.
Zhao 2018
Zhao J, Huang X, Xu B, Yan Y, Zhang Q, Li Y. Whether vitamin
D was associated with clinical outcome aQer IVF/ICSI: a
systematic review and meta-analysis. Reproductive Biology and
Endocrinology 2018;16(1):13.
Zhou 2007
Zhou X, Liu F, Zhai S. ELect of L-carnitine and/or L-acetyl-
carnitine in nutrition treatment for male infertility: a systematic
review. Asia Pacific Journal of Clinical Nutrition 2007;16 Suppl
1:383-90. [MEDLINE: 17392136]
Zini 1993
Zini A, de Lamirande E, Gagnon C. Reactive oxygen species in
semen of infertile patients: levels of superoxide dismutase- and
catalase-like activities in seminal plasma and spermatozoa.
International Journal of Andrology 1993; Vol. 16, issue 3:183-8.
[0105-6263: (Print)]
Zini 2011
Zini A, Dohle G. Are varicoceles associated with increased
deoxyribonucleic acid fragmentation? [Review]. Fertility and
Sterility 2011;96(6):1283-7.
 
References to other published versions of this review
Showell 2008
Showell MG, Brown J, Yazdani A, Stankiewicz MT,
Hart RJ. Antioxidants for male subfertility. Cochrane
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
65
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Database of Systematic Reviews 2008, Issue 4. [DOI:
10.1002/14651858.CD007411]
Showell 2011
Showell MG, Brown J, Yazdani A, Stankiewicz MT,
Hart RJ. Antioxidants for male subfertility. Cochrane
Database of Systematic Reviews 2011, Issue 1. [DOI:
10.1002/14651858.CD007411.pub2]
Showell 2014
Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A,
Stankiewicz MT, Hart RJ. Antioxidants for male subfertility.
Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI:
10.1002/14651858.CD007411.pub3]
 
* Indicates the major publication for the study
 
C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised single-centre cross-over trial
Duration of study: 8 months
Participants Country: Japan
Population: infertile men, N = 10
Mean age: 36 years (treatment group age range 24 to 49 years, control age range 30 to 37 years)
Inclusion criteria: male infertility (ROS > 5 x 10,000 counts/10,000,000 viable spermatozoa)
Exclusion criteria: azoospermia, pyospermia
Interventions Ethylcysteine 600 mg (n = 5)
versus
Vitamin E 600 mg (n = 5)
Duration of treatment: 3 months, with a one month wash out, then cross-over for another 3 months.
Only data from the first phase were used in data analysis
Outcomes Sperm parameters, blood serum and seminal plasma levels of ethylcysteine and vitamin E
Notes In Japanese. Data extraction translated by Ichiro, a colleague of Samantha Roberts, 29.01.2009
Author contacted 'no further information is available'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were divided randomly"
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Not mentioned
Akiyama 1999 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No incomplete outcome data
Selective reporting (re-
porting bias)
Unclear risk Sperm parameters reported. No protocol available.
Akiyama 1999  (Continued)
 
 
Methods Randomised controlled open-label trial
Duration of the study: unclear
Participants Country: Egypt
Population: men with isolated idiopathic athenozospermia, prior to intrauterine insemination (IUI), N =
60
Mean age: unknown, quote "both treatment groups were homogenous at the time of randomisation re-
garding the type and duration of infertility"
Inclusion criteria: couples with idiopathic athenozospermia (progressive motility < 32%) with normal
other seminal criteria and normal infertility workup for female partner
Exclusion criteria: unclear
Interventions N-acetylcysteine (NAC) 600 mg (n = 30)
versus
No treatment (n = 30)
Duration of treatment: 12 weeks
Outcomes Sperm concentration, progressive sperm motility, clinical pregnancy rate
Notes Conference abstract, no full text.
Attempted to contact authors 04.02.2014, unable to find e-mail address. Letter posted 12.02.2014
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Couples were randomised"
Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Open-labelled"
Attallah 2013 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Unknown - conference abstract
Attallah 2013  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: from May 2008 to November 2010
Participants Country: Iran
Population: infertile men with varicocele grade III, N = 160 (only 112 completed the study)
Mean age: age range from 20 to 43 (mean ± SD: 29.07 ± 6.8) years
Inclusion criteria: the presence of a grade III varicocele assessed by clinical parameters and was con-
firmed by Doppler ultrasound scanning
Exclusion criteria: evidence of leukocytospermia, low testicular volume < 15 mL, congenital urogenital
abnormalities and urogenital infections
Interventions Zinc 66 mg (n = 32)
versus
Folic acid 5 mg (n = 26)
versus
Zinc 66 mg + Folic acid 5 mg (n = 29)
versus
Placebo (n = 25)
Duration of treatment: 6 months, after varicocelectomy
Outcomes Sperm parameters; number, morphology, halo formation rate, motility, forward progressive motility,
chromomycin A3 positivity
Notes Trial registration: IRCT138802261910N1
E-mailed the author 03.03.2014 (nematollahimahani@yahoo.com / nnematollahi@kmu.ac.ir).
Author replied 06.03.2014 with information included in the ROB table. Author e-mailed again to ask
about pregnancy data and dropouts from which group. The author informed us that Azizollahi 2011
was part of this trial and gave pregnancy and dropout data (there were originally 40 in each group).
Quote: "At that time we observed 2 pregnancies in zinc/folic acid group, 1 pregnancy in zinc group, and
no pregnancy in placebo and folic acid group. These data were just 6 months after the start of the trial."
Risk of bias
Azizollahi 2013 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "For randomisation we used a table with 200 numbers (1 to 200). Be-
fore the trial we gave each group a number between 1 and 4 and allocated
each group into the table. By this method the first, fiQh, ninth, 13th and ... pa-
tients were allocated into the group 1 and the same manner was applied to the
other groups"
Allocation concealment
(selection bias)
Low risk Quote: "We used sealed containers with the randomisation number on them.
Drugs or placebo were in opaque capsules"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Our study was double blind. Neither the urologist nor the patient or
examiner in the lab were aware of the arrangement of the study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Our study was double blind. Neither the urologist nor the patient or
examiner in the lab were aware of the arrangement of the study"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Information gained from communication with the author explained the
dropout numbers
Selective reporting (re-
porting bias)
Low risk Clinical pregnancy rate data gained from email correspondence with the au-
thor. Protocol available.
Azizollahi 2013  (Continued)
 
 
Methods Randomised double-blind trial
Duration of study: 9 months, follow-up 3 months
Participants Country: Italy
Population: infertile men with idiopathic asthenozoospermia, N = 60
Mean age: 30 (range 24 to 38) years
Inclusion criteria: primary infertility > 2 years after regular intercourse with a fertile woman, 20 to 40
years of age, normal rheologic characteristics, sperm count > 20 x 106 /mL, sperm motility < 50%, nor-
mal sperm morphological features > 30%, seminal WBC < 1 x 106 /mL, negative sperm culture and
chlamydia and mycoplasma urealyticum, normal serum gonadotropins, T, E2 and PRL, absence of in-
fectious or genital disease, no anatomic abnormalities of the genital tract, absence of systemic dis-
eases or treatment with other drugs within the 3 months before enrolment in the study, absence of
smoking, alcohol or recreational drug use or of occupational chemical exposure
Interventions L-carnitine 3 g (n = 15)
versus
L-acetyl carnitine 3 g (n = 15)
versus
L-carnitine 2 g + L-acetyl carnitine 1 g (n = 14)
versus
Balercia 2005 
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Placebo (n = 15)
Duration of treatment: 6 months
Outcomes Sperm parameters
Notes 2018: email sent on 07.03.2018 to author Balercia (g.balercia@aoumbertoprimo.marche.it: error, found
new email: g.balercia@univpm.it) to ask if pregnancy rate were clinical pregnancies, how they were
conceived, methods of randomisation and blinding
Reply from author on 12.03.2018: Quote: "Pregnancies were clinical pregnancies, spontaneously con-
ceived. I had at this time no data about the weekly progression, but the outcome of all pregnancies was
newborn babies."
New information added to RoB table. Added data in meta-analysis on clinical pregnancy, live birth and
progressive motility ('Antioxidants vs placebo/no treatment' and 'head to head')
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from email): "The randomisation was made by blinded key"
Allocation concealment
(selection bias)
Low risk Quote (from email): "sealed opaque envelopes provided by the monitor" (reply
email)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): "The randomisation was made by a blinded key, sealed
opaque envelopes provided by the monitor, without any access for the re-
searchers (except the hypothesis of adverse events). The key of randomization
was available just at the end of the study." (reply email)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 1 withdrawal from the L carnitine 2 g/day + L acetyl carnitine 1 g/day group
Quote (from email): "as far your last question, I can confirm the results con-
cerning the drop-out has not be considered in data analysis" (reply email) Con-
clusion: no ITT.
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Balercia 2005  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: 10 months, follow-up 3 months
Participants Country: Italy
Population: infertile men with idiopathic asthenozoospermia, N = 60
Mean age: 32 (range 27 to 32) years
Balercia 2009 
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Inclusion criteria: age 20 to 40 years, infertility > 2 years, regular sexual intercourse with a potentially
fertile female, normal rheologic characteristics (appearance, consistency and liquefaction) of semen
and volume and pH in normal range, sperm count > 20 x 106 /mL, sperm motility < 50% (WHO 1999),
normal morphology > 30%, seminal WBC < 1 x 106 /mL and a negative sperm culture and chlamydia
and Mycoplasma urealyticum (M.urealyticum) detection, normal levels of gonadotropins, absence of
genital disease and anatomical abnormalities of the genital tract including variocoele and antibodies,
absence of systemic disease or treatment with other drugs within 3 months of being enrolled in the
study, absence of smoking, alcohol and drug addiction and exposure to occupational chemicals
Exclusion criteria: transient decrease in semen quality during run in and those who had sudden im-
provement in semen parameters during run in
Interventions Coenzyme Q10 200 mg (n = 30)
versus
Placebo (n = 30)
Duration of treatment: 6 months
Outcomes Primary: sperm parameters, variations of coenzyme Q10 and ubiqiunol concentrations in seminal plas-
ma and spermatozoa
Secondary: pregnancy rate
Notes 2018: added data on progressive sperm motility
Email sent to author (g.balercia@staff.univpm.it) to ask if pregnancies were clinical and if he has live
birth rates
Reply of author Balercia on 29.03.2018: Quote: "Like the other study, I can confirm that pregnancies
were clinical pregnancies, spontaneously conceived, but I had no data about the weekly progression
(our outcome was another and we just reported the pregnancies as “collateral” data). All pregnancies
gave newborn babies (patient/parent contacted us to share the joyful moment”)". Data added.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk At end of trial the paper mentions - quote: "after opening randomisation list"
page 1789
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Semen quality was assessed by the same biologist"
Blinding not mentioned.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "5 patients dropped out of the study", 2 from the treatment group and 3
from the placebo group; this was discovered after opening the randomisation
list at the end of the study. ITT was carried out
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Balercia 2009  (Continued)
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
71
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Methods Randomised clinical trial
Duration of study: unclear, from 2011 to 2013
Participants Country: Iran
Population: subfertile men with varicocele grade 2-3, N = 40
Mean age: 30.1 ± 4.4 (range: 22-45) years
Inclusion criteria: age < 45 years, primary infertility, leQ-sided varicocele (grade 2-3) diagnosed by pal-
pation and Doppler duplex ultrasound. Female partner with age < 35 years, normal ovulatory cycles
and patent tubes (confirmed by hysterosalpingography or laparoscopy).
Exclusion criteria: varicocele grade I, azoospermia, recurrent varicocele, leukocytospermia, urogenital
infections, testicular size discrepancy, abnormal hormonal profile, anatomical disorders, Klinefelter’s
syndrome, cancer, fever in the 90 days prior to sugery, seminal sperm antibodies, excessive alcohol and
drug consumption, previous history of scrotal trauma or surgery, occupational exposure. Female part-
ner with endometriosis, cycle irregularity, or gross anatomical abnormalities
Interventions N-acetylcysteine (NAC) 200 mg (n = 20)
versus
No treatment (n = 20)
Duration of treatment: 3 months, directly after varicocelectomy
Outcomes Sperm parameters, DNA-fragmentation (TUNEL), protamine deficiency, ROS levels
Notes Email sent to last author Nasr-Esfahani (mh.nasr-esfahani@royaninstitute.org) on 06.03.2018 to ask
about the allocation concealment, sequence generation and definition of pregnancies and method of
conceiving. Reply the same day from author (06.03.2018): Quote: "Clinical, spontaneous, pregnancies
confirmed by heartbeat." Rest of information in RoB.
Authors replied on 04.04.18 answering that data was presented with SEM
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from email):"Randomisation done by table. We used computer-gener-
ated or random allocation software and with one block"
Allocation concealment
(selection bias)
High risk Quote (from email): "Dr would prescribe the NAC based on randomization ta-
ble"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding of participants or health care providers (control is no treatment)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): “All parameters assessed in this study were carried out by
a single trained individual unaware of treatment assignment.” "Lab collect-
ed the sample based on a table of allocation and handed the sample over to
the researcher that carried out the semen analysis and sperm functional tests
and was unaware to randomization. A third person called the patients and en-
Barekat 2016 
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quired about pregnancy and whether it was confirmed by heartbeat. Finally,
the data gathered and analyzed independently of Dr or researchers"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: “In this study, five individuals were excluded from the treatment group
due to lack of compliance with NAC use, according to the study protocol"
Lack of compliance directly related to treatment, furthermore 25% dropout is
high. No ITT.
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Barekat 2016  (Continued)
 
 
Methods Randomised trial
Duration of study: unclear
Participants Country: Italy
Population: men with severe idiopathic oligoasthenospermia (sperm concentration < 5000 /μl), N = 42
Mean age: group A and B 35 (range 30 to 40) years, Group C 31 (range 24 to 34) years
Inclusion criteria: severe idiopathic oligoasthenospermia (sperm concentration < 5000 /μl)
Exclusion criteria: genomic, hormonal or inflammatory diseases
Interventions Acetyl-carnitine 1 g + L-carnitine 2 g + Cinnoxicam (n = 14)
versus
Acetyl-carnitine 1 g + L-carnitine 2 g (n = 14)
versus
No treatment (n = 14)
Duration of treatment: unclear
Outcomes Sperm parameters
Notes Conference abstract. No full text or data given. Contacted authors but no reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomised (1patient = 1 block) analysis of variance"
Was this at the time of sequence generation or at data analysis?
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment.
Biagiotti 2003 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Unclear conference abstract
Biagiotti 2003  (Continued)
 
 
Methods Randomised single-centre,triple-blinded, clinical trial
Duration of study: from January 2011 to August 2014, follow-up 14 months
Participants Country: Denmark
Population: men part of an infertile couple with impaired semen quality, N = 307
Mean age: 34.8 ± 6.6 years
Inclusion criteria: impaired semen quality (determined by WHO criteria) and vitamin D insufficient (25
OHD level #50 nmol/L)
Exclusion criteria: serious comorbidities
Interventions Vitamin D 1400 IU + calcium 500 mg (n = 151) plus vitamin D 300,000 IU oil once orally
versus
Placebo (n = 156) plus placebo oil once orally
Duration of treatment: 150 days (5 months)
Outcomes Sperm parameters, reproductive hormones, live birth rate
Notes Power calculation performed.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Infertile men were randomly assigned 1:1 (in blocks of 10) to either
placebo or.."
"Included men were given a specific trial identity number determined by min-
imization using the computer program Minim (21). Minimization was done us-
ing four groups based on serum 25OHD, sperm concentration, body mass in-
dex (BMI) and serum inhibin B"
Allocation concealment
(selection bias)
Low risk Quote: "Randomization and manufacture of the high initial dose of vitamin D
and placebo were performed by Glostrup Apotek."
Blinding of participants
and personnel (perfor-
mance bias) 
Low risk Quote: "triple-blinded", "To avoid unblinding, the principal investigator gave
the necessary clinical information to the sponsor, who had a list of numbers
headed by X or Y. This ensured that both the principal investigator and the
Blomberg Jensen 2018 
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All outcomes sponsor were unaware whether the patient was allocated to the vitamin D plus
calcium (active) group or the placebo group (i.e., double blinding)."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The trial remained blinded until all biochemical analyses, data han-
dling, and statistical analyses by an independent statistician had been com-
pleted (i.e., triple blinding)."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Twenty men in the placebo group and 18 in the vitamin D plus calcium
group were lost to follow-up. In total, 269 of 307 men (87.6%) completed the
study (Fig. 1). By counting returned tablets, it was evident that one man in the
vitamin D group and three in the placebo group were noncompliant; however,
all data from these four men were included in all the analyses."
Quote: "Twenty-nine of the 269 men completing the trial reported their part-
ner was pregnant before start of the intervention, whereas five men lost their
partner during the study period, leaving 235 with the possibility of effecting a
pregnancy."
ITT. No explanation given for lost to follow-up? Therefore unclear risk
Selective reporting (re-
porting bias)
Low risk All the outcomes from the protocol were reported
Blomberg Jensen 2018  (Continued)
 
 
Methods Randomised double-blind controlled trial
Duration of study: from May 2013 to October 2014
Participants Country: Thailand
Population: men with abnormal semen analysis, N = 68
Mean age: treatment group (folate only) 26.08 ± 0.76 years, control group 24.7 ± 10.84 years
Inclusion criteria: abnormal semen analysis of at least one parameter according to WHO Criteria
2010(13) (concentration < 15 million/ml, motility < 40%, or morphology < 4%), failure of the female
partner to conceive after one year of regular unprotected sexual intercourse, no history of tamoxifen
and folate allergy
Exclusion criteria: use of tamoxifen and folate within three months before recruitment, use of other
medicines or vitamin during study period
Interventions Placebo (n = 15)
versus
Tamoxifen citrate 20 mg (n = 15)
versus
Folate 5 mg (n = 15)
versus
Tamoxifen citrate 20 mg + Folate 5 mg (n = 15)
Duration of treatment: 3 months
Boonyarangkul 2015 
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Outcomes Sperm parameters, hyaluronan binding assay, hypo-osmotic swelling test and DNA damage (Comet as-
say, tail length)
Notes Only folate and placebo arm included.
Email sent to author on 06.03.2018 to Boonyarangkul (doctor_artit@yahoo.co.th) to ask about the ran-
domisation process, blinding of outcome assessment, drop-out rate and funding of trial. Reminder
email sent on 22.03.2018 to authors Boonyarangkul and Chiamchanya (doctor_artit@yahoo.co.th;
charoenchai12@hotmail.com). No reply to date (19.04.2018)
Data used in meta-analysis, however a sensitivity analysis was performed due to great baseline imbal-
ance between these two groups, especially sperm concentration
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
High risk Baseline imbalance in concentration control versus folate group
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "Eight patients were excluded from the study (three patients declined
to participate and five patients stop medication before completing the trial)"
Unclear in which groups they participated. Data analysis by the authors was
done without the 8 dropouts
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Boonyarangkul 2015  (Continued)
 
 
Methods Randomised double-blind placebo-controlled study
Duration of study: from December 2014 to June 2015, follow-up unclear
Participants Country: Italy
Population: infertile men with oligo- and/or astheno- and/or teratozoospermia, N = 104, divided in two
clusters, 52 patients with varicocele grade I-III and 52 patients without varicocele
Mean age: 32.5 ± 6.7 years
Inclusion criteria: age 18 – 50 years, oligo-, astheno- and/or teratozoospermia, with or without varic-
ocele, having a history of infertility for more than 12 months, varicocele patients were not surgically
treated before and during the treatment, patients without varicocele were suffering from idiopathic
male infertility, no other previous history of diseases affecting fertility. Fertile female partners were re-
Busetto 2018 
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quired with regular menstrual cycles, age <40 and couples not looking for fertility-related procedures
(IVF/ICSI/IUI) for the next 90 days
Exclusion criteria: known hypersensitivity to any of the treatment compounds, history of undescended
testes or cancer, endocrine disorders, history of post-pubertal mumps, genitourinary surgery, obstruc-
tive azoospermia or obstructive pathology of the urogenital system, autoimmune disease, cystic fibro-
sis, history of taking any therapy affecting fertility within last 3 months, excessive consumption of alco-
hol or regular use of illicit or “recreational” drugs, positive serology for HIV, participants following any
special diet, any condition which in the opinion of the investigator might put the participanr at risk by
participating in this study, participants involved in any other clinical trials
Interventions Proxeed Plus 2 sachets (n = 52) (l-carnitine 1000 mg, fumarate 725 mg, acetyl-l-carnitine 500 mg, fruc-
tose 1000 mg, CoQ10 20 mg, vitamin C 90 mg, zinc 10 mg, folic acid 200 μg and vitamin B12 1.5 μg)
versus
Placebo 2 sachets (n = 52)
Duration of treatment: 6 months
Outcomes Sperm parameters, pregnancy rate
Notes Power calculation performed.
Email sent to author Busetto (gianmaria.busetto@uniroma1.it) on 07.03.2018 to ask about allocat-
ian concealment, blinding of outcome assessment and if the pregnancies were clinical and sponta-
neous conceived. Reply from author on 07.03.2018: Quote: "All natural pregnancies, spontaneously
conceived, confirmed by ultrasound and we had just one abortion." See RoB.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The block randomisation method was used to randomise subjects into
groups resulting in equal sample sizes to ensure a balance across the groups
over time."
Quote (from email): "Randomisation schedule (nQuery Advisor nTerim 2.0
(2012) program)"
Allocation concealment
(selection bias)
Low risk Quote (from email): "The randomization was done by an external company
(non-pharmaceutical)"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote (from email): "We used a double blind system and so researched didn't
know anything about the randomization". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): "An external statistician evaluated everything external"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk "Ten patients dropped out from the study leaving 45 patients with varicocele
and 49 without varicocele."
"As for the ANCOVA, the p-values refer to the intention-to-treat population
(ITT). The last observation carried forward (LOCF) method was used for replac-
ing the missing data"
Reasons for dropout not mentioned.
Busetto 2018  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Busetto 2018  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: follow-up 9 months
Participants Country: Italy
Population: idiopathic men with variocoele or idiopathic oligo-asthenospermia (OAT), N = 325
Mean age: 34 (range 27 to 40) years
Inclusion criteria: men with OAT and with deficiencies in all sperm patterns whose chief complaint was
primary couple infertility > 12 months with regular intercourse. Normal sperm appearance, consisten-
cy, liquefaction, volume, pH. Female partner without fertility problems. Varicoceles.
Exclusion criteria: azoospermia, seminal WBC concentration more than 1000,000/mL, positive urethral
chlamydia swab test, oligospermia < 5,000,000 /mL, hormonal alterations, age > 40 years, presence of
anti-sperm antibodies, drug, tobacco or alcohol abuse, ongoing medical treatments, presence of hy-
drocoele, diabetes,hypertension, x-ray exposure in previous 8 months, peptic ulcer, unexplained gas-
tric pain, previous hypersensitivity to NSAIDS or carnitines, carnitine metabolism deficiency, bilateral
variocoele, prostate abnormalities, previous or current testicular pathology, testicle echographic ab-
normalities
Interventions Placebo starch tablets 2 times/day + glycerine suppository (1 every 4 days) (n = 118)
versus
L-carnitine 1 x 2 g/day + acetyl-L-carnitine 500 x 2 mg/day + glycerine suppository (n = 101)
versus
L-carnitine 1x 2 g/day + acetyl-L-carnitine 500 x 2 mg/day + glycerine suppository + cinnoxicam suppos-
itory 1 x 30 mg (every 4 days) (n = 106)
Duration of treatment: 6 months
Outcomes Primary: sperm parameters
Secondary: pregnancy, side effects
Notes Cinnoxicam is a NSAID, therefore the third arm was not included in meta-analysis as per protocol
Continuous data taken from Cavallini 2004a 'excluded conference abstract' no data for placebo group
Unit of analysis variocoele therefore cannot extract data that were presented as median (interquartile
range)
Author contacted regarding uneven numbers and missing placebo and continuous data
Author replied that raw data were not available due to computer crash
Risk of bias
Bias Authors' judgement Support for judgement
Cavallini 2004 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "casual random tables"
Allocation concealment
(selection bias)
Low risk Quote: "drug placebos identical in appearance", "anonymized carnitine and
cinnoxicam and glycerine suppository containers; and filled and sealed anony-
mous color coded boxes", "the color code was disclosed to physicians by phar-
macists and by IRB at the end of the research"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "All study personnel and participants were blinded to treatment assign-
ment for the duration of the study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All study personnel and participants were blinded to treatment assign-
ment for the duration of the study"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 325 randomised but only 185 accounted for; 55 dropouts from 185 (42%), 53
reasons given for the dropouts
Selective reporting (re-
porting bias)
Unclear risk Sperm parameters as primary outcome. Intention to collect biochemical preg-
nancy data as secondary outcome recorded in the methods. No protocol avail-
able.
Cavallini 2004  (Continued)
 
 
Methods Randomised placebo-controlled trial
Duration of study: unclear
Participants Country: Canada
Population: healthy asthenozoospermic men who were patients of an infertility clinic, N = 28
Mean age: placebo group 35.2 years, treatment group 400 mg 38.3 years and treatment group 800 mg
34.4 years
Inclusion criteria: asthenozoospermic, sperm motility < 50% of total sperm
Exclusion criteria: unclear
Interventions Docosahexaenoic acid (DHA) 400 mg (n = 9)
versus
Docosahexaenoic acid (DHA) 800 mg(n = 10)
versus
Placebo (n = 9)
Duration of treatment: 3 months
Outcomes Sperm parameters
Notes Data with SEs converted to SDs. Placebo arms split
Conquer 2000 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The 28 subjects were randomly assigned to ..."
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All men randomised were in the analysis, no dropouts.
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Conquer 2000  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: from February 2010 to May 2011
Participants Country: Iran
Population:infertile men with palpable varicocele grade 2-3, N = 115
Mean age: 27.6 ± 5.3 years.
Inclusion criteria: a palpable varicocele in physical examination and accompanying abnormalities
in count, motility, or morphology of sperm in two separate semen analyses (according WHO criteria
1999), age range between 18 and 50, weight between 50 kg and 100 kg, being married
Negative inclusion criteria:
• absence of azoospermia,• diabetes mellitus,• hormonal disorders (according to medical history and clinical examination),• tobacco smoking, opium or recreational drugs addiction,• regular usage of vitamins or nutritional supplements,• active or chronic genitourinary infection (based on medical history, physical examination, semen and
urine analysis),• history of peptic ulcer,• previous reaction to or intolerance to vitamin C.
Cyrus 2015 
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Exclusion criteria: missed follow-up, incorrect usage of the capsules, demonstrating side effects due to
vitamin C, commencement of smoking or opium addiction during the follow-up period, delayed com-
plications of varicocelectomy such as: hydrocele, recurrence of varicocele, and testicular atrophy.
Interventions Vitamin C 500 mg (n = 46)
versus
Placebo (n = 69)
Duration of treatment: 3 months, after varicocelectomy
Outcomes Primary: mean sperm count, motility (mean perc ent of type A plus type B divided by all motility types) ,
morphology index (before and after surgery)
Secondary: complications of surgery, varicocele grade, age and weight
Notes Trial registration: IRCT201103042134N2
Email sent to author on 06.03.2018 to dr Kabir (aikabir@yahoo.com) to ask about funding and if the
new matched cases were randomised.
Reply on 23.03.2018 with all questions answered (see RoB)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Simple randomization method using Excel 2010 software (Microsoft
Corporation, Washington, USA) by RANDBETWEEN(0;1000000)”function."
Quote: "Five patients from the intervention group and eight patients from
controls did not show-up for the follow-up visits and were substituted with
matched new cases"
Reply from authors by email: new cases were randomised
Allocation concealment
(selection bias)
Low risk Quote: "The allocation sequence was produced by our statistician and was
delivered to our pharmacist. Participants were enrolled by the two executive
urologists who were unaware of the results of the allocation table. Then based
on the number in the sequence being odd or even each new patient after varic-
ocele surgery was assigned to intervention or placebo group by our pharma-
cist who supplied the drugs. The ratio of placebo to intervention group was
1.5"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Analyzed in a reference laboratory (Sina Laboratory of Arak) by an ex-
perienced specialist in pathology and clinical laboratory medicine. Complica-
tions of surgery, varicocele grade, age and weight were determined"
Reply from authors by email: outcome assessors were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Five patients from the intervention group and eight patients from
controls did not show-up for the follow-up visits and were substituted with
matched new cases"
Quote (from email): "We were able to have access to some of these drop-out
cases. None of them mentioned disease-, medication-, or study-related causes
Cyrus 2015  (Continued)
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for loss to follow up. Moving out from the city, changing their mind for partici-
pating in the study immediately after accepting to participate, personal secret
causes and so on were among some of these reasons."
Selective reporting (re-
porting bias)
Low risk Quote: "Our secondary complications were rare and they were excluded from
the study and only those with clinically cured varicocele were selected for the
final analysis. If there was any other unaccounted factor from Ivanissevich
method that could affect the results, since both groups had the same type of
operation, it would be balanced in the two groups"
All the outcomes from the aim of the study and methods were reported.
Cyrus 2015  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: 4 weeks
Participants Country: USA
Population: men with sperm agglutination, N = 30
Mean age: range 25 to 45 years
Inclusion criteria: sperm agglutination over 25%, negative sperm antibodies, physically normal, no in-
flammatory disease
Exclusion criteria: unclear
Interventions Ascorbic acid (vitamin C) 1000 mg (n = 10)
versus
Ascorbic acid (vitamin C) 200 mg (n = 10)
versus
Placebo (n = 10)
Duration of treatment: 3 weeks
Outcomes Seminal parameters
Notes Placebo numbers split by 2. Data were given in SE converted to SD
New comment 2018: progressive forward motility instead of total motility, data total sperm motility
moved to outcome progressive sperm motility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "By random selection, three groups of 10 subjects each.."
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Dawson 1990 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Each subject was told he was receiving AA and expected improvement
in sperm quality"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No dropouts
Selective reporting (re-
porting bias)
Unclear risk All specified outcomes were reported. No protocol available.
Dawson 1990  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: from January 2013 to February 2014
Participants Country: China
Population: men with idiopathic oligoasthenozoospermia (N = 86)
Mean age: treatment group 31.5 ± 3.7 years, control group, 32.0 ± 4.1 years
Inclusion criteria: 18 to 45-year-old male infertility patients, no contraception after marriage and infer-
tility more than 12 months, normal sex life, no abnormal fertility of the women. According to WHO re-
quirements 5 × 106/mL <s perm concentration < 20 × 106/mL, 10% < forward motility sperm percentage
< 50%.
Exclusion criteria: severe oligozoospermia; dead sperm disease due to erectile dysfunction (ED) or ret-
rograde ejaculation or non-ejaculation; drug, uncontrolled bacterial prostatitis, fever and other factors
affecting fertility; taking drugs that may affect sperm function; congenital malformations, fine tract ob-
struction, testicular atrophy; tuberculosis, liver, kidney and haematopoietic system of severe primary
disease, mental illness.
Interventions Vitamin D 200 IU + calcium 600 mg chewable tablet once daily (n = 43)
versus
Vitamin E 100 mg + vitamin C 100 mg three times a day (n = 43)
Duration of treatment: 3 months
Outcomes Sperm parameters, adverse reactions, pregnancy rate
Notes Email sent on 23.07.2018 to dr Deng (dengxiaolin@hsc.pku.edu.cn) with questions regarding the ran-
domisation, blinding, outcome data assessment. No reply to date
Risk of bias
Bias Authors' judgement Support for judgement
Deng 2014 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "86 patients were randomly divided into treatment group and control
group"
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded: treatment A once daily chewable tablets, treatment B tablets
three times a day
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Deng 2014  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: unclear
Participants Country: Japan
Population: infertile men with oligoasthenospermia, N = 96
Mean age: unclear
Inclusion criteria: unclear
Exclusion criteria: unclear
Interventions Vardenafil 10 mg (n = 23)
versus
Sildenafil 50 mg (n = 25)
versus
L-carnitine 1000 mg (n = 26)
versus
No treatment (n = 22)
Duration of treatment: 12 weeks
Outcomes Seminal parameters
Notes Excluded were vardenafil (n = 23) and sildenafil (n = 25)
Dimitriadis 2010 
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Tried multiple times to contact authors for randomisation details and methods. No response. Last con-
tacted in Feburary 2014. E-mail addresses tried: saitomo@kochi-u.ac.jp, akrosnin@hotmail.com
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control no treatment.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No dropouts or lost to follow-up mentioned.
Selective reporting (re-
porting bias)
Unclear risk All data points accounted for. No protocol available.
Dimitriadis 2010  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: unclear
Participants Country: Turkey
Population: infertile men with a leQ-sided clinical varicocele, N = 56
Mean age: 25.8 ± 4.6 years
Inclusion criteria: males diagnosed with a leQ-sided clinical varicocele in the urology polyclinic, and for
whom subinguinal varicocelectomy was planned
Exclusion criteria: the use of alcohol, tobacco or any drugs including vitamins
Interventions Vitamin E 600 mg (n = 22)
versus
No treatment (n = 23)
Duration of treatment: 12 months, start after varicocelectomy
Outcomes Sperm parameters, pregnancy rate
Notes Power calculation performed
Ener 2016 
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Email sent to author on 06.03.2018 to dr Ener (kemalener75@yahoo.com) to ask about funding, the
randomisation process, blinding of outcome assessment and if the reported pregnancies were clini-
cal pregnancies and how they were conceived. Reminder email sent to Ener and Ozayar (eozayar@ya-
hoo.com.tr) on 22.03.2018.
No reply to date (19.04.2018), data on pregnancy not used, unknown if clinical
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control group is no treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "A total of 45 patients were included in the study."
Quote: "Of note, our cohort was not without limitation. During the study set-
up, the sample size was calculated as 56. However, 11 patients who could not
use vitamin E regularly, or did not come to visit in control periods, were ex-
cluded from the study."
Not clear in which groups drop-outs belonged
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Ener 2016  (Continued)
 
 
Methods Randomised controlled triple-blinded trial
Duration of study: 12 weeks
Participants Country: Iran
Population: asthenozoospermic infertile men, N = 50
Mean age: unclear
Inclusion criteria: patients interest in contribution aged 20-45 who have passed at least one year from
the date they have decided to have a baby, not to using pregnancy protection methods, affected by id-
iopathic asthenozoospermia based on WHO criteria, normal serum gonadotropin, testosterone and
prolactin values
Exclusion criteria: affected by genital system infection or taking drug for the infection during past three
months, affected by anatomical anomalies in genital system such as varicocoele, surgical history on
testicles and vasdeferane
Eslamian 2013 
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Interventions Docosahexaenoic acid (DHA) 465 mg + vitamin E 600 IU (n = 25)
versus
Placebo (n = 25)
Duration of treatment: 12 weeks
Outcomes Sperm parameters, serum fatty acid concentration and sperm membrane fatty acid concentration
Notes In Arabic, translated. Tried multiple times to contact authors for further study details with no response.
Last tried to contact Feburary 2014: janati@avicenna.ac.ir
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stratified blocked randomisation
Allocation concealment
(selection bias)
Low risk Cans containing capsules marked as A1, A2, B1, B2 and patients, researchers
and physician were unaware of the types of drugs
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Cans containing capsules marked as A1, A2, B1, B2 and patients, re-
searchers and physician were unaware of the types of drugs"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Triple-blinded" "Cans containing capsules marked as A1, A2, B1, B2
and patients, researchers and physician were unaware of the types of drugs"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Withdrawals and exclusions:
Intervention group (3 withdrawals): one man could not refer to the clinic in
sixth week, the wife of the other one got pregnant, and another one was ex-
cluded because he have not taken more than 10% of the capsules
Control group (6 withdrawals): two men could not refer to the clinic in sixth
week, one man could not refer to the clinic in 12th week. One man used com-
plementary Coenzyme Q10, and another one was excluded because he have
not taken more than 10% of the capsules
Selective reporting (re-
porting bias)
Unclear risk Sperm parameters reported. No protocol available.
Eslamian 2013  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: quote: "from January 2010 to July 2014" (information from email)
Participants Country: Spain
Population: men from infertile couples participating in an IVF/ICSI program, N = 113 according to final
manuscript and authors, grouped into three categories: normozoospermic, oligozoospermic and as-
thenozoospermic.
Exposito 2016 
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Mean age: 37.6 ± 3.8 years
Inclusion criteria: duration of infertility of at leat 12 months and female age less than 40, as this a
mandatory criterion in all Spanish public hospitals
Exclusion criteria: quote: "the patient does not sign the informed consent" (information from email)
Interventions Vitamin E (α-tocopherol) 400 mg (n = 55, n = 50 completed treatment)
versus
Placebo (n = 59, n = 51 completed treatment)
Duration of treatment: 3 months
Outcomes Sperm concentration, sperm count, progressive motility (A+B%), pregnancy rate
Notes Conference abstract. Trial registration: EudraCT 2007-000960-25
Email sent to author Exposito (antonia.expositonavarro@osakidetza.eus;) and Matorras (JOSEROBER-
TO.MATORRASWEINIG@osakidetza.eus) on 20.02.2018 and 07.03.2018 to request full text or data re-
garding the outcomes in the OAT/azoospermic group
Reply from author Matorras on 13.03.2018, received draQ of manuscript.("we hope we are able to sub-
mit it for publication in two months") and asked some more questions about design/methods and data
(means with SD) on the subgroup of men with male factor (so without the normospermic men). Reply
on 24.03.2018: see RoB.
Data not usable in meta-analysis due to the fact that is data for all the 3 categories (normozoospermic,
oligozoospermic and asthenozoospermic) together.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from email): "To maintain the blindness to the investigator and the
subject, the investigator receives the information of the treatment allocation
number from the computer system."
Computer randomisation
Allocation concealment
(selection bias)
Low risk Quote (from email): "To maintain the blindness to the investigator and the
subject, the investigator receives the information of the treatment allocation
number from the computer system. The subject receives his study medication
package from the study site of the institution."
Investigator receives a number belonging to a study medication package
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blind". Placebo used.
Quote (from email): "All the active and placebo capsules are identical in ap-
pearance, shape, smell and taste"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote (from email): "At the end 101 couples completed the treatment (placebo
group N=51 and vitamin E group N=50). Nine couples withdrew from this study
before completing their 3 months of treatment due to IVF cycle cancelled or a
lack of continuing interest(8%) (five of the placebo group and four of the vita-
min E group)(N=104) .Three couples achieved spontaneous pregnancy at 50, 60
Exposito 2016  (Continued)
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
88
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
and 90 days of treatment;two of them belonged to placebo group and the oth-
er belonged to the vitamin E group (2.7%)"
Quote (from email): "The data analysis was done with the people who com-
pleted the study (n=101)"
No ITT. Reasons for drop-out well explained and balanced.
Selective reporting (re-
porting bias)
Low risk All the outcomes from the aim of the study and methods were reported
Exposito 2016  (Continued)
 
 
Methods Randomised controlled, intention-to-treat, single centre study.
Duration of study: 12 months, from January 2003 to June 2005
Participants Country: Italy
Population: men with persistent oligospermia (5 to 20 m/ml), N = 42
Mean age: treatment group 32 (27.5 to 35.5) years, control 33 (23 to 36) years
Inclusion criteria: having performed a retrograde embolization with concomitant oligospermia, persis-
tent oligospermia and infertility > 12 months
Exclusion criteria: smoking, alcohol consumption, taking any fertility drugs within 3 months prior to the
study, serious medical or psychiatric condition, abnormal hormonal profile, sperm infection
Interventions N-acetylcysteine (NAC) 600 mg + vitamins-minerals (vitamin C, vitamin E, vitamin A, thiamine, ri-
boflavin, piridoxin, nicotinamide, pantothenate, biotin, cyanocobalamin, ergocalciferol, calcium, mag-
nesium, phosphate, iron, manganese, copper, zinc) (n = 20)
versus
No treatment (n = 22)
Duration of treatment: 90 days
Outcomes Primary: seminal parameters
Secondary: pregnancy (undefined) and adverse effects
Notes Power calculation performed.
Attempted to contact author regarding median data. No response yet (2014)
2018: motility reported as WHO Class A motile sperm instead of total motility, added to table 'data not
usable for meta-analysis'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Subjects were randomly assigned to either antioxidant therapy or no
medical therapy. Randomisation number was assigned by random allocation
software using a block randomisation design"
Galatioto 2008 
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Allocation concealment
(selection bias)
Low risk Quote: "All steps of randomisation process were performed blindly in the phar-
macy of our hospital"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All ejaculate analysis was analyzed blindly with respect to the treat-
ment groups"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "intention to treat"
Selective reporting (re-
porting bias)
Unclear risk No protocol available.
Galatioto 2008  (Continued)
 
 
Methods 'Open perspective randomised' study
Duration of study: unclear
Participants Country: Russia
Population: men with varicocele, N = 114
Mean age: 34.1 ± 12.1 years
Inclusion criteria: aged 25-45 years, participants’ wives had not become pregnant in the last 12 months
or more, despite regular unprotected sexual intercourse between the partners; oligo-,asteno- and/or
teratozoospermia, varicocele evident upon palpation confirmed by Doppler ultrasonography of scro-
tum blood vessels, normal constitutional development as determined by the physical exam
Exclusion criteria: previously established genetic causes of infertility (Klinefelter syndrome, microdele-
tions AZF, CFTR), azoospermia, clinical and laboratory evidence for inflammatory changes to sex
glands, pyospermia, follicle-stimulating hormone (FSH) overproduction, immunologic infertility (MAR-
test IgG > 10%), pronounces somatic pathology, psychosexual or ejaculatory disfunction
Interventions SpermActin-forte (acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid) (n = 38)
versus
SpermActin-forte + Vitamin complex 'Man's formula' (n = 38)
versus
No treatment (n = 38)
Duration of treatment: 3 months, after microsurgical varicocelectomy (MVE)
Outcomes Sperm parameters, DNA fragmentation, side-effects
Notes Article in Russian, translated by Andrew Dubovyi. Ethical approval and obtaining informed consent not
mentioned in text.
Gamidov 2017 
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Email sent to author Ovchinnikov (r_ovchinnikov@oparina4.ru) on 29.03.2018 to ask about the ran-
domisation process, blinding of outcome assesors, drop-outs and which side-effects they aimed for
("No side effects related to the pharmacological treatment were observed."). Reply on 11.04.18, see
RoB.
Data on adverse events used. Other data not usable due to the use of medians and interquartile ranges
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Using adaptive dynamic randomization with stratification patients
were assigned to one of three groups of 38 subjects"
Quote (from email): "It was computer randomized block design"
Allocation concealment
(selection bias)
Unclear risk Quote (from email): "Randomization was done by the researchers"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment, furthermore group A uses 1 tablet, group B uses 2
tablets
Quote (from email):"The study was not blinded"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): question was the person who assed the outcomes blind-
ed? "Yes"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote (from email):"There were no lost to follow-up participants (the samples
were small)"
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Quote (from email) when asking about which adverse events were aimed for:
"We have not registered any side effects, including gastro-intestinal, urologi-
cal, neurological complications, etc"
Gamidov 2017  (Continued)
 
 
Methods Randomised placebo-controlled double-blind parallel three-arm multicentre trial
Duration of study: follow-up 6 months
Participants Country: India
Population: Idiopathic oligoasthenozoospermia men, N = 138 (N = 125 completed the study)
Mean age: 30.74 (range 24-45) years
Inclusion criteria: age 21-50 years, infertility >1 year, sperm count less than 15 million/mL, sperm total
motility < 40%, no history of taking therapy for infertility, no history of OAT, regular sexual intercourse
with a potentially normal fertile female, willing to sign informed consent and likely to be available for
all visits during follow-up period
Exclusion criteria: primary testicular disease, any organic cause for infertility including varicocele,
prostate-vesiculo-epididymitis,genital infectious disease,planning for any other ART during study peri-
od, serum follicle-stimulating hormone FSH >15 mIU/mL, abnormal serum levels of LH, testosterone,
Gopinath 2013 
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estradiol and prolactin, presence of antispermatozoa antibodies, severe oligospermia (< 2 million
sperm/mL), azoospermia, seminal WBCs more than 1 x 106 mL, major hepatic and renal disease, my-
opathy, history of allergy to any ingredient of the formulation, not likely to be available for follow-up,
have participated in another clinical trial in the past 3 months, female partners with anatomic or physi-
ological alterations causing subfertility
Interventions Fixed doses combination (FDC) 2 tablets (Coenzyme Q10 50 mg + L-carnitine 500 mg + lycopene 2.5 mg
+ zinc 12.5 mg) (n = 46)
versus
Fixed doses combination (FDC) 1 tablet + 1 Placebo tablet (n = 43)
versus
Placebo 2 tablets (n = 36)
Duration of treatment: 180 days
Outcomes Primary: improvement in sperm count, total sperm motility (90 and 180 days)
Secondary: pregnancy rate, side effects
Notes Email sent on 06.03.2018 to dr Zaveri (drhemantzaveri@gmail.com) to ask about the pregnancies (clini-
cal? How conceived?), the randomisation process, blinding of outcome assessment and allocation of 13
dropouts. Reminder email sent on 27.03.2018. Reply on 30.03.2018 from author; see text in RoB.
Pregnancy data not used, distribution in groups unknown, only reply from author quote: "No pregnan-
cies were not followed up to stage 12 weeks. So no pregnancy was clinical. 9 pregnancies were con-
ceived through ART 3 Conceived spontaneous" Numbers from text: 6 in FDC 2, 7 in FDC 1, 2 in Placebo.
Pregnancy data used in table 1.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from email): "Procedures were computer"
Allocation concealment
(selection bias)
Low risk Quote: "Centrally randomised to one of three treatment arms (arm 1-3) in a
1:1:1 ratio"
Central randomisation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blinded". Placebo used
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): "Yes outcome assessment was blinded "
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 13 lost to follow-up (dropout), quote: "at different stage during the study"
Asked by email in which groups or what reasons. Quote (reply email): "5 in pa-
ternia BID, 6 in placebo, 2 in paternia BID"
Data-analysis only on the 125 who completed the study. Low risk because
dropouts accounted for.
Gopinath 2013  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Gopinath 2013  (Continued)
 
 
Methods Randomised controlled double-blind trial
Duration of study: unclear
Participants Country: France
Population: infertile males, N = 64
Mean age: unclear
Inclusion criteria: TUNEL assay showed a presence of fragmented DNA ≥ 15% of ejaculated spermato-
zoa
Exclusion criteria: variocele, genitourinary inflammation, infection, smoking
Interventions Vitamin C 1000 mg + Vitamin E 1000 mg (n = 32)
versus
Placebo (n = 32)
Duration of treatment: 2 months
Outcomes Sperm parameters
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The study was double-blinded with both the authors and the patients
unaware of which of the patients was in the treatment or control arm of the
study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No dropouts
Selective reporting (re-
porting bias)
Unclear risk No protocol available.
Greco 2005 
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Methods Randomised triple-blind placebo-controlled trial
Duration of study: unclear, in 2014
Participants Country: Iran
Population: men with idiopathic asthenozoospermia, N = 48
Mean age: 33.56 ± 5.07 years
Inclusion criteria: unwilling childlessness at least 24 months in duration with a female partner, no med-
ical condition that could account for infertility, normal fertile female partner according to investiga-
tions, all patients were needed to have stopped all medical therapy R12 weeks before study initiation
Exclusion criteria: the history of epididymo-orchitis, prostatitis, genital trauma, testicular torsion, in-
guinal or genital surgery, urinary tract infection, or previous hormonal therapy, another genital disease
(cryptorchidism, current genital inflammation or varicocele), severe general or central nervous sys-
tem disease and endocrinopathy, use of cytotoxic drugs, immunosuppressants, anticonvulsants, an-
drogens, or antiandrogens, recent history of sexually transmitted infection, psychologic or physiologic
abnormalities that would impair sexual performance or the ability to provide semen samples, drug or
alcohol abuse, hepatobiliary disease, significant renal insufficiency, occupational and environmental
subjections to possible reproductive toxins, BMI of >30 kg/m2, participation in another investigational
study, unlikely availability for follow-up
Interventions Alpha-lipoic acid (ALA) 600 mg (n = 23)
versus
Placebo (n = 21)
Duration of treatment: 12 weeks
Outcomes Sperm parameters, markers of oxidative stress (total antioxidant capacity (TAC) and malondialdehyde
(MDA)), side-effects
Notes Email sent to last author Haidari (haidari58@gmail.com) on 06.03.2018 to ask what side effects they
aimed for and reasons for lost to follow-up.
Reminder email sent on 22.03.2018 to Haidari and Dadfar (mdadfar@yahoo.com). No reply to date
(19.04.2018).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Each eligible patient received a randomization number which was de-
termined by a computer-generated schedule. Then a randomization table was
generated by the method of random permuted blocks"
Allocation concealment
(selection bias)
Low risk Quote: "Persons who were operationally independent from the study investi-
gator performed the study randomization"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The investigator, clinician prescriber, and patients were blinded to the
treatment condition"
Haghighian 2015 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Patients'data collected during this trial were kept confidential and
locked in a secure area. Randomization codes of the study were opened only
after all participants had completed the study protocol"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk N = 48, quote: "44 completed the study, rest lost to follow-up: data analysis
with 23 of 24 in ALA group, 21 of 24 in placebo group"
Reasons lost to follow-up not mentioned.
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Haghighian 2015  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: from January 2013 to June 2014
Participants Country: Iraq
Population: infertile men with idiopathic oligozoospermia (OA), N = 128 (in flow chart "182")
Mean age: 37.54 ± 2.46 years
Inclusion criteria: repeated exhibition of OA without detectable cause (idiopathic OA)
Exclusion criteria: leukocytospermia, altered testicular volume of a minimum of 20 ml as depicted by
ultrasonography, varicocele as detected by clinical examination and ultrasonography, abnormal FSH
levels, couples with combined male and female factors
Interventions Tamoxifen 20 mg (n = 45)
versus
L-carnitine 1000 mg (n = 20)
versus
Tamoxifen 20 mg + L-carnitine 1000 mg (n = 34)
versus
Placebo (n = 29)
Duration of treatment: 3 to 6 months followed by ICSI
Outcomes Sperm parameters, fertility and pregnancy outcome following ICSI
Notes Email sent to author Haje on 06.03.2018 (milathaji@yahoo.com) to ask about randomisation, dropouts,
amount of pregnancies (intead of %) and if they were clinical, and to provide raw data specified for
amount of months treatment used?
Reminder email sent on 22.03.2018. No reply to date (19.04.2018).
Data not usable: range of treatment 3 - 6 months, not specified as separates, pregnancy in % instead of
numbers, unknown if clinical or not.
Risk of bias
Haje 2015 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Dropouts not mentioned. Furthermore baseline characteristics not mentioned
Selective reporting (re-
porting bias)
Unclear risk Primary and secondary outcomes are mentioned and provided. No protocol
available.
Haje 2015  (Continued)
 
 
Methods Randomised double-blinded placebo cross-over trial
Duration of study: unclear
Participants Country: UK
Population: men with high levels of reactive oxygen species (ROS) of a couple undergoing IVF, N = 30
Mean age: unclear, median age 32 years
Inclusion criteria: attending fertility clinic, high levels of ROS in semen. Female partner has patent
tubes and is ovulating
Exclusion criteria: men with antisperm antibodies, > 20% spermatozoa with Ig (immunoglobulin A) or
IgG antibodies and sperm concentration < 5 x 106 mL
Interventions Vitamin E 600 mg (n = 15)
versus
Placebo (n = 15)
Duration of treatment: 3 months, 1 month wash-out, 3 more months after cross-over
Outcomes Primary outcomes: sperm parameters
Secondary outcomes: adverse effects, live birth
Notes Power calculation performed.
Attempted to contact author regarding median data, no response as yet (2014). Only first phase data
used in analysis
Kessopoulou 1995 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The study was a randomised double blind placebo controlled trial".
"The randomisation was performed by the manufacturer"
Allocation concealment
(selection bias)
Unclear risk Quote: "The randomisation was performed by the manufacturer"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "the code was blind for the researcher and patients. The code was bro-
ken at the end of the trial"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "30 patients completed the study over 2 years"
Changed to unclear risk in 2018 (was low risk); not reported how many were
randomised to start with, or how many drop-outs
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported as stated in the methods section. No protocol available.
Kessopoulou 1995  (Continued)
 
 
Methods Randomised double-blind parallel trial
Duration of study: from January 1985 to June 1986
Participants Country: Japan, 25 centres
Population: men with abnormal sperm count or motility, N = 375
Mean age: unclear, average 32.8 (SD 4.8) years
Inclusion criteria: average sperm count ≤ 40 × 106 /mL measured on ≥ 2 occasions OR average sperm
count ≥ 40 count ≤ 40 × 106 /mL measured on ≥ 2 occasions AND sperm motility < 50%
Exclusion criteria: sperm count only measured at 1 occasion, average sperm count ≤ 2 × 106/mL, sperm
motility = 0%, testicular size < 8 mL using orchidometer bilaterally, use of hormone or anti-hormone
drug within preceding 3 months before the study period, WBC > 5/HPF in the semen or the presence
of possible genito-urinary infection, presence of hypoganadism or endocrine disease, presence of un-
descended testes, genito-uninary tract obstruction, varicocele or any other serious associated condi-
tion also included concomitant use of anti-hormonal and hormonal treatment and the 2 patients with
polypharmacy were excluded from the data analysis
Interventions Mecobalamin (vitamin B12) 6.000 mcg (n = 125)
versus
Mecobalamin (vitamin B12) 1.500 mcg (n = 124)
versus
Placebo (n = 126)
Kumamoto 1988 
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Duration of treatment: 12 weeks
Outcomes Sperm concentration, sperm motility
Notes Article in Japanese, translated by Dr Tomoko Kumaga and Tan Wantao.
No contact details available for authors. No useable data available.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The 396 patients were divided into 3 groups (6000ug/day, 1500ug/day,
placebo) by randomisation. The implementation of randomisation and alloca-
tion concealment was carried out by two people (Doctor Yamamoto, Doctor
Shimizu)
Allocation concealment
(selection bias)
Unclear risk See above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No ITT. 21 lost to follow-up; 19 dropouts, 2 polypharmacy
2018 Change in RoB to unclear. Not sure in which groups dropouts belonged.
Selective reporting (re-
porting bias)
High risk Subgroup analysis performed as an addition post-treatment
Kumamoto 1988  (Continued)
 
 
Methods Randomised placebo-controlled, double-blind cross-over trial
Duration of study: 10 months
Participants Country: Italy
Population: infertile men with oligoasthenoteratozoospermia (OAT), N = 100
Mean age: unclear, range: 20 to 40 years
Inclusion criteria: age between 20 to 40 years with infertility lasting longer than 2 years, regular sexu-
al intercourse with a gynaecologically normal female partner with no female infertility, absence of en-
docrine disease, genital infections, obstructive cryptorchism, antisperm antibodies, normal sperm pa-
rameters with no significant differences after 3 tests, mild oligospermia with perm concentration 10 to
20 x 106/mL and motility 10% to 30%
Exclusion criteria: unclear
Interventions L-carnitine 2 g (n = 43)
Lenzi 2003 
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versus
Placebo (n = 43)
Duration of treatment: 2 months of washout, 2 months of therapy/placebo, 2 more months of washout,
2 more months of placebo/therapy
Outcomes Sperm parameters, pregnancy rate
Notes Power calculation performed
First phase data: attempted to contact author regarding standard deviations, how many were in each
group for the first phase and how many of the 4 who went to assisted reproduction did so in the first
phase and what do they mean by 172 cycles. No response yet (2014). Added to outcome data 'not us-
able for meta-analysis'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blinded", "seemingly identical placebo"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 14 withdrew - 4 went onto assisted reproduction, 6 did not return for second
period and 4 due to pregnancy in first phase. Therefore should only be ?4 at
the most lost from first phase. No ITT
All withdrawals accounted for for whole trial however how many were lost in
the first phase in first phase
Selective reporting (re-
porting bias)
Unclear risk All outcomes are reported. No protocol available.
Lenzi 2003  (Continued)
 
 
Methods Randomised placebo-controlled, double-blind trial
Duration of study: 8 months
Participants Country: Italy
Population: infertile men with OAT, N = 60
Mean age: unclear, range 20 to 40 years
Lenzi 2004 
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Inclusion criteria: oligoasthenoteratospermia, age between 20 to 40 years, infertility > 2 years with reg-
ular intercourse, no endocrine disease, cryptorchidism, genital infections or obstructions, variocoele or
testicular hypertrophy, antisperm antibodies
Exclusion criteria: none
Interventions L-carnitine 2 g + L-acetyl-carnitine 1000 mg (n = 30)
versus
Placebo (n = 26)
Duration of treatment: 6 months
Outcomes Sperm parameters, pregnancy rate
Notes Power calculation performed
Attempted to contact author regarding 8-month follow-up data. No reply as yet (2014)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Mentions coding: quote: "When codes were broken at the end of the study"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 4 men withdrew from the placebo group. 60 randomised 56 analysed. No ITT
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Lenzi 2004  (Continued)
 
 
Methods Randomised double-blinded parallel trial
Duration of study: 3 months
Participants Country: Eastern China
Population: infertile men with oligoasthenospermia, N = 150
Mean age: treatment group 30 ± 5.5 (23 to 45) years, control group 32 ± 3.5 (24 to 46) years
Li 2005 
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Inclusion criteria: no smoking or alcohol use, any fertility medication needed to be stopped 2 weeks be-
fore
Exclusion criteria: none
Interventions L-carnitine 2 g + acetyl-L-carnitine 1 g (n = 85) (90 with ITT)
versus
Vitamin E 200 mg + vitamin C 200 mg (n = 53) (60 with ITT)
Duration of treatment: 3 months
Outcomes Sperm parameters, pregnancy rate
Notes Article in Chinese, translated by Shaofu Li 10.11.2008.
Contact author regarding methods of randomisation, concealment and whether SD or SEs used and
query that this is the same trial as Li 2005a
2018: added data on progressive motility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "Double-blind" but unclear who is blinded as the control is another an-
tioxidant i.e. not placebo
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Attrition explained. Withdrawal: 5 from treatment group and 7 from control
Selective reporting (re-
porting bias)
Unclear risk No protocol available.
Li 2005  (Continued)
 
 
Methods Randomised trial
Duration: unclear
Participants Country: Eastern China
Population: infertile men with oligoasthenospermia, N = 80
Mean age: 29 ± 3.5 (23 to 40) years
Li 2005a 
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Inclusion criteria: no smoking or alcohol, any fertility medication needed to be stopped 2 weeks before
Exclusion criteria: none
Interventions L-carnitine 2 g (n = 40)
versus
Vitamin E 100 mg + Vitamin C 200 mg (n = 40)
Duration of treatment: 3 months
Outcomes Seminal parameters, pregnancy rate
Notes Article in Chinese, translated by Shaofu Li 10.11.2008.
Attempted to contact author re methods of randomisation, concealment and whether SD or SEs used
and whether this is the same trial as Li 2005. Also asked whether there were any data on pregnancy
rate. Translator replied 22.09.2009 no pregnancy data were available in the text of the trial
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Withdrawal: 8 from treatment (n = 32) and 9 from control (n = 31). 21% loss to
follow-up. No ITT
Selective reporting (re-
porting bias)
Unclear risk No protocol available.
Li 2005a  (Continued)
 
 
Methods Randomised controlled cross-over trial
Duration of study: 10 months
Participants Country: Italy
Population: infertile men with oligoasthenospermia, N = 100
Mean age: unclear, range 20 to 40 years
Lombardo 2002 
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Inclusion criteria: age 20 to 40 years,infertility > 2 years, 3 baseline semen analysis demonstrating con-
centration 10 to 20 106/mL, 10% to 30% total motility, forward progression < 15%, abnormal morpho-
logical forms < 70%, curvilinear velocity 10 to 30 /second + linearity < 4
Exclusion criteria: unclear
Interventions L-carnitine 2 g (n = ?)
versus
Placebo (n = ?)
Duration of treatment: 2 months
Outcomes Sperm parameters
Notes Abstract only
Attempted to contact author re first phase data, outcomes, randomisation, concealment and whether
there was a full publication of the trial
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 86 patients completed the trial out of 100. Need to see full trial for the reasons
for withdrawals and ITT
Selective reporting (re-
porting bias)
Unclear risk Abstract only
Lombardo 2002  (Continued)
 
 
Methods Randomised double-blind controlled trial
Duration of study: from July 2009 to September 2010
Participants Country: Mexico
Population: men with idiopathic oligoasthenozoospermia, N = 54
Mean age: unclear
Martinez 2015 
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Inclusion criteria: patient between the ages of 20 to 45 years with a diagnosis of idiopathic oligoas-
thenozoospermia. The diagnosis of oligoasthenozoospermia was reached by performing two semen
analyses on different dates with an interval of three weeks between them.
Exclusion criteria: infertile patients with normal findings on semen analysis, chronic smokers, antiox-
idants use in the last 6 months prior to the study, chronic degenerative diseases such as diabetes or
high blood pressure
Hormonal abnormalities
Interventions Resveratrol (3,5,4´-trihydroxystilbene) 25 mg + 725 mg microcrystalline cellulose (n = 18)
versus
SG1002 (hydrogen sulfide) 750 mg (n = 18)
versus
Placebo 750 mg microcrystalline cellulose (n = 18)
Duration of treatment: 75 days
Outcomes Sperm parameters (with A+B type sperm motility)
Notes SG1002 (hydrogen sulfide) excluded because it is a gaseous transmitter
Email sent to second author Sordia-Hernandez (luissordia@telmexmail.com) on 22.03.2018 to ask de-
tails about the randomisation process and for him to provide more data (SDs).
Inconsistence in sentence about adverse events: 3 side effects in SG1002 group, however in the sen-
tence before only 2 in this group?
Data not usable, no SD's. No reply to date (19.04.2018).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blind".
Quote: "Bottles and capsules for each treatment were identical and identified
by a code unknown to the researchers or subject."
Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Sperm analysis performed by lab technicians, blinded to the treat-
ment group"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Of the seven subjects who did not complete the study (3 from the
placebo group, 2 from the resveratrol treatment group and 2 from the SG1002
treatment group), none returned for follow-up visits and therefore no data
on sperm count, motility or abnormality was available and an intent to treat
analysis could not be carried out. Four of these subjects were lost in follow-up
while the other three withdrew due to unpleasant smelling sweat (SG1002
Martinez 2015  (Continued)
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treatment group), nausea and flatulence (SG1002 treatment group), and in-
convenience (SG1002 treatment group)."
Quote: "All study subjects who did not comply with medication given as pre-
scribed, who discontinued the drug or were hypersensitive to it were eliminat-
ed"
Reasons enough explained, all 3 in SG1002 due to side effects, however we did
not include this arm
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Martinez 2015  (Continued)
 
 
Methods Randomised double-blind controlled trial
Duration of study: 10 weeks
Participants Country: Spain
Population: infertile men, N = 42 (abstract), N = 64 (from author)
Mean age: treatment group 35.23 years, placebo 36.10 years, overall average age 35 years
Inclusion criteria: men suffering from male factor infertility, according to the WHO guidelines (WHO
1999), and who were undergoing infertility evaluation during the period 2009 to 2011
Exclusion criteria: oncological patients, those suffering from metabolic disease, chromosomal or ge-
netic alterations, and patients on anticoagulant treatment
Interventions Brudy Plus 1500 mg of DHA-enriched oil (DHA 1000 mg + eicosapentaenoic acid (EPA) 135 mg) (n = 35)
versus
Placebo (n = 29)
Duration of treatment: 10 weeks
Outcomes Sperm DNA fragmentation, seminal parameters, lipid composition, antioxidant capacity
Notes Conference abstract only.
Contacted author multiple times by e-mail (JuanCarlos.Martinez@ivi.es) for further study details. Clar-
ified that the abstract details were different from that in the final study, a copy of the unofficial manu-
script was submitted to the review authors. Last contact was on 26.02.2014
2018: added data on progressive sperm motility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random list with a computer program
Allocation concealment
(selection bias)
Low risk Closed and numerated envelopes with allocation group
Martinez-Soto 2010 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants knew that they was included in group A or B but only Brudy tech-
nology knew the assignation to the control group or experimental group
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Martinez-Soto 2010  (Continued)
 
 
Methods Randomised double-blind, placebo-controlled trial
Duration of study: from May 2008 to August 2012
Participants Country: Iran
Population: infertile men with idiopathic OAT, N = 235
Mean age: treatment (L-carnitine) group 30 ± 1.7 years, control group 30 ± 4.6 years
Inclusion criteria: age 25 – 40 years, infertile men with OAT, healthy fertile wives
Exclusion criteria: existence of genital abnormalities (undescended testes, varicocele, atrophy of
testes), occupational chemical exposure history, systemic diseases, abnormal semen volume, pH, ag-
glutination or viscosity, derum hormonal abnormalities (FSH, LH, testosterone, estradiol, prolactin),
wives with known fertility risk factors confirmed by gynecologist
Interventions Pentoxifylline 800 mg + L-carnitine 1000 mg (n = 58)
versus
Pentoxifylline 800 mg + Placebo (n = 59)
versus
L-carnitine 1000 mg + Placebo (n = 59)
versus
Placebo (n = 59)
Duration of treatment: 3 months
Outcomes Sperm parameters (progressive sperm motility), selection of type of assisted reproductive techniques
(ART)
Notes Only data from L-carnitine and placebo arm used.
Email sent to author (dr.ketabchi@gmail.com) on 06.03.2018 to ask about the randomisation process
and blinding of the outcome assessment
Mehni 2014 
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Reminder email sent to Ketabchi on 22.03.2018. No reply to date (19.04.2018).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomized by Bloch method to four groups"
Bloch (block?) method, does this mean computerised? Insufficient explanation
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "After intervention 23 patients excluded from study (3 patients for drug
intolerance in group I, and 20 patients for uncooperative in group II and III)"
Data-analysis only with for those who completed the study (N = 212)
According to figure 1: 5 patients (instead of 3 mentioned in text) dropped out
due to drug intolerance in group I? Type error?
Reasons and exact numbers for dropout not given for L-carnitine arm specifi-
cally.
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Mehni 2014  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: unclear
Participants Country: Serbia
Population: men with oligo-asthenozoospermia, N = 175
Mean age: unclear
Inclusion criteria: men visiting the Andrology center, (18-50 years) and with difficulty in conceiving > 12
months
Exclusion criteria: unclear
Interventions Proxeed Plus (L-carnitine 2 g, acetyl-L-carinitine 1 g, vitamins and minerals) (n = 125)
versus
Placebo (n = 50)
Micic 2017 
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Duration of treatment: 6 months (and 2 months wash-out)
Outcomes Progressive motility, seminal plasma carnitine
Notes Conference abstract only.
Email sent to last author Agarwal (AGARWAA@ccf.org) on 20.02.2018. Answer on 21.02.18 "this study is
not published in a journal at this time"
New email on 06.03.2018 to ask raw data (means with SD) and more information about randomisa-
tion/blinding outcome/dropout rates.
Reply on 22.03.18 from Agarwal & Micic (savamicic2016@gmail.com) with more information in a word
document. Only medians with IQR. See RoB.
Data not usable, medians with IQR.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from email): "Random list was made using the nQuery Advisor nTerim
2.0 (2012) program"
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote (from email): "This is a double blind study. Neither the patient,
providers, nor investigators responsible for collecting data or analyzing labo-
ratory specimens have been knowledgeable regarding the assignment of ac-
tive or placebo product. A file has been maintained at each of the sites under
the responsibility of the primary investigator which will provide product iden-
tification for each subject. Upon entry into the study, subjects have been as-
signed a unique study identification number."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): "Neither the patient, providers, nor investigators respon-
sible for collecting data or analyzing laboratory specimens have been knowl-
edgeable regarding the assignment of active or placebo product. "
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote (from email): "From the treated group (total 125 ) drop out was 6 sub-
jects; 2 of them got flu with high temperature, 2 went form Serbia (new job), 2
stopped without reason. And from the placebo group ( total 5o ) drop out was
4; 2 drop out without explanation , 1 underwent abdominal surgery, and 1 di-
vorced"
Selective reporting (re-
porting bias)
Unclear risk Abstract only
Micic 2017  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: 3 months
Participants Country: Italy
Population: infertile men with with asthenospermia, N = 180
Morgante 2010 
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Mean age: range 25 and 49 years
Inclusion criteria: age between 28 and 45, sperm concentration < 20 x 106 spermatozoa /mL, sperm pro-
gressive motility < 30%, normal morphology < 30%, leucocyte < 1 x 106 /mL, no infections
Exclusion criteria: men younger than 28 and over 45, sperm concentration > 20 x 106 spermatozoa /
mL, sperm progressive motility > 30%, normal morphology > 30%, leucocyte > 1 x 106 /mL, current in-
fections, history of testicular pathology: cryptorchidism, varicocele, surgical operations, radiotherapy
or chemotherapy, use of anabolic steroids, deficiency of hypothalamic-pituitary-gonadal axis, genital
tract infections
Interventions L-arginine 1660 mg + carnitine 150 mg + acetyl-carnitine 50 mg + ginseng 200 mg in one vial (n = 90)
versus
No treatment (n = 90)
Duration of treatment: 3 months
Outcomes Sperm parameters, sexual satisfaction
Notes Article in Italian, translated by Roberto D'Amico.
Contacted author by email (giuseppe.morgante@unisi.it) to clarify study details, recruitment, randomi-
sation, blinding, ethics approval, study population, withdrawals and to clarify progressive mortality.
Last response was on 12.03.2014
Quote: "Total motility and progressive motility are similar terms for the same definition: all the sperma-
tozoa that have progressive or not linear motility"
2018: motility data included as progressive motility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Morgante 2010  (Continued)
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Methods Randomised controlled trial
Duration of study: 3 months
Participants Country: Iran
Population: infertile men with OAT who have been trying for pregnancy for > 1 year unprotected inter-
course, N = 60 (analysed N = 47)
Mean age: 34 years
Inclusion criteria: seminal WBC < 1,000,000 /mL, absence of anatomical abnormalities of the genital
tract, absence of infectious genital diseases or systemic diseases, absence of treatment with other
drugs and dietary supplement during the 3 months before enrolling in the study, at last absence of
smoking, drug, and alcohol use or occupational chemical exposure
Exclusion criteria: seminal WBC > 1,000,000 /mL, presence of anatomical abnormalities of the genital
tract, presence of infectious genital diseases or systemic diseases, presence of treatment with other
drugs and dietary supplement during the 3 months before enrolling in the study, currently smoking, us-
ing drug, or alcohol use or occupational chemical exposure
Interventions Coenzyme Q10 (CoQ10) 200 mg (n = 23)
versus
Placebo (n = 24)
Duration of treatment: 3 months
Outcomes Sperm motility and concentration, progression, total antioxidant capacity (TAC)
Notes Power calculation performed
Contacted regarding methods, randomisation, allocation concealment, recruitment, blinding and
dropouts.
Response from Azadeh Nadjarzadeh (azmm1383@yahoo.com)in October 2013
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (from email):"Participants were randomised using block randomisation.
It was done by Dr Motevallian who is epidemiologist and it has done before
study"
Allocation concealment
(selection bias)
Low risk Quote (from email): "Before the trial a colleague, that had not role in the study,
coded the bottles of Coenzyme Q10 and placebo (that were similar) in A and B
and give them to one of the staL of Avicenna Research centre. Only that person
has a list of randomisation and give A or B bottles to the participants according
to their code"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote (from email): "Both participants and investigators blinded"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (from email): "The appearance and the bottles of capsules were similar
and none of outcome assessors knew group, because everyone had a code af-
ter being allocated group A and B"
Nadjarzadeh 2011 
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "13 dropped out for personal reasons" - 22%: 7 from treatment group
and 6 from the control group
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Nadjarzadeh 2011  (Continued)
 
 
Methods Randomised comparative study
Duration of study: unclear
Participants Country: Tunisia
Population: infertile males with OAT, N = unclear
Mean age: unclear
Inclusion criteria: males with OAT.
Exclusion criteria: unclear
Interventions Vitamin E 400 mg + Selenium 200 μg (n = 12)
versus
Vitamin B2, B6 and B12 (n = 8)
Duration of treatment: 3 months
Outcomes Seminal parameters
Notes Abstract only
Attempted to contact authors regarding methods of randomisation and data. No reply as yet (2014).
No extractable data from the abstract.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "In a prospective randomised comparative study"
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Nozha 2001 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Nozha 2001  (Continued)
 
 
Methods Randomised controlled open trial
Duration of study: follow-up 12 months
Participants Country: Kuwait
Population: men with asthenozoospermia attending infertility and andrology clinic, N = 100
Mean age: treatment group 37.8 ± 7.9 years, control group 38.1 ± 8.2 years
Inclusion criteria: men with asthenozoospermia, spermatozoal motility impaired with >4 0% non-
motile sperm, have been trying to conceive for at least one year plus no obvious female factor
Exclusion criteria: none mentioned
Interventions Zinc 500 mg (n = 49)
versus
No treatment (n = 48)
Duration of treatment: 3 months
Outcomes Sperm parameters
Notes Attempted to contact authors regarding methods randomisation and concealment questioned. No re-
ply as yet (2014).
Data on sperm count/motility not used; only percentage of increase/decrease given
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Omu 1998 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 100 men randomised, 97 analysed, dropouts are not accounted for
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Omu 1998  (Continued)
 
 
Methods Randomised controlled open trial
Duration of study: unclear
Participants Country: Kuwait
Population: men with asthenozoospermia attending infertility clinic in Kuwait, N = 45
Mean age: 35 ± 1 years
Inclusion criteria: asthenozoospermia with normal sperm concentration (20 to 250 million/mL) but
with 40% or more immotile sperm
Exclusion criteria: asthenozoospermia but sperm concentration of < 20 million/mL
Interventions Zinc 400 mg (n = 11)
versus
Zinc 400 mg + Vitamin E 20 mg (n = 12)
versus
Zinc 400 mg + Vitamin E 20 mg + Vitamin C 10 mg (n = 14)
versus
No treatment (n = 8)
Duration of intervention: 3 months
Outcomes Sperm parameters
Notes Attempted to contact author regarding methods of randomisation, it states that quote: "8 men served
as non- therapy control".
No reply as yet (2014).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Omu 2008 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is another antioxidant or no treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All outcomes are reported. No dropouts
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Omu 2008  (Continued)
 
 
Methods Randomised double-blind cross-over trial
Duration of study: unclear, from 2005 to 2006
Participants Country: Iran
Population: infertile men, N = 30
Mean age: 29.5 (SD 5.48) years
Inclusion criteria: at least two abnormal spermograms based on WHO criteria with a two-week interval
during four weeks, normal range of gonadotropins, testosterone an prolactin concentrations
Exclusion criteria: variocoele, testicular atrophy, ejaculatory disorders, use of medications, azoosper-
mia, endocrinological disorders, ICSI candidacy or other causes of infertility
Interventions L-carnitine 2 g (n = 15)
versus
Placebo (n = 15)
Duration of treatment: 8 weeks, washout period of 8 weeks, changed intervention and use for 8 more
weeks
Outcomes Sperm parameters
Notes Abstract in English, full text in Arabic. Contacted the author and he is filling out the data extraction
sheets. Author responded but data queries remain contacted again re SDs and pregnancies in first
phase of cross-over. Author responded saying that the data were given in SDs and there were 3 preg-
nancies in the first phase
2018: added data on progessive motility for first phase (2 months).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Peivandi 2010 
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
114
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Allocation concealment
(selection bias)
Low risk Quote: "sealed opaque envelopes"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "outcome assessor was blinded"
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "loss to follow up was not accounted for"
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Peivandi 2010  (Continued)
 
 
Methods Randomised trial with add-on intervention
Duration of study: unclear
Participants Country: Iran
Population: men with male factor infertility and varicocele, N = 100
Mean age: treatment group 26.73 ± 6.25 years, control group 27.52 ± 5.23 years
Inclusion criteria: leQ-sided clinical or subclinical varicocele plus one of these factors: primary infertili-
ty, secondary infertility, or impaired semen analysis.
Exclusion criteria: right- sided isolated varicocele, bilateral varicocele, and each side varicocele that did
not decompress in lying position, or any medical or surgical history of male factor infertility
- Medical: opium or drug abuse, any prior medical treatment for infertility, recurrent urinary tract infec-
tion, sexually transmitted disease, prostatitis, mumps in childhood, epididymo-orchitis, and so forth
- Surgical: cryptorchidism, orchiopexy, prior varicocelectomy repair, inguinal hernia repair, other in-
guinal surgeries, and so forth
Interventions L-carnitine 750 mg (n = 50)
versus
No treatment (n = 50)
Duration of treatment: 6 months, after varicocelectomy
Outcomes Sperm parameters, DNA damage (TUNEL, PDA test), adverse effects
Notes Email sent to last author Noori (m_noori560@yahoo.com) on 06.03.2018: Asked about the SD's for
sperm motility (A+B%), concentration and DNA fragmentation. Asked about allocation concealment
and blinding of outcome assessment. Reminder email sent to Noori and Pourmand (n.pourmand@ya-
hoo.com) on 22.03.2018.
Pourmand 2014 
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Only data on adverse events used. No reply to date (19.04.2018).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Block randomization was performed for controlling less probable vari-
ation in varicocelectomy technique or surgeon within the time of study"
Not specified how block randomisation was performed.
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control group is no treatment after varicocelectomy
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk See appendix, none lost to follow-up
Selective reporting (re-
porting bias)
Unclear risk All the outcomes from the aim of the study and methods were reported. No
protocol available.
Pourmand 2014  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: from January 2012 to March 2013
Participants Country: Panama
Population: infertile healthy men, N = 60 (quote: "60 patients completed the study", how may were ran-
domised?)
Mean age: unclear
Inclusion criteria: infertile healthy men without previous treatments, non smokers, no alcoholics or
drug users
Exclusion criteria: varicocele and leukocyte-spermia were excluded
Interventions L-carnitine 1 g/12 hours (n = ?)
versus
Spermotrend (Catalysis) 1 x /8 hours (n = ?)
versus
Maca extract 1 g/12 hours (n = ?)
versus
Poveda 2013 
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Placebo 1x/12 hours (n = ?)
Duration of treatment: 13 weeks
Outcomes Sperm motility, sperm concentration, normal sperm morphology
Notes Conference abstract only.
Letter written and posted regarding methods and data 12.02.2014
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Poveda 2013  (Continued)
 
 
Methods Randomised double-blind cross-over trial
Duration of study: unclear
Participants Country: UK (two centres)
Population: men with severe oligozoospermia, N = 64
Mean age: unclear
Inclusion criteria: sperm count of less than 10 million per ejaculate on each of 2 occasions immediately
preceding the trial, no uncorrected varicoceles or testicular maldescent, testicular biopsy already per-
formed (Johnsen 1970), no drugs taken in past 3 months which were known to affect spermatogenesis,
no history of biliary disease owing to a suggestion that arginine might interfere with the metabolism of
bile salts, the wives of all these men had been fully investigated with regard to fertility
Exclusion criteria: men with varicocoele
Interventions Arginine 4 g (n = 35)
Pryor 1978 
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versus
Placebo (n = 29)
Duration of treatment: 12 weeks, than cross-over without intervening wash-out period
Outcomes Total sperm motility, hormone levels
Notes No data available for sperm parameters. Unable to contact author
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 10 withdrew reasons were given but unsure from which group, the paper stat-
ed that they used ITT but data not presented.
The study did not report the outcomes for the different phases of the trial (i.e.
not separated into phase 1 phase 2). Pregnancy data are separated into phase
one data but probably biochemical and will be used in biochemical pregnancy
table.
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. Pregnancy not stated in the methods section as an out-
come of interest but reported in the results. No protocol available.
Pryor 1978  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: unclear
Participants Country: Iran
Population: men from infertile couples with proved male factor infertility, N = 83
Mean age: unclear
Inclusion criteria: infertile men (OAT) with sperm concentrations of < 20 x 106 mL-1, sperm motility <
50% (grades a, b, c) and sperm normal morphology < 30%
Exclusion criteria: unclear
Interventions Folic acid 5 mg + Placebo (n = 20)
Raigani 2014 
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versus
Folic acid 5 mg + Zinc sulphate 220 mg (n = 21)
versus
Zinc sulphate 220 mg + Placebo (n = 24)
versus
Placebo + Placebo (n = 18)
Duration of treatment: 16 weeks
Outcomes Sperm concentration, motility (grade A+B+C), morphology, sperm viability, sperm mitochondrial func-
tion, sperm chromatin status (DNA damage measured by staining methods), semen and blood fo-
late/zinc/B12, total antioxidant capacity (TAC) and malondialdehyde (MDA) concentration
Notes Trial registration: IRCT138706091079N2
Email sent to last author Sadeghi (Sadeghi@avicenna.ac.ir) on 06.03.2018 to ask about the mean age,
exclusion criteria, if there are means+SD instead of medians of the sperm concentration and sperm
motility, randomisation process, dropouts/lost to follow-ups
Reminder email sent to Sadeghi on 22.03.2018. No reply to date (19.04.2018).
Data on DNA fragmentation used (means+SD), however motility/concentration in medians (IQ range) so
added in data outcome 'not suitable for meta-analysis'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly allocated into four treatment groups with different supple-
mentations."
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blinded". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Semen analysis and sperm function assays were assessed individually
and blindly by two laboratory experts"
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Low risk Reported all the outcomes from the methods and protocol; trial registration
(IRCT138706091079N2)
Raigani 2014  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Rolf 1999 
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Duration of study: 8 weeks
Participants Country: Germany
Population: men with infertility for over one year, N = 33
Mean age: treatment group 36.1 ± 5.0 years, control group 35.2 ± 4.8 years
Inclusion criteria: asthenozoospermia (< 50% motile) diagnosed after 2 examinations, normal or re-
duced sperm concentration (> 20 x 106 per ejaculate) and without infection of access glands
Exclusion criteria: unclear
Interventions Vitamin C 1000 mg + Vitamin E 800 mg (n = 15)
versus
Placebo (n = 16)
Duration of treatment: 8 weeks
Outcomes Primary: sperm parameters
Secondary: pregnancy rate and adverse effects
Notes Power calculation performed.
Contacted author about the allocation concealment and pregnancy and adverse effects were out-
comes in their protocol. Author Rolf replied saying that pregnancy and adverse effects were stated in
the protocol
2018: progressive forward motility instead of total motility, data total sperm motility moved to out-
come progressive sperm motility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomisation was performed with random numbers without further
stratification by the pharmacist and the code was withheld from researchers
and patients"
Allocation concealment
(selection bias)
Unclear risk Pharmacist performing randomisation and code withheld from patients and
researchers. However no mention of type of containers or envelopes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double - patients and researchers
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All data reported, 2 patients withdrew from the trial: quote: "results from two
patients were rejected from analysis." 1 from the treatment group due to poor
compliance and 1 from the placebo group due to genital tract infection. No ITT
Selective reporting (re-
porting bias)
Unclear risk All semen outcomes reported and author states (e-mail 22.09.09) that preg-
nancy and adverse effects were set a priori in the protocol. No protocol avail-
able.
Rolf 1999  (Continued)
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Methods Randomised double-blind placebo-controlled trial
Duration of study: 56 weeks
Participants Country: Iran
Population: men with idiopathic oligoasthenoteratospermia, asthenospermia or teratospermia of 2
years duration, N = 468 (548 recruited)
Mean age: 31 (25 to 48) years
Inclusion criteria: sperm count > 5 x 106 /mL, over 2 years of failed conception, no female fertility prob-
lems, no history of possible cause for male infertility
Exclusion criteria: abnormal testes, history of cancer or chemotherapy, testosterone or antiandrogen
use, use of selenium or N-acetylcystine supplements, abnormal hormone levels, genital disease, geni-
tal inflammation or variocoele, history of genital surgery, major surgery, central nervous system injury,
a known sperm defect or retrograde ejaculation. Y chromosome abnormalities, sexually transmitted
disease, genitourinary infection, leukocytospermia, smoking, any environmental exposures to repro-
ductive toxins. Medical, neurological or psychological problems. A history of drug or alcohol abuse, he-
patobiliary disease or significant renal insufficiency. Any endocrine abnormality, a b BMI of 30 kg/m2 or
over, participation in another investigational study and a likelihood of being unavailable for follow-up
Interventions Selenium 200 µg (n = 116)
versus
N-acetylcysteine (NAC) 600 mg (n = 118)
versus
Selenium 200 µg + N-acetylcysteine (NAC) 600 mg (n = 116)
versus
Placebo (n = 118)
Duration of treatment: 26 weeks or 6.5 weeks
Outcomes Primary outcome: sperm parameters
Secondary outcomes: spontaneously reported adverse events
Notes Power calculation performed.
Attempted to contact authors regarding side effect data that had not yet been added to the review due
to the query of multiple comparisons. Also to ask whether data is in SD (as reported in the text) or SE,
as requested by statistician 24.09.2010
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomisation table generated by the method of random permuted
blocks. Patient randomisation numbers were allocated to each site in ascend-
ing sequence in blocks."
Allocation concealment
(selection bias)
Low risk Quote: "Assignment to treatment groups was performed using a sealed enve-
lope technique."
Safarinejad 2009 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Eligible patients were randomly assigned to double blind.."
Quote: "Placebo pills were coated with titanium oxide to ensure an identical
appearance and smell."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Analysed: n = 105 in selenium group (loss 11), n = 106 in placebo group (loss
12), n = 105 in N-acetylcysteine group (loss 13) and n = 104 in selenium + N-
acetylcysteine group (loss 12)
All withdrawals were accounted for in each treatment group. Withdrawal was
mainly due to withdrawal of consent followed by lost to follow-up and lastly
for reasons of missing data. No ITT
Selective reporting (re-
porting bias)
Unclear risk The published report includes all expected outcomes. No protocol available.
Safarinejad 2009  (Continued)
 
 
Methods Randomised double-blind controlled trial
Duration of study: from February 2005 until October 2006, follow-up 14 months
Participants Country: Iran
Population: infertile men with idiopathic oligoasthenoteratospermia, N = 212 (recruited 268)
Mean age: treatment group 28 ± 9 years, placebo group 28 ± 10 years
Inclusion criteria: minimum 2 years unprotected intercourse with 2 years unwilling childlessness. male
infertility diagnosed if 1 or more standard semen parameters were below cutoff levels accepted by
WHO. A fertile female partner. No known medical condition that could account for infertility, testicu-
lar volume 12 mL or greater. No medical therapy for at least 12 weeks before the study begins. Only pa-
tients seeking medical attention for infertility were included
Exclusion criteria: azoospermia or severe oligospermia (sperm count less than 5 million/mL. An histo-
ry of epypidymo-orchitis, prostatitis, genital trauma, testicular torsion, inguinal or genital surgery. Any
genital or central nervous system disease, endocrinopathy, cytotoxic drugs, immunosuppressants, an-
ticonvulsives, androgens, antiandrogens, a recent history of Sexually transmitted disease. Psycholog-
ical or physiological abnormalities that would impair sexual functioning or ability to produce sperm
samples. Drug, alcohol or substance abuse. Liver disease, renal insufficiency or chromosome abnor-
malities. occupational and environmental exposures to reproductive toxins. A BMI of 30 kg/m2 or over,
participation in another investigational study and a likelihood of being unavailable for follow-up
Interventions Coenzyme Q10 (CoQ10) 300 mg (n = 106)
versus
Placebo (n = 106)
Duration of treatment: 26 weeks or 6.5 months
Outcomes Primary outcomes: sperm parameters and testicular volume
Secondary outcomes: adverse effects and hormone levels
Safarinejad 2009a 
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Notes Power calculation performed.
Attempted to contact authors to ask whether data is in SD (as reported in the text) or SE, as requested
by statistician 24.09.2010
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Each eligible patient received a randomisation number, which was de-
termined by a computer generated schedule. Therafter a randomisation table
was generated by the method of random permuted blocks. Individuals who
were geographically and operationally independent of the study investigator
performed the study randomisation"
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The clinician prescriber and the patients were blinded to the treat-
ment condition. To maintain and guarantee blinding CoQ10 and placebo were
identical in appearance."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Participant data collected during this trial were kept confidential and
locked in a secure office area. Randomisation codes were opened only after all
patients had completed the whole study protocol."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients who dropped out of the trial were accounted for - 8 from treatment
group and 10 from placebo group for reasons such as withdrawal of consent,
missing data and loss to follow-up.
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Safarinejad 2009a  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: from June 2010 to January 2011
Participants Country: Iran
Population: infertile men with primary infertility for at least 2 years, N = 228
Mean age: treatment group 31 years, control group 32 years
Inclusion criteria: history of primary infertility of more than 2 years, abnormal sperm count and motility
according to WHO criteria, wife age between 20 and 40 years, documentation of fertile female partner,
no known medical or surgical condition which can result in infertility
Exclusion criteria: history of cancer chemotherapy or radiotherapy, history of genital disease such as
cryptorchidism and varicocoele, history of genital surgery, BMI 30 kg/m2 or greater, any endocrinopa-
thy, Y chromosome microdeletion or karyotype abnormalities, leukocytospermia (more than 106 WBC
per mL), drug, alcohol or substance abuse, tobacco use, use of anticonvulsants, androgens or antian-
drogens, significant liver (serum bilirubin greater than 2.0 mg/dL) or renal function (serum creatinine
greater than 2.0 mg/dL) impairment, occupational and environmental exposure to reproductive toxins,
severe oligozoospermia (less than 5 x 106 /mL), azoospermia and testicular volume less than 12 mL
Safarinejad 2012 
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Interventions Coenzyme Q10 (Ubiquinol) 200 mg (n = 114)
versus
Placebo (n = 114)
Duration of treatment: 26 weeks
Outcomes Sperm volume, sperm density, sperm motility, sperm morphology, seminal plasma antioxidant status
Notes Power calculation performed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random number table
Allocation concealment
(selection bias)
Low risk The randomisation codes were centrally assigned by the co-ordination centre
after checking the main eligibility criteria
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All investigators and study staL were blinded to treatment allocation during
the whole study period, All of the participants were naive for treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All investigators and study staL were blinded to treatment allocation during
the whole study period, All of the participants were naive for treatment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 228 were randomised of 264 eligible
Ubiquinol group – 13 excluded at end of treatment (3 protocol violations, 4
withdrawal of consent and 6 lost to follow-up). At 12 weeks follow-up a further
5 were lost to follow-up
Placebo group – 12 excluded at end of treatment (4 protocol violations, 4 with-
drawal of consent, 6 lost to follow-up. At 12 weeks follow-up a further 7 were
lost to follow-up
Selective reporting (re-
porting bias)
High risk The authors do not pre-specify which outcome measures will be reported. The
primary outcome is a % change from baseline at the end of the treatment peri-
od
Safarinejad 2012  (Continued)
 
 
Methods Randomised double-blind trial
Duration of study: 3 months and two weeks
Participants Country: UK
Population: men attending subfertility clinic with low sperm motility, N = 64 (recruited N = 69)
Mean age: 33.3 ± 0.64 years
Inclusion criteria: low sperm motility
Scott 1998 
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
124
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Exclusion criteria: not mentioned
Interventions Selenium 100 µg (n = 16)
versus
Selenium 100 µg + Vitamin A 1 mg + Vitamin C 10 mg + Vitamin E 15 mg (n = 30)
versus
Placebo (n = 18)
Duration of treatment: 3 months
Outcomes Primary outcome: sperm parameters
Secondary outcome: pregnancy rates
Notes Uneven numbers, multivitamin numbers are double the other groups
Asked author if they have separate numbers for pregnancy data. Currently have 5 pregnancies in the 2
treatment groups and none in placebo
Furthermore; who was blinded, was the placebo identical when group 2 contained so many different vi-
tamins. Was there any allocation concealment?
Author has retired and is not able to be contacted. Data not added to table 'data for undefined or bio-
chemical pregnancy'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "As the patients entered the trial they were randomly allocated to one
of three treatments, which had in turn been randomised within each block of
four numbers and 'blinded' using a numeric code."
Unclear as to why the uneven nature of the numbers in the groups i.e. 30 in
multivitamin group and 16 in selenium, 18 in placebo
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Numbers of withdrawals and reasons (non compliance) were reported
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Scott 1998  (Continued)
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Methods Randomised double-blind placebo-controlled trial
Duration of study: from March 2015 to November 2015
Participants Country: Iran
Population: Idiopathic subfertile men, N = 114
Mean age:
Inclusion criteria: Idiopathic subfertile male with sperm rates 5 - 20 million cells/mL, and according to
failure of female to conceive after one year regular and unprotected intercourse
Exclusion criteria: chromatically fertility disorder (Y chromosome deletions), use of zinc three months
before recruitment
Interventions Zinc sulphate 10 mL solution of 0.5% (n = 61)
versus
Placebo 10 ml (n = 53)
Duration of treatment: 3 months
Outcomes Sperm parameters, side-effects, serum and semen plasma levels of zinc
Notes Trial registration: IR.IUMS.REC.1394.26155
Email sent to second author Norouzi (sr.norouzi@yahoo.com) on 06.03.2018 to ask if they can provide
mean+SD instead of median, and if the motility is total motility or progressive motility.
Reply on 11.03.2018: "yes we use SD for motility and total concentration, for both of them instead of a
median. Motility means group A+ B (progressive motility)"
New email on 12.03.2018 to ask if they can then provide mean + SD. Reply on 04.04.18 answering "In
this study we used the SPSS software (SPSS, Inc., Chicago, IL, USA, version 20) for statistical analyses.
After normality testing confirmed by Shapiro-wilk test, quantitative data were reported as mean ± SD.
Unfortunately there are some spelling and statistical errors in the final version of article. In the review
process, some changes have been made in the manuscript and subtitle of the tables have been deleted.
So all outcome are Mean ± SD."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "In the current study males were divided into groups A and B by block
randomized sampling."
Quote: "sub fertile males were assigned according to a simple computer
schedule into two groups to receive zinc sulfate or placebo."
Allocation concealment
(selection bias)
Low risk Quote: "Solutions were coded from 1 to 120 according to the randomization
list by hospital pharmacy. Each code was given to one participant to receive
one container of solution that according to their group called participates took
zinc sulfate (0.5) or placebo."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blind"
Quote: "Containers of zinc solution and placebo were similar, and all of them
had zinc syrup label. The secretary of infertility unit did not know about the
Sharifzadeh 2016 
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box content and patients by showing their groups label could receive the med-
icine."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "seven subjects in the zinc group withdrew because of adverse gas-
trointestinal side effects, and three subjects in the zinc group and four subjects
in the placebo group withdrew because of lack of motivation"
Dropouts accounted for and reasons mentioned. No ITT
Selective reporting (re-
porting bias)
Low risk Reported all the outcomes from the methods section and according to the
protocol: trial registration (IR.IUMS.REC.1394.26155)
Sharifzadeh 2016  (Continued)
 
 
Methods Randomised double-blind trial
Duration of study: 24 weeks, follow-up unclear
Participants Country: USA
Population: infertile men aged 18 to 65 years, N = 26
Mean age: 36.2 ± 5.8 years, 35.3 ± 7.5 years
Inclusion criteria: males 18 to 65 years with infertility of at least six months duration, sperm concentra-
tion of at least 5 million sperm/mL, motility of 10% to 50%, absent pyospermia and normal FSH and
testosterone levels
Exclusion criteria: history of post-pubertal mumps, cryptorchism, vasal or epididymal surgery, histo-
ry of medication or chemotherapy. recent alcohol, chronic marijuana. Use of testosterone or steroids.
Exposure to environmental toxins. Recent history of fever or diabetes, liver failure, renal failure, en-
docrine disorder, untreated variocoele, urogenital infection, or prior vasectomy reversal
Interventions L-carnitine 2000 mg + L-acetylcarnitine 1000 mg (n = 12)
versus
Placebo (n = 9)
Duration of treatment: 4 months
Outcomes Primary outcome: sperm parameters
Secondary outcomes: pregnancy rate
Notes Author replied 21.09.2009 saying: Quote "The published 2006 trial is the published version of the 2003
abstract (Pryor 2003)" and giving details of randomisation and concealment. Author says he will try
and find out about the 5 patients that dropped out.
Why did - "5 additional patients entered the study but dropped out before completion" - when did
these patients enter and were they randomised? Quote: "One of these 5 dropped out because of preg-
nancy three months after starting carnitine" Pryor paper excluded as it is the same study as Sigman,
author also gave details of randomisation and allocation concealment, author will try to find info on 5
patients who dropped out.
Sigman 2006 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomised to receive carnitine or placebo"
Quote: "The randomisation was done by a third party a company that over-
saw the trial.  We sent the patient number of new recruited patients in to them,
they assigned them a study number that was associated with a collection of
medication/placebo."
The author replied to randomisation query 23.09.09 saying that the protocol
stated that - "treatments will be assigned randomly to a subject number.  The
numbers will range from 1-84 for study centre 1 and 85-168 for study centre
2.  Randomisation of treatments for each centre will be done independently.
 One half of subject numbers will be placebo, the other half, active ingredient."
Allocation concealment
(selection bias)
Low risk Quote: "The investigators and study sites had the study medication/placebo
packets identified by number only. They were blinded to what was in the med-
ication/placebo packets.  We were sent the code at the conclusion of the trial."
The author replied to a query on allocation concealment on 23.09.09 saying
that the protocol stated that - " Integrated Data Solutions, Inc. will keep the
randomisation code in a separate sealed envelope for each site until the end of
the study. The randomisation lists will be provided to the packaging company
for packaging of the packets into patient medication boxes.” 
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Both the investigators and the patient were blinded to the treatment
arm assignment."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "5 additional patients entered the study but dropped out before com-
pletion. One of these dropped out because of pregnancy three months after
starting carnitine." Author replied to query re drop outs, quote: "I have data
on one drop out at my site - the drop out occurred after randomisation to car-
nitine. The drop out occurred before the first follow-up study visit.  The other
four drop outs were from the other study site - I am trying to get that data for
you" (23.09.09)
Selective reporting (re-
porting bias)
Unclear risk All outcomes of interest were reported. No protocol available.
Sigman 2006  (Continued)
 
 
Methods Randomised controlled open-label trial
Duration of study: unclear, from 2008 to 2009
Participants Country: Russia
Population: men with chronic prostatitis and abnormal fertility for more than 6 months, N = 30
Mean age: unclear, range 18 to 40 years
Sivkov 2011 
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Interventions Selznic (selenium + zinc + vitamins) (n = 15)
versus
Placebo (n = 15)
Duration of treatment: 3 months
Outcomes Sperm motility, sperm concentration
Notes Article in Russian, translated by Vasya Vlassov.
No SD available. Need to contact authors regarding methods, standard deviations, type of control and
any pregnancy data. Author Vasya 17.02.14 saying that the control was placebo and SD's not given.
Emailed the institution 18.02.2014 regarding methods and data, no reply as of 07.03.2013.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk No allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "Open labelled". However placebo used, might be a translation prob-
lem
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Sivkov 2011  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: unclear
Participants Country: Greece
Population: oligoasthenospermic infertile (OAI) men, N = 39
Mean age: unclear
Inclusion criteria: unclear
Exclusion criteria: unclear
Sofikitis 2016 
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Interventions Avanafil 150 mg (n = 13)
versus
L-carnitine 1.5 g (n = 14)
versus
No treatment (n = 12)
Duration of treatment: 12 weeks
Outcomes Sperm parameters, length of sperm midpiece (LMP), outcome of hypoosmotic swelling test (%HPST),
seminal plasma citrate concentration
Notes Abstract only.
Email sent to Dimitriadis (helabio@yahoo.gr) on 21.02.2018 to ask for data/full text, reply the same day
from the author: Quote: "This work has not been published as a full paper".
New email sent on 26.02.2018 to ask if we could receive data (mean+SD) for the L-carnitine and placebo
group.
Reminder email sent on 22.03.2018. No reply received to date (19.04.2018).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control is no treatment group
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Unclear, only abstract available
Sofikitis 2016  (Continued)
 
 
Methods Randomised double-blind controlled trial
Duration of study: 6 months, follow-up unclear
Participants Country: Saudi Arabia
Suleiman 1996 
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Population: asthenozospermic men attending a fertility centre, N = 110
Mean age: treatment group 34.8 (27 to 52) years, control group 33.2 (22 to 45) years
Inclusion criteria: asthenospermic (≥ 20 x 106 /mL). sperm motility ≤ 40%, normal sperm count, leuco-
cyte concentration < 5%, normal fructose concentration, normal female
Exclusion criteria: unclear
Interventions Vitamin E 300 mg (n = 52)
versus
Placebo (n = 35)
Duration of treatment: 6 months
Outcomes Primary outcome: motility and MDA concentration
Secondary outcome: live birth, pregnancy, miscarriage
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Either 100mg vitamin E or a placebo was prescribed in a random dou-
ble blind fashion". Method of randomisation not stated
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote:"Double blinded". Placebo used.
Quote: "If the semen sample improved and the patient's spouse became preg-
nant, the treatment was stopped; otherwise it was continued for 6 months.
The placebo was given for 6 months"
This could suggest that the investigators or clinicians had knowledge of
whether the patients were in the placebo or antioxidant group, therefore this
trial was rated as high risk.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
High risk The exact dropout figures for each group is unclear. Quote: "A total of 110 pa-
tients were enrolled in the study, but some of the patients dropped out and
some leQ the region and failed to continue. When the experiment was termi-
nated, 52 patients were found to have taken vitamin E and 35 patients to have
taken the placebo." Assuming the groups were equal initially then the placebo
group lost 20 men and the intervention lost 3. A drop out rate of >20%
Selective reporting (re-
porting bias)
Unclear risk All outcomes stated in the methods were reported in results. No protocol
available.
Suleiman 1996  (Continued)
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Methods Randomised double-blind controlled trial
Duration of study: 1.5 years, follow-up 13 weeks
Participants Country: Australia
Population: infertile men, couple undergoing IVF, N = 60 (recruited N = 82)
Mean age: treatment group 37.1 ± 5.1 years, placebo group 35.5 ± 4.3 years
Inclusion criteria: men with sperm samples showing oxidative stress and a significant level of DNA frag-
mentation (> 25% TUNEL positive)
Exclusion criteria: female partner with diminished ovarian reserve or if the female partner is aged over
39 years
Interventions Menevit (folate 0.5 mg + garlic 1000 mg + lycopene 6 mg + vitamin E 400 IU + vitamin C 100 mg + zinc 25
mg + selenium 26 μg + palm oil) (n = 40)
versus
Placebo (containing palm oil) (n = 20)
Duraton of treatment: 3 months, prior to IVF cycle
Outcomes Primary outcome: embryo quality
Secondary outcomes: pregnancy, multiple pregnancy, fertilisation rate, side effects
Notes Power calculation performed
Associate Professor Tremellen provided live birth data in December 2014 "Only one pregnancy failed
in the Menevit arm after 13 weeks (late miscarriage 19 weeks of male infant). All other pregnancies,
including the twin pregnancies went on to live birth and all babies appear to be doing well from the
records". There were three sets of twins in the combined antioxidants group and nil in the placebo
group. Each twin pregnancy and live birth was counted as one event in the data analyses due to the
protocol specifications of the review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote:"The randomisation schedule was computer generated in blocks of six
by Bayer Consumer Care Australia". Using a 2:1 ratio
Quote: "There were no significant differences between the active and the
placebo group in terms of important baseline prognostic characteristics..."
Allocation concealment
(selection bias)
Low risk Quote: "the appropriately numbered bottles of capsules delivered to the clin-
ical site without any participant knowing the treatment sequence. Patients
were allocated the next numerical treatment package (one to sixty as they be-
came eligible for enrolment"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-blind". Placebo used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Tremellen 2007 
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All withdrawals were accounted for, 2 from the intervention group, 4 from
placebo all due to the couples not going through to embryo transfer
Selective reporting (re-
porting bias)
Unclear risk All specified outcomes are reported. No protocol available.
Tremellen 2007  (Continued)
 
 
Methods Randomised controlled trial
Duration of study: from August 2007 to August 2009
Participants Country: China
Population: infertile men with asthenozoospermia, N = 135
Mean age: unclear, range 23 to 26 years
Inclusion criteria: male asthenozoospermia patients, aged 23 to 26 years old, with a history of infertility
for about 1 to 10 years, and with no contraception measures after marriage at least 12 months, has nor-
mal sex life, the wife’s fertility is normal., semen analysis for at least twice based on WHO criteria (For-
ward mobile sperm (a + b level) < 50%, and fast forward movement sperm (a level) < 25%, sperm densi-
ty > 20 x 106 /mL), tests for peripheral blood chromosome and reproductive hormones (FSH, LH, PRL, T)
were normal, the tests for semen ureaplasma mycoplasma and chlamydia trachomatis were negative,
semen WBC < 1 x 106 /mL
Exclusion criteria:cryptorchidism, testicular dysplasia, varicoceles, reproductive tract infection
Interventions L-carnitine 2 g + Vitamin E (n = 68)
versus
Vitamin E (n = 67)
Duration of treatment: 3 months
Outcomes Pregnancy rates, adverse effects, % forward motile sperm, sperm density, % sperm normal morpholo-
gy
Notes Article in Chinese, translated by Liu Qi.
E-mailed Qin (translator) regarding pregnancy and adverse event data, then may need to write to the
authors. No reply to date.
2018: added data on progressive sperm motility
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "A total of 135 patients with asthenozoospermia were randomly divid-
ed into Groups".
Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Wang 2010 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 22 dropouts. Numbers from each group are given but no reasons are provided
for the withdrawals. ITT not used in the trial analysis
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Wang 2010  (Continued)
 
 
Methods Randomised double-blind placebo-controlled trial
Duration of study: from July 1997 to August 1998
Participants Country: the Netherlands
Population: fertile and subfertile men, N = 103 (recruited subfertile N = 258)
Mean age: 34.3 ± 3.9 years
Inclusion criteria for subfertile group: failure of the woman to conceive after 1 year regular unprotected
intercourse and sperm concentration of 5 to 20 million/mL
Exclusion criteria for subfertile group: chromosomal disorders, cryptorchidism, vasectomy, use of folic
acid or zinc supplements in the previous 3 months, vitamin B deficiency
Interventions Folic acid 5 mg (n = 22)
versus
Zinc sulphate 66 mg (n = 23)
versus
Zinc sulphate 66 mg + Folic acid 5 mg (n = 24)
versus
Placebo (n = 25)
Duration of treatment: 26 weeks
Outcomes Sperm parameters
Notes Data in median and range. Use of fertile and subfertile men.
Attempted to contact authors regarding means and standard deviations. Letter returned to sender
Risk of bias
Bias Authors' judgement Support for judgement
Wong 2002 
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
134
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Low risk Quote: "eligible fertile and subfertile men were randomly assigned according
to a simple computer-generated randomisation schedule in four blocks to re-
ceive folic acid and placebo, zinc sulphate and placebo, zinc sulphate and folic
acid, or placebo and placebo, which resulted in eight subgroups." "At the end
of the trial, the research fellow received the randomisation list that matched
the codes from the hospital pharmacy."
Allocation concealment
(selection bias)
Low risk Quote: "capsules were coded by the hospital pharmacy according to the ran-
domisation list."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind"
Quote: "Neither the research fellow and the participants knew whether the
participants received folic acid, zinc sulphate or placebo capsules"
Quote: "Folic acid and placebo capsules were yellow and identical in appear-
ance. Zinc sulphate and placebo capsules were white and identical in appear-
ance"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 9 men withdrew from the subfertile arm of the trial, 1 due to side effects (gas-
trointestinal) and 8 due to lack of motivation. It is unclear which treatment
groups these men were randomised to
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported. No protocol available.
Wong 2002  (Continued)
 
 
Methods Randomised pilot study
Duration of study: unclear
Participants Country: Belgium
Population: men attending andrology clinic, N = 22
Mean age: unclear
Inclusion criteria: unclear
Exclusion criteria: unclear
Interventions Acetyl-cysteine 600 mg (n = 5)
versus
Mixture of essential fatty acid (EFA) (DHA 1 g + y-linolenic acid + arachidonic acid 100 mg) + α-toco-
pherol (vitamin E) + β-carotene (n = 12)
versus
Acetylcysteine + essential fatty acid (EFA) + antioxidants (n = 5)
Duration of treatment: 4 to 6 months
Zalata 1998 
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Outcomes Sperm parameters, DNA damage (oh8dG)
Notes Abstract only.
No extractable data. Attempted to contact authors re availability of data as means, if published?, meth-
ods of randomisation and allocation concealment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Abstract only
Zalata 1998  (Continued)
 
 
Methods Randomised, placebo-controlled trial
Duration of study: 3 months
Participants Country: Hungary
Population: subfertile men, N = 20 (recruited N = 26)
Mean age: treatment group 29.6 years, placebo group 28.3 years
Inclusion criteria: unsuccessful attempt at pregnancy for over one year. A healthy female partner ex-
amined by a gynaecologist. Sperm volume < 2 mL and/or sperm concentration < 20 million/mL and/or
morphology ratio < 30% and/or motility < 50%. No genital tract infection, no bacteria or fungi in urine
or semen. Hormones are within physiological range. Intact renal function. No excessive magnesium in-
take
Exclusion criteria: unclear
Interventions Magnesium 3000 mg (n = 10)
versus
Placebo (n = 10)
Zavaczki 2003 
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Duration of treatment: 90 days
Outcomes Primary: sperm parameters
Secondary: clinical pregnancy and side effects
Notes Attempted to contact authors regarding methods of randomisation and allocation concealment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "The members of Group P received the same number of placebo tablets
which closely resembled the Magnerot tablets."
Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 20 were randomised and 14 were analysed. Quote: "To date 26 patients have
participated in the study and 20 men (10 in both groups) have completed the
program of treatment. Six patients (2 in group M and 4 in group P were ex-
cluded from the program, including five cases for poor compliance, since they
did not attend the control meeting at the end of treatment. One patient from
Group M experienced severe diarrhoea and so his treatment was halted."
Selective reporting (re-
porting bias)
Unclear risk All sperm data for outcomes in the trial were given, however clinical pregnancy
only reported in the results section and not mentioned in methods. No proto-
col available.
Zavaczki 2003  (Continued)
ART: assisted reproductive technique;BMI: body mass index;FSH: follicle-stimulating hormone; ICSI: intracytoplasmic sperm
injection; IgG: immunogobulin G;ITT: intenttion-to-treat; mg: milligram; IQR: interquartile range; IU: international unit;
IUI: intrauterine insemination; IVF: in vitro fertilisation; MDA: malondialdehyde; NSAID: non-steroidal anti-inflammatory;
OAT:oligoasthenoteratozoospermia; PRL: prolactin;RoB: risk of bias; ROS: reactive oxygen species; SD: standard deviation; SE: standard
error; SEM: standard error of the mean; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling; WBC: white blood cell;
WHO: World Health Organization
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adel 2015 Ineligible based on intervention: main intervention is oral Vitamin E. However there was also an
in vitro Berberine wash added to the collected sperm in 10 random participants from both groups
(treatment group with oral Vitamin E or untreated group)
Alahmar 2017 Ineligible based on study design: "prospective randomised trial", however there was no control
group, only comparison before and after treatment with antioxidants
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Study Reason for exclusion
Alizadeh 2018 Ineligible based on intervention: Curcumin Nanomicelle is a herbal product
Alsalman 2018 Ineligible based on control: subfertile men with zinc treatment versus fertile men without treat-
ment
Anarte 2012 Ineligible based on study population: normozoospermic men and donors
Anarte 2013 Ineligible based on study population: normozoospermic men and donors
Azizollahi 2013a Ineligible based on outcome: seminal antioxidant levels and endocrine parameters. Furthermore,
same study population/group as Azizollahi 2013 which was already included in the 2014 update
Cai 2012 Ineligible based on study population: not subfertile men
Calogero 2015 Ineligible based on population: idiopathic infertile men, not male factor
Capece 2017 Ineligible based on intervention: treatment with myo-inositol plus herbal extracts (Tribulus Ter-
restris, Alga Ecklonia Bicyclis)
Chattopadhyay 2016 Ineligible based on study design: not a randomised controlled trial
Chen 2012 Ineligible based on intervention: includes fertility drugs like tamoxifen. Group A tamoxifen + vita-
min E, Group B tamoxifen
Ciftci 2009 Ineligible based on population: includes men with idiopathic infertility and normal sperm parame-
ters.
Comhaire 2005 Ineligible based on study design: used non-randomised controls recruited from another unrelated
trial
Ebisch 2003 Ineligible based on study population: inappropriate population, polymorphisms
Elgindy 2008 Ineligible based on study population: antioxidant given to the women
Ghafarizadeh 2018 Ineligible based on intervention: in vitro selenium, no oral intake
Ghanem 2010 Ineligible based on intervention: clomiphene + vitamin E versus placebo, fertility enhancing drug
Gulati 2015 Ineligible based on study design: prospective cohort study, not a randomised controlled trial
Gulino 2016 Ineligible based on control: healthy fertile patients with intervention or control group of healthy
patients undergoing IVF for a female factor
Hafeez 2011 Ineligible based on intervention: plant extracts, herbal formulation
Iacono 2014 Ineligible based on intervention: fertility enhancing drug, protocol exclusion criteria. Group A Ta-
mofixfen citrate with antioxidant, group B tamoifen alone and group C placebo.
Jawad 2013 Ineligible based on study design: not randomised quote: "men were classified into groups". Num-
bers of men in the groups were uneven
Kanta Goswami 2017 Ineligible based on study design: prospective study, not randomised
Keskes-Ammar 2003 Ineligible based on population: includes infertile men who are normospermic, oligospermic or
azoospermic. No subpopulation with extraction data
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Study Reason for exclusion
Kim 2010 Ineligible based on study population: female participants not men
Korosi 2017 Ineligible based on intervention: oral myo-inositol supplement with treatment of the semen with
myo-inositol incubation. The control group did not receive any form of treatment (no oral, no incu-
bation). Not able to differentiate between effect due to oral supplement or incubation
Kumar 2011 Ineligible based on intervention: used a herbo-mineral supplement
Lenzi 1993 Ineligible based on intervention: route of supplementation was intramuscular not oral
Lu 2010 Ineligible based on study population: women
Martinez-Soto 2016 Ineligible based on study population: also included infertile men with normospermic parameters.
No subgroup analysis
Merino 1997 Ineligible based on intervention: pentoxifylline no longer included, fertility enhancing drug
Micic 1988 Ineligible based on intervention: pentoxifylline no longer included, fertility enhancing drug
Micic 2001 Ineligible based on study design: not randomised, 105 men in the treatment group and 35 in con-
trol. Abstract only
Movahedin 2014 Ineligible based on (repetitive) study population: same study as Pourmand 2014, second author
Movahedin
Nadjarzadeh 2014 Ineligible based on (repetitive) study population: exact same population, including the baseline
characteristics and period of inclusion, as Nadjarzadeh 2011. Different outcome parameters (semi-
nal plasma levels of antioxidant enzymes and oxidative stress)
Nashivochnikova 2014 Ineligible based on study design: no RCT, full-text received from first author by email, after transla-
tion of full-text (in Russian) to English found out there was no control group.
NCT01075334 Ineligible based on no data to publish: study was terminated, not being able to recruit enough par-
ticipants (contact with author)
NCT01520584 Ineligible based on no data to publish: recruiting participants not successful (contact with author)
Nematollahi-Mahani 2014 Ineligible based on outcome: endocrine parameters and seminal antioxidant level. Furthermore,
same study population as Azizollahi 2013 (included in update 2014)
Niederberger 2011 Ineligible based on study design: a commentary on Ghanem 2010
Nikolova 2007 Ineligible based on study design: not randomised, allocation method is by alternation. Translated
from Bulgarian by Ivan Sola. "50 of them were randomly invited to participate depending on their
order of attendance to the clinic"
Pawlowicz 2001 Ineligible based on study design: not randomised
Polak 2013 Ineligible based on study population: women
Raigani 2010 Ineligible based on outcome: measurement of MTHFR genotype. Furthermore, same study popula-
tion as Raigani 2014 which is an included study
Safarinejad 2011 Ineligible based on intervention: pentoxifylline no longer included, fertility enhancing drug
Safarinejad 2011a Ineligible based on intervention: saffron, herbal not a supplement
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Study Reason for exclusion
Singh 2016 Ineligible based on study design: not randomised, based on conference abstract
Soylemez 2012 Ineligible based on study population: not subfertile men
Stanislavov 2009 Ineligible based on study design: not randomised, the study uses alternate allocation, odd and
even numbers. Appears to be a report of the study Nikolova 2007
Stanislavov 2014 Ineligible based on intervention: L-arginine combined with herbal extract
Tang 2011 Ineligible based on intervention: tamoxifen, protocol exclusion criteria (tamoxifen + Q10 versus ta-
moxifen). Quote: “trials that included men taking other fertility enhancing drugs”
Verzeletti 2012 Ineligible based on intervention: Spirulina platensis (4 g) and Resveratrol (500 mg) are plant ex-
tracts not antioxidant supplements
Vicari 2001 Ineligible based on control: inappropriate control (anti-inflammatory) group. Treatment is not
compared to placebo or another antioxidant
Vicari 2001a Ineligible based on control: Inappropriate comparison. The same antioxidant is compared at differ-
ent times - L-carnitine + acetyl-carnitine versus L-carnitine + acetyl-carnitine
Vicari 2002 Ineligible based on control: inappropriate control (anti-inflammatory). Treatment is not compared
to placebo or another antioxidant
Wang 1983 Ineligible based on intervention: pentoxifylline no longer included, fertility enhancing drug
Wang 2010a Ineligible based on intervention: fertility enhancing drug, protocol exclusion criteria. Group A L-car-
nitine + tamoxifen, Group B L-carnitine, Group C tamoxifen. No placebo or no treatment control
Wu 2012 Ineligible based on study design: probably not randomised, no mention of randomisation in the ab-
stract and uneven numbers between the groups, attempted to contact authors with no reply
IVF: in vitro fertilisation; MTHFR: Methylene tetrahydrofolate reductas; RCT: randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Prospective observational study
Duration of study: from March 2013 to April 2015
Participants Country: India
Population: men with idiopathic male infertility with high reactive oxygen species (ROS), N = 175
Inclusion criteria: unclear
Exclusion criteria: unclear
Interventions Diet rich in antioxidants and lifestyle changes (n = 80)
versus
Combined oral antioxidant (n = 95)
versus
Goswami 2015 
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Placebo (n = 75)
Duration of treatment: unclear
Outcomes Semen parameters, antioxidant concentrations (CoQ-10, L-carnitine, zinc), plasma total antioxi-
dant capacity (TAC), total glutathione (GSH), sperm DNA fragmentation (TUNEL assay)
Notes Conference abstract only. Not clear if it is a randomised clinical trial.
Email sent to authors Goswami and Chakravarty (bncirm@gmail.com; syednkabir@yahoo.com) on
20.02.2018 and 06.03.2018.
No reply to date (march 2018)
Goswami 2015  (Continued)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Pre treatment with antioxidants versus no treatment for male partner in couples undergoing as-
sisted reproductive technology (ART) for male infertility: a randomized controlled trial.
Methods Interventional (clinical trial)
Design
Randomised: permuted block randomisation, variable method of allocation concealment: sequen-
tially numbered, sealed, opaque envelopes
Blinding and masking: open-label
Participants Inclusion criteria
Couples undergoing ART due to male factor infertility with the following parameters
• Mild Oligozoospermia 1 to 15 million/mL
AND/OR
• Asthenozoospermia < 32% progressive motility
AND/OR
• Teratozoospermia < 4% normal morphology
Exclusion criteria
• Severe oligozoospermia < 1 million/mL• Taken treatment in past 3 months for male infertility• Female age > 37 years• Female partner - moderate or severe endometriosis
Interventions Drug: tablet Vitamin C 500 mg, capsule Vitamin E 400 mg and tablet Zinc 140 mg
Control: no treatment
Duration: 3 months
Outcomes Primary
• Clinical pregnancy rate
CTRI/2013/02/003431 
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Secondary
• Ongoing pregnancy rate• Miscarriage rate• Fertilisation rate• Live birth rate• Changes in sperm parameters
Starting date February 2013
Contact information Dr Mohan S Kamath, MS,DNB, Fellow ( Reproductive Medicine) Associate Professor
Reproductive Medicine Unit
Christian Medical College and Hospital
Vellore 632004
India
Telephone: 04162283301
Email: dockamz@gmail.com
Affiliation: Christian Medical College and Hospital
Notes Email sent 26.03.14. Dr Kamath replied 3.04.14 saying that they were still in the recruitment phase
and were hoping to finish the trial in 2015.
Email sent 07.02.18. Dr Kamath replied 08.02.18 saying that they are still recruiting and hope to
complete the recruitment by Mid 2018 and results should be available by the end of 2018. They
have recruited approximately 150-160 participants.
CTRI/2013/02/003431  (Continued)
 
 
Trial name or title Randomized, placebo-controlled, double-blind, multi-centre pilot study to investigate the effect of
AM019016 on male spermatogenesis in subjects with diagnosed unspecific (idiopathic) subfertility.
Methods Interventional (clinical trial)
Design
Allocation: randomised controlled trial
Masking: blinded (patient/participant, investigator/therapist)
Control: placebo
Assignment: parallel
Study design purpose: treatment
Participants Males with minimum age of 18 years
Inclusion criteria
• Men with existing unfulfilled child wish• Unspecific (idiopathic) subfertility diagnosed by an already existing sperm analysis (may not be
older than four weeks) and whilst observing a sexual abstinence period of at least 2 days to a
maximum of 7 days; according to WHO reference values (2010, 5th Edition):
DRKS00011616 
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• < 39 million total number of spermatozoa per ejaculate sample and/or• < 32 % progressive motile spermatozoa• Readiness to comply with at least 2 to a maximum of 7 Days of sexual abstinence before creating
a Spermogram• Consent to take a dietary food for three months
Exclusion criteria
• Presumed or established organic causes of subfertility• Azoospermia, aspermia, anejaculation• Varicocele of the testis, assessment according to medical examination discretion• Urogenital infections such as e.g. Prostatitis, epididymitis, Orchitis, sexually transmitted diseases• Known relevant endocrine disorders, e.g. Hypogonadotropic hypogonadism (assessment accord-
ing to Medical discretion)• Operational interventions in the past:• Orchidopexy in cryptorchid or hodentorsion, varicocele surgery, hodentrauma, pelvic, inguinal or
scrotal surgical procedures• Any surgical intervention during the last 6 months before the start of the study and planned inter-
ventions during the study• Systemic disorders that could influence the outcome of the study, assessment by medical judg-
ment (e.g. diabetes, renal failure, hepatic impairment malignancy, obesity)• Pesticide exposure in the past and present• Ingestion of substances or other forms of therapy that could influence the study result according
to medical discretion, e.g.• Medication, e.g. Anabolic agents, sulfasalazines, alpha-blockers, cimetidine and aldosterone an-
tagonists, androgens, 6 months before study initiation and during the study• Regular intake of dietary supplements / supplementary balanced diets in the last 6 months before
the start of the study and during the study(with the exception of the study preparation)• Applied therapy to improve sperm quality in the last 6 months before the start of the study and
during the study• Application of antioxidants in the last 6 months before study start and during the study• Known intolerance / allergic reactions to the ingredients of the investigational medicinal product• Significant changes in the patient's lifestyle, especially regarding medication intake, diet, smok-
ing, alcohol last month study start and during the study• Drug, alcohol and / or drug abuse• Simultaneous participation in another clinical trial or participate in such an event within the last
30 days• Signs that the participant is expected to fail test plan (e.g. lack of co-operation)• Application of antioxidants in the last 6 months before study start and during the study• Known intolerance / allergic reactions to the ingredients of the investigational medicinal product• Significant changes in the patient's lifestyle, especially regarding medication intake, diet, smok-
ing, alcohol last month Study start and during the study• Drug, alcohol and / or drug abuse• Simultaneous participation in another clinical trial or participate in such an event within the last
30 days• Signs that the participant is expected to fail test plan (e.g. lack of co-operation)• Simultaneous participation in another clinical trial or participate in such an event within the last
30 days• Signs that the participant is expected to fail test plan (e.g. lack of co-operation)
Interventions Drug: Taking AM019016 (verum), dietary food, 3 capsules once a day
Ingredients: Vitamin D, E, C, B12, B6, B2, Folic Acid, L-Carnithine, L-Arginine, Coenzyme Q10, Zinc,
Selenium, β-carotene, Copper, Pigrafert (combination of pine bark, grape seed, green tea extract).
Control: Taking AM019016 (placebo), 3 capsules once a day
DRKS00011616  (Continued)
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Ingredients Placebo: maltodextrin, release agent magnesium salts of feed fatty acids and dye E171
and hydropropylmethylcellulose in the capsule shell. Free of gluten and lactose.
Duration: 12 weeks
Outcomes Primary
Parameters for the assessment of the benefit by preparation and evaluation of spermograms ac-
cording to the WHO criteria (2010, 5th edition)
• change in progressive motility (visit 1 vs. visit 2)• Change of sperm concentration (visit 1 vs. visit 2); change of sperm morphology (visit 1 vs. visit 2);
change of sperm total (visit 1 vs. visit 2)• Change in total motility (visit 1 vs. visit 2)• Change of the ejaculate volume (visit 1 vs. visit 2)• Occurrence of pregnancy during the study and about 3 months after visit 2• Global evaluation of the benefit by the physician (to visit 2) on a scale with the four assessment
points "very good", "good", "moderate" and "bad"
Secondary
Parameters for the assessment of tolerability:
• Adverse events and serious adverse advents during the clinical trial• Global evaluation of the tolerability by the physician and subjects using a scale with the four as-
sessment points "very good", "good", "moderate" and "bad" at final visit.
Starting date July 2017
Contact information Holger Baumgraß
Urologische Praxis
Förster-Funke-Allee 104
14532 Kleinmachnow
Germany
+49(0)33203 58 50
holger.baumgrass@t-online.de
Notes Secondary ID: S15(a)/2017
DRKS00011616  (Continued)
 
 
Trial name or title The effect of oral vitamin D3 supplementation on spermogram quantitative and qualitative indica-
tors in infertile male
Methods Interventional (clinical trial)
Design
Randomisation: non-randomised. Randomly by tossing coin.
Blinding: triple-blind
Placebo: used
IRCT2016111830947N1 
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
144
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Assignment: parallel
Purpose: treatment
Participants Males.
Inclusion criteria
• Be healthy physically and mentally• Older than 20 years and less than 45 years• Body mass index is 18/5-30• Not to intake any vitamin D3 at therapeutic doses in last 3 months• Not to intake supplementation in non-therapeutic doses in last 3 months• Not to intake medications that influence on the level of vitamin D3 includes glucocorticoids and
anti convulsion drugs that influence on spermatogenesis such as cimetidine• Spirnolactone should not have be used according to urologist in last 3 months• Lack of azoospermia in spermogram• Having disrupt sperm of unknown origin(idiopatice)• Lack of genital tract infection or drug treatment in this regard during the past three months ac-
cording to the clinical records and according to patients saying• Lack of anatomical abnormalities of the genital tract such as varicocele grade two and above• Testes and vas deferens history of surgery• No contact with pesticides• Heavy metals and high temperature• Not using cigarette or hookah in last 3 month• Not using alcohol or narcotic• The serum level of vitamin D3 should be less than 30 or equal to 30 Ng in litre• No disorder in prolactin levels or TSH.
Exclusion criteria
• Not taking more than one dose of vitamin D3• The existence of some signs or symptoms which prohibit the continuous of using according to
urologist and nutritionist• Start taking other supplements drugs that have been banned their entry criteria during the study
Interventions Drug: the supplement of vitamin D3 (each week 1 pill of supplement vitamin D3 for 8 weeks and in
remaining 4 weeks 1 supplement vitamin D3 pill as a maintenance dose)
Control: placebo of vitamin D3 (each week 1 pill of Placebo vitamin D3 for 8 weeks and in remaining
4 weeks? 1 pill of Placebo vitamin D3 as a maintenance dose)
Duration: 12 weeks
Outcomes Primary: spermogram qualitative indicators
Secondary: hormonal markers related to spermatogenesis(LH? FSH? TT? FT? SHBG)
Starting date February 2017
Contact information Afsaneh Talebi
Iran University of Medical Sciences, School of Nursing and Midwifery
Yasemi Rashid street, Valiasr street, Tehran.
Iran, Islamic Republic Of
00982143651820
IRCT2016111830947N1  (Continued)
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Talebi.a@tak.iums.ac.ir / AfsanehTalebi68@gmail.com
Notes  
IRCT2016111830947N1  (Continued)
 
 
Trial name or title The effects of folic acid, vitamin E, selenium on semen parameters in infertile men
Methods Interventional (clinical trial)
Design
Randomisation: randomised. Sampling based on table of random numbers.
Blinding: single-blind
Placebo: used
Assignment: parallel
Purpose: treatment
Participants Males.
Inclusion criteria
• Willingness to participate in the study• Age range 25 to 54 years• Does not use of micronutrients out of study• Rejection of any obstructive disorder during radiological studies and anatomical examination• Abnormal parameters be approved by two semen analysis within two weeks
Exclusion criteria
• Unwillingness to participate in the study• Azoospermia or aspermia men• Men with severe varicocele• Recent urogenital infection that has been treated with antioxidants• History of allergic reactions to micronutrients• Treated with the following drugs: sulfasalazine- methotrexate-Nitrofurantoin -colchicine –alpha
blockers and cimetidine - spironolactone - antidepressants, beta-blocker-phenothiazine-meto-
clopramide-heroin- cocaine-cannabis-thiazide diuretic
Interventions Drug: Selenium tablets (200 micrograms), vitamin zahravi Manufacturing Co. (400IU), folic acid
tablets (5 mg) Galinuse Manufacturing Co. - all once-daily,
Control: placebo daily
Duration: 12 weeks
Outcomes Primary
• Sperm count• Sperm morphology• Sperm motility• White blood cell count
IRCT2017012432153N1 
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Starting date April 2017
Contact information Azima Sara
School of Nursing and Midwifery
Nemazee squair, Shiraz, Iran
009871 36474254
Azimas@sums.ac.ir
Notes  
IRCT2017012432153N1  (Continued)
 
 
Trial name or title Assessment of the efficacy of dietary supplement Spermotrend in the treatment of male infertility
Methods Interventional (clinical trial)
Design
Allocation: randomised
Masking: triple-blind (participant, caregiver, investigator)
Placebo control
Parallel assignment
Participants Males, 19 years to 60 years
Inclusion criteria
• Male infertility unrelated to major testicular conditions• Must have at least one altered seminal parameter• Signed informed consent
Exclusion criteria
• Hydrocele, varicocele, orchitis, epididymitis, irradiation or chemotherapy• Previously treated and cured testicular condition• Non-transmissible chronic diseases• Use of antioxidant agents within 6 months• Use of vitamins within 6 months• Use of anti-inflammatory drugs within 6 months• Use of hormones prescribed by an andrologist within 6 months• Positive serology/HIV• Leukocytospermia
Interventions Drug: Spermotrend (vitamins plus other antioxidants) twice a day
Control: placebo twice a day
Duration: 12 weeks
Outcomes Primary
NCT00975115 
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• Parameters of seminal analysis at weeks 24
Secondary
• Fertilisation achievement• Presence of mild or severe adverse effects
Starting date September 2009
Contact information Miguel Aguilar Charara, MD
"Ramón González Coro" Gynecologic and Obstetric Hospita
53 7 838 2626 ext 277
Gynecologic and Obstetric Hospital
Havana, Cuba, 10400
miguel.aguilar@infomed.sld.cu
Notes Email sent 08.02.2018 to miguel.aguilar@infomed.sld.cu
NCT00975115  (Continued)
 
 
Trial name or title Impact of folates in the care of the male infertility (FOLFIV)
Methods Interventional (Clinical Trial). Phase 3
Design
Allocation: randomised
Intervention model: parallel assignment
Masking: quadruple (participant, care provider, investigator, outcomes assessor)
Participants Males, 18 years to 60 years
Inclusion criteria
• Couple - male is from 18 to 60 years old• Couple - male presents with infertility indicating interest in in vitro fertilisation with or without
intracytoplasmic sperm injection (IVF +/- ICSI)• Couple - male is 18 to 38 years old• Couple - male does not present particular factors of infertility• Couple - interest in IVF +/- ICSI• Couple with social insurance• both members of the couple having signed the consent
Exclusion criteria
• Aetiology of not genetic known male infertility: infertility of neoplastic origin, infertility of defini-
tive obstructive origin• Presence of a factor of feminine infertility: a definitive infertility tubal, turned out ovarian inca-
pacity (FSH > 9 and/or CFA <= 8)• Infertile men requiring fresh or frozen sperm• Men or women with HIV or hepatitis B or C• Men with epilepsy
NCT01407432 
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• Men receiving anti-folic treatment• Men presenting with a sensitivity to folic acid or one of the constituents of the drug• Couple of which one of the partners refuses to participate in the study
Interventions Drug: Folic acid 15 mg per day (tablets of 5 mg)
Control: Placebo of folic acid
Duration: 3-4 months
Outcomes Primary
• The rates of pregnancy in IVF +/- ICSI and spontaneous pregnancy according to the arm of treat-
ment
Secondary
• The rate of improvement of the sperm parameters with acid folic treatment• The rate of improvement of the nuclear quality of gametes with acid folic treatment• The rate of pregnancy of couple with infertile men treated by folic acid according to the methyl-
ene-tetrahydrofolate reductase (MTHFR) genotype• The difference between the MTHFR genotype of the patients on sperm parameters according to
the arm of treatment
Starting date November 2011
Contact information Mathieu-d'Argent E
Service of gynaecology-obstetrics and medicine of the reproduction, Tenon Hospital - APHP
Paris, France, 75020
Notes Email sent 08.02.18 to emmanuelle.mathieu@aphp.fr.
Received an answer 09.02.18 that the trial recruiting phase is completed. Submitting the results
within a few weeks.
NCT01407432  (Continued)
 
 
Trial name or title Myo-inositol on human semen parameters
Official title: Effect of treatment with myo-inositol on human semen parameters in patients under-
going In vitro fertilization cycles
Methods Interventional (clinical trial), phase 2/3
Design
Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: screening
Participants Male 25 years to 65 years
Inclusion criteria
• Undergoing IVF cycle, OAT
NCT01828710 
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Exclusion criteria
• Not undergoing IVF cycle
Interventions Sham arm (normospermic): 4000 mg/die of myo-inositol + 400 µg of folic acid (phase 2)
Active arm (OAT): myo-inositol 4000 mg/die associated to 400 µg of folic acid (phase 3)
Placebo arm (normospermic): 400 µg of folic acid
Duration: three months
Outcomes Primary
• sperm concentration
Starting date August 2012
Contact information Palumbo MA
Division of Obstetrics and Gynaecology/Department of Surgery
Center of Physiopathology of Human Reproduction
S. Bambino Hospital / University of Catania
Catania, Italy,95010
Other Study ID Numbers: INO-2103-GC
Notes Email sent 07.02.18 to Gulino (docferdi@hotmail.it) to ask if this study correlates with the same
study population of study NCT01560065 (Gulino 2016)
NCT01828710  (Continued)
 
 
Trial name or title The effects of administration of combined docosahexaenoic acid and vitamin E supplements on
spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia
Methods Interventional (clinical trial)
Design
Allocation: randomised
Intervention model: parallel assignment
Masking: quadruple (participant, care provider, investigator, outcomes assessor)
Participants Males, 20 years to 45 years
Inclusion criteria
• Willing to participate in the study and completing the informed consent form• Should be infertile (no conception after 12 months intercourse without any contraception)• age 20 to 45 years, idiopathic asthenospermia according to WHO criteria• Normal hormonal profile
Exclusion criteria
• Any infection in genitourinary (GU) tract
NCT01846325 
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• Any anatomical abnormality in GU tract• Any chronic disease during last 3 months• Any surgery in GU tract• Consumption of omega-3 fatty acids and/or vitamin E supplements during last 3 months
Interventions Drug: docosahexaenoic acid (DHA)
Groups
Experimental: capsule DHA 460 mg + vitamin E 600 mg per day
Active comparator: vitamin E 600 mg + placebo
Active comparator: 460 mg DHA + placebo
Placebo comparator: DHA-shaped placebo + vitamin E-shaped placebo
Outcomes Primary
• Sperm motility
Secondary
• Sperm count• Seminal oxidative stress
Starting date December 2013
Contact information Dr Azita Hekmatdoost
National Nutrition and Food Technology Institute
a_hekmat2000@yahoo.com
Notes Email sent 07.02.18 to a_hekmat2000@yahoo.com, reply on the same day: study completed. Not
yet submitted the manuscript
NCT01846325  (Continued)
 
 
Trial name or title Oral astaxanthin and semen quality, fertilization and embryo development in assisted reproduc-
tion technique procedures (Astax-ART)
Methods Interventional (clinical trial)
Design
Allocation: randomised
Intervention model: parallel assignment
Masking: triple (participant, care provider, investigator)
Participants Males, 18 years and older
Inclusion criteria
• Oligoasthenozoospermia with of without teratozoospermia by WHO criteria from the year 2010• Fresh semen• Female partner younger than 38 years
NCT02310087 
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• Idiopathic or tubal infertility in female partners• At least 4 oocytes retrieved in previous ovarian function in ART cycle, if previously performed• 1st, 2nd or 3rd cycle of ART
Exclusion criteria
• Genetic indication for ART procedure• Donated semen• Polycystic ovary syndrome in female partner• Dietary supplementation intake of antioxidants (selenium, zinc, vitamin E, vitamin C, vitamin A)
in male participant in the last three months• Smoking in male participant > 20 cigarettes per day
Interventions Astaxanthin with vitamin E
Drug: four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan), single daily dose
Placebo: four tablets of placebo daily taken in single daily dose
Duration: 3 months
Outcomes Primary
• Semen quality
Secondary
• Follicle stimulating hormone (FSH)• Fertilization and embryo development in ART• Pregnancy rates and miscarriage rates in 1st trimester after ART
Starting date November 2014
Contact information Bojana Pinter, MD, PhD / Senka Imamovic Kumalic, MD
Division of Ob/Gyn, University Medical Centre Ljubljana
Ljubljana, Slovenia, 1000
bojana.pinter@kclj.si / senka81@gmail.com
Notes Sent email 07.02.18 to bojana.pinter@kclj.si and senka81@gmail.com
Received a reply on the same day from dr Pinter: still recruiting, expecting to finish the study in
2018
NCT02310087  (Continued)
 
 
Trial name or title Males, antioxidants, and infertility trial (MOXI)
Methods Interventional (Clinical Trial)
Design
Allocation: randomised
Intervention model: parallel assignment
Masking: triple (participant, care provider, investigator)
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Participants Males, 18 years and older
Inclusion criteria
Couple
• 12 or more months of infertility (primary or secondary)• Heterosexual• Cohabitating and able to have regular intercourse
Male
• ≥ 18 years of age• At least one abnormal semen parameter on a semen analysis within the past 6 months: sperm
concentration ≤15 Million/mL, total motility• ≤ 40% normal morphology (Kruger) ≤ 4%DNA fragmentation (SCSA, DNA fragmentation index)
>25%
Female
• - ≥18 years of age and ≤40 years of age• - For women ≥ 35 years of age, evidence of normal ovarian reserve as assessed by menstrual cycle
day 3 (+/-2 days) FSH ≤10 IU/L with estradiol 70 pg/mL, AMH ≥ 1.0 ng/mL, OR antral follicle count
>10 within one year prior to study initiation• Evidence of at least one patent fallopian tube as determined by an hysterosalpingogram or la-
paroscopy showing at least one patent fallopian tube or a saline infusion sonogram showing
spillage of contrast material• Regular cycles defined as ≥25 days and ≤ 35 days in duration• Evidence of ovulation including biphasic basal body temperatures, positive ovulation predictor
kits, or progesterone level ≥3 ng/mL• Regular cycles defined as ≥25 days and ≤ 35 days in duration• Evidence of ovulation including biphasic basal body temperatures, positive ovulation predictor
kits, or progesterone level ≥3 ng/mL• Evidence of ovulation including biphasic basal body temperatures, positive ovulation predictor
kits, or progesterone level ≥3 ng/mL
Exclusion criteria
Couple
• Previous sterilisation procedures (vasectomy, tubal ligation); the prior procedure may affect
study outcomes• Planning in vitro fertilisation in the next 6 months
Male
• Sperm concentration < 5 million/mL on screening semen analysis• Current use of a medication or drug that would affect reproductive function or metabolism (see
Appendix C for list)• Current multivitamin or herb use (requires 1 month wash-out)• Current serious medical illnesses, such as cancer, heart disease, or cirrhosis• Current use of anticoagulants• Untreated hypothyroidism• Uncontrolled diabetes mellitus
Female
• History of surgically or medically confirmed moderate or severe endometriosis• Body mass index >35 kg/m2
NCT02421887  (Continued)
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• Currently pregnant• History of polycystic ovarian syndrome• Current serious medical illnesses, such as cancer, heart disease, or cirrhosis• History of systemic chemotherapy or pelvic radiation• Current use of a medication or drug that would affect reproductive function or metabolism
Interventions Drug: antioxidant supplement
Ingredients: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20
mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
Control: placebo
Outcomes Primary
• Live birth rate
Secondary
• Pregnancy rate• Miscarriage rate• Time to pregnancy• Change in semen parameters, using WHO 5 criteria• Percentage of sperm with fragmented DNA
Starting date December 2015
Contact information Anne Z Steiner, MD University of North Carolina
Heping Zhang, Principal Investigator, Yale University
Notes Still recruiting according to the Yale/Stanford site/Penn Medicine sites, February 2018
NCT02421887  (Continued)
 
 
Trial name or title Neotililty trial: Effect of coenzyme Q10 on semen parameters in men with idiopathic infertility
Methods Interventional (Clinical Trial)
Design
Intervention model: single-group assignment
Masking: none (open-label)
Participants Males, 20 years to 50 years
Inclusion criteria
• Signs the informed consent form• Patients will be recruited in the study if they will fulfilled the criteria of history of primary infertility
of more than 2 years, abnormal sperm count and motility• Age between 20 and 50 years• No known medical or surgical condition which can result in infertility
Exclusion criteria
• Voluntary withdrawal
NCT03104998 
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• Poor compliance of visit/treatment• A history of cancer chemotherapy or radiotherapy• A history of genital disease such as cryptorchidism and varicocele; a history of genital surgery• Body mass index 30 kg/m or greater; any endocrinopathy• Y chromosome microdeletions or karyotype abnormalities• Leukocytospermia• Drug or substance abuse; tobacco use;• Use of anticonvulsants, androgens or antiandrogens• Significant liver (serum bilirubin greater than 2.0 mg/dL)• Renal function (serum creatinine greater than 2.0 mg/dL) impairment• Patients with severe oligozoospermia (less than 5 X 106/mL), azoospermia and testicular volume
less than 12 mL will also be excluded from study
Interventions Drug: coenzyme Q10 200 mg daily
Control: placebo daily
Duration: 26 weeks
Outcomes Primary
• Measure the change in semen parameters after 26 weeks of coenzyme q10
Secondary
• Adverse event
Starting date August 2017
Contact information Anum Siddiqui, PharmD / Masood Jawaid, MRCS,FCPS
HillPark Hospital
Karachi, Pakistan
9221-34315195
anum.siddiqui@pharmevo.biz
Sonia_naqvi@hotmail.com
Notes  
NCT03104998  (Continued)
 
 
Trial name or title The impact of a nutritional supplement (Impryl®) on male fertility (SUMMER)
Methods Interventional (Clinical Trial)
Design
Allocation: randomised
Intervention model: multicentre, randomised double-blind placebo-controlled clinical trial/superi-
ority study
Masking: triple (participant, care provider, investigator)
Participants Males, 18 years to 50 years
NCT03337360 
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Inclusion criteria
• Couples with failure to conceive for at least 12 months and starting with EM
OR
• Couples starting with 1st cycle of IUI (with/without ovarian stimulation)
OR
• Couples starting with 1st/2nd/3rd cycle of IVF/ICSI
Furthermore
• Male with age 18-50 years• Female partner with age 18-43 years• Willing and able to give informed consent
Exclusion criteria
• Planned or performed diagnostic testicular biopsy (TESE) or percutaneous epididymal sperm as-
piration (PESA)• Use of donor-, cryopreserved- or electro-ejaculated semen• Ovulation induction (OI) without IUI• IVF for an absolute tubal factor• Embryo-transfers after cryopreservation• Embryo-transfer after pre-implantation genetic diagnosis• Known genetic abnormalities related to infertility• Known urological abnormality such as a varicocele or bilateral cryptorchism• Use of other vitamin supplements
Interventions Drug: Impryl, one tablet daily
Ingredients: food supplement with betaine, cystine, zinc, niacin, folic acid (di5MTHF-glucosamine),
Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (Riboflavin)
Control: placebo, one tablet daily
Duration: 6 months
Outcomes Primary
• Ongoing pregnancy rate ≥10-12 weeks of gestation
Secondary
• Overall pregnancy rate• The time between start of intervention and reaching ongoing pregnancy• The time between start of fertility treatment and reaching ongoing pregnancy• Change in semen parameters leading to change in treatment category• Number of miscarriages• Live birth rate• Adverse effects• Embryo fertilisation rate• Embryo-utilisation rate
Starting date April 2018
Contact information Roos Smits, MD
NCT03337360  (Continued)
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Radboud University
Nijmegen, the Netherlands, 6500HB
+31 (0) 651751244
roos.smits@radboudumc.nl
Notes  
NCT03337360  (Continued)
ART: assisted reproductive technique;FSH: follicle-stimulating hormone; ICSI: intracytoplasmic sperm injection; IVF: in vitro fertilisation;
OAT:oligoasthenoteratozoospermia; WHO: World Health Organization
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Comparison 1.   Antioxidant(s) versus placebo or no treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Live birth; type of antioxidant 7 750 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.79 [1.20, 2.67]
1.1 Carnitines 1 60 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.0 [0.24, 4.25]
1.2 Coenzyme Q10 1 60 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.16 [0.53, 8.82]
1.3 Vitamin D + Calcium 1 330 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.03 [0.59, 1.80]
1.4 Vitamin E 2 140 Peto Odds Ratio (Peto, Fixed,
95% CI)
8.51 [2.36, 30.70]
1.5 Zinc 1 100 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.74 [1.02, 13.74]
1.6 Combined antioxidants 1 60 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.42 [1.15, 10.13]
2 Live birth; placebo or no treatment 7 750 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.79 [1.20, 2.67]
2.1 Placebo 6 650 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.65 [1.08, 2.52]
2.2 No treatment 1 100 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.74 [1.02, 13.74]
3 Live birth; IVF/ICSI 2 90 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.61 [1.27, 10.29]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Live birth; as-treated analysis 7 649 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.71 [1.13, 2.58]
4.1 Carnitines 1 59 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.04 [0.25, 4.41]
4.2 Coenzyme Q10 1 55 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.10 [0.51, 8.64]
4.3 Vitamin D + Calcium 1 269 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.01 [0.57, 1.81]
4.4 Vitamin E 2 117 Peto Odds Ratio (Peto, Fixed,
95% CI)
6.44 [1.72, 24.04]
4.5 Zinc 1 97 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.67 [1.00, 13.51]
4.6 Combined antioxidants 1 52 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.34 [1.04, 10.76]
5 Clinical pregnancy; type of antioxidant 11 786 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.97 [1.91, 4.63]
5.1 Carnitines 1 60 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.0 [0.24, 4.25]
5.2 Coenzyme Q10 1 60 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.16 [0.53, 8.82]
5.3 Folic acid 1 53 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.0 [0.0, 0.0]
5.4 Magnesium 1 26 Peto Odds Ratio (Peto, Fixed,
95% CI)
8.73 [0.17, 445.08]
5.5 N-acetylcysteine (NAC) 2 100 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.00 [0.71, 5.63]
5.6 Vitamin E 2 117 Peto Odds Ratio (Peto, Fixed,
95% CI)
6.71 [1.98, 22.69]
5.7 Zinc 2 153 Peto Odds Ratio (Peto, Fixed,
95% CI)
4.43 [1.39, 14.14]
5.8 Zinc + Folic acid 1 53 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.86 [0.15, 99.84]
5.9 Combined antioxidants 2 164 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.19 [1.44, 7.08]
6 Clinical pregnancy; placebo or no treat-
ment
11 786 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.97 [1.91, 4.63]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6.1 Placebo 9 626 Peto Odds Ratio (Peto, Fixed,
95% CI)
3.01 [1.81, 5.03]
6.2 No treatment 2 160 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.84 [1.16, 6.96]
7 Clinical pregnancy; IVF/ICSI 2 90 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.64 [0.94, 7.41]
8 Adverse events 13   Peto Odds Ratio (Peto, Fixed,
95% CI)
Subtotals only
8.1 Miscarriage 3 247 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.74 [0.40, 7.60]
8.2 Gastrointestinal 11 948 Peto Odds Ratio (Peto, Fixed,
95% CI)
2.51 [1.25, 5.03]
8.3 Euphoria 1 86 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.21 [0.16, 9.01]
8.4 Ectopic pregnancy 1 60 Peto Odds Ratio (Peto, Fixed,
95% CI)
4.48 [0.07, 286.49]
9 Sperm DNA fragmentation; type of an-
tioxidant
4 254 Mean Difference (IV, Random,
95% CI)
-3.00 [-12.61, 2.61]
9.1 Docosahexaenoic acid (DHA) 1 36 Mean Difference (IV, Random,
95% CI)
-14.10 [-23.22, -4.98]
9.2 Folic acid 1 38 Mean Difference (IV, Random,
95% CI)
-5.80 [-13.40, 1.80]
9.3 Folic acid + Zinc 1 39 Mean Difference (IV, Random,
95% CI)
-1.20 [-9.36, 6.96]
9.4 N-acetylcysteine (NAC) 1 35 Mean Difference (IV, Random,
95% CI)
3.90 [-0.42, 8.22]
9.5 Vitamin C + Vitamin E 1 64 Mean Difference (IV, Random,
95% CI)
-13.80 [-17.50, -10.10]
9.6 Zinc 1 42 Mean Difference (IV, Random,
95% CI)
1.30 [-8.62, 11.22]
10 Sperm DNA fragmentation (data not
suitable for meta-analysis)
    Other data No numeric data
10.1 Folic acid     Other data No numeric data
10.2 Combined antioxidants     Other data No numeric data
11 Total sperm motility at 3 months or
less; type of antioxidant
18   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
11.1 Carnitines 5 244 Mean Difference (IV, Random,
95% CI)
11.91 [-0.85, 24.66]
11.2 Coenzyme Q10 1 47 Mean Difference (IV, Random,
95% CI)
3.61 [-6.13, 13.35]
11.3 Folic acid 1 51 Mean Difference (IV, Random,
95% CI)
8.40 [-5.81, 22.61]
11.4 Magnesium 1 20 Mean Difference (IV, Random,
95% CI)
14.5 [-6.01, 35.01]
11.5 N-acetylcysteine (NAC) 1 35 Mean Difference (IV, Random,
95% CI)
14.60 [0.32, 28.88]
11.6 PUFAs 2 64 Mean Difference (IV, Random,
95% CI)
-8.35 [-17.40, 0.69]
11.7 Selenium 1 34 Mean Difference (IV, Random,
95% CI)
14.9 [1.14, 28.66]
11.8 Vitamin C + Vitamin E 1 64 Mean Difference (IV, Random,
95% CI)
2.90 [-7.76, 13.56]
11.9 Vitamin E 1 45 Mean Difference (IV, Random,
95% CI)
18.9 [4.90, 32.90]
11.10 Zinc 2 76 Mean Difference (IV, Random,
95% CI)
15.37 [-5.14, 35.88]
11.11 Zinc + Folic acid 1 54 Mean Difference (IV, Random,
95% CI)
6.80 [-7.57, 21.17]
11.12 Zinc + Vitamin E 1 20 Mean Difference (IV, Random,
95% CI)
26.0 [12.85, 39.15]
11.13 Zinc + Vitamin E + Vitamin C 1 22 Mean Difference (IV, Random,
95% CI)
26.0 [12.62, 39.38]
11.14 Combined antioxidants 4 383 Mean Difference (IV, Random,
95% CI)
12.43 [8.39, 16.46]
12 Total sperm motility at 3 months or
less (data not suitable for meta analysis)
    Other data No numeric data
12.1 Carnitines     Other data No numeric data
12.3 Folic acid     Other data No numeric data
12.4 Folic acid + Zinc     Other data No numeric data
12.5 Vitamin E     Other data No numeric data
12.6 Zinc     Other data No numeric data
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
12.7 Combined antioxidants     Other data No numeric data
13 Total sperm motility at 6 months; type
of antioxidant
13   Mean Difference (IV, Random,
95% CI)
Subtotals only
13.1 Carnitines 3 136 Mean Difference (IV, Random,
95% CI)
11.73 [1.87, 21.60]
13.2 Coenzyme Q10 3 479 Mean Difference (IV, Random,
95% CI)
6.59 [1.80, 11.37]
13.3 Folic acid 1 51 Mean Difference (IV, Random,
95% CI)
1.70 [-8.49, 11.89]
13.4 N-acetylcysteine (NAC) 1 211 Mean Difference (IV, Random,
95% CI)
1.90 [1.20, 2.60]
13.5 Selenium 1 211 Mean Difference (IV, Random,
95% CI)
3.20 [2.50, 3.90]
13.6 Selenium + N-acetylcysteine (NAC) 1 210 Mean Difference (IV, Random,
95% CI)
6.30 [5.60, 7.00]
13.7 Vitamin D + Calcium 1 260 Mean Difference (IV, Random,
95% CI)
-4.0 [-9.57, 1.57]
13.8 Vitamin E 2 132 Mean Difference (IV, Random,
95% CI)
11.20 [4.70, 17.70]
13.9 Zinc 1 57 Mean Difference (IV, Random,
95% CI)
0.0 [-10.19, 10.19]
13.10 Zinc + Folic acid 1 54 Mean Difference (IV, Random,
95% CI)
2.60 [-8.82, 14.02]
13.11 Combined antioxidants 2 229 Mean Difference (IV, Random,
95% CI)
9.35 [3.19, 15.51]
14 Total sperm motility at 6 months(data
not suitable for meta analysis)
    Other data No numeric data
14.1 Carnitines     Other data No numeric data
14.2 Folic acid     Other data No numeric data
14.3 Zinc     Other data No numeric data
14.4 Zinc + Folic acid     Other data No numeric data
14.5 Combined antioxidants     Other data No numeric data
15 Total sperm motility at 9 months or
more; type of antioxidant
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
15.1 Carnitines 1 59 Mean Difference (IV, Random,
95% CI)
8.54 [3.01, 14.07]
15.2 Coenzyme Q10 3 479 Mean Difference (IV, Random,
95% CI)
1.90 [-1.56, 5.36]
15.3 Vitamin E 1 45 Mean Difference (IV, Random,
95% CI)
2.20 [-8.48, 12.88]
16 Total sperm motility over time 26   Mean Difference (IV, Random,
95% CI)
Subtotals only
16.1 Total sperm motility at 3 months or
less
18 1105 Mean Difference (IV, Random,
95% CI)
10.19 [4.35, 16.04]
16.2 Total sperm motility at 6 months 13 1768 Mean Difference (IV, Random,
95% CI)
6.00 [3.92, 8.09]
16.3 Total sperm motility at 9 months or
more
5 583 Mean Difference (IV, Random,
95% CI)
3.29 [0.36, 6.23]
17 Progressive sperm motility at 3
months or less; type of antioxidant
14   Mean Difference (IV, Random,
95% CI)
Subtotals only
17.1 Carnitines 3 199 Mean Difference (IV, Random,
95% CI)
20.63 [19.40, 21.87]
17.2 Coenzyme Q10 1 47 Mean Difference (IV, Random,
95% CI)
4.60 [-3.54, 12.74]
17.3 Docosahexaenoic acid (DHA) 1 36 Mean Difference (IV, Random,
95% CI)
-6.60 [-8.57, -4.63]
17.4 Folic acid 2 81 Mean Difference (IV, Random,
95% CI)
5.68 [-5.02, 16.38]
17.5 N-acetylcysteine (NAC) 1 60 Mean Difference (IV, Random,
95% CI)
3.80 [-1.03, 8.63]
17.6 PUFAs 1 44 Mean Difference (IV, Random,
95% CI)
6.40 [4.83, 7.97]
17.7 Vitamin C 2 145 Mean Difference (IV, Random,
95% CI)
16.03 [-3.90, 35.95]
17.8 Vitamin C + Vitamin E 1 31 Mean Difference (IV, Random,
95% CI)
0.20 [-9.77, 10.17]
17.9 Zinc 2 157 Mean Difference (IV, Random,
95% CI)
1.14 [-3.37, 5.64]
17.10 Zinc + Folic acid 1 54 Mean Difference (IV, Random,
95% CI)
3.80 [-13.66, 21.26]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
17.11 Combined antioxidants 1 180 Mean Difference (IV, Random,
95% CI)
15.20 [13.62, 16.78]
18 Progressive sperm motility at 3
months (data not usable for meta-analy-
sis)
    Other data No numeric data
18.1 Combined antioxidants     Other data No numeric data
19 Progressive sperm motility at 6
months; type of antioxidant
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
19.1 Carnitines 1 59 Mean Difference (IV, Random,
95% CI)
15.94 [11.01, 20.87]
19.2 Coenzyme Q10 1 60 Mean Difference (IV, Random,
95% CI)
5.0 [2.13, 7.87]
19.3 Folic acid 2 81 Mean Difference (IV, Random,
95% CI)
-1.77 [-10.21, 6.67]
19.4 Vitamin D + Calcium 1 260 Mean Difference (IV, Random,
95% CI)
-4.0 [-9.59, 1.59]
19.5 Zinc 1 57 Mean Difference (IV, Random,
95% CI)
2.0 [-13.56, 17.56]
19.6 Zinc + Folic acid 1 54 Mean Difference (IV, Random,
95% CI)
2.70 [-14.58, 19.98]
20 Progessive sperm motility at 6 months
(data not usable for meta-analysis)
    Other data No numeric data
20.1 Combined antioxidants     Other data No numeric data
21 Progressive sperm motility at 9
months or more; type of antioxidant
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
21.1 Carnitines 1 59 Mean Difference (IV, Random,
95% CI)
7.77 [2.68, 12.87]
21.2 Coenzyme Q10 1 60 Mean Difference (IV, Random,
95% CI)
-0.90 [-2.68, 0.88]
22 Progressive sperm motility over time 15   Mean Difference (IV, Random,
95% CI)
Subtotals only
22.1 Progressive sperm motility at 3
months or less
13 884 Mean Difference (IV, Random,
95% CI)
9.75 [5.26, 14.24]
22.2 Progressive sperm motility at 6
months
5 521 Mean Difference (IV, Random,
95% CI)
6.11 [0.57, 11.66]
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
163
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
22.3 Progressive sperm motility at 9
months or more
2 119 Mean Difference (IV, Random,
95% CI)
4.64 [-1.67, 10.95]
23 Sperm concentration at 3 months or
less; type of antioxidant
21   Mean Difference (IV, Random,
95% CI)
Subtotals only
23.1 Carnitines 4 247 Mean Difference (IV, Random,
95% CI)
10.43 [0.99, 19.87]
23.2 Coenzyme Q10 1 47 Mean Difference (IV, Random,
95% CI)
-0.10 [-12.37, 12.17]
23.3 Folic acid 2 81 Mean Difference (IV, Random,
95% CI)
8.54 [-22.31, 39.39]
23.4 Magnesium 1 20 Mean Difference (IV, Random,
95% CI)
5.20 [-2.61, 13.01]
23.5 N-acetylcysteine (NAC) 2 95 Mean Difference (IV, Random,
95% CI)
4.59 [-0.27, 9.46]
23.6 PUFAs 3 108 Mean Difference (IV, Random,
95% CI)
3.44 [1.70, 5.17]
23.7 Selenium 1 25 Mean Difference (IV, Random,
95% CI)
21.20 [-11.43, 53.83]
23.8 Vitamin C 1 115 Mean Difference (IV, Random,
95% CI)
9.70 [0.09, 19.31]
23.9 Vitamin C + Vitamin E 2 95 Mean Difference (IV, Random,
95% CI)
1.36 [-10.01, 12.72]
23.10 Vitamin E 1 45 Mean Difference (IV, Random,
95% CI)
18.9 [3.92, 33.88]
23.11 Zinc 2 157 Mean Difference (IV, Random,
95% CI)
8.75 [2.25, 15.24]
23.12 Zinc + Folic acid 1 54 Mean Difference (IV, Random,
95% CI)
18.0 [1.11, 34.89]
23.13 Combined antioxidants 3 344 Mean Difference (IV, Random,
95% CI)
6.71 [-1.91, 15.33]
24 Sperm concentration at 3 months or
less (data not suitable for meta analysis)
    Other data No numeric data
24.1 Carnitines     Other data No numeric data
24.2 Vitamin E     Other data No numeric data
24.3 Folic acid     Other data No numeric data
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
24.4 Zinc     Other data No numeric data
24.5 Folic acid + Zinc     Other data No numeric data
24.6 Combined antioxidants     Other data No numeric data
25 Sperm concentration at 6 months;
type of antioxidant
11   Mean Difference (IV, Random,
95% CI)
Subtotals only
25.1 Carnitines 2 115 Mean Difference (IV, Random,
95% CI)
2.60 [-3.13, 8.33]
25.2 Coenzyme Q10 3 479 Mean Difference (IV, Random,
95% CI)
6.87 [1.18, 12.55]
25.3 Folic acid 2 81 Mean Difference (IV, Random,
95% CI)
2.44 [-37.87, 42.75]
25.4 N-acetylcysteine (NAC) 1 211 Mean Difference (IV, Random,
95% CI)
3.30 [1.80, 4.80]
25.5 Selenium 1 211 Mean Difference (IV, Random,
95% CI)
4.10 [2.45, 5.75]
25.6 Selenium + N-acetylcysteine (NAC) 1 210 Mean Difference (IV, Random,
95% CI)
8.60 [6.89, 10.31]
25.7 Vitamin E 1 45 Mean Difference (IV, Random,
95% CI)
5.90 [-10.83, 22.63]
25.8 Zinc 1 57 Mean Difference (IV, Random,
95% CI)
9.70 [-7.00, 26.40]
25.9 Zinc + Folic acid 1 54 Mean Difference (IV, Random,
95% CI)
17.70 [-1.88, 37.28]
25.10 Combined antioxidants 2 229 Mean Difference (IV, Random,
95% CI)
13.68 [8.06, 19.31]
26 Sperm concentration at 6 months(data
not suitable for meta analysis)
    Other data No numeric data
26.1 Carnitines     Other data No numeric data
26.2 Folic acid     Other data No numeric data
26.3 Zinc     Other data No numeric data
26.4 Zinc + Folic acid     Other data No numeric data
26.5 Vitamin D + Calcium     Other data No numeric data
27 Sperm concentration at 9 months;
type of antioxidant
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
27.1 Carnitines 1 59 Mean Difference (IV, Random,
95% CI)
4.17 [-1.71, 10.06]
27.2 Coenzyme Q10 3 479 Mean Difference (IV, Random,
95% CI)
2.74 [-1.57, 7.05]
27.3 Vitamin E 1 45 Mean Difference (IV, Random,
95% CI)
11.40 [-2.56, 25.36]
28 Sperm concentration over time 26   Mean Difference (IV, Random,
95% CI)
Subtotals only
28.1 Sperm concentration at 3 months or
less
20 1244 Mean Difference (IV, Random,
95% CI)
7.51 [4.23, 10.79]
28.2 Sperm concentration 6 months 11 1430 Mean Difference (IV, Random,
95% CI)
7.49 [4.76, 10.23]
28.3 Sperm concentration at 9 months or
more
5 583 Mean Difference (IV, Random,
95% CI)
3.61 [0.17, 7.06]
 
 
Analysis 1.1.   Comparison 1 Antioxidant(s) versus placebo
or no treatment, Outcome 1 Live birth; type of antioxidant.
Study or subgroup Antioxidant Placebo or
no treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
1.1.1 Carnitines  
Balercia 2005 2/15 1/5 2.12% 0.61[0.04,9.64]
Balercia 2005 2/15 1/5 2.12% 0.61[0.04,9.64]
Balercia 2005 5/15 1/5 3.48% 1.83[0.21,15.73]
Subtotal (95% CI) 45 15 7.72% 1[0.24,4.25]
Total events: 9 (Antioxidant), 3 (Placebo or no treatment)  
Heterogeneity: Tau2=0; Chi2=0.55, df=2(P=0.76); I2=0%  
Test for overall effect: Not applicable  
   
1.1.2 Coenzyme Q10  
Balercia 2009 6/30 3/30 8.17% 2.16[0.53,8.82]
Subtotal (95% CI) 30 30 8.17% 2.16[0.53,8.82]
Total events: 6 (Antioxidant), 3 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
   
1.1.3 Vitamin D + Calcium  
Blomberg Jensen 2018 30/166 29/164 51.07% 1.03[0.59,1.8]
Subtotal (95% CI) 166 164 51.07% 1.03[0.59,1.8]
Total events: 30 (Antioxidant), 29 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.93)  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
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Study or subgroup Antioxidant Placebo or
no treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
   
1.1.4 Vitamin E  
Kessopoulou 1995 1/15 0/15 1.05% 7.39[0.15,372.38]
Suleiman 1996 9/55 0/55 8.76% 8.66[2.23,33.64]
Subtotal (95% CI) 70 70 9.81% 8.51[2.36,30.7]
Total events: 10 (Antioxidant), 0 (Placebo or no treatment)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=3.27(P=0)  
   
1.1.5 Zinc  
Omu 1998 8/50 2/50 9.55% 3.74[1.02,13.74]
Subtotal (95% CI) 50 50 9.55% 3.74[1.02,13.74]
Total events: 8 (Antioxidant), 2 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.99(P=0.05)  
   
1.1.6 Combined antioxidants  
Tremellen 2007 20/40 4/20 13.68% 3.42[1.15,10.13]
Subtotal (95% CI) 40 20 13.68% 3.42[1.15,10.13]
Total events: 20 (Antioxidant), 4 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.22(P=0.03)  
   
Total (95% CI) 401 349 100% 1.79[1.2,2.67]
Total events: 83 (Antioxidant), 41 (Placebo or no treatment)  
Heterogeneity: Tau2=0; Chi2=13.28, df=8(P=0.1); I2=39.74%  
Test for overall effect: Z=2.83(P=0)  
Test for subgroup differences: Chi2=12.72, df=1 (P=0.03), I2=60.69%  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
 
 
Analysis 1.2.   Comparison 1 Antioxidant(s) versus placebo or
no treatment, Outcome 2 Live birth; placebo or no treatment.
Study or subgroup Antioxidant Placebo/No
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
1.2.1 Placebo  
Balercia 2005 2/15 1/5 2.12% 0.61[0.04,9.64]
Balercia 2005 2/15 1/5 2.12% 0.61[0.04,9.64]
Balercia 2005 5/15 1/5 3.48% 1.83[0.21,15.73]
Balercia 2009 6/30 3/30 8.17% 2.16[0.53,8.82]
Blomberg Jensen 2018 30/166 29/164 51.07% 1.03[0.59,1.8]
Kessopoulou 1995 1/15 0/15 1.05% 7.39[0.15,372.38]
Suleiman 1996 9/55 0/55 8.76% 8.66[2.23,33.64]
Tremellen 2007 20/40 4/20 13.68% 3.42[1.15,10.13]
Subtotal (95% CI) 351 299 90.45% 1.65[1.08,2.52]
Total events: 75 (Antioxidant), 39 (Placebo/No treatment)  
Heterogeneity: Tau2=0; Chi2=11.9, df=7(P=0.1); I2=41.19%  
Test for overall effect: Z=2.33(P=0.02)  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
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Study or subgroup Antioxidant Placebo/No
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
   
1.2.2 No treatment  
Omu 1998 8/50 2/50 9.55% 3.74[1.02,13.74]
Subtotal (95% CI) 50 50 9.55% 3.74[1.02,13.74]
Total events: 8 (Antioxidant), 2 (Placebo/No treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.99(P=0.05)  
   
Total (95% CI) 401 349 100% 1.79[1.2,2.67]
Total events: 83 (Antioxidant), 41 (Placebo/No treatment)  
Heterogeneity: Tau2=0; Chi2=13.28, df=8(P=0.1); I2=39.74%  
Test for overall effect: Z=2.83(P=0)  
Test for subgroup differences: Chi2=1.37, df=1 (P=0.24), I2=27.14%  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
 
 
Analysis 1.3.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome 3 Live birth; IVF/ICSI.
Study or subgroup Antioxidant Placebo/no
treatm
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Kessopoulou 1995 1/15 0/15 7.13% 7.39[0.15,372.38]
Tremellen 2007 20/40 4/20 92.87% 3.42[1.15,10.13]
   
Total (95% CI) 55 35 100% 3.61[1.27,10.29]
Total events: 21 (Antioxidant), 4 (Placebo/no treatm)  
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=2.4(P=0.02)  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
 
 
Analysis 1.4.   Comparison 1 Antioxidant(s) versus placebo
or no treatment, Outcome 4 Live birth; as-treated analysis.
Study or subgroup Antioxidant Placebo or
no treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
1.4.1 Carnitines  
Balercia 2005 2/15 1/5 2.23% 0.61[0.04,9.64]
Balercia 2005 2/15 1/5 2.23% 0.61[0.04,9.64]
Balercia 2005 5/14 1/5 3.72% 1.99[0.23,16.9]
Subtotal (95% CI) 44 15 8.17% 1.04[0.25,4.41]
Total events: 9 (Antioxidant), 3 (Placebo or no treatment)  
Heterogeneity: Tau2=0; Chi2=0.64, df=2(P=0.72); I2=0%  
Test for overall effect: Z=0.06(P=0.95)  
   
1.4.2 Coenzyme Q10  
Balercia 2009 6/28 3/27 8.48% 2.1[0.51,8.64]
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
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Study or subgroup Antioxidant Placebo or
no treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Subtotal (95% CI) 28 27 8.48% 2.1[0.51,8.64]
Total events: 6 (Antioxidant), 3 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.02(P=0.31)  
   
1.4.3 Vitamin D + Calcium  
Blomberg Jensen 2018 30/136 29/133 51.12% 1.01[0.57,1.81]
Subtotal (95% CI) 136 133 51.12% 1.01[0.57,1.81]
Total events: 30 (Antioxidant), 29 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
   
1.4.4 Vitamin E  
Kessopoulou 1995 1/15 0/15 1.11% 7.39[0.15,372.38]
Suleiman 1996 9/52 0/35 8.68% 6.33[1.56,25.63]
Subtotal (95% CI) 67 50 9.79% 6.44[1.72,24.04]
Total events: 10 (Antioxidant), 0 (Placebo or no treatment)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=2.77(P=0.01)  
   
1.4.5 Zinc  
Omu 1998 8/49 2/48 10.02% 3.67[1,13.51]
Subtotal (95% CI) 49 48 10.02% 3.67[1,13.51]
Total events: 8 (Antioxidant), 2 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.96(P=0.05)  
   
1.4.6 Combined antioxidants  
Tremellen 2007 20/36 4/16 12.42% 3.34[1.04,10.76]
Subtotal (95% CI) 36 16 12.42% 3.34[1.04,10.76]
Total events: 20 (Antioxidant), 4 (Placebo or no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.02(P=0.04)  
   
Total (95% CI) 360 289 100% 1.71[1.13,2.58]
Total events: 83 (Antioxidant), 41 (Placebo or no treatment)  
Heterogeneity: Tau2=0; Chi2=10.8, df=8(P=0.21); I2=25.9%  
Test for overall effect: Z=2.55(P=0.01)  
Test for subgroup differences: Chi2=10.15, df=1 (P=0.07), I2=50.73%  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
 
 
Analysis 1.5.   Comparison 1 Antioxidant(s) versus placebo or no
treatment, Outcome 5 Clinical pregnancy; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
1.5.1 Carnitines  
Balercia 2005 5/15 1/5 4.26% 1.83[0.21,15.73]
Favours placebo/no treatm 5000.002 100.1 1 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Balercia 2005 2/15 1/5 2.59% 0.61[0.04,9.64]
Balercia 2005 2/15 1/5 2.59% 0.61[0.04,9.64]
Subtotal (95% CI) 45 15 9.43% 1[0.24,4.25]
Total events: 9 (Antioxidant), 3 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0.55, df=2(P=0.76); I2=0%  
Test for overall effect: Not applicable  
   
1.5.2 Coenzyme Q10  
Balercia 2009 6/30 3/30 9.99% 2.16[0.53,8.82]
Subtotal (95% CI) 30 30 9.99% 2.16[0.53,8.82]
Total events: 6 (Antioxidant), 3 (Placebo/no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
   
1.5.3 Folic acid  
Azizollahi 2013 0/40 0/13   Not estimable
Subtotal (95% CI) 40 13 Not estimable
Total events: 0 (Antioxidant), 0 (Placebo/no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.5.4 Magnesium  
Zavaczki 2003 1/12 0/14 1.28% 8.73[0.17,445.08]
Subtotal (95% CI) 12 14 1.28% 8.73[0.17,445.08]
Total events: 1 (Antioxidant), 0 (Placebo/no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
   
1.5.5 N-acetylcysteine (NAC)  
Attallah 2013 6/30 4/30 10.88% 1.6[0.42,6.16]
Barekat 2016 5/20 2/20 7.61% 2.75[0.55,13.79]
Subtotal (95% CI) 50 50 18.49% 2[0.71,5.63]
Total events: 11 (Antioxidant), 6 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%  
Test for overall effect: Z=1.32(P=0.19)  
   
1.5.6 Vitamin E  
Kessopoulou 1995 1/15 0/15 1.28% 7.39[0.15,372.38]
Suleiman 1996 11/52 0/35 12.01% 6.64[1.84,23.93]
Subtotal (95% CI) 67 50 13.29% 6.71[1.98,22.69]
Total events: 12 (Antioxidant), 0 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%  
Test for overall effect: Z=3.06(P=0)  
   
1.5.7 Zinc  
Azizollahi 2013 1/40 0/13 0.95% 3.76[0.04,357.94]
Omu 1998 10/50 2/50 13.7% 4.48[1.35,14.88]
Subtotal (95% CI) 90 63 14.65% 4.43[1.39,14.14]
Total events: 11 (Antioxidant), 2 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=2.51(P=0.01)  
Favours placebo/no treatm 5000.002 100.1 1 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
   
1.5.8 Zinc + Folic acid  
Azizollahi 2013 2/40 0/13 1.87% 3.86[0.15,99.84]
Subtotal (95% CI) 40 13 1.87% 3.86[0.15,99.84]
Total events: 2 (Antioxidant), 0 (Placebo/no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
   
1.5.9 Combined antioxidants  
Busetto 2018 10/52 2/52 13.77% 4.45[1.34,14.73]
Tremellen 2007 21/40 6/20 17.24% 2.44[0.84,7.13]
Subtotal (95% CI) 92 72 31.01% 3.19[1.44,7.08]
Total events: 31 (Antioxidant), 8 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.46); I2=0%  
Test for overall effect: Z=2.85(P=0)  
   
Total (95% CI) 466 320 100% 2.97[1.91,4.63]
Total events: 83 (Antioxidant), 22 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=6.8, df=13(P=0.91); I2=0%  
Test for overall effect: Z=4.8(P<0.0001)  
Test for subgroup differences: Chi2=5.45, df=1 (P=0.61), I2=0%  
Favours placebo/no treatm 5000.002 100.1 1 Favours antioxidant
 
 
Analysis 1.6.   Comparison 1 Antioxidant(s) versus placebo or no
treatment, Outcome 6 Clinical pregnancy; placebo or no treatment.
Study or subgroup Antioxidant Placebo/No
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
1.6.1 Placebo  
Azizollahi 2013 1/40 0/13 0.95% 3.76[0.04,357.94]
Azizollahi 2013 2/40 0/13 1.87% 3.86[0.15,99.84]
Azizollahi 2013 0/40 0/13   Not estimable
Balercia 2005 5/15 1/5 4.26% 1.83[0.21,15.73]
Balercia 2005 2/15 1/5 2.59% 0.61[0.04,9.64]
Balercia 2005 2/15 1/5 2.59% 0.61[0.04,9.64]
Balercia 2009 6/30 3/30 9.99% 2.16[0.53,8.82]
Barekat 2016 5/20 2/20 7.61% 2.75[0.55,13.79]
Busetto 2018 10/52 2/52 13.77% 4.45[1.34,14.73]
Kessopoulou 1995 1/15 0/15 1.28% 7.39[0.15,372.38]
Suleiman 1996 11/52 0/35 12.01% 6.64[1.84,23.93]
Tremellen 2007 21/40 6/20 17.24% 2.44[0.84,7.13]
Zavaczki 2003 1/12 0/14 1.28% 8.73[0.17,445.08]
Subtotal (95% CI) 386 240 75.42% 3.01[1.81,5.03]
Total events: 67 (Antioxidant), 16 (Placebo/No treatment)  
Heterogeneity: Tau2=0; Chi2=5.54, df=11(P=0.9); I2=0%  
Test for overall effect: Z=4.23(P<0.0001)  
   
1.6.2 No treatment  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
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Study or subgroup Antioxidant Placebo/No
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Attallah 2013 6/30 4/30 10.88% 1.6[0.42,6.16]
Omu 1998 10/50 2/50 13.7% 4.48[1.35,14.88]
Subtotal (95% CI) 80 80 24.58% 2.84[1.16,6.96]
Total events: 16 (Antioxidant), 6 (Placebo/No treatment)  
Heterogeneity: Tau2=0; Chi2=1.25, df=1(P=0.26); I2=19.85%  
Test for overall effect: Z=2.29(P=0.02)  
   
Total (95% CI) 466 320 100% 2.97[1.91,4.63]
Total events: 83 (Antioxidant), 22 (Placebo/No treatment)  
Heterogeneity: Tau2=0; Chi2=6.8, df=13(P=0.91); I2=0%  
Test for overall effect: Z=4.8(P<0.0001)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
 
 
Analysis 1.7.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome 7 Clinical pregnancy; IVF/ICSI.
Study or subgroup Antioxidant Placebo/no
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Kessopoulou 1995 1/15 0/15 6.93% 7.39[0.15,372.38]
Tremellen 2007 21/40 6/20 93.07% 2.44[0.84,7.13]
   
Total (95% CI) 55 35 100% 2.64[0.94,7.41]
Total events: 22 (Antioxidant), 6 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.59); I2=0%  
Test for overall effect: Z=1.84(P=0.07)  
Favours placebo/no treatm 1000.01 100.1 1 Favours antioxidant
 
 
Analysis 1.8.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome 8 Adverse events.
Study or subgroup Antioxidant Placebo/no
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
1.8.1 Miscarriage  
Omu 1998 1/50 0/50 14.2% 7.39[0.15,372.38]
Suleiman 1996 2/52 0/35 26.99% 5.43[0.32,93.28]
Tremellen 2007 3/40 2/20 58.81% 0.72[0.11,4.97]
Subtotal (95% CI) 142 105 100% 1.74[0.4,7.6]
Total events: 6 (Antioxidant), 2 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=1.93, df=2(P=0.38); I2=0%  
Test for overall effect: Z=0.73(P=0.46)  
   
1.8.2 Gastrointestinal  
Busetto 2018 4/52 0/52 12.31% 7.85[1.07,57.35]
Cavallini 2004 2/39 2/47 12.12% 1.21[0.16,9.01]
Gamidov 2017 0/38 0/38   Not estimable
Favours antioxidant 1000.01 100.1 1 Favours placebo/no treatm
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Study or subgroup Antioxidant Placebo/no
treatment
Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Gopinath 2013 4/89 4/36 19.62% 0.33[0.07,1.62]
Kessopoulou 1995 0/15 1/15 3.17% 0.14[0,6.82]
Pourmand 2014 5/50 0/50 15.21% 8.04[1.34,48.12]
Safarinejad 2009a 0/106 0/106   Not estimable
Sharifzadeh 2016 7/61 0/53 20.9% 7.2[1.56,33.11]
Sigman 2006 0/12 0/9   Not estimable
Tremellen 2007 3/40 0/20 8.16% 4.72[0.41,54.32]
Zavaczki 2003 2/10 1/10 8.51% 2.11[0.19,23.05]
Subtotal (95% CI) 512 436 100% 2.51[1.25,5.03]
Total events: 27 (Antioxidant), 8 (Placebo/no treatment)  
Heterogeneity: Tau2=0; Chi2=13.92, df=7(P=0.05); I2=49.71%  
Test for overall effect: Z=2.58(P=0.01)  
   
1.8.3 Euphoria  
Cavallini 2004 2/39 2/47 100% 1.21[0.16,9.01]
Subtotal (95% CI) 39 47 100% 1.21[0.16,9.01]
Total events: 2 (Antioxidant), 2 (Placebo/no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
   
1.8.4 Ectopic pregnancy  
Tremellen 2007 1/40 0/20 100% 4.48[0.07,286.49]
Subtotal (95% CI) 40 20 100% 4.48[0.07,286.49]
Total events: 1 (Antioxidant), 0 (Placebo/no treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
Test for subgroup differences: Chi2=0.68, df=1 (P=0.88), I2=0%  
Favours antioxidant 1000.01 100.1 1 Favours placebo/no treatm
 
 
Analysis 1.9.   Comparison 1 Antioxidant(s) versus placebo or no
treatment, Outcome 9 Sperm DNA fragmentation; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.9.1 Docosahexaenoic acid (DHA)  
Martinez-Soto 2010 21 11 (9.8) 15 25.1 (16) 15.36% -14.1[-23.22,-4.98]
Subtotal *** 21   15   15.36% -14.1[-23.22,-4.98]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=3.03(P=0)  
   
1.9.2 Folic acid  
Raigani 2014 20 33.1 (8.2) 18 38.9 (14.5) 16.47% -5.8[-13.4,1.8]
Subtotal *** 20   18   16.47% -5.8[-13.4,1.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
   
1.9.3 Folic acid + Zinc  
Raigani 2014 21 37.7 (10.9) 18 38.9 (14.5) 16.06% -1.2[-9.36,6.96]
Favours antioxidant 5025-50 -25 0 Favours placebo/no treatm
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 21   18   16.06% -1.2[-9.36,6.96]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.9.4 N-acetylcysteine (NAC)  
Barekat 2016 15 89.8 (5.4) 20 85.9 (7.6) 18.53% 3.9[-0.42,8.22]
Subtotal *** 15   20   18.53% 3.9[-0.42,8.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
   
1.9.5 Vitamin C + Vitamin E  
Greco 2005 32 9.1 (7.2) 32 22.9 (7.9) 18.82% -13.8[-17.5,-10.1]
Subtotal *** 32   32   18.82% -13.8[-17.5,-10.1]
Heterogeneity: Not applicable  
Test for overall effect: Z=7.3(P<0.0001)  
   
1.9.6 Zinc  
Raigani 2014 24 40.2 (18.3) 18 38.9 (14.5) 14.76% 1.3[-8.62,11.22]
Subtotal *** 24   18   14.76% 1.3[-8.62,11.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.8)  
   
Total *** 133   121   100% -5[-12.61,2.61]
Heterogeneity: Tau2=76.55; Chi2=43.69, df=5(P<0.0001); I2=88.55%  
Test for overall effect: Z=1.29(P=0.2)  
Test for subgroup differences: Chi2=43.69, df=1 (P<0.0001), I2=88.55%  
Favours antioxidant 5025-50 -25 0 Favours placebo/no treatm
 
 
Analysis 1.10.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 10 Sperm DNA fragmentation (data not suitable for meta-analysis).
Sperm DNA fragmentation (data not suitable for meta-analysis)
Study Intervention Control P-value
Folic acid
Boonyarangkul 2015 Folic acid
DNA tail length, COMET assay
3 month:
Mean = 4.04 (n = 15)
SE = 0.94
6 month:
Mean = 6.01
SE = 1.49
Placebo
DNA tail length, COMET assay
3 month:
Mean = 10.08 (n = 15)
SE = 3.39
6 month:
Mean = 8.69
SE = 4.28
Not provided
Combined antioxidants
Gamidov 2017 SpermActin-forte (acetyl-L-carnitine,
L-carnitine fumarate and alpha-lipoic
acid)
Median = 24 (18.2 - 28.6) (n = 38)
Median (interquartile range)
No treatment
Median 20.3 (12.7 - 21.5) (n = 38)
Median (interquartile range)
Not provided
Gamidov 2017 SpermActin-forte + Vitamin complex
'Man's formula'
Median = 25 (20.5 - 29.2) (n = 38)
Median (interquartile range)
No treatment
Median 20.3 (12.7 - 21.5) (n = 38)
Median (interquartile range)
Not provided
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Analysis 1.11.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 11 Total sperm motility at 3 months or less; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.11.1 Carnitines  
Balercia 2005 15 59.9 (8) 5 44.6 (7.7) 15.1% 15.3[7.43,23.17]
Balercia 2005 14 55.1 (10.2) 5 44.6 (7.7) 14.93% 10.5[1.89,19.11]
Balercia 2005 15 56.5 (11.6) 5 44.6 (7.7) 14.85% 11.9[2.96,20.84]
Dimitriadis 2010 26 35.6 (15.5) 22 24.7 (10.8) 15.19% 10.9[3.43,18.37]
Lenzi 2003 43 11 (15.5) 43 8.8 (10.8) 15.54% 2.2[-3.45,7.85]
Peivandi 2010 15 48.3 (0.2) 15 17 (0.1) 16.02% 31.3[31.21,31.39]
Sigman 2006 12 28.6 (38.1) 9 37.6 (33) 8.36% -9[-39.49,21.49]
Subtotal *** 140   104   100% 11.91[-0.85,24.66]
Heterogeneity: Tau2=264.15; Chi2=193.59, df=6(P<0.0001); I2=96.9%  
Test for overall effect: Z=1.83(P=0.07)  
   
1.11.2 Coenzyme Q10  
Nadjarzadeh 2011 23 41.9 (15.6) 24 38.3 (18.4) 100% 3.61[-6.13,13.35]
Subtotal *** 23   24   100% 3.61[-6.13,13.35]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
   
1.11.3 Folic acid  
Azizollahi 2013 26 53.3 (15.3) 25 44.9 (33) 100% 8.4[-5.81,22.61]
Subtotal *** 26   25   100% 8.4[-5.81,22.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.25)  
   
1.11.4 Magnesium  
Zavaczki 2003 10 33.5 (29.8) 10 19 (14.4) 100% 14.5[-6.01,35.01]
Subtotal *** 10   10   100% 14.5[-6.01,35.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.39(P=0.17)  
   
1.11.5 N-acetylcysteine (NAC)  
Barekat 2016 15 58.2 (20.9) 20 43.6 (21.9) 100% 14.6[0.32,28.88]
Subtotal *** 15   20   100% 14.6[0.32,28.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=2(P=0.05)  
   
1.11.6 PUFAs  
Conquer 2000 9 39.4 (24.3) 5 47.2 (18.6) 15.81% -7.8[-30.56,14.96]
Conquer 2000 10 32 (16.1) 4 47.2 (18.6) 18.96% -15.2[-35.98,5.58]
Martinez-Soto 2010 21 41.5 (18.7) 15 48 (15.5) 65.23% -6.5[-17.7,4.7]
Subtotal *** 40   24   100% -8.35[-17.4,0.69]
Heterogeneity: Tau2=0; Chi2=0.52, df=2(P=0.77); I2=0%  
Test for overall effect: Z=1.81(P=0.07)  
   
1.11.7 Selenium  
Scott 1998 16 30.2 (22.8) 18 15.3 (17.4) 100% 14.9[1.14,28.66]
Subtotal *** 16   18   100% 14.9[1.14,28.66]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=2.12(P=0.03)  
   
1.11.8 Vitamin C + Vitamin E  
Greco 2005 32 41.6 (22) 32 38.7 (21.5) 100% 2.9[-7.76,13.56]
Subtotal *** 32   32   100% 2.9[-7.76,13.56]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.59)  
   
1.11.9 Vitamin E  
Ener 2016 22 61.4 (18.3) 23 42.5 (28.7) 100% 18.9[4.9,32.9]
Subtotal *** 22   23   100% 18.9[4.9,32.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.65(P=0.01)  
   
1.11.10 Zinc  
Azizollahi 2013 32 48.9 (27.7) 25 44.9 (33) 45.87% 4[-12.11,20.11]
Omu 2008 11 49 (12) 8 24 (12) 54.13% 25[14.07,35.93]
Subtotal *** 43   33   100% 15.37[-5.14,35.88]
Heterogeneity: Tau2=171.19; Chi2=4.47, df=1(P=0.03); I2=77.64%  
Test for overall effect: Z=1.47(P=0.14)  
   
1.11.11 Zinc + Folic acid  
Azizollahi 2013 29 51.7 (17.2) 25 44.9 (33) 100% 6.8[-7.57,21.17]
Subtotal *** 29   25   100% 6.8[-7.57,21.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
   
1.11.12 Zinc + Vitamin E  
Omu 2008 12 50 (18) 8 24 (12) 100% 26[12.85,39.15]
Subtotal *** 12   8   100% 26[12.85,39.15]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.88(P=0)  
   
1.11.13 Zinc + Vitamin E + Vitamin C  
Omu 2008 14 50 (20) 8 24 (12) 100% 26[12.62,39.38]
Subtotal *** 14   8   100% 26[12.62,39.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.81(P=0)  
   
1.11.14 Combined antioxidants  
Gopinath 2013 43 50.1 (11.3) 18 42.1 (10.6) 21.89% 8[2.05,13.95]
Gopinath 2013 46 51.6 (13) 18 42.1 (10.6) 21.12% 9.5[3.33,15.67]
Morgante 2010 90 40.3 (6.4) 90 25.1 (4.2) 39.25% 15.2[13.62,16.78]
Scott 1998 30 27 (20.3) 18 15.3 (17.4) 10.41% 11.7[0.87,22.53]
Sivkov 2011 15 38.3 (20.3) 15 18 (17.4) 7.33% 20.3[6.77,33.83]
Subtotal *** 224   159   100% 12.43[8.39,16.46]
Heterogeneity: Tau2=10.15; Chi2=8.82, df=4(P=0.07); I2=54.63%  
Test for overall effect: Z=6.04(P<0.0001)  
Test for subgroup differences: Chi2=34.77, df=1 (P=0), I2=62.61%  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Analysis 1.12.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome
12 Total sperm motility at 3 months or less (data not suitable for meta analysis).
Total sperm motility at 3 months or less (data not suitable for meta analysis)
Study Intervention Control P value
Carnitines
Cavallini 2004 L-carnitine + Acetyl-carnitine
Median = 22.3 (n = 39)
Interquartile range = 28.4 - 15.2
Placebo
Median = 14.0 (n = 47)
Interquartile range = 17.4 - 5.1
Not provided
Folic acid
Raigani 2014 Folic acid
Median = 35 (15 - 50) (n = 20)
Median (25th - 75h percentile)
16 weeks
Placebo
Median = 35 (21 - 42.5) (n = 18)
Median (25th - 75h percentile)
16 weeks
Not provided
Folic acid + Zinc
Raigani 2014 Folic acid + Zinc
Median = 35 (26.3 - 50) (n = 21)
Median (25th - 75h percentile)
16 weeks
Placebo
Median = 35 (21 - 42.5) (n = 18)
Median (25th - 75h percentile)
16 weeks
Not provided
Vitamin E
Kessopoulou 1995 Vitamin E
Median = 7 (n = 15)
Min/max = -27 - 34
Placebo
Median = 7 (n = 15)
Min/max = -33 - 36
Not provided
Zinc
Raigani 2014 Zinc
Median = 35 (17 - 50) (n = 24)
Median (25th - 75h percentile)
16 weeks
Placebo
Median = 35 (21 - 42.5) (n = 18)
Median (25th - 75h percentile)
16 weeks
Not provided
Combined antioxidants
Galatioto 2008 N-acetylcysteine (NAC) 600 mg + vita-
mins-minerals
% of motile sperm (Class A WHO) = 58%
(n = 20)
No treatment
% of motile sperm (Class A WHO) = 51%
(n = 22)
P = 0.847
 
 
Analysis 1.13.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 13 Total sperm motility at 6 months; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 Carnitines  
Balercia 2005 14 61 (9) 5 43.4 (9.9) 21.74% 17.6[7.72,27.48]
Balercia 2005 15 60.4 (10.5) 5 43.4 (9.9) 21.45% 17[6.82,27.18]
Balercia 2005 15 64.5 (8.4) 5 43.4 (9.9) 21.94% 21.1[11.43,30.77]
Lenzi 2004 30 31.1 (13.5) 26 29.6 (9.5) 25.16% 1.5[-4.56,7.56]
Sigman 2006 12 32.3 (24.2) 9 40 (33) 9.71% -7.7[-33.24,17.84]
Subtotal *** 86   50   100% 11.73[1.87,21.6]
Heterogeneity: Tau2=91.19; Chi2=18.57, df=4(P=0); I2=78.46%  
Test for overall effect: Z=2.33(P=0.02)  
   
1.13.2 Coenzyme Q10  
Balercia 2009 30 39.4 (6.8) 30 34.9 (8) 29.2% 4.5[0.74,8.26]
Safarinejad 2009a 98 27.6 (2.2) 96 23.1 (2.1) 35.41% 4.5[3.89,5.11]
Safarinejad 2012 112 35.8 (2.7) 113 25.4 (2.1) 35.39% 10.4[9.77,11.03]
Subtotal *** 240   239   100% 6.59[1.8,11.37]
Heterogeneity: Tau2=16.75; Chi2=176.67, df=2(P<0.0001); I2=98.87%  
Test for overall effect: Z=2.7(P=0.01)  
Favours placebo/no treatm 4020-40 -20 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
1.13.3 Folic acid  
Azizollahi 2013 26 51.5 (10.2) 25 49.8 (24) 100% 1.7[-8.49,11.89]
Subtotal *** 26   25   100% 1.7[-8.49,11.89]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.33(P=0.74)  
   
1.13.4 N-acetylcysteine (NAC)  
Safarinejad 2009 105 24.8 (2.9) 106 22.9 (2.2) 100% 1.9[1.2,2.6]
Subtotal *** 105   106   100% 1.9[1.2,2.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.36(P<0.0001)  
   
1.13.5 Selenium  
Safarinejad 2009 105 26.1 (2.9) 106 22.9 (2.2) 100% 3.2[2.5,3.9]
Subtotal *** 105   106   100% 3.2[2.5,3.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=9.02(P<0.0001)  
   
1.13.6 Selenium + N-acetylcysteine (NAC)  
Safarinejad 2009 104 29.2 (2.9) 106 22.9 (2.2) 100% 6.3[5.6,7]
Subtotal *** 104   106   100% 6.3[5.6,7]
Heterogeneity: Not applicable  
Test for overall effect: Z=17.71(P<0.0001)  
   
1.13.7 Vitamin D + Calcium  
Blomberg Jensen 2018 129 41 (22.7) 131 45 (23.1) 100% -4[-9.57,1.57]
Subtotal *** 129   131   100% -4[-9.57,1.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.41(P=0.16)  
   
1.13.8 Vitamin E  
Ener 2016 22 60.1 (16.1) 23 55 (26.9) 22.81% 5.1[-7.79,17.99]
Suleiman 1996 52 48.9 (15.5) 35 35.9 (12.8) 77.19% 13[7.02,18.98]
Subtotal *** 74   58   100% 11.2[4.7,17.7]
Heterogeneity: Tau2=4.93; Chi2=1.19, df=1(P=0.28); I2=15.81%  
Test for overall effect: Z=3.38(P=0)  
   
1.13.9 Zinc  
Azizollahi 2013 32 49.8 (11.3) 25 49.8 (24) 100% 0[-10.19,10.19]
Subtotal *** 32   25   100% 0[-10.19,10.19]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.13.10 Zinc + Folic acid  
Azizollahi 2013 29 52.4 (17.8) 25 49.8 (24) 100% 2.6[-8.82,14.02]
Subtotal *** 29   25   100% 2.6[-8.82,14.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.45(P=0.66)  
   
1.13.11 Combined antioxidants  
Favours placebo/no treatm 4020-40 -20 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Busetto 2018 52 39 (8) 52 34.6 (7.1) 38.78% 4.4[1.49,7.31]
Gopinath 2013 43 55.8 (11.9) 18 44.1 (9.5) 31.25% 11.7[6.04,17.36]
Gopinath 2013 46 57.4 (14.6) 18 44.1 (9.5) 29.98% 13.3[7.2,19.4]
Subtotal *** 141   88   100% 9.35[3.19,15.51]
Heterogeneity: Tau2=23.28; Chi2=9.82, df=2(P=0.01); I2=79.63%  
Test for overall effect: Z=2.97(P=0)  
Test for subgroup differences: Chi2=101.11, df=1 (P<0.0001), I2=90.11%  
Favours placebo/no treatm 4020-40 -20 0 Favours antioxidant
 
 
Analysis 1.14.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 14 Total sperm motility at 6 months(data not suitable for meta analysis).
Total sperm motility at 6 months(data not suitable for meta analysis)
Study Intervention Control P value
Carnitines
Cavallini 2004 L-carnitine + Acetyl-carnitine
Median = 23.6 (n = 39)
Interquartile range = 28.9 - 16.0
Placebo
Median = 13.2 (n = 47)
Interquartile range = 18.6 - 9.0
Not provided
Folic acid
Wong 2002 Folic acid
Median = 35 (n = 22)
Range = 5 - 65
Placebo
Median = 30 (n = 25)
Range = 5 - 80
Not provided
Zinc
Wong 2002 Zinc
Median = 35 (n = 23)
Range = 10 - 65
Placebo
Median = 30 (n = 25)
Range = 5 - 80
Not provided
Zinc + Folic acid
Wong 2002 Zinc + Folic acid
Median = 35 (n = 24)
Range 5 - 70
Placebo
Median = 30 (n = 25)
Range = 5 - 80
Not provided
Combined antioxidants
Micic 2017 Proxeed Plus
Median = 31.0 (20.0 - 41.0) (n = 125 )
Median (interquartile range)
Progressive sperm motility
Placebo
Median 29.0 (15.5 - 35.5) (n = 50)
Median (interquartile range)
Progressive sperm motility
Not provided
 
 
Analysis 1.15.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 15 Total sperm motility at 9 months or more; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.15.1 Carnitines  
Balercia 2005 15 54.3 (9) 5 42.7 (10) 31.36% 11.6[1.72,21.48]
Balercia 2005 15 50.6 (5.7) 5 42.7 (10) 35.93% 7.9[-1.33,17.13]
Balercia 2005 14 49 (7.8) 5 42.7 (10) 32.71% 6.3[-3.37,15.97]
Subtotal *** 44   15   100% 8.54[3.01,14.07]
Heterogeneity: Tau2=0; Chi2=0.59, df=2(P=0.74); I2=0%  
Test for overall effect: Z=3.02(P=0)  
   
1.15.2 Coenzyme Q10  
Favours placebo/no treatm 2010-20 -10 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Balercia 2009 30 33 (6.3) 30 35.3 (8) 26.35% -2.3[-5.94,1.34]
Safarinejad 2009a 98 24.2 (2.1) 96 22.8 (2.2) 36.82% 1.4[0.79,2.01]
Safarinejad 2012 112 31.2 (2.4) 113 25.8 (2.2) 36.83% 5.4[4.8,6]
Subtotal *** 240   239   100% 1.9[-1.56,5.36]
Heterogeneity: Tau2=8.35; Chi2=93.67, df=2(P<0.0001); I2=97.86%  
Test for overall effect: Z=1.08(P=0.28)  
   
1.15.3 Vitamin E  
Ener 2016 22 59.3 (16.2) 23 57.1 (20.2) 100% 2.2[-8.48,12.88]
Subtotal *** 22   23   100% 2.2[-8.48,12.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Test for subgroup differences: Chi2=4.06, df=1 (P=0.13), I2=50.68%  
Favours placebo/no treatm 2010-20 -10 0 Favours antioxidant
 
 
Analysis 1.16.   Comparison 1 Antioxidant(s) versus placebo
or no treatment, Outcome 16 Total sperm motility over time.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.16.1 Total sperm motility at 3 months or less  
Attallah 2013 30 22.5 (11) 30 18.7 (7.8) 4.52% 3.8[-1.03,8.63]
Azizollahi 2013 26 53.3 (15.3) 9 44.9 (33) 2.77% 8.4[-13.95,30.75]
Azizollahi 2013 29 51.7 (17.2) 8 44.9 (33) 2.64% 6.8[-16.91,30.51]
Azizollahi 2013 32 48.9 (27.7) 8 44.9 (33) 2.53% 4[-20.8,28.8]
Balercia 2005 15 59.9 (8) 5 44.6 (7.7) 4.3% 15.33[7.45,23.21]
Balercia 2005 15 56.5 (11.6) 5 44.6 (7.7) 4.2% 11.9[2.96,20.84]
Balercia 2005 14 55.1 (10.2) 5 44.6 (7.7) 4.23% 10.5[1.89,19.11]
Barekat 2016 15 58.2 (20.9) 20 43.6 (21.9) 3.65% 14.6[0.32,28.88]
Conquer 2000 9 39.4 (24.3) 5 47.2 (18.6) 2.73% -7.8[-30.56,14.96]
Conquer 2000 10 32 (16.1) 4 47.2 (18.6) 2.93% -15.2[-35.98,5.58]
Dimitriadis 2010 26 35.6 (15.5) 22 24.7 (10.8) 4.33% 10.9[3.43,18.37]
Ener 2016 22 61.4 (18.3) 23 42.5 (28.7) 3.68% 18.9[4.9,32.9]
Gopinath 2013 46 51.6 (13) 18 42.1 (10.6) 4.43% 9.5[3.33,15.67]
Gopinath 2013 43 50.1 (11.3) 18 42.1 (10.6) 4.45% 8[2.05,13.95]
Greco 2005 32 41.6 (22) 32 38.7 (21.5) 4.04% 2.9[-7.76,13.56]
Lenzi 2003 43 11 (15.5) 43 8.8 (10.8) 4.47% 2.2[-3.45,7.85]
Martinez-Soto 2010 21 41.5 (18.7) 15 48 (15.5) 3.98% -6.5[-17.7,4.7]
Morgante 2010 90 40.3 (6.4) 90 25.1 (4.2) 4.65% 15.2[13.62,16.78]
Nadjarzadeh 2011 23 41.9 (15.6) 24 38.3 (18.4) 4.13% 3.6[-6.14,13.34]
Omu 2008 11 49 (12) 3 24 (12) 3.53% 25[9.68,40.32]
Omu 2008 14 50 (20) 2 24 (12) 3.05% 26[6.34,45.66]
Omu 2008 12 50 (18) 3 24 (12) 3.35% 26[9.03,42.97]
Peivandi 2010 15 48.3 (0.2) 15 17 (0.1) 4.66% 31.3[31.21,31.39]
Scott 1998 16 30.2 (22.8) 9 15.3 (12.3) 3.7% 14.9[1.14,28.66]
Scott 1998 30 27 (20.3) 9 15.3 (12.3) 4.02% 11.7[0.87,22.53]
Sigman 2006 12 28.6 (38.1) 9 37.6 (33) 2.06% -9[-39.49,21.49]
Zavaczki 2003 10 33.5 (29.8) 10 19 (14.4) 2.96% 14.5[-6.01,35.01]
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 661   444   100% 10.19[4.35,16.04]
Heterogeneity: Tau2=190.69; Chi2=993.76, df=26(P<0.0001); I2=97.38%  
Test for overall effect: Z=3.42(P=0)  
   
1.16.2 Total sperm motility at 6 months  
Azizollahi 2013 26 51.5 (10.2) 9 49.8 (14.4) 2.8% 1.7[-8.49,11.89]
Azizollahi 2013 29 52.4 (17.8) 8 49.8 (13.6) 2.39% 2.6[-8.84,14.04]
Azizollahi 2013 32 49.8 (11.3) 8 49.8 (13.6) 2.8% 0[-10.21,10.21]
Balercia 2005 14 61.1 (9.1) 5 43.4 (9.9) 2.91% 17.7[7.8,27.6]
Balercia 2005 15 60.4 (10.5) 5 43.4 (9.9) 2.81% 17[6.82,27.18]
Balercia 2005 15 64.5 (8.4) 5 43.4 (9.9) 3.01% 21.1[11.44,30.76]
Balercia 2009 30 39.4 (6.8) 30 34.9 (8) 6.64% 4.5[0.74,8.26]
Blomberg Jensen 2018 129 41 (22.7) 131 45 (23.1) 5.28% -4[-9.57,1.57]
Busetto 2018 52 31.7 (8.2) 52 32.6 (9.2) 6.94% -0.9[-4.25,2.45]
Ener 2016 22 60.1 (16.1) 23 55 (26.9) 2% 5.1[-7.79,17.99]
Gopinath 2013 46 57.4 (14.6) 18 44.1 (9.5) 4.92% 13.3[7.21,19.39]
Gopinath 2013 43 55.8 (11.9) 18 44.1 (9.5) 5.22% 11.7[6.05,17.35]
Lenzi 2004 30 31.1 (13.5) 26 29.6 (9.5) 4.94% 1.5[-4.56,7.56]
Safarinejad 2009 105 26.1 (2.9) 36 22.9 (2.2) 8.32% 3.2[2.29,4.11]
Safarinejad 2009 104 29.2 (2.9) 35 22.9 (2.2) 8.32% 6.3[5.38,7.22]
Safarinejad 2009 105 24.8 (2.9) 35 22.9 (2.2) 8.32% 1.9[0.98,2.82]
Safarinejad 2009a 98 27.6 (2.2) 96 23.1 (2.1) 8.4% 4.5[3.89,5.11]
Safarinejad 2012 112 35.8 (2.7) 113 25.4 (2.1) 8.39% 10.4[9.77,11.03]
Sigman 2006 12 32.3 (24.2) 9 40 (33) 0.62% -7.7[-33.24,17.84]
Suleiman 1996 52 48.9 (15.5) 35 35.9 (12.8) 4.99% 13[7.02,18.98]
Subtotal *** 1071   697   100% 6[3.92,8.09]
Heterogeneity: Tau2=13.4; Chi2=391.52, df=19(P<0.0001); I2=95.15%  
Test for overall effect: Z=5.64(P<0.0001)  
   
1.16.3 Total sperm motility at 9 months or more  
Balercia 2005 15 54.3 (9) 5 42.7 (10) 6.67% 11.6[1.72,21.48]
Balercia 2005 15 50.6 (5.7) 5 42.7 (10) 7.38% 7.9[-1.33,17.13]
Balercia 2005 14 49 (7.8) 5 42.7 (10) 6.88% 6.3[-3.37,15.97]
Balercia 2009 30 32.9 (6.3) 30 35.3 (8) 19.2% -2.4[-6.04,1.24]
Ener 2016 22 59.3 (16.2) 23 57.1 (20.2) 5.91% 2.2[-8.48,12.88]
Safarinejad 2009a 98 24.2 (2.1) 96 22.8 (2.2) 26.98% 1.4[0.79,2.01]
Safarinejad 2012 112 31.2 (2.4) 113 25.8 (2.2) 26.98% 5.4[4.8,6]
Subtotal *** 306   277   100% 3.29[0.36,6.23]
Heterogeneity: Tau2=8.21; Chi2=98.01, df=6(P<0.0001); I2=93.88%  
Test for overall effect: Z=2.2(P=0.03)  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
 
 
Analysis 1.17.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 17 Progressive sperm motility at 3 months or less; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.17.1 Carnitines  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Balercia 2005 15 34.9 (9.2) 5 22.3 (7.8) 2.15% 12.6[4.33,20.87]
Balercia 2005 14 33.9 (8.4) 5 22.3 (7.8) 2.22% 11.6[3.47,19.73]
Balercia 2005 15 38.9 (7.1) 5 22.3 (7.8) 2.45% 16.6[8.88,24.32]
Mehni 2014 51 24.6 (1.5) 59 3.3 (2.7) 43.58% 21.3[20.5,22.1]
Peivandi 2010 15 30 (0.2) 15 9 (0.9) 49.61% 21[20.53,21.47]
Subtotal *** 110   89   100% 20.63[19.4,21.87]
Heterogeneity: Tau2=0.75; Chi2=10.87, df=4(P=0.03); I2=63.2%  
Test for overall effect: Z=32.69(P<0.0001)  
   
1.17.2 Coenzyme Q10  
Nadjarzadeh 2011 23 28.9 (14.8) 24 24.3 (13.6) 100% 4.6[-3.54,12.74]
Subtotal *** 23   24   100% 4.6[-3.54,12.74]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.11(P=0.27)  
   
1.17.3 Docosahexaenoic acid (DHA)  
Martinez-Soto 2010 21 37.8 (3.2) 15 44.4 (2.8) 100% -6.6[-8.57,-4.63]
Subtotal *** 21   15   100% -6.6[-8.57,-4.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=6.57(P<0.0001)  
   
1.17.4 Folic acid  
Azizollahi 2013 26 48.6 (32.6) 25 34.1 (36.5) 27.7% 14.5[-4.52,33.52]
Boonyarangkul 2015 15 20.4 (15.4) 15 18.1 (13.4) 72.3% 2.3[-8.03,12.63]
Subtotal *** 41   40   100% 5.68[-5.02,16.38]
Heterogeneity: Tau2=13.45; Chi2=1.22, df=1(P=0.27); I2=18.07%  
Test for overall effect: Z=1.04(P=0.3)  
   
1.17.5 N-acetylcysteine (NAC)  
Attallah 2013 30 22.5 (11) 30 18.7 (7.8) 100% 3.8[-1.03,8.63]
Subtotal *** 30   30   100% 3.8[-1.03,8.63]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.54(P=0.12)  
   
1.17.6 PUFAs  
Haghighian 2015 23 33.5 (2.9) 21 27.1 (2.4) 100% 6.4[4.83,7.97]
Subtotal *** 23   21   100% 6.4[4.83,7.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=8(P<0.0001)  
   
1.17.7 Vitamin C  
Cyrus 2015 46 54.5 (18.3) 69 44.9 (21.4) 48.48% 9.6[2.29,16.91]
Dawson 1990 10 51 (22.1) 5 49 (25.3) 27.47% 2[-24.07,28.07]
Dawson 1990 10 94 (32) 5 49 (25.3) 24.05% 45[15.25,74.75]
Subtotal *** 66   79   100% 16.03[-3.9,35.95]
Heterogeneity: Tau2=199.24; Chi2=5.62, df=2(P=0.06); I2=64.38%  
Test for overall effect: Z=1.58(P=0.11)  
   
1.17.8 Vitamin C + Vitamin E  
Rolf 1999 15 34.1 (11.8) 16 33.9 (16.3) 100% 0.2[-9.77,10.17]
Subtotal *** 15   16   100% 0.2[-9.77,10.17]
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
1.17.9 Zinc  
Azizollahi 2013 32 40.8 (35.6) 25 34.1 (36.5) 5.69% 6.7[-12.19,25.59]
Sharifzadeh 2016 51 25.5 (11.1) 49 24.7 (12.5) 94.31% 0.8[-3.84,5.44]
Subtotal *** 83   74   100% 1.14[-3.37,5.64]
Heterogeneity: Tau2=0; Chi2=0.35, df=1(P=0.55); I2=0%  
Test for overall effect: Z=0.49(P=0.62)  
   
1.17.10 Zinc + Folic acid  
Azizollahi 2013 29 37.9 (27.5) 25 34.1 (36.5) 100% 3.8[-13.66,21.26]
Subtotal *** 29   25   100% 3.8[-13.66,21.26]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
   
1.17.11 Combined antioxidants  
Morgante 2010 90 40.3 (6.4) 90 25.1 (4.2) 100% 15.2[13.62,16.78]
Subtotal *** 90   90   100% 15.2[13.62,16.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=18.84(P<0.0001)  
Test for subgroup differences: Chi2=634.89, df=1 (P<0.0001), I2=98.42%  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
 
 
Analysis 1.18.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome
18 Progressive sperm motility at 3 months (data not usable for meta-analysis).
Progressive sperm motility at 3 months (data not usable for meta-analysis)
Study Intervention Control P value
Combined antioxidants
Gamidov 2017 SpermActin-forte + Vitamin complex
'Man's formula'
Median = 36.5 (26 - 47) (n = 38 )
Median (interquartile range)
No treatment
Median = 34.5 (27 - 40) (n = 38)
Median (interquartile range)
Not provided
Gamidov 2017 SpermActin-forte (acetyl-L-carnitine,
L-carnitine fumarate and alpha-lipoic
acid)
Median = 30.5 (26 - 37) (n = 38)
Median (interquartile range)
No treatment
Median = 34.5 (27 - 40) (n = 38)
Median (interquartile range)
Not provided
Micic 2017 Proxeed Plus
Median = 30.0 (12.0 - 39.0) (n = 125)
Median (interquartile range)
Placebo
Median 28.5 (11.5 - 32.0) (n = 50)
Median (interquartile range)
Not provided
 
 
Analysis 1.19.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 19 Progressive sperm motility at 6 months; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.19.1 Carnitines  
Favours placebo/no treatm 10050-100 -50 0 Favours antioxidant
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
183
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Balercia 2005 15 43.8 (7.1) 5 24 (8.5) 35.57% 19.8[11.53,28.07]
Balercia 2005 15 37.5 (9.2) 5 24 (8.5) 31.53% 13.5[4.71,22.29]
Balercia 2005 14 38.1 (8.2) 5 24 (8.5) 32.9% 14.1[5.5,22.7]
Subtotal *** 44   15   100% 15.94[11.01,20.87]
Heterogeneity: Tau2=0; Chi2=1.31, df=2(P=0.52); I2=0%  
Test for overall effect: Z=6.33(P<0.0001)  
   
1.19.2 Coenzyme Q10  
Balercia 2009 30 15.1 (7.3) 30 10.1 (3.3) 100% 5[2.13,7.87]
Subtotal *** 30   30   100% 5[2.13,7.87]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.42(P=0)  
   
1.19.3 Folic acid  
Azizollahi 2013 26 40 (25) 25 40.3 (34) 26.37% -0.3[-16.73,16.13]
Boonyarangkul 2015 15 15 (10.1) 15 17.3 (16.6) 73.63% -2.3[-12.13,7.53]
Subtotal *** 41   40   100% -1.77[-10.21,6.67]
Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.84); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
1.19.4 Vitamin D + Calcium  
Blomberg Jensen 2018 129 31 (23) 131 35 (23) 100% -4[-9.59,1.59]
Subtotal *** 129   131   100% -4[-9.59,1.59]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
   
1.19.5 Zinc  
Azizollahi 2013 32 42.3 (23.2) 25 40.3 (34) 100% 2[-13.56,17.56]
Subtotal *** 32   25   100% 2[-13.56,17.56]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
   
1.19.6 Zinc + Folic acid  
Azizollahi 2013 29 43 (30.2) 25 40.3 (34) 100% 2.7[-14.58,19.98]
Subtotal *** 29   25   100% 2.7[-14.58,19.98]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.31(P=0.76)  
Test for subgroup differences: Chi2=31.49, df=1 (P<0.0001), I2=84.12%  
Favours placebo/no treatm 10050-100 -50 0 Favours antioxidant
 
 
Analysis 1.20.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome
20 Progessive sperm motility at 6 months (data not usable for meta-analysis).
Progessive sperm motility at 6 months (data not usable for meta-analysis)
Study Intervention Control P value
Combined antioxidants
Micic 2017 Proxeed Plus
Median = 31.0 (20.0 - 41.0) (n = 125)
Median (interquartile range)
Placebo
Median 29.0 (15.5 - 35.5) (n = 50)
Median (interquartile range)
Not provided
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Analysis 1.21.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 21 Progressive sperm motility at 9 months or more; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.21.1 Carnitines  
Balercia 2005 15 30.2 (7.8) 5 23.2 (9) 33.34% 7[-1.82,15.82]
Balercia 2005 14 28.5 (8.3) 5 23.2 (9) 31.97% 5.3[-3.71,14.31]
Balercia 2005 15 34 (7) 5 23.2 (9) 34.69% 10.8[2.15,19.45]
Subtotal *** 44   15   100% 7.77[2.68,12.87]
Heterogeneity: Tau2=0; Chi2=0.79, df=2(P=0.67); I2=0%  
Test for overall effect: Z=2.99(P=0)  
   
1.21.2 Coenzyme Q10  
Balercia 2009 30 10.1 (3.2) 30 11 (3.8) 100% -0.9[-2.68,0.88]
Subtotal *** 30   30   100% -0.9[-2.68,0.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
Test for subgroup differences: Chi2=9.93, df=1 (P=0), I2=89.93%  
Favours placebo/no treatm 10050-100 -50 0 Favours antioxidant
 
 
Analysis 1.22.   Comparison 1 Antioxidant(s) versus placebo or
no treatment, Outcome 22 Progressive sperm motility over time.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.22.1 Progressive sperm motility at 3 months or less  
Attallah 2013 30 22.5 (11) 30 18.7 (7.8) 6.96% 3.8[-1.03,8.63]
Azizollahi 2013 26 48.6 (32.6) 9 34.1 (21.9) 3.21% 14.5[-4.52,33.52]
Azizollahi 2013 32 40.8 (35.6) 8 34.1 (20.6) 3.24% 6.7[-12.17,25.57]
Azizollahi 2013 29 37.9 (27.5) 8 34.1 (20.6) 3.54% 3.8[-13.63,21.23]
Balercia 2005 15 34.9 (9.2) 5 22.3 (7.8) 6.03% 12.6[4.33,20.87]
Balercia 2005 14 33.9 (8.4) 5 22.3 (7.8) 6.07% 11.6[3.47,19.73]
Balercia 2005 15 38.9 (7.1) 5 22.3 (7.8) 6.19% 16.6[8.88,24.32]
Boonyarangkul 2015 15 20.4 (15.4) 15 18.1 (13.4) 5.41% 2.3[-8.03,12.63]
Cyrus 2015 46 54.5 (18.3) 69 44.9 (21.4) 6.31% 9.6[2.29,16.91]
Dawson 1990 10 94 (32) 5 49 (25.3) 1.75% 45[15.25,74.75]
Dawson 1990 10 51 (22.1) 5 49 (25.3) 2.13% 2[-24.07,28.07]
Haghighian 2015 23 33.5 (2.9) 21 27.1 (2.4) 7.5% 6.4[4.83,7.97]
Martinez-Soto 2010 21 37.8 (3.2) 15 44.4 (2.8) 7.46% -6.6[-8.57,-4.63]
Mehni 2014 51 24.6 (1.5) 59 3.3 (2.7) 7.55% 21.3[20.5,22.1]
Morgante 2010 90 40.3 (6.4) 90 25.1 (4.2) 7.5% 15.2[13.62,16.78]
Nadjarzadeh 2011 23 28.9 (14.8) 24 24.3 (13.6) 6.07% 4.6[-3.54,12.74]
Peivandi 2010 15 30 (0.2) 15 9 (0.9) 7.57% 21[20.53,21.47]
Rolf 1999 15 34.1 (11.8) 16 33.9 (16.3) 5.51% 0.2[-9.77,10.17]
Subtotal *** 480   404   100% 9.75[5.26,14.24]
Heterogeneity: Tau2=69.33; Chi2=1113.92, df=17(P<0.0001); I2=98.47%  
Test for overall effect: Z=4.25(P<0.0001)  
   
Favours antioxidant 10050-100 -50 0 Favours placebo/no treatm
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.22.2 Progressive sperm motility at 6 months  
Azizollahi 2013 32 42.3 (23.2) 8 40.3 (19.2) 7.34% 2[-13.54,17.54]
Azizollahi 2013 26 40 (25) 9 40.3 (20.4) 6.87% -0.3[-16.73,16.13]
Azizollahi 2013 29 43 (30.2) 8 40.3 (19.2) 6.47% 2.7[-14.56,19.96]
Balercia 2005 15 43.8 (7.1) 5 24 (8.5) 12.51% 19.8[11.53,28.07]
Balercia 2005 15 37.5 (9.2) 5 24 (8.5) 12.08% 13.5[4.71,22.29]
Balercia 2005 14 38.1 (8.2) 5 24 (8.5) 12.23% 14.1[5.5,22.7]
Balercia 2009 30 15.1 (7.3) 30 10.1 (3.3) 16.56% 5[2.13,7.87]
Blomberg Jensen 2018 129 31 (23) 131 35 (23) 14.73% -4[-9.59,1.59]
Boonyarangkul 2015 15 15 (10.1) 15 17.3 (16.6) 11.22% -2.3[-12.13,7.53]
Subtotal *** 305   216   100% 6.11[0.57,11.66]
Heterogeneity: Tau2=46.24; Chi2=32.84, df=8(P<0.0001); I2=75.64%  
Test for overall effect: Z=2.16(P=0.03)  
   
1.22.3 Progressive sperm motility at 9 months or more  
Balercia 2005 15 30.2 (7.8) 5 23.2 (9) 21.41% 7[-1.82,15.82]
Balercia 2005 14 28.5 (8.3) 5 23.2 (9) 21.03% 5.3[-3.71,14.31]
Balercia 2005 15 34 (7) 5 23.2 (9) 21.77% 10.8[2.15,19.45]
Balercia 2009 30 10.1 (3.2) 30 11 (3.8) 35.79% -0.9[-2.68,0.88]
Subtotal *** 74   45   100% 4.64[-1.67,10.95]
Heterogeneity: Tau2=28.11; Chi2=10.72, df=3(P=0.01); I2=72.02%  
Test for overall effect: Z=1.44(P=0.15)  
Test for subgroup differences: Chi2=1.99, df=1 (P=0.37), I2=0%  
Favours antioxidant 10050-100 -50 0 Favours placebo/no treatm
 
 
Analysis 1.23.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 23 Sperm concentration at 3 months or less; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.23.1 Carnitines  
Balercia 2005 15 39.3 (18.1) 5 31.4 (12.9) 13.67% 7.9[-6.65,22.45]
Balercia 2005 15 41 (17.3) 5 31.4 (12.9) 13.82% 9.6[-4.7,23.9]
Balercia 2005 14 36.9 (19.7) 5 31.4 (12.9) 13.21% 5.5[-9.81,20.81]
Dimitriadis 2010 26 15.4 (6.7) 22 16.3 (7) 19.57% -0.9[-4.8,3]
Mehni 2014 51 9.3 (1.7) 59 0.8 (1.8) 20.23% 8.5[7.85,9.15]
Peivandi 2010 15 46 (3.6) 15 16.5 (7.3) 19.5% 29.5[25.39,33.61]
Subtotal *** 136   111   100% 10.43[0.99,19.87]
Heterogeneity: Tau2=114.47; Chi2=122.45, df=5(P<0.0001); I2=95.92%  
Test for overall effect: Z=2.17(P=0.03)  
   
1.23.2 Coenzyme Q10  
Nadjarzadeh 2011 23 16.1 (12.9) 24 16.2 (27.7) 100% -0.1[-12.37,12.17]
Subtotal *** 23   24   100% -0.1[-12.37,12.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.99)  
   
1.23.3 Folic acid  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Azizollahi 2013 26 46.8 (42.3) 25 24.6 (22) 57.04% 22.2[3.8,40.6]
Boonyarangkul 2015 15 66.6 (29.8) 15 76.2 (50.7) 42.96% -9.6[-39.36,20.16]
Subtotal *** 41   40   100% 8.54[-22.31,39.39]
Heterogeneity: Tau2=346.25; Chi2=3.17, df=1(P=0.07); I2=68.48%  
Test for overall effect: Z=0.54(P=0.59)  
   
1.23.4 Magnesium  
Zavaczki 2003 10 16.1 (10.2) 10 10.9 (7.4) 100% 5.2[-2.61,13.01]
Subtotal *** 10   10   100% 5.2[-2.61,13.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.3(P=0.19)  
   
1.23.5 N-acetylcysteine (NAC)  
Attallah 2013 30 36.6 (9.2) 30 31.9 (10.6) 93.82% 4.7[-0.32,9.72]
Barekat 2016 15 45.4 (27.5) 20 42.4 (31.4) 6.18% 3[-16.57,22.57]
Subtotal *** 45   50   100% 4.59[-0.27,9.46]
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%  
Test for overall effect: Z=1.85(P=0.06)  
   
1.23.6 PUFAs  
Conquer 2000 10 44.6 (41.1) 5 43.1 (40.5) 0.16% 1.5[-42.19,45.19]
Conquer 2000 9 37.8 (36.9) 4 43.1 (40.5) 0.14% -5.3[-51.74,41.14]
Haghighian 2015 23 26.4 (3.2) 21 22.9 (2.7) 98.71% 3.5[1.76,5.24]
Martinez-Soto 2010 21 29.1 (26.4) 15 30.5 (26.2) 0.99% -1.4[-18.82,16.02]
Subtotal *** 63   45   100% 3.44[1.7,5.17]
Heterogeneity: Tau2=0; Chi2=0.44, df=3(P=0.93); I2=0%  
Test for overall effect: Z=3.89(P=0)  
   
1.23.7 Selenium  
Scott 1998 16 48.7 (35.2) 9 27.5 (42.4) 100% 21.2[-11.43,53.83]
Subtotal *** 16   9   100% 21.2[-11.43,53.83]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
   
1.23.8 Vitamin C  
Cyrus 2015 46 58.4 (24.3) 69 48.7 (27.8) 100% 9.7[0.09,19.31]
Subtotal *** 46   69   100% 9.7[0.09,19.31]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.98(P=0.05)  
   
1.23.9 Vitamin C + Vitamin E  
Greco 2005 32 27.5 (24.6) 32 20.3 (21.2) 49.63% 7.2[-4.05,18.45]
Rolf 1999 15 20.6 (13.5) 16 25 (17.8) 50.37% -4.4[-15.48,6.68]
Subtotal *** 47   48   100% 1.36[-10.01,12.72]
Heterogeneity: Tau2=34.83; Chi2=2.07, df=1(P=0.15); I2=51.76%  
Test for overall effect: Z=0.23(P=0.82)  
   
1.23.10 Vitamin E  
Ener 2016 22 49.5 (27.9) 23 30.6 (23) 100% 18.9[3.92,33.88]
Subtotal *** 22   23   100% 18.9[3.92,33.88]
Heterogeneity: Not applicable  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=2.47(P=0.01)  
   
1.23.11 Zinc  
Azizollahi 2013 32 41.5 (40.2) 25 24.6 (22) 14.17% 16.9[0.52,33.28]
Sharifzadeh 2016 51 17.2 (13.5) 49 9.8 (8.9) 85.83% 7.4[2.93,11.87]
Subtotal *** 83   74   100% 8.75[2.25,15.24]
Heterogeneity: Tau2=7.6; Chi2=1.2, df=1(P=0.27); I2=16.84%  
Test for overall effect: Z=2.64(P=0.01)  
   
1.23.12 Zinc + Folic acid  
Azizollahi 2013 29 42.6 (39.9) 25 24.6 (22) 100% 18[1.11,34.89]
Subtotal *** 29   25   100% 18[1.11,34.89]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.09(P=0.04)  
   
1.23.13 Combined antioxidants  
Gopinath 2013 43 24.9 (7) 18 14.9 (5.9) 29.77% 10[6.56,13.44]
Gopinath 2013 46 26.4 (8.9) 18 14.9 (5.9) 29.51% 11.5[7.75,15.25]
Morgante 2010 90 18.2 (3.5) 90 19.1 (3) 31.13% -0.9[-1.85,0.05]
Scott 1998 30 34 (34.5) 9 27.5 (30) 9.59% 6.5[-16.66,29.66]
Subtotal *** 209   135   100% 6.71[-1.91,15.33]
Heterogeneity: Tau2=61.89; Chi2=71.01, df=3(P<0.0001); I2=95.78%  
Test for overall effect: Z=1.53(P=0.13)  
Test for subgroup differences: Chi2=13.93, df=1 (P=0.31), I2=13.84%  
Favours placebo/no treatm 5025-50 -25 0 Favours antioxidant
 
 
Analysis 1.24.   Comparison 1 Antioxidant(s) versus placebo or no treatment, Outcome
24 Sperm concentration at 3 months or less (data not suitable for meta analysis).
Sperm concentration at 3 months or less (data not suitable for meta analysis)
Study Intervention Control P value
Carnitines
Cavallini 2004 L-carnitine + Acetyl-carnitine
Median = 20.9 (n = 39)
Interquartile range = 25.6 - 14.8
Placebo
Median = 12.3 (n = 47)
Interquartile range = 16.0 - 9.1
Not provided
Lenzi 2003 L-carnitine
Mean = 9 (1st phase data) (n = 43)
No SD given
Placebo
Mean = 5.3 (n = 43)
No SD given
P = 0.03
Vitamin E
Kessopoulou 1995 Vitamin E
Median = -15 (n = 15)
Min/max = -58 - 59
Placebo
Median = 0 (n = 15)
Min/max = -37 - 160
Not provided
Folic acid
Raigani 2014 Folic acid
Median 15 (9.7 - 24) (n = 20)
Median (25th - 75th percentile)
16 weeks
Placebo
Median 12 (7.5 - 27.3)
Median (25th - 75th percentile)
16 weeks
Not provided
Zinc
Raigani 2014 Zinc
Median 13.2 (7 - 27) (n = 24)
Median (25th - 75th percentile)
16 weeks
Placebo
Median 12 (7.5 - 27.3)
Median (25th - 75th percentile)
16 weeks
Not provided
Folic acid + Zinc
Raigani 2014 Folic acid + Zinc
Median 10.5 (8.06 - 17.7) (n = 21)
Placebo
Median 12 (7.5 - 27.3)
Not provided
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Sperm concentration at 3 months or less (data not suitable for meta analysis)
Study Intervention Control P value
Median (25th - 75th percentile)
16 weeks
Median (25th - 75th percentile)
16 weeks
Combined antioxidants
Gamidov 2017 SpermActin-forte (acetyl-L-carnitine,
L-carnitine fumarate and alpha-lipoic
acid)
Median = 26.5 (2.3 - 48)
Median (interquartile range)
No treatment
Median = 22 (11.5 - 26.6)
Median (interquartile range)
Not provided
Gamidov 2017 SpermActin-forte + Vitamin complex
'Man's formula'
Median = 23.5 (10 -34.5) (n = 38)
Median (interquartile range)
No treatment
Median = 22 (11.5 - 26.6) (n = 38)
Median (interquartile range)
Not provided
 
 
Analysis 1.25.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 25 Sperm concentration at 6 months; type of antioxidant.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.25.1 Carnitines  
Balercia 2005 15 45.5 (21.4) 5 33.7 (14.4) 11.86% 11.8[-4.83,28.43]
Balercia 2005 15 39.6 (20) 5 33.7 (14.4) 12.53% 5.9[-10.28,22.08]
Balercia 2005 14 37.4 (16.4) 5 33.7 (14.4) 14.07% 3.7[-11.57,18.97]
Lenzi 2004 30 22.1 (9.1) 26 22.2 (17) 61.54% -0.1[-7.4,7.2]
Subtotal *** 74   41   100% 2.6[-3.13,8.33]
Heterogeneity: Tau2=0; Chi2=1.88, df=3(P=0.6); I2=0%  
Test for overall effect: Z=0.89(P=0.37)  
   
1.25.2 Coenzyme Q10  
Balercia 2009 30 44.9 (19.3) 30 46.4 (19.8) 18.39% -1.5[-11.39,8.39]
Safarinejad 2009a 98 26.4 (4.4) 96 20.8 (4.3) 40.78% 5.6[4.38,6.82]
Safarinejad 2012 112 28.7 (4.6) 113 16.8 (4.4) 40.83% 11.9[10.72,13.08]
Subtotal *** 240   239   100% 6.87[1.18,12.55]
Heterogeneity: Tau2=20.22; Chi2=57.08, df=2(P<0.0001); I2=96.5%  
Test for overall effect: Z=2.37(P=0.02)  
   
1.25.3 Folic acid  
Azizollahi 2013 26 49.1 (16.8) 25 29.9 (6.6) 60.1% 19.2[12.24,26.16]
Boonyarangkul 2015 15 53.3 (22.8) 15 76.1 (70.8) 39.9% -22.8[-60.44,14.84]
Subtotal *** 41   40   100% 2.44[-37.87,42.75]
Heterogeneity: Tau2=691.29; Chi2=4.62, df=1(P=0.03); I2=78.38%  
Test for overall effect: Z=0.12(P=0.91)  
   
1.25.4 N-acetylcysteine (NAC)  
Safarinejad 2009 105 26.8 (5.3) 106 23.5 (5.8) 100% 3.3[1.8,4.8]
Subtotal *** 105   106   100% 3.3[1.8,4.8]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=4.31(P<0.0001)  
   
1.25.5 Selenium  
Safarinejad 2009 105 27.6 (6.4) 106 23.5 (5.8) 100% 4.1[2.45,5.75]
Subtotal *** 105   106   100% 4.1[2.45,5.75]
Heterogeneity: Not applicable  
Favours placebo/no treatm 2010-20 -10 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=4.87(P<0.0001)  
   
1.25.6 Selenium + N-acetylcysteine (NAC)  
Safarinejad 2009 104 32.1 (6.8) 106 23.5 (5.8) 100% 8.6[6.89,10.31]
Subtotal *** 104   106   100% 8.6[6.89,10.31]
Heterogeneity: Not applicable  
Test for overall effect: Z=9.85(P<0.0001)  
   
1.25.7 Vitamin E  
Ener 2016 22 53.9 (22) 23 48 (34.2) 100% 5.9[-10.83,22.63]
Subtotal *** 22   23   100% 5.9[-10.83,22.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
   
1.25.8 Zinc  
Azizollahi 2013 32 39.6 (30.5) 25 29.9 (33) 100% 9.7[-7,26.4]
Subtotal *** 32   25   100% 9.7[-7,26.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.26)  
   
1.25.9 Zinc + Folic acid  
Azizollahi 2013 29 47.6 (40.4) 25 29.9 (33) 100% 17.7[-1.88,37.28]
Subtotal *** 29   25   100% 17.7[-1.88,37.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
   
1.25.10 Combined antioxidants  
Busetto 2018 52 51.4 (13.9) 52 43.7 (13.6) 32.25% 7.7[2.41,12.99]
Gopinath 2013 43 31.7 (9.7) 18 15.9 (7.7) 34.68% 15.8[11.21,20.39]
Gopinath 2013 46 33.2 (12.4) 18 15.9 (7.7) 33.07% 17.3[12.25,22.35]
Subtotal *** 141   88   100% 13.68[8.06,19.31]
Heterogeneity: Tau2=18.26; Chi2=7.69, df=2(P=0.02); I2=73.98%  
Test for overall effect: Z=4.77(P<0.0001)  
Test for subgroup differences: Chi2=34.67, df=1 (P<0.0001), I2=74.04%  
Favours placebo/no treatm 2010-20 -10 0 Favours antioxidant
 
 
Analysis 1.26.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 26 Sperm concentration at 6 months(data not suitable for meta analysis).
Sperm concentration at 6 months(data not suitable for meta analysis)
Study Intervention Control P value
Carnitines
Cavallini 2004 L-carnitine + Acetyl-carniitne
Median = 20.6 (n = 39)
Interquartile range = 24.9 - 15.1
Placebo
Median = 10.9 (n = 47)
Interquartile range = 15.1 - 9.0
Not provided
Folic acid
Wong 2002 Folic acid
Median = 14 (n = 22)
Range = 0.9 - 130
Placebo
Median = 9 (n = 25)
Range = 0.8 - 80
Not provided
Zinc
Wong 2002 Zinc
Median = 16 (n = 23)
Placebo
Median = 9 (n = 25)
Not provided
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Sperm concentration at 6 months(data not suitable for meta analysis)
Study Intervention Control P value
Range = 0.6 - 80 Range = 0.8 - 80
Zinc + Folic acid
Wong 2002 Zinc + Folic acid
Median = 12 (n = 24)
Range = 0.5 - 180
Placebo
Median = 9 (n = 25)
Range = 0.8 - 80
Not provided
Vitamin D + Calcium
Blomberg Jensen 2018 Vitamin D + Calcium
Median = 12.8 (n = 133)
25th, 75th percentiles = 3.4, 32.3
At 5 months.
Placebo
Median = 13.3 (n = 136)
25th, 75th percentiles = 4.2, 38.5
At 5 months
Not provided
 
 
Analysis 1.27.   Comparison 1 Antioxidant(s) versus placebo or no treatment,
Outcome 27 Sperm concentration at 9 months; type of antioxidant.
Study or subgroup Favours place-
bo/no treatm
Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.27.1 Carnitines  
Balercia 2005 15 31.2 (8.6) 5 30.1 (9.3) 40.57% 1.1[-8.14,10.34]
Balercia 2005 15 39.4 (13.9) 5 30.1 (9.3) 29.88% 9.3[-1.47,20.07]
Balercia 2005 14 33.3 (13.6) 5 30.1 (9.3) 29.56% 3.2[-7.63,14.03]
Subtotal *** 44   15   100% 4.17[-1.71,10.06]
Heterogeneity: Tau2=0; Chi2=1.33, df=2(P=0.52); I2=0%  
Test for overall effect: Z=1.39(P=0.16)  
   
1.27.2 Coenzyme Q10  
Balercia 2009 30 44.2 (20.4) 30 49.6 (20.5) 12.5% -5.4[-15.75,4.95]
Safarinejad 2009a 98 22.8 (3.8) 96 21.2 (3.8) 43.71% 1.6[0.53,2.67]
Safarinejad 2012 112 22.4 (4.2) 113 16.2 (3.7) 43.79% 6.2[5.17,7.23]
Subtotal *** 240   239   100% 2.74[-1.57,7.05]
Heterogeneity: Tau2=10.74; Chi2=39.85, df=2(P<0.0001); I2=94.98%  
Test for overall effect: Z=1.25(P=0.21)  
   
1.27.3 Vitamin E  
Ener 2016 22 58.6 (20.2) 23 47.2 (27.2) 100% 11.4[-2.56,25.36]
Subtotal *** 22   23   100% 11.4[-2.56,25.36]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.6(P=0.11)  
Test for subgroup differences: Chi2=1.38, df=1 (P=0.5), I2=0%  
Favours placebo/no treatm 2010-20 -10 0 Favours antioxidant
 
 
Analysis 1.28.   Comparison 1 Antioxidant(s) versus placebo
or no treatment, Outcome 28 Sperm concentration over time.
Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.28.1 Sperm concentration at 3 months or less  
Attallah 2013 30 36.6 (9.2) 30 31.9 (10.6) 5.78% 4.7[-0.32,9.72]
Azizollahi 2013 26 46.8 (42.3) 9 24.6 (13.2) 2.15% 22.2[3.8,40.6]
Favours placebo/no treatm 4020-40 -20 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Azizollahi 2013 29 42.6 (39.9) 8 24.6 (12.4) 2.41% 18[1.13,34.87]
Azizollahi 2013 32 41.5 (40.2) 8 24.6 (12.4) 2.51% 16.9[0.53,33.27]
Balercia 2005 15 39.3 (18.1) 5 31.4 (12.9) 2.88% 7.9[-6.65,22.45]
Balercia 2005 15 41 (17.3) 5 31.4 (12.9) 2.94% 9.6[-4.7,23.9]
Balercia 2005 14 36.9 (19.7) 5 31.4 (12.9) 2.72% 5.5[-9.81,20.81]
Barekat 2016 15 45.4 (27.5) 20 42.4 (31.4) 1.97% 3[-16.57,22.57]
Boonyarangkul 2015 15 66.6 (29.8) 15 76.2 (50.7) 1.03% -9.6[-39.36,20.16]
Conquer 2000 10 44.6 (41.1) 9 43.1 (40.5) 0.71% 1.5[-35.23,38.23]
Cyrus 2015 46 58.4 (24.3) 69 48.7 (27.8) 4.25% 9.7[0.09,19.31]
Dimitriadis 2010 26 15.4 (6.7) 22 16.3 (7) 6.11% -0.9[-4.8,3]
Ener 2016 22 49.5 (27.9) 23 30.6 (23) 2.79% 18.9[3.92,33.88]
Gopinath 2013 46 26.4 (8.9) 18 14.9 (5.9) 6.15% 11.5[7.75,15.25]
Gopinath 2013 43 24.9 (7) 18 14.9 (5.9) 6.23% 10[6.56,13.44]
Greco 2005 32 27.5 (24.6) 32 20.3 (21.2) 3.74% 7.2[-4.05,18.45]
Haghighian 2015 23 26.4 (3.2) 21 22.9 (2.7) 6.57% 3.5[1.76,5.24]
Martinez-Soto 2010 21 29.1 (4.5) 15 30.5 (4.9) 6.3% -1.4[-4.54,1.74]
Mehni 2014 51 9.3 (1.7) 59 0.8 (1.8) 6.67% 8.5[7.85,9.15]
Morgante 2010 90 18.2 (3.5) 90 19.1 (3) 6.65% -0.9[-1.85,0.05]
Nadjarzadeh 2011 23 16.1 (12.9) 24 16.2 (27.7) 3.45% -0.1[-12.37,12.17]
Peivandi 2010 15 46 (3.6) 15 16.5 (7.3) 6.06% 29.5[25.39,33.61]
Rolf 1999 15 20.6 (13.5) 16 25 (17.8) 3.79% -4.4[-15.48,6.68]
Scott 1998 16 48.7 (35.2) 18 27.5 (42.4) 1.28% 21.2[-4.9,47.3]
Zavaczki 2003 10 16.1 (10.2) 10 10.9 (7.4) 4.85% 5.2[-2.61,13.01]
Subtotal *** 680   564   100% 7.51[4.23,10.79]
Heterogeneity: Tau2=41.74; Chi2=453.49, df=24(P<0.0001); I2=94.71%  
Test for overall effect: Z=4.49(P<0.0001)  
   
1.28.2 Sperm concentration 6 months  
Azizollahi 2013 29 47.6 (40.4) 8 29.9 (18.7) 1.65% 17.7[-1.88,37.28]
Azizollahi 2013 32 39.6 (30.5) 8 29.9 (18.7) 2.15% 9.7[-7,26.4]
Azizollahi 2013 26 49.1 (16.8) 9 29.9 (19.8) 2.69% 19.2[4.74,33.66]
Balercia 2005 15 45.5 (21.4) 5 33.7 (14.4) 2.16% 11.8[-4.83,28.43]
Balercia 2005 15 39.6 (20) 5 33.7 (14.4) 2.26% 5.9[-10.28,22.08]
Balercia 2005 14 37.4 (16.4) 5 33.7 (14.4) 2.47% 3.7[-11.57,18.97]
Balercia 2009 30 44.9 (19.3) 30 46.4 (19.8) 4.46% -1.5[-11.39,8.39]
Boonyarangkul 2015 15 53.3 (22.8) 15 76.1 (70.8) 0.5% -22.8[-60.44,14.84]
Busetto 2018 52 40.8 (18.2) 52 41.4 (17.9) 6.35% -0.6[-7.54,6.34]
Ener 2016 22 53.9 (22) 23 48 (34.2) 2.14% 5.9[-10.83,22.63]
Gopinath 2013 46 33.2 (12.4) 18 15.9 (7.7) 7.85% 17.3[12.25,22.35]
Gopinath 2013 43 31.7 (9.7) 18 15.9 (7.7) 8.24% 15.8[11.21,20.39]
Lenzi 2004 30 22.1 (9.1) 26 22.2 (17) 6.08% -0.1[-7.4,7.2]
Safarinejad 2009 105 26.8 (5.3) 35 23.5 (5.8) 10.04% 3.3[1.13,5.47]
Safarinejad 2009 104 32.1 (6.8) 35 23.5 (5.8) 9.95% 8.6[6.28,10.92]
Safarinejad 2009 105 27.6 (6.4) 36 23.5 (5.8) 9.99% 4.1[1.84,6.36]
Safarinejad 2009a 98 26.4 (4.4) 96 20.8 (4.3) 10.5% 5.6[4.38,6.82]
Safarinejad 2012 112 28.7 (4.6) 113 16.8 (4.4) 10.51% 11.9[10.72,13.08]
Subtotal *** 893   537   100% 7.49[4.76,10.23]
Heterogeneity: Tau2=18.18; Chi2=131.48, df=17(P<0.0001); I2=87.07%  
Test for overall effect: Z=5.37(P<0.0001)  
   
1.28.3 Sperm concentration at 9 months or more  
Favours placebo/no treatm 4020-40 -20 0 Favours antioxidant
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Study or subgroup Antioxidant Placebo/no
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Balercia 2005 15 39.4 (13.9) 5 30.1 (9.3) 7.75% 9.3[-1.47,20.07]
Balercia 2005 15 31.2 (8.6) 5 30.1 (9.3) 9.67% 1.1[-8.14,10.34]
Balercia 2005 14 33.3 (13.6) 5 30.1 (9.3) 7.68% 3.2[-7.63,14.03]
Balercia 2009 30 44.2 (20.4) 30 49.6 (20.5) 8.22% -5.4[-15.75,4.95]
Ener 2016 22 58.6 (20.2) 23 47.2 (27.2) 5.12% 11.4[-2.56,25.36]
Safarinejad 2009a 98 22.8 (3.8) 96 21.2 (3.8) 30.76% 1.6[0.53,2.67]
Safarinejad 2012 112 22.4 (4.2) 113 16.2 (3.7) 30.81% 6.2[5.17,7.23]
Subtotal *** 306   277   100% 3.61[0.17,7.06]
Heterogeneity: Tau2=9.76; Chi2=42.28, df=6(P<0.0001); I2=85.81%  
Test for overall effect: Z=2.06(P=0.04)  
Favours placebo/no treatm 4020-40 -20 0 Favours antioxidant
 
 
Comparison 2.   Head-to-head antioxidant(s)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Live birth; type of antioxidant 1   Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 L-carnitine vs L-acetyl carnitine 1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.13, 7.92]
1.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.06, 1.79]
1.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.06, 1.79]
2 Clinical pregnancy; type of an-
tioxidant
2   Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 L-carnitine vs L-acetyl carnitine 1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.13, 7.92]
2.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.06, 1.79]
2.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.06, 1.79]
2.4 Vitamin D + Calcium vs Vitamin
E + Vitamin C
1 86 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.13 [1.21, 21.79]
3 Total sperm motility at 3 months
or less; type of antioxidant
8   Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Docosahexaenoic acid (DHA)
400 mg vs Docosahexaenoic acid
800 mg
1 19 Mean Difference (IV, Random, 95% CI) 7.40 [-11.35, 26.15]
3.2 Ethylcysteine vs Vitamin E 1 10 Mean Difference (IV, Random, 95% CI) -1.90 [-41.97, 38.17]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.3 L-acetyl carnitine + L-carnitine
vs Vitamin E + Vitamin C
1 138 Mean Difference (IV, Random, 95% CI) 23.10 [20.14, 26.06]
3.4 L-carnitine vs L-acetyl carnitine 1 30 Mean Difference (IV, Random, 95% CI) 3.40 [-3.73, 10.53]
3.5 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 4.80 [-1.76, 11.36]
3.6 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 1.40 [-6.42, 9.22]
3.7 Selenium vs combined antioxi-
dants
1 46 Mean Difference (IV, Random, 95% CI) 3.20 [-10.13, 16.53]
3.8 Vitamin C 200mg vs Vitamin C
1000mg
1 20 Mean Difference (IV, Random, 95% CI) -43.0 [-67.10, -18.90]
3.9 Zinc vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -4.40 [-14.21, 5.41]
3.10 Zinc vs Zinc + Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -2.80 [-12.90, 7.30]
3.11 Zinc + Folic acid vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -0.60 [-7.73, 6.53]
3.12 Zinc vs Zinc + Vitamin E 1 18 Mean Difference (IV, Random, 95% CI) -1.0 [-13.00, 13.00]
3.13 Zinc vs Zinc + Vitamin E + Vita-
min C
1 12 Mean Difference (IV, Random, 95% CI) -1.0 [-19.66, 17.66]
3.14 Zinc + Vitamin E vs Zinc + Vita-
min E + Vitamin C
1 18 Mean Difference (IV, Random, 95% CI) 0.0 [-18.97, 18.97]
4 Total sperm motility at 6 months;
type of antioxidant
3   Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 L-carnitine vs L-acetyl carnitine 1 30 Mean Difference (IV, Random, 95% CI) 4.10 [-2.70, 10.90]
4.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 3.40 [-2.87, 9.67]
4.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) -0.70 [-7.73, 6.33]
4.4 N-acetylcysteine (NAC) vs Sele-
nium + N-acetylcysteine (NAC)
1 234 Mean Difference (IV, Random, 95% CI) -4.40 [-5.14, -3.66]
4.5 Selenium vs N-acetylcysteine
(NAC)
1 234 Mean Difference (IV, Random, 95% CI) 1.30 [0.56, 2.04]
4.6 Selenium vs Selenium + N-
acetylcysteine (NAC)
1 232 Mean Difference (IV, Random, 95% CI) -3.10 [-3.85, -2.35]
4.7 Zinc vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -1.70 [-6.42, 3.02]
4.8 Zinc + Folic acid vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) 0.90 [-5.46, 7.26]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.9 Zinc vs Zinc + Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -2.60 [-9.13, 3.93]
5 Total sperm motility at 6 months
(data not suitable for meta analy-
sis)
    Other data No numeric data
5.1 Folic acid vs Zinc + Folic acid     Other data No numeric data
5.2 Zinc vs Folic acid     Other data No numeric data
5.3 Zinc vs Zinc + Folic acid     Other data No numeric data
6 Total sperm motility at 9 months
or more; type of antioxidant
1   Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 L-carnitine vs L-acetyl carnitine 1 30 Mean Difference (IV, Random, 95% CI) 3.70 [-1.69, 9.09]
6.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 5.30 [-0.73, 11.33]
6.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 1.60 [-3.29, 6.49]
7 Progessive sperm motility at 3
months or less; type of antioxidant
5   Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 L-carnitine vs L-acetyl carnitine 1 30 Mean Difference (IV, Random, 95% CI) 4.0 [-1.88, 9.88]
7.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 29 Mean Difference (IV, Random, 95% CI) 5.0 [-0.68, 10.68]
7.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 29 Mean Difference (IV, Random, 95% CI) 1.0 [-5.41, 7.41]
7.4 L-acetyl carnitine + L-carnitine
vs Vitamin E + Vitamin C
1 138 Mean Difference (IV, Random, 95% CI) 13.30 [11.21, 15.39]
7.5 L-carnitine vs Vitamin E + Vita-
min C
1 63 Mean Difference (IV, Random, 95% CI) 30.50 [27.70, 33.30]
7.6 L-carnitine + Vitamin E vs Vita-
min E
1 113 Mean Difference (IV, Random, 95% CI) 14.10 [10.11, 18.09]
7.7 Vitamin D + Calcium vs Vitamin
E + Vitamin C
1 86 Mean Difference (IV, Random, 95% CI) 6.90 [5.38, 8.42]
8 Progressive sperm motility at 6
months; type of antioxidant
1   Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 L-carnitine vs L-acetyl carnitine 1 30 Mean Difference (IV, Random, 95% CI) 6.30 [0.42, 12.18]
8.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 29 Mean Difference (IV, Random, 95% CI) 5.70 [0.10, 11.30]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
8.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 29 Mean Difference (IV, Random, 95% CI) -0.60 [-6.93, 5.73]
9 Progressive sperm motility at 9
months; type of antioxidant
1   Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 L-carnitine vs L-acetyl carnitine 1 30 Mean Difference (IV, Random, 95% CI) 3.80 [-1.50, 9.10]
9.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 29 Mean Difference (IV, Random, 95% CI) 5.50 [-0.11, 11.11]
9.3 L-acetyl carnitine vs L-carnitine
+ L-acetyl carnitine
1 29 Mean Difference (IV, Random, 95% CI) 1.70 [-4.17, 7.57]
10 Sperm concentration at 3
months or less; type of antioxidant
7   Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Docosahexaenoic acid (DHA)
400 mg vs Docosahexaenoic acid
(DHA) 800 mg
1 19 Mean Difference (IV, Random, 95% CI) -6.80 [-41.87, 28.27]
10.2 Ethylcysteine vs Vitamin E 1 10 Mean Difference (IV, Random, 95% CI) 2.20 [-16.65, 21.05]
10.3 L-carnitine vs Vitamin E + Vita-
min C
1 63 Mean Difference (IV, Random, 95% CI) 15.5 [12.49, 18.51]
10.4 L-carnitine + Vitamin E vs Vita-
min E
1 113 Mean Difference (IV, Random, 95% CI) 1.90 [-10.52, 14.32]
10.5 L-carnitine vs L-acetyl carni-
tine
1 30 Mean Difference (IV, Random, 95% CI) 1.70 [-10.97, 14.37]
10.6 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 4.10 [-9.17, 17.37]
10.7 L-acetyl carnitine vs L-carni-
tine + L-acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 2.40 [-11.14, 15.94]
10.8 Selenium vs combined antiox-
idants
1 46 Mean Difference (IV, Random, 95% CI) 14.70 [-6.51, 35.91]
10.9 Zinc vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -5.30 [-23.38, 12.78]
10.10 Zinc + Folic acid vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -4.20 [-22.22, 13.82]
10.11 Zinc vs Zinc + Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -1.10 [-18.65, 16.45]
11 Sperm concentration at 6
months; type of antioxidant
3   Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 L-carnitine vs L-acetyl carni-
tine
1 30 Mean Difference (IV, Random, 95% CI) 5.90 [-8.92, 20.72]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
11.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 8.10 [-5.54, 21.74]
11.3 L-acetyl carnitine vs L-carni-
tine + L-acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 2.20 [-10.89, 15.29]
11.4 N-acetylcysteine (NAC) vs Se-
lenium + N-acetylcysteine (NAC)
1 234 Mean Difference (IV, Random, 95% CI) -5.30 [-6.86, -3.74]
11.5 Selenium vs N-acetylcysteine
(NAC)
1 234 Mean Difference (IV, Random, 95% CI) 0.80 [-0.71, 2.31]
11.6 Selenium vs Selenium + N-
acetylcysteine (NAC)
1 232 Mean Difference (IV, Random, 95% CI) -4.5 [-6.20, -2.80]
11.7 Zinc vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -9.5 [-20.29, 1.29]
11.8 Zinc + Folic acid vs Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -1.5 [-15.06, 12.06]
11.9 Zinc vs Zinc + Folic acid 1 80 Mean Difference (IV, Random, 95% CI) -8.0 [-23.69, 7.69]
12 Sperm concentration at 6
months (data not suitable for meta
analysis)
    Other data No numeric data
12.1 Zinc vs Folic acid     Other data No numeric data
12.2 Zinc vs Zinc + Folic acid     Other data No numeric data
12.3 Folic acid vs Zinc + Folic acid     Other data No numeric data
13 Sperm concentration at 9
months or more; type of antioxi-
dant
1   Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 L-carnitine vs L-acetyl carni-
tine
1 30 Mean Difference (IV, Random, 95% CI) 8.2 [-0.07, 16.47]
13.2 L-carnitine vs L-carnitine + L-
acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) 6.10 [-3.74, 15.94]
13.3 L-acetyl carnitine vs L-carni-
tine + L-acetyl carnitine
1 30 Mean Difference (IV, Random, 95% CI) -2.10 [-10.24, 6.04]
 
 
Analysis 2.1.   Comparison 2 Head-to-head antioxidant(s), Outcome 1 Live birth; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
2.1.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 2/15 2/15 100% 1[0.13,7.92]
Favours antioxidant B 1000.01 100.1 1 Favours antioxidant A
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Study or subgroup Antioxidant A Antioxidant B Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Subtotal (95% CI) 15 15 100% 1[0.13,7.92]
Total events: 2 (Antioxidant A), 2 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.1.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 2/15 5/15 100% 0.34[0.06,1.79]
Subtotal (95% CI) 15 15 100% 0.34[0.06,1.79]
Total events: 2 (Antioxidant A), 5 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
   
2.1.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 2/15 5/15 100% 0.34[0.06,1.79]
Subtotal (95% CI) 15 15 100% 0.34[0.06,1.79]
Total events: 2 (Antioxidant A), 5 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
Test for subgroup differences: Chi2=0.79, df=1 (P=0.67), I2=0%  
Favours antioxidant B 1000.01 100.1 1 Favours antioxidant A
 
 
Analysis 2.2.   Comparison 2 Head-to-head antioxidant(s), Outcome 2 Clinical pregnancy; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
2.2.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 2/15 2/15 100% 1[0.13,7.92]
Subtotal (95% CI) 15 15 100% 1[0.13,7.92]
Total events: 2 (Antioxidant A), 2 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.2.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 2/15 5/15 100% 0.34[0.06,1.79]
Subtotal (95% CI) 15 15 100% 0.34[0.06,1.79]
Total events: 2 (Antioxidant A), 5 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
   
2.2.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 2/15 5/15 100% 0.34[0.06,1.79]
Subtotal (95% CI) 15 15 100% 0.34[0.06,1.79]
Total events: 2 (Antioxidant A), 5 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
   
2.2.4 Vitamin D + Calcium vs Vitamin E + Vitamin C  
Deng 2014 7/43 1/43 100% 5.13[1.21,21.79]
Subtotal (95% CI) 43 43 100% 5.13[1.21,21.79]
Favours antioxidant B 1000.01 100.1 1 Favours antioxidant A
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Study or subgroup Antioxidant A Antioxidant B Peto Odds Ratio Weight Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI   Peto, Fixed, 95% CI
Total events: 7 (Antioxidant A), 1 (Antioxidant B)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.21(P=0.03)  
Test for subgroup differences: Chi2=8.15, df=1 (P=0.04), I2=63.17%  
Favours antioxidant B 1000.01 100.1 1 Favours antioxidant A
 
 
Analysis 2.3.   Comparison 2 Head-to-head antioxidant(s), Outcome
3 Total sperm motility at 3 months or less; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.3.1 Docosahexaenoic acid (DHA) 400 mg vs Docosahexaenoic acid 800 mg  
Conquer 2000 9 39.4 (24.3) 10 32 (16.1) 100% 7.4[-11.35,26.15]
Subtotal *** 9   10   100% 7.4[-11.35,26.15]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
   
2.3.2 Ethylcysteine vs Vitamin E  
Akiyama 1999 5 40.9 (30.1) 5 42.8 (34.4) 100% -1.9[-41.97,38.17]
Subtotal *** 5   5   100% -1.9[-41.97,38.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.93)  
   
2.3.3 L-acetyl carnitine + L-carnitine vs Vitamin E + Vitamin C  
Li 2005 85 38.3 (9.7) 53 15.2 (7.9) 100% 23.1[20.14,26.06]
Subtotal *** 85   53   100% 23.1[20.14,26.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=15.28(P<0.0001)  
   
2.3.4 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 59.9 (8) 15 56.5 (11.6) 100% 3.4[-3.73,10.53]
Subtotal *** 15   15   100% 3.4[-3.73,10.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
   
2.3.5 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 59.9 (8) 15 55.1 (10.2) 100% 4.8[-1.76,11.36]
Subtotal *** 15   15   100% 4.8[-1.76,11.36]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
   
2.3.6 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 56.5 (11.6) 15 55.1 (10.2) 100% 1.4[-6.42,9.22]
Subtotal *** 15   15   100% 1.4[-6.42,9.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
   
2.3.7 Selenium vs combined antioxidants  
Scott 1998 16 30.2 (22.8) 30 27 (20.3) 100% 3.2[-10.13,16.53]
Favours Antioxidant B 5025-50 -25 0 Favours Antioxidant A
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 16   30   100% 3.2[-10.13,16.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
2.3.8 Vitamin C 200mg vs Vitamin C 1000mg  
Dawson 1990 10 51 (22.1) 10 94 (32) 100% -43[-67.1,-18.9]
Subtotal *** 10   10   100% -43[-67.1,-18.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.5(P=0)  
   
2.3.9 Zinc vs Folic acid  
Azizollahi 2013 40 48.9 (27.7) 40 53.3 (15.3) 100% -4.4[-14.21,5.41]
Subtotal *** 40   40   100% -4.4[-14.21,5.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
2.3.10 Zinc vs Zinc + Folic acid  
Azizollahi 2013 40 48.9 (27.7) 40 51.7 (17.2) 100% -2.8[-12.9,7.3]
Subtotal *** 40   40   100% -2.8[-12.9,7.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
2.3.11 Zinc + Folic acid vs Folic acid  
Azizollahi 2013 40 51.7 (17.2) 40 52.3 (15.3) 100% -0.6[-7.73,6.53]
Subtotal *** 40   40   100% -0.6[-7.73,6.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.87)  
   
2.3.12 Zinc vs Zinc + Vitamin E  
Omu 2008 6 49 (12) 12 50 (18) 100% -1[-15,13]
Subtotal *** 6   12   100% -1[-15,13]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
   
2.3.13 Zinc vs Zinc + Vitamin E + Vitamin C  
Omu 2008 6 49 (12) 6 50 (20) 100% -1[-19.66,17.66]
Subtotal *** 6   6   100% -1[-19.66,17.66]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.11(P=0.92)  
   
2.3.14 Zinc + Vitamin E vs Zinc + Vitamin E + Vitamin C  
Omu 2008 12 50 (18) 6 50 (20) 100% 0[-18.97,18.97]
Subtotal *** 12   6   100% 0[-18.97,18.97]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Antioxidant B 5025-50 -25 0 Favours Antioxidant A
 
 
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
200
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 2.4.   Comparison 2 Head-to-head antioxidant(s),
Outcome 4 Total sperm motility at 6 months; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 64.5 (8.4) 15 60.4 (10.5) 100% 4.1[-2.7,10.9]
Subtotal *** 15   15   100% 4.1[-2.7,10.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.18(P=0.24)  
   
2.4.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 64.5 (8.4) 15 61.1 (9.1) 100% 3.4[-2.87,9.67]
Subtotal *** 15   15   100% 3.4[-2.87,9.67]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
   
2.4.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 60.4 (10.5) 15 61.1 (9.1) 100% -0.7[-7.73,6.33]
Subtotal *** 15   15   100% -0.7[-7.73,6.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.2(P=0.85)  
   
2.4.4 N-acetylcysteine (NAC) vs Selenium + N-acetylcysteine (NAC)  
Safarinejad 2009 118 24.8 (2.9) 116 29.2 (2.9) 100% -4.4[-5.14,-3.66]
Subtotal *** 118   116   100% -4.4[-5.14,-3.66]
Heterogeneity: Not applicable  
Test for overall effect: Z=11.6(P<0.0001)  
   
2.4.5 Selenium vs N-acetylcysteine (NAC)  
Safarinejad 2009 116 26.1 (2.9) 118 24.8 (2.9) 100% 1.3[0.56,2.04]
Subtotal *** 116   118   100% 1.3[0.56,2.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.43(P=0)  
   
2.4.6 Selenium vs Selenium + N-acetylcysteine (NAC)  
Safarinejad 2009 116 26.1 (2.9) 116 29.2 (2.9) 100% -3.1[-3.85,-2.35]
Subtotal *** 116   116   100% -3.1[-3.85,-2.35]
Heterogeneity: Not applicable  
Test for overall effect: Z=8.14(P<0.0001)  
   
2.4.7 Zinc vs Folic acid  
Azizollahi 2013 40 49.8 (11.3) 40 51.5 (10.2) 100% -1.7[-6.42,3.02]
Subtotal *** 40   40   100% -1.7[-6.42,3.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
2.4.8 Zinc + Folic acid vs Folic acid  
Azizollahi 2013 40 52.4 (17.8) 40 51.5 (10.2) 100% 0.9[-5.46,7.26]
Subtotal *** 40   40   100% 0.9[-5.46,7.26]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.28(P=0.78)  
   
2.4.9 Zinc vs Zinc + Folic acid  
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Azizollahi 2013 40 49.8 (11.3) 40 52.4 (17.8) 100% -2.6[-9.13,3.93]
Subtotal *** 40   40   100% -2.6[-9.13,3.93]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.44)  
Test for subgroup differences: Chi2=131.07, df=1 (P<0.0001), I2=93.9%  
Favours antioxidant B 105-10 -5 0 Favours antioxidant A
 
 
Analysis 2.5.   Comparison 2 Head-to-head antioxidant(s), Outcome 5
Total sperm motility at 6 months (data not suitable for meta analysis).
Total sperm motility at 6 months (data not suitable for meta analysis)
Study Antioxidant A Antioxidant B P value
Folic acid vs Zinc + Folic acid
Wong 2002 Folic acid
Median = 35
Range = 5 - 65
"Forward motile sperm"
Zinc + Folic acid
Median = 35
Range = 5 - 70
"Forward motile sperm"
Not provided
Zinc vs Folic acid
Wong 2002 Zinc
Median = 35
Range = 10 - 65
"Forward motile sperm"
Folic acid
Median = 35
Range = 5 - 65
"Forward motile sperm"
Not provided
Zinc vs Zinc + Folic acid
Wong 2002 Zinc
Median = 35
Range = 10 - 65
"Forward motile sperm"
Zinc + Folic acid
Median = 35
Range = 5 - 70
"Forward motile sperm"
Not provided
 
 
Analysis 2.6.   Comparison 2 Head-to-head antioxidant(s), Outcome
6 Total sperm motility at 9 months or more; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.6.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 54.3 (9) 15 50.6 (5.7) 100% 3.7[-1.69,9.09]
Subtotal *** 15   15   100% 3.7[-1.69,9.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.35(P=0.18)  
   
2.6.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 54.3 (9) 15 49 (7.8) 100% 5.3[-0.73,11.33]
Subtotal *** 15   15   100% 5.3[-0.73,11.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.72(P=0.08)  
   
2.6.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 50.6 (5.7) 15 49 (7.8) 100% 1.6[-3.29,6.49]
Subtotal *** 15   15   100% 1.6[-3.29,6.49]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.52)  
Favours antioxidant B 2010-20 -10 0 Favours antioxidant A
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=0.91, df=1 (P=0.63), I2=0%  
Favours antioxidant B 2010-20 -10 0 Favours antioxidant A
 
 
Analysis 2.7.   Comparison 2 Head-to-head antioxidant(s), Outcome
7 Progessive sperm motility at 3 months or less; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.7.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 38.9 (7.1) 15 34.9 (9.2) 100% 4[-1.88,9.88]
Subtotal *** 15   15   100% 4[-1.88,9.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
   
2.7.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 38.9 (7.1) 14 33.9 (8.4) 100% 5[-0.68,10.68]
Subtotal *** 15   14   100% 5[-0.68,10.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.73(P=0.08)  
   
2.7.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 34.9 (9.2) 14 33.9 (8.4) 100% 1[-5.41,7.41]
Subtotal *** 15   14   100% 1[-5.41,7.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.31(P=0.76)  
   
2.7.4 L-acetyl carnitine + L-carnitine vs Vitamin E + Vitamin C  
Li 2005 85 23.4 (7.9) 53 10.1 (4.6) 100% 13.3[11.21,15.39]
Subtotal *** 85   53   100% 13.3[11.21,15.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=12.49(P<0.0001)  
   
2.7.5 L-carnitine vs Vitamin E + Vitamin C  
Li 2005a 32 58.3 (7.1) 31 27.8 (3.8) 100% 30.5[27.7,33.3]
Subtotal *** 32   31   100% 30.5[27.7,33.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=21.35(P<0.0001)  
   
2.7.6 L-carnitine + Vitamin E vs Vitamin E  
Wang 2010 61 45.4 (11.1) 52 31.3 (10.5) 100% 14.1[10.11,18.09]
Subtotal *** 61   52   100% 14.1[10.11,18.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=6.93(P<0.0001)  
   
2.7.7 Vitamin D + Calcium vs Vitamin E + Vitamin C  
Deng 2014 43 28.3 (4.5) 43 21.4 (2.4) 100% 6.9[5.38,8.42]
Subtotal *** 43   43   100% 6.9[5.38,8.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=8.87(P<0.0001)  
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=237.44, df=1 (P<0.0001), I2=97.47%  
Favours antioxidant B 10050-100 -50 0 Favours antioxidant A
 
 
Analysis 2.8.   Comparison 2 Head-to-head antioxidant(s), Outcome
8 Progressive sperm motility at 6 months; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.8.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 43.8 (7.1) 15 37.5 (9.2) 100% 6.3[0.42,12.18]
Subtotal *** 15   15   100% 6.3[0.42,12.18]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.1(P=0.04)  
   
2.8.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 43.8 (7.1) 14 38.1 (8.2) 100% 5.7[0.1,11.3]
Subtotal *** 15   14   100% 5.7[0.1,11.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.99(P=0.05)  
   
2.8.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 37.5 (9.2) 14 38.1 (8.2) 100% -0.6[-6.93,5.73]
Subtotal *** 15   14   100% -0.6[-6.93,5.73]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Test for subgroup differences: Chi2=2.97, df=1 (P=0.23), I2=32.56%  
Favours antioxidant B 10050-100 -50 0 Favours antioxidant A
 
 
Analysis 2.9.   Comparison 2 Head-to-head antioxidant(s), Outcome
9 Progressive sperm motility at 9 months; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.9.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 34 (7) 15 30.2 (7.8) 100% 3.8[-1.5,9.1]
Subtotal *** 15   15   100% 3.8[-1.5,9.1]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
   
2.9.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 34 (7) 14 28.5 (8.3) 100% 5.5[-0.11,11.11]
Subtotal *** 15   14   100% 5.5[-0.11,11.11]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.92(P=0.05)  
   
2.9.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 30.2 (7.8) 14 28.5 (8.3) 100% 1.7[-4.17,7.57]
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 15   14   100% 1.7[-4.17,7.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Test for subgroup differences: Chi2=0.84, df=1 (P=0.66), I2=0%  
Favours antioxidant B 10050-100 -50 0 Favours antioxidant A
 
 
Analysis 2.10.   Comparison 2 Head-to-head antioxidant(s), Outcome
10 Sperm concentration at 3 months or less; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.10.1 Docosahexaenoic acid (DHA) 400 mg vs Docosahexaenoic acid (DHA) 800
mg
 
Conquer 2000 9 37.8 (36.9) 10 44.6 (41.1) 100% -6.8[-41.87,28.27]
Subtotal *** 9   10   100% -6.8[-41.87,28.27]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
   
2.10.2 Ethylcysteine vs Vitamin E  
Akiyama 1999 5 20.1 (14.8) 5 17.9 (15.6) 100% 2.2[-16.65,21.05]
Subtotal *** 5   5   100% 2.2[-16.65,21.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.23(P=0.82)  
   
2.10.3 L-carnitine vs Vitamin E + Vitamin C  
Li 2005a 32 34.6 (7.4) 31 19.1 (4.5) 100% 15.5[12.49,18.51]
Subtotal *** 32   31   100% 15.5[12.49,18.51]
Heterogeneity: Not applicable  
Test for overall effect: Z=10.08(P<0.0001)  
   
2.10.4 L-carnitine + Vitamin E vs Vitamin E  
Wang 2010 61 58.5 (34.7) 52 56.6 (32.6) 100% 1.9[-10.52,14.32]
Subtotal *** 61   52   100% 1.9[-10.52,14.32]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.3(P=0.76)  
   
2.10.5 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 41 (17.3) 15 39.3 (18.1) 100% 1.7[-10.97,14.37]
Subtotal *** 15   15   100% 1.7[-10.97,14.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.79)  
   
2.10.6 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 41 (17.3) 15 36.9 (19.7) 100% 4.1[-9.17,17.37]
Subtotal *** 15   15   100% 4.1[-9.17,17.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
   
2.10.7 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Balercia 2005 15 39.3 (18.1) 15 36.9 (19.7) 100% 2.4[-11.14,15.94]
Subtotal *** 15   15   100% 2.4[-11.14,15.94]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
   
2.10.8 Selenium vs combined antioxidants  
Scott 1998 16 48.7 (35.2) 30 34 (34.5) 100% 14.7[-6.51,35.91]
Subtotal *** 16   30   100% 14.7[-6.51,35.91]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.36(P=0.17)  
   
2.10.9 Zinc vs Folic acid  
Azizollahi 2013 40 41.5 (40.2) 40 46.8 (42.3) 100% -5.3[-23.38,12.78]
Subtotal *** 40   40   100% -5.3[-23.38,12.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
   
2.10.10 Zinc + Folic acid vs Folic acid  
Azizollahi 2013 40 42.6 (39.9) 40 46.8 (42.3) 100% -4.2[-22.22,13.82]
Subtotal *** 40   40   100% -4.2[-22.22,13.82]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.46(P=0.65)  
   
2.10.11 Zinc vs Zinc + Folic acid  
Azizollahi 2013 40 41.5 (40.2) 40 42.6 (39.9) 100% -1.1[-18.65,16.45]
Subtotal *** 40   40   100% -1.1[-18.65,16.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.12(P=0.9)  
Test for subgroup differences: Chi2=24.5, df=1 (P=0.01), I2=59.19%  
Favours antioxidant B 10050-100 -50 0 Favours antioxidant A
 
 
Analysis 2.11.   Comparison 2 Head-to-head antioxidant(s),
Outcome 11 Sperm concentration at 6 months; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.11.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 45.5 (21.4) 15 39.6 (20) 100% 5.9[-8.92,20.72]
Subtotal *** 15   15   100% 5.9[-8.92,20.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.44)  
   
2.11.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 45.5 (21.4) 15 37.4 (16.4) 100% 8.1[-5.54,21.74]
Subtotal *** 15   15   100% 8.1[-5.54,21.74]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.24)  
   
2.11.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
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Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Balercia 2005 15 39.6 (20) 15 37.4 (16.4) 100% 2.2[-10.89,15.29]
Subtotal *** 15   15   100% 2.2[-10.89,15.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
   
2.11.4 N-acetylcysteine (NAC) vs Selenium + N-acetylcysteine (NAC)  
Safarinejad 2009 118 26.8 (5.3) 116 32.1 (6.8) 100% -5.3[-6.86,-3.74]
Subtotal *** 118   116   100% -5.3[-6.86,-3.74]
Heterogeneity: Not applicable  
Test for overall effect: Z=6.64(P<0.0001)  
   
2.11.5 Selenium vs N-acetylcysteine (NAC)  
Safarinejad 2009 116 27.6 (6.4) 118 26.8 (5.3) 100% 0.8[-0.71,2.31]
Subtotal *** 116   118   100% 0.8[-0.71,2.31]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
2.11.6 Selenium vs Selenium + N-acetylcysteine (NAC)  
Safarinejad 2009 116 27.6 (6.4) 116 32.1 (6.8) 100% -4.5[-6.2,-2.8]
Subtotal *** 116   116   100% -4.5[-6.2,-2.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.19(P<0.0001)  
   
2.11.7 Zinc vs Folic acid  
Azizollahi 2013 40 39.6 (30.5) 40 49.1 (16.8) 100% -9.5[-20.29,1.29]
Subtotal *** 40   40   100% -9.5[-20.29,1.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.73(P=0.08)  
   
2.11.8 Zinc + Folic acid vs Folic acid  
Azizollahi 2013 40 47.6 (40.4) 40 49.1 (16.8) 100% -1.5[-15.06,12.06]
Subtotal *** 40   40   100% -1.5[-15.06,12.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.83)  
   
2.11.9 Zinc vs Zinc + Folic acid  
Azizollahi 2013 40 39.6 (30.5) 40 47.6 (40.4) 100% -8[-23.69,7.69]
Subtotal *** 40   40   100% -8[-23.69,7.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
Test for subgroup differences: Chi2=41.86, df=1 (P<0.0001), I2=80.89%  
Favours antioxidant B 2010-20 -10 0 Favours antioxidant A
 
 
Analysis 2.12.   Comparison 2 Head-to-head antioxidant(s), Outcome 12
Sperm concentration at 6 months (data not suitable for meta analysis).
Sperm concentration at 6 months (data not suitable for meta analysis)
Study Antioxidant A Antioxidant B P value
Zinc vs Folic acid
Wong 2002 Zinc
Median = 16
Range = 0.6 - 80
Folic acid
Median = 14
Range = 0.9 - 130
Not provided
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Sperm concentration at 6 months (data not suitable for meta analysis)
Study Antioxidant A Antioxidant B P value
Zinc vs Zinc + Folic acid
Wong 2002 Zinc
Median = 16
Range = 0.6 - 80
Zinc + Folic acid
Median = 12
Range = 0.5 - 180
Not provided
Folic acid vs Zinc + Folic acid
Wong 2002 Folic acid
Median = 14
Range = 0.9 - 130
Zinc + Folic acid
Median = 12
Range = 0.5 - 180
Not provided
 
 
Analysis 2.13.   Comparison 2 Head-to-head antioxidant(s), Outcome
13 Sperm concentration at 9 months or more; type of antioxidant.
Study or subgroup Antioxidant A Antioxidant B Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.13.1 L-carnitine vs L-acetyl carnitine  
Balercia 2005 15 39.4 (13.9) 15 31.2 (8.6) 100% 8.2[-0.07,16.47]
Subtotal *** 15   15   100% 8.2[-0.07,16.47]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.94(P=0.05)  
   
2.13.2 L-carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 39.4 (13.9) 15 33.3 (13.6) 100% 6.1[-3.74,15.94]
Subtotal *** 15   15   100% 6.1[-3.74,15.94]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.22)  
   
2.13.3 L-acetyl carnitine vs L-carnitine + L-acetyl carnitine  
Balercia 2005 15 31.2 (8.6) 15 33.3 (13.6) 100% -2.1[-10.24,6.04]
Subtotal *** 15   15   100% -2.1[-10.24,6.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.51(P=0.61)  
Test for subgroup differences: Chi2=3.31, df=1 (P=0.19), I2=39.64%  
Favours antioxidant B 2010-20 -10 0 Favours antioxidant A
 
 
A D D I T I O N A L   T A B L E S
 
Undefined or biochemical preg-
nancy
Antioxidant Control Peto OR [CI]
Antioxidant(s) versus placebo or no treatment  
Combined antioxidants Events Total Events Total  
Galatioto 2008 1 20 0 22 8.17 [0.16 to 413.39]
Gopinath 2013 13 92 2 46 2.72 [0.88 to 8.46]
Arginine          
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Pryor 1978 2 35 2 29 0.82 [0.11 to 6.16]
Carnitines 25 154 3 145  
Sigman 2006 1 12 1 9 0.74 [0.04 to 13.02]
Peivandi 2010 3 15 0 15 8.57 [0.82 to 89.45]
Lenzi 2004 4 30 0 26 7.20 [0.95 to 54.34]
Lenzi 2003 6 43 0 43 8.37 [1.61 to 43.58]
Cavallini 2004 9 39 1 47 7.50 [2.01 to 27.98]
Coenzyme Q10 6 136 3 136  
Safarinejad 2009a 0 106 0 106 Not estimable
Balercia 2009 6 30 3 30 2.16 [0.53 to 8.82]
Nadjarzadeh 2011 0 23 0 24 Not estimable
Vitamin C + Vitamin E          
Rolf 1999 0 15 0 16 Not estimable
Vitamin E          
Ener 2016 5 28 5 28 1.00 [0.26 to 3.88]
Head-to-head antioxidant(s) Events Total Events Total  
L-acetyl carnitine + L-carnitine vs
Vitamin E + Vitamin C
         
Li 2005 10 85 2 53 2.72 [0.81 to 9.14]
L-carnitine + Vitamin E versus Vit-
amin E
         
Wang 2010 21 68 3 67 6.01 [2.49 to 14.47]
 
Table 1.   Data for undefined or biochemical pregnancy  (Continued)
 
 
Study ID Design, popu-
lation
Out-
comes
described
in meth-
ods sec-
tion
Out-
comes re-
ported on
in results
In meta-analysis
Y or N
Results Conclusions
+ = positive effect
- = negative or no effect
Akiyama
1999
Cross-over,
head-to-head
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Ethylcystein did not im-
prove sperm density
+
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Infertile men,
high ROS levels
N = 10
and motility but "sperm
function" increased and
ROS levels decreased,
compared to vitamin E
Ethylcysteine shown
to be effective for im-
provement of sperm pa-
rameters when com-
pared to vitamin E
Attallah
2013
Parallel, no
treatment
Idiopathic
athenozosper-
mia, IUI
N = 30
Conference ab-
stract
Sperm pa-
rameters,
chemical
and clini-
cal preg-
nancy
Sperm pa-
rameters,
chemical
and clini-
cal preg-
nancy
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
NAC increased sperm
concentration and
motility
Clinical pregnancy was
not significantly differ-
ent between the groups
+
NAC improves semen
quality and improves
pregnancy rates prior to
IUI, no improvement of
pregnancy rate
Azizollahi
2013
Multiple arm
trial
Men post-varic-
ocelectomy
N = 160
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
Mild improvement in
sperm parameters with
the use of antioxidants
zinc, folic acid or both
+
Co-administration of
zinc and folic acid im-
proved sperm para-
meters and increased
varicocelectomy out-
comes, only zinc an im-
provement in pregnan-
cy rate
Balercia
2005
Multiple arm,
placebo
Infertile men
N = 60
Sperm pa-
rameters
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
Y - live birth
Improvement in motili-
ty in LAC group.
+
Long-term carnitine is
effective in increasing
sperm motility. No evi-
dence of increased live
birth or clinical preg-
nancy.
Balercia
2009
Parallel, place-
bo
Infertile and
unexplained
N = 60
Sperm pa-
rameters
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
Co enzyme Q10 in-
creased sperm motility.
+
Q10 effective in improv-
ing sperm kinetic fea-
tures in asthenosper-
mia. No evidence of in-
creased live birth or
clinical pregnancy.
Barekat
2016
Parallel, no
treatment
Subfertile men
with varicocele
N = 40
Sperm pa-
rameters,
DNA frag-
mentation
Sperm pa-
rameters,
DNA frag-
menta-
tion, clin-
ical spon-
taneous
pregnan-
cies
Y - sperm parame-
ters
Y - DNA fragmen-
tation
Y - pregnancy rate,
clinical
(SEs converted to
SDs)
Sperm parameters sig-
nificantly improved af-
ter surgery compared to
before surgery in both
the NAC and control
groups. NAC might have
an additional value by
improving sperm motil-
ity post-varicocelecto-
my
+
The results of this study
revealed that NAC im-
proved chromatin in-
tegrity and pregnan-
cy rate when adminis-
tered as adjunct thera-
py post-varicocelecto-
my
Biagiotti
2003
Multiple arm,
no treatment
Sperm pa-
rameters
Sperm pa-
rameters
N - no data avail-
able
A significant improve-
ment in morphology
+
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Severe idio-
pathic oligoas-
thenospermia
N = 42
Conference ab-
stract
concentration, motility
in the carnitine group
No side effects
Quality of semen is pos-
itively associated with
fertilisation and implan-
tation rates in assisted
reproduction
Blomberg
Jensen
2018
Parallel, place-
bo
Infertile men
with impaired
semen quality
N = 307
Sperm pa-
rameters,
reproduc-
tive hor-
mones,
live birth
rate
Sperm pa-
rameters,
reproduc-
tive hor-
mones,
live birth
rate
Y - sperm parame-
ters
Y - live birth rate
Vitamin D was not as-
sociated with changes
in semen parameters,
although spontaneous
pregnancies tended to
be
higher in couples in
which the man was in
the treatment group
±
Vitamin D did not im-
prove semen quality.
The positive impact of
vitamin D supplemen-
tation on live birth rate
and serum inhibin B in
oligozoospermic and vi-
tamin D–deficient men
may be of clinical im-
portance and warrant
verification by others.
Boon-
yarangkul
2015
Multiple arm,
placebo, ta-
moxifen exclud-
ed
Men with ab-
normal semen
analysis
N = 68
Sperm
parame-
ters, DNA
damage
(Comet
assay)
Sperm pa-
rameters,
DNA tail
length
Y - sperm parame-
ters
Folate alone significant-
ly decreased DNA tail
length at 3-months.
Sperm motility was sig-
nificantly increased af-
ter 3-months Folate
alone.
+
Our study indicated
that folate in combi-
nation with Tamoxifen
citrate could improve
sperm quality including
semen parameters and
sperm DNA integrity
Busetto
2018
Parallel, place-
bo
Infertile men
with OAT, 50%
included with
varicocele
N = 104
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
Sperm
concentration, total
sperm count, progres-
sive and total motility
were significantly in-
creased in supplement-
ed (Proxeed Plus) pa-
tients. Increased preg-
nancy rate
+
Supplementation
with metabolic and an-
tioxidant compounds
could be efficacious
when included in
strategies to improve
fertility
Cavallini
2004
Multiple arm,
placebo
Idiopathic OAT
men with varic-
ocele
N = 325
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
N - sperm para-
meters, only me-
dians given in full
text. Means in con-
ference abstract
but no data giv-
en for placebo
group and data for
group 3 (carnitine
+ cinoxacin) ver-
sus group 2 (car-
nitines) unable to
be used as 3 in-
cludes cinoxacin
an anti-inflamma-
tory drug. Analy-
sis 1.12; Analysis
Significant increase in
sperm parameters for
carnitines when com-
pared to placebo.
Carnitine groups had
a significantly higher
pregnancy rate than
placebo group
+
The antioxidant plus
anti-inflammatory
group was more effec-
tive in improving sperm
parameters and preg-
nancy than those of car-
nitines alone or place-
bo however carnitines
alone were more effec-
tive than placebo
Table 2.   Outcomes and conclusions from all included studies  (Continued)
Antioxidants for male subfertility (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
211
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
1.14; Analysis 1.24;
Analysis 1.26
N - pregnancy
rate, unclear if
clinical Table 1
Y - adverse events
Conquer
2000
Multiple arm,
placebo
Astheno-
zoospermic
men
N = 28
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
(SEs converted to
SDs)
DHA showed no effect
on sperm motility or
concentration
±
DHA supplementation
increased DHA levels
in the sperm but not
motility or concentra-
tion
Cyrus
2015
Parallel, place-
bo
Infertile men
with varicocele
N = 115
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Vitamin C was not effec-
tive on sperm count but
improved sperm motili-
ty and morphology sig-
nificantly
+
Ascorbic acid can play
a role as adjuvant treat-
ment
after varicocelectomy
in infertile men
Dawson
1990
Multiple arm,
placebo
Men with sperm
agglutination
N = 30
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
(SEs converted to
SDs)
The group receiving
1000 mg of AA showed
more improvement in
parameters than the
200mg group and the
placebo
+
Vitamin C can improve
sperm parameters, es-
pecially dosage of 1000
mg.
Deng 2014 Head-to-head
Men with idio-
pathic oligoas-
thenozoosper-
mia
N = 86
Sperm pa-
rameters,
adverse
reactions,
pregnan-
cy rate
Sperm pa-
rameters,
adverse
reactions,
pregnan-
cy rate
Y - sperm parame-
ters
Y - clinical preg-
nancy rate
Vitamin D is a safe op-
tion for the treatment
of idiopathic oligoas-
thenozoospermia and
can effectively improve
the semen quality
especially the progres-
sive sperm motility
+
Vitamin D can improve
forward movement
sperm number and per-
centage, improve the
woman's clinical preg-
nancy rate, and is well
tolerated
Dimitri-
adis 2010
Multiple arm,
no treat-
ment, varde-
nafil/sildenafil
arms excluded
Men with
oligoas-
thenospermia
N = 75
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
An improvement in
sperm concentration
with carnitine versus no
treatment
+
Enhancement of Leydig
cell secretory function
may increase sperm
concentration and
motility
Ener 2016 Parallel, no
treatment
Infertile men
with varicocele
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
N - pregnancy
rate, unknown if
clinical Table 1
The administration of
vitamin
E increased all of the
parameters; however
not statistically signifi-
cant
-
Vitamin E supplementa-
tion does not
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N = 56 improve the sperm pa-
rameters after varicoc-
electomy
Eslamian
2013
Parallel, place-
bo
Asthenos-
zoospermic
men
N = 50
Sperm pa-
rameters
sperm pa-
rameters,
sperm
mem-
brane and
serum fat-
ty acids
N - sperm parame-
ters, data not us-
able, no continu-
ous data but cate-
gories from 'signif-
icantly improve-
ment' to 'wors-
ened'
Sperm parameters im-
proved with DHA + vita-
min E supplementation
+
Sperm parameters im-
prove with DHA + vita-
min E supplementation
Exposito
2016
Parallel, place-
bo
Normozoosper-
mig, oligo-
zoospermic
and astheno-
zoospermic
men
N = 113
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
N - sperm parame-
ters
N - pregnancy rate
Both not includ-
ed because data
included normo-
spermic men
50% of oligozoosper-
mic men improved
sperm concentration
and sperm count to
normozoospermic lev-
els. This trend was al-
so observed in astheno-
zoospermic men, but
nog significantly
+
Vitamin E treatment by
oral administration im-
proves semen parame-
ters
Galatioto
2008
Parallel, no
treatment
Men with
persistent
oligospermia
after embolisa-
tion of varico-
cele
N = 42
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
N - sperm parame-
ters, only medians
given
N - pregnancy, un-
clear if clinical Ta-
ble 1
N - adverse events
Significant difference
in sperm count in com-
bined antioxidant
group but not in motili-
ty.
One pregnancy in the
NAC group
No significant adverse
effects
±
NAC does not improve
pregnancy rate, no sig-
nificant adverse events,
but do significantly in-
crease sperm count
Gamidov
2017
Multiple arm,
no treatment
Men with varic-
ocele
N = 114
Sperm
parame-
ters, DNA
fragmen-
tation,
adverse
events
Sperm
parame-
ters, DNA
fragmen-
tation,
adverse
events
N - sperm parame-
ters, only medians
with IQR Analysis
1.18; Analysis 1.24;
Analysis 1.24
N - DNA fragmen-
tation, only me-
dians with IQR
Analysis 1.10
Y - adverse events
SpermActine (SA) re-
sulted in a 22.3% de-
crease in the level of
sperm DNA fragmenta-
tion at 3 months. SA +
vitamin complex result-
ed in a 27% increase in
the sperm concentra-
tion at 3 months. There
were no side effects of
pharmacotherapy.
+
Antioxidant therapy
leads to an improve-
ment in the basic sperm
parameters (sperm con-
centration and motil-
ity) and a decrease in
the level of sperm DNA
fragmentation in the
short term. There were
no side effects
Gopinath
2013
Multiple arm,
placebo
Idiopathic OAT
men
N = 138
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Y - sperm parame-
ters
N - pregnancy
rate, not clinical
Table 1
Y - adverse events
Combined antioxidant
significantly improved
sperm count and to-
tal motility in both
treatment arms (1 vs 2
tablets). Mild adverse
events were reported,
no severe.
+
Exogenous administra-
tion of fixed dose com-
bination of antioxidants
is safe and effective
therapy in improving
the male subfertility re-
garding sperm parame-
ters. Only mild adverse
Table 2.   Outcomes and conclusions from all included studies  (Continued)
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events when using com-
bined antioxidants
Greco
2005
Parallel, place-
bo
Infertile males
with high DNA
fragmentation
N = 64
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
No significant differ-
ence in concentration
or motility however
DNA fragmentation was
significantly reduced in
the vitamin C + E when
compared to placebo
+
A short oral treatment
of Vitamin C + E can re-
duce DNA fragmenta-
tion
Haghighi-
an 2015
Parallel, place-
bo
Men with idio-
pathic astheno-
zoospermia
N = 48
Sperm pa-
rameters,
adverse
events
Sperm pa-
rameters,
adverse
events
Y - sperm parame-
ters
N - adverse
events, reported
"none", however
not clear which
side effects they
aimed for
Sperm parameters were
significantly
higher in ALA group. No
side effects due to the
oral administration of
ALA were observed in
any participants.
+
Medical therapy of as-
thenoteratospermia
with ALA supplement
could improve quality
of semen parameters
Haje 2015 Multiple arm,
placebo, ta-
mofixen arms
excluded
Infertile men
with idiopathic
OAT
N = 128
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
N - sperm para-
meters, range of
treatment 3 - 6
months and not
divided
N - pregnancy
rate, unclear if
pregnancy and no
numbers but per-
centage
L-carnitine no improve-
ment of sperm count
or motility. Only ta-
moxifen or tamofixen
+ L-carnitine improved
pregnancy rate, not sig-
nificantly.
±
Administration of ta-
moxifen or L-carnitine
can improve sperm
parameters and ICSI
outcomes. Combining
those result in maxi-
mum therapeutic effect
Kessopoulou
1995
Cross-over,
placebo
Male infertility
N = 30
Sperm pa-
rameters,
adverse
events,
live birth
Sperm pa-
rameters,
adverse
effects,
live birth
N - sperm parame-
ters, only medi-
ans given Analysis
1.12; Analysis 1.24
Y - pregnancy rate,
clinical
Y - live births
Y - adverse events
No differences in sperm
outcomes were seen
between the groups. 1
pregnancy in the vita-
min E group and nil in
the placebo (first phase
data)
+
No difference in semen
parameters. There is ev-
idence of increased live
birth and clinical preg-
nancy rate.
Kumamo-
to 1988
Multiple arm,
placebo
Men with ab-
normal sperm
count or motil-
ity
N = 396
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, only scales
given
No statistical difference
in sperm outcomes in
vitamin B 12 groups or
placebo
-
No improvement in
sperm parameters after
use of vitamin B12
Lenzi 2003 Cross-over,
placebo
Infertile men
with OAT
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
N - pregnancy
rate, no definition
The patient groups
showed no differences
in sperm outcomes be-
tween therapy (car-
nitine) and placebo
groups.
+
The pregnancies ob-
tained during the car-
nitine therapy period
could suggest that car-
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N = 100 of pregnancy giv-
en see Table 1
Six pregnancies in the
carnitine group and
nil in the placebo (first
phase)
nitines may also lead to
improvement in sperm
function and fertilisa-
tion
Lenzi 2004 Parallel, place-
bo
Infertile men
with OAT
N = 60
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Y - sperm parame-
ters
N - pregnancy
rate, no definition
of pregnancy giv-
en Table 1
N - adverse events
Four participants tak-
ing carnitine induced a
pregnancy in their part-
ner and nil in the place-
bo
+
No evidence of im-
proved sperm parame-
ters
Li 2005 Head-to-head
Infertile men
with OAT
N = 150
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
N - pregnancy
rate, no definition
given Table 1
L-carnitine and acetyl
carnitine more effec-
tive than vitamin E + vi-
tamin C for pregnancy,
sperm parameters and
no evidence of adverse
events
+
L-carnitine and acetyl
carnitine more effec-
tive than vitamin E + vi-
tamin C for pregnancy,
sperm parameters and
no evidence of adverse
events
Li 2005a Head-to-head
Infertile men
with OAT
N = 80
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Statistical significance
for carnitines over vita-
min E + C
+
Improvement of sperm
parameters for car-
nitines compared to vit-
amin E + C
Lombardo
2002
Cross-over
Infertile men
with OAT
N = 100
Conference ab-
stract
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, no data avail-
able
Sperm parameters
(concentration, motil-
ity) carnitines versus
placebo
+
Improvement of sperm
parameters
Martinez
2015
Multiple arm,
placebo,
SG1002 arm ex-
cluded
Men with idio-
pathic OAT
N = 54
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, no SDs given
Resveratrol
treatment did not sig-
nificantly affect any of
the parameters.
-
Resveratrol treatment
did not significantly af-
fect any of the para-
meters. SG1002 may
reverse oligoastheno-
zoospermia. It seems to
be more potent antioxi-
dant than resveratrol
Mar-
tinez-Soto
2010
Parallel, place-
bo
Infertile men
N = 50
Conference ab-
stract + manu-
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
No differences were
found in
traditional sperm pa-
rameters or lipid com-
position of the sperm
membrane after DHA
treatment, only reduc-
tion in the percentage
+
Positive effect only on
DNA fragmentation
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script from au-
thor
of spermatozoa with
DNA damage
Mehni
2014
Multiple arm,
placebo, pen-
toxifylline arms
excluded
Infertile men
with OAT
N = 235
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
L-carnitine only im-
proved sperm motility,
combined with pentox-
ifylline it improves all
sperm parameters.
+
Positive effect only
sperm motility
Micic 2017 Parallel, place-
bo
Men with OAT
N = 175
Conference ab-
stract
Sperm
motility
Sperm
motility
N - sperm motil-
ity, data given in
medians with IQR
Analysis 1.18
Proxeed Plus signifi-
cantly improved pro-
gressive sperm motility
+
Proxeed Plus significant
improvement in per-
centage of progressive
sperm motility after
six months of therapy
and also underlines the
importance of dura-
tion of therapy (3 and 6
months)
Morgante
2010
Parallel, no
treatment
Infertile men
with idiopath-
ic asthenosper-
mia
N = 180
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Significant improve-
ment in sperm motility.
+
Improvement of sexual
satisfaction
Significant improve-
ment in sperm motility
Nad-
jarzadeh
2011
Parallel, place-
bo
Men with Idio-
pathic OAT
N = 60
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Non-significant changes
in semen parameters of
CoQ10 group.
-
CoQ10 further evidence
suggesting that supple-
mentation is associat-
ed with alleviating ox-
idative stress, although
it does not show any
significant effects on
sperm concentration,
motility and morpholo-
gy
Nozha
2001
Head-to-head
Men with OAT
N = unclear, 20?
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, no data avail-
able
Vitamin E + selenium
significantly improves
sperm motility
+
Vitamin E + selenium
associated with im-
proved sperm motility
when compared with vi-
tamin B
Omu 1998 Parallel, no
treatment
Men with as-
thenozooper-
mia
Sperm pa-
rameters
Sperm pa-
rameters,
pregnan-
cy, live
birth
N - sperm para-
meters, only %
increase or de-
crease, not usable
Significant improve-
ment in sperm quality
by zinc therapy
+
Zinc has a role in im-
proving sperm para-
meters. Significant in-
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N = 100 Y - pregnancy rate,
clinical
Y - live birth
crease in pregnancy,
not live birth
Omu 2008 Multiple arm,
no treatment
Men with as-
thenozoosper-
mia
N = 100
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Zinc therapy alone, in
combination with vita-
min E or with vitamin E
+C were associated with
comparably improved
sperm parameters and
less sperm DNA frag-
mentation
+
Zinc therapy reduces
asthenozoospermia
Peivandi
2010
Cross-over,
placebo
Infertile men
N = 30
Sperm pa-
rameters
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
N - pregnancy
rate, no defined as
clinical Table 1
Significant improve-
ments in mean sperm
concentration and pro-
gressive sperm motili-
ty upon two months of
L-carnitine intake but
no significant changes
were found in sperm
volume or morphology.
+
Sperm outcomes and
biochemical pregnan-
cies. L-carnitine intake
effectively improved
the mean sperm count
and progressive sperm
motility
Pour-
mand
2014
Parallel, no
treatment
Men with male
factor infertility
and varicocele
N = 100
Sperm
parame-
ters, DNA
fragmen-
tation,
adverse
events
Sperm
parame-
ters, DNA
fragmen-
tation,
adverse
events
N - sperm parame-
ters, no SD given
N - DNA fragmen-
tation, no SD giv-
en
Y - adverse events
No statistical differ-
ence between the two
groups (varicocelecto-
my with L-carnitine or
with no adjuvant thera-
py).
-
Addition of 750 mg of L-
carnitine orally daily to
standard inguinal varic-
ocelectomy does not
add any extra benefit in
terms of improvement
in semen analysis para-
meters or
DNA damage
Poveda
2013
Multiple arm,
placebo
Infertile men
N = 60
Conference ab-
stract
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm para-
meters, data not
available
L-carnitine significant-
ly improves sperm
concentration, Sper-
motrend and Maca im-
prove sperm motility.
+
Sperm concentration
with L-carnitine and
motility with com-
bined antioxidant Sper-
motrend
Pryor
1978
Cross-over,
placebo
Men with se-
vere oligo-
zoospermia
N = 64
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
N - sperm parame-
ters, bar graph of
% patients show-
ing an increase in
motility and den-
sity
N - pregnancy
rate, not clear if
clinical. Includ-
ed in biochemical
analysis Table 1
Arginine was no more
effective than placebo
for sperm parameters
and biochemical preg-
nancy rates
-
There was no difference
in the conception rates
of the wives or changes
in the quality of the se-
men during each period
of treatment
Raigani
2014
Multiple arm,
placebo
Sperm pa-
rameters,
Sperm pa-
rameters,
N - sperm para-
meters, data pro-
Sperm concentration,
DNA fragmentation not
-
Table 2.   Outcomes and conclusions from all included studies  (Continued)
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Men with
proven male
factor infertility
N = 83
DNA frag-
mentation
DNA frag-
mentation
vided in medians
with IQR
Y - DNA fragmen-
tation (mean with
SD)
significantly improved
in either group
Zinc sulphate and folic
acid supplementa-
tion did not ameliorate
sperm quality in infer-
tile men with
severely compromised
sperm parameters, OAT
Rolf 1999 Asthenosper-
mia
(N = 33)
Sperm pa-
rameters,
pregnan-
cy rates,
adverse
events
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Y - sperm parame-
ters
N - pregnancy
rate, not stated as
clinical pregnancy
N - adverse
events, not clear
which side effects
aimed for
No adverse events or
pregnancies in either
group
-
Overall no difference
vitamin E + C versus
placebo
Safarine-
jad 2009
Multiple arm,
placebo
Men with idio-
pathic OAT
N = 468
Sperm pa-
rameters,
adverse
events
Sperm pa-
rameters,
adverse
events
Y - sperm parame-
ters
N - adverse
events, not speci-
fied which adverse
events aimed for
All semen parameters
significantly improved
with selenium and N-
acetyl-cysteine treat-
ment. Administering se-
lenium plus N-acetyl-
cysteine resulted in ad-
ditive beneficial effects.
Zero adverse events
+
Supplemental selenium
and N-acetyl-cysteine
improve semen quality.
Zero adverse events
Safarine-
jad 2009a
Parallel, place-
bo
Men with idio-
pathic OAT
N = 212
Sperm pa-
rameters,
adverse
events
Sperm pa-
rameters,
adverse
events
Y - sperm parame-
ters
N - adverse
events, not speci-
fied which adverse
events aimed for
Significant improve-
ment in sperm density
and motility after coen-
zyme Q10 therapy. Zero
adverse events
+
Coenzyme Q10 supple-
mentation resulted in a
statistically significant
improvement in certain
sperm parameters. Zero
adverse events
Safarine-
jad 2012
Parallel, place-
bo
Infertile men
N = 228
Sperm pa-
rameters
Sperm pa-
rameters
Y - sperm parame-
ters
Sperm parameters im-
proved significantly af-
ter coenzyme Q10
+
Coenzyme Q10 was sig-
nificantly effective in
men with unexplained
oligoasthenoterato-
zoospermia for im-
proving sperm densi-
ty, sperm motility and
sperm morphology
Scott 1998 Multiple arm,
placebo
Men with sub-
fertility and low
sperm motility
N = 69
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
N - pregnancy
rate, not usable
due to pooling of
data in the two in-
tervention groups
Table 1
Sperm motility in-
creased in both sele-
nium-treated groups,
only significant if both
treatment groups were
combined. Sperm den-
sity unaffected
±
Selenium supplemen-
tation in subfertile men
with low selenium sta-
tus can improve sperm
motility and the chance
of successful concep-
tion. However, not all
patients responded;
Table 2.   Outcomes and conclusions from all included studies  (Continued)
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56% showed a positive
response to treatment
Shar-
ifzadeh
2016
Parallel, place-
bo
Idiopathic sub-
fertile men
N = 114
Sperm pa-
rameters,
adverse
events
Sperm pa-
rameters,
adverse
events
Y- sperm parame-
ters
Y - adverse events
Significant increase in
concentration in zinc
group
+
Normal sperm per-
centage and total
sperm concentration in-
creased after zinc sul-
phate treatment
Sigman
2006
Parallel, place-
bo
Infertile men
with low sperm
motility
N = 26
Sperm pa-
rameters,
pregnan-
cy rate
Sperm pa-
rameters,
pregnan-
cy rate
Y - sperm parame-
ters
N - pregnancy
rate, biochemical
Table 1
No statistically signifi-
cant or clinically signif-
icant increase in motili-
ty or total motile sperm
counts between base-
line, 12 week, or 24
weeks in the carnitine
or placebo arms.
-
Carnitine supplementa-
tion demonstrated no
clinically or statistical-
ly significant effect on
sperm motility or total
motile sperm counts.
No difference in preg-
nancy rate
Sivkov
2011
Parallel, place-
bo
Men with
chronic prosta-
titis and infertil-
ity
N = 30
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, no SD given
Analysis 1.12
One-month course of
therapy produced no
side effects, had a posi-
tive effect on low fertili-
ty of ejaculate.
+
Selenium + zinc im-
prove
Sofikitis
2016
Multiple arm,
no treatment,
Avanafil exclud-
ed
Oligoas-
thenospermic
infertile men
N = 39
Abstract only
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, no data avail-
able
No significant differ-
ence in L-carnitine
group regarding sperm
parameters
-
No direct conclusion
made about L-carni-
tine. From result sec-
tion concluded: no im-
pact on sperm parame-
ters after use of L-carni-
tine
Suleiman
1996
Parallel, place-
bo
Asthenosper-
mic men
N = 110
Sperm pa-
rameters
Sperm pa-
rameters,
pregnan-
cy rate,
live birth,
miscar-
riage
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
Y - live birth
Y - adverse events:
miscarriage
Vitamin E significant-
ly decreased the MDA
concentration in sper-
matozoa and improved
sperm motility. Signifi-
cant increase pregnan-
cy/live birth rate
+
Vitamin E increases
sperm motility, preg-
nancy rate and live birth
rate compared to place-
bo
Tremellen
2007
Parallel, place-
bo
Male factor in-
fertility
Pregnan-
cy rate,
adverse
events
Pregnan-
cy rate,
adverse
events,
live birth
Y - pregnancy rate,
clinical
Y - live birth
Y - adverse events
Antioxidant group
recorded a statistical-
ly significant improve-
ment in viable pregnan-
cy rate. Side-effects on
the Menevit antioxidant
+
Menevit antioxidant ap-
pears to be a useful an-
cillary treatment that
significantly improves
Table 2.   Outcomes and conclusions from all included studies  (Continued)
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N = 60 provided
by author
were rare (8%) and mild
in nature.
pregnancy rates in cou-
ples undergoing IVF-
ICSI treatment. Side-ef-
fects on the Menevit an-
tioxidant were rare (8%)
and mild in nature.
Wang
2010
Head-to-head
Infertile men
with astheno-
zoospermia
N = 135
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Sperm pa-
rameters,
pregnan-
cy rate,
adverse
events
Y - sperm parame-
ters
N - pregnancy
rate, not clear if
clinical Table 1
N - adverse
events, zero
found, however
not clear which
they aimed for
Significant increase in
L-carnitine + vitamin E
group for sperm motil-
ity, no difference for
sperm density and mor-
phology. Pregnancy
rate significantly higher
in L-carnitine + vitamin
E group
+
L-carnitine (+vitamin E)
significantly improves
sperm motility and
pregnancy rate
Wong
2002
Multiple arm,
placebo
Fertile and sub-
fertile men
N = 103
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, only medians
provided Analy-
sis 1.14; Analysis
1.26; Analysis 2.5;
Analysis 2.12
Subfertile men demon-
strated a significant
74% increase in total
normal sperm count
and a minor increase of
4% abnormal sperma-
tozoa
+
Total normal sperm
count increases after
combined zinc sulphate
and folic acid treatment
in both subfertile and
fertile men
Zalata
1998
Head-to-head,
pilot
Men attending
andrology clinic
N = 22
Conference ab-
stract
Sperm pa-
rameters
Sperm pa-
rameters
N - sperm parame-
ters, only before
and after median
data given
No significant differ-
ence in sperm para-
meters after treat-
ment (acetyl-cysteine
or DHA). DNA damage
measured by oh8dG
(fmol/ug) was signifi-
cantly decreased after
supplementation
-
No improvement of
sperm parameters
Zavaczki
2003
Parallel, place-
bo
Men with idio-
pathic infertility
N = 20
Sperm
parame-
ters, clin-
ical preg-
nancy,
adverse
events
Sperm
parame-
ters, clin-
ical preg-
nancy,
adverse
events
Y - sperm parame-
ters
Y - pregnancy rate,
clinical
Y - adverse events
No significant changes
in sperm characteristics
were detected
-
Magnesiumt neither
leads to a significant
improvement of sperm
variables nor does it in-
crease the pregnancy
rates
Table 2.   Outcomes and conclusions from all included studies  (Continued)
DHA: docosahexaenoic acid; IUI: intrauterine insemination; NAC: N-acetylcysteine; OAT:oligoasthenoteratozoospermia; ROS: reactive
oxygen species
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Keywords CONTAINS "antioxidants" or "antioxidant levels" or "vitamin" or "vitamin A" or "vitamin B" or "Vitamin-B-12" or "Vitamin-B-12-
Therapeutic-Use" or "vitamin B6" or "vitamin C" or "Vitamin D" or "vitamin E" or "vitamins" or "selenium" or "folic acid" or "glutathione"
or "Menevit anti-oxidant" or "carnitene" or "ascorbic acid" or "zinc" or "fatty acids" or "oil" or "fish oils" or "plant extracts" or "flavonoids"
or "L-arginine" or "pycnogenol" or "folate" or "ubiquinol "or "coenzyme Q10"or "L-carnitin" or "L-carnitine" or "multivitamins" or
"beta-caritine" or "N-acetyl cysteine" or "L-acetyl-carnitine" or "acetyl L-carnitine" or "acetylcysteine" or "ethylcysteine" or "alpha
tocopherol" or "pentoxifylline" or "omega-3"or "omega-6 fatty acid" or "inositol" or "Myo-inositol" or "d-chiro-inositol" or "melatonin"
or "docosahexaenoic acid" or "Magnesium" or "nutritional supplement" or "nutritional supplements" or Title CONTAINS "antioxidants"
or "antioxidant levels" or "vitamin" or "vitamin A" or "vitamin B" or "Vitamin-B-12" or "Vitamin-B-12-Therapeutic-Use" or "vitamin B6" or
"vitamin C" or "nutritional supplement" or "nutritional supplements"
AND
Keywords CONTAINS "idiopathic asthenospermia" or "idiopathic oligozoospermia" or "IVF" or "ICSI" or "Intrauterine Insemination" or
"ART" or "Sperm" or "sperm DNA integrity" or "sperm damage" or "sperm quality" or "sperm parameters" or "oligo-asthenozoospermia"
or "Oligoasthenospermia" or "oligoasthenoteratozoospermia" or "oligospermia" or "oligozoospermia" or "asthenospermia" or
"asthenozoospermia" or "assisted reproduction techniques" or "azoospermia" or "Male" or "male subfertility" or Title CONTAINS
"idiopathic asthenospermia" or "idiopathic oligozoospermia" or "Sperm" or "sperm DNA integrity" or "sperm damage" or "sperm quality"
or "sperm parameters" or "oligo-asthenozoospermia" or "Oligoasthenospermia" or "oligoasthenoteratozoospermia" or "oligospermia" or
"oligozoospermia" or "asthenospermia" or "asthenozoospermia" or "assisted reproduction techniques" or "azoospermia" or "Male" (318
hits)
Appendix 2. CENTRAL Register of Studies Online (CRSO) search strategy
Searched 1 Febuary 2018
Web platform
#1 MeSH descriptor: [Infertility, Male] explode all trees 664
#2 asthenozoospermia or oligospermia or azoospermia:ti,ab,kw 462
#3 Asthenospermia or Teratospermia:ti,ab,kw 75
#4 MeSH descriptor: [Spermatozoa] explode all trees 440
#5 Sperm*:ti,ab,kw 3994
#6 male subfertility:ti,ab,kw 197
#7 male infertility:ti,ab,kw 1604
#8 subfertile men:ti,ab,kw 48
#9 infertile men:ti,ab,kw 265
#10 semen:ti,ab,kw 1255
#11 oligoasthenoteratozoospermia:ti,ab,kw 25
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 5016
#13 MeSH descriptor: [Antioxidants] explode all trees 4250
#14 antioxidant*:ti,ab,kw 8353
#15 radical scavenger*:ti,ab,kw 687
#16 MeSH descriptor: [Vitamins] explode all trees 2263
#17 vitamin*:ti,ab,kw 19677
#18 MeSH descriptor: [Zinc] explode all trees 1393
#19 zinc:ti,ab,kw 4285
#20 MeSH descriptor: [Selenium] explode all trees 584
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#21 Selenium:ti,ab,kw 1456
#22 Glutathione or folate:ti,ab,kw 4279
#23 ubiquin$ or folic acid:ti,ab,kw 3446
#24 coenzyme q10:ti,ab,kw 524
#25 MeSH descriptor: [Carnitine] explode all trees 559
#26 carnitine$ or carotenoid 1792
#27 astaxanthin$ or lycopene 564
#28 menevit 3
#29 multivitamin$ 904
#30 betacarotene$ or beta carotene$ 1694
#31 ascorbic acid 3534
#32 acetylcysteine 1587
#33 MeSH descriptor: [Acetylcysteine] explode all trees 738
#34 Acetylcysteine 1587
#35 cysteine or ethylcysteine 1083
#36 alpha-tocopherol$ 2596
#37 fish oil$ 2286
#38 omega$ 4656
#39 MeSH descriptor: [Fatty Acids] explode all trees 19683
#40 fatty acid$ 10373
#41 arginine or flavonoid or carotenoid or riboflavin 5416
#42 pycnogenol$ or lutein$ or lipoic acid$ or Inositol 1626
#43 MeSH descriptor: [Inositol] explode all trees 340
#44 myoinositol or mesoinositol or melatonin 1767
#45 cysteine or docosahexaenoic or magnesium 9176
#46 nutritional supplement$ 2441
#47 nutraceutical$ 383
#48 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 73432
#49 #12 and #48 419
Appendix 3. MEDLINE search strategy
Searched 1946 to 1 Febuary 2018
OVID platform
1 exp male infertility/ (25443)
2 (asthenozoospermia or oligospermia or azoospermia).tw. (6718)
3 Asthenospermia.tw. (319)
4 Teratospermia.tw. (157)
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5 exp Spermatozoa/ (61935)
6 Sperm$.tw. (123530)
7 (male$ adj2 subfertil$).tw. (716)
8 (male$ adj2 infertil$).tw. (10031)
9 (subfertil$ adj2 men).tw. (493)
10 (infertil$ adj2 men).tw. (4006)
11 (male$ adj2 fertility).tw. (5274)
12 semen.tw. (26643)
13 oligoasthenoteratozoospermi$.tw. (360)
14 or/1-13 (153999)
15 exp antioxidants/ or free radical scavengers/ (411638)
16 (antioxidant$ or radical scavengers).tw. (161958)
17 exp vitamins/ or exp ascorbic acid/ or exp dehydroascorbic acid/ or exp vitamin a/ or exp vitamin e/ or exp vitamin u/ or exp alpha-
tocopherol/ or exp beta carotene/ or exp beta-tocopherol/ or exp gamma-tocopherol/ (318144)
18 vitamin$.tw. (184483)
19 exp Zinc/ (55556)
20 exp Selenium/ (18842)
21 (Glutathione$ or folate).tw. (134066)
22 exp Glutathione Peroxidase/ or exp folic acid/ (52442)
23 exp Ubiquinone/ (8226)
24 (ubiquin$ or folic acid).tw. (25733)
25 coenzyme q10.tw. (2906)
26 exp Carnitine/ (8935)
27 (carnitine$ or carotenoid$).tw. (30261)
28 (astaxanthin$ or lycopene$).tw. (5723)
29 menevit.tw. (3)
30 multivitamin$.tw. (3391)
31 (betacarotene$ or beta carotene$).tw. (12411)
32 ascorbic acid.tw. (28266)
33 n-acetylcysteine.tw. (9954)
34 exp Acetylcysteine/ (11959)
35 Acetylcysteine.tw. (10732)
36 Acetyl cysteine.tw. (3094)
37 Acetyl-carnitine.tw. (168)
38 ethylcysteine.tw. (62)
39 alpha-tocopherol$.tw. (14639)
40 (fish adj2 oil$).tw. (9589)
41 omega$.tw. (44863)
42 exp fatty acids/ or exp fish oils/ or exp cod liver oil/ or exp fatty acids, omega-3/ or exp plant oils/ (448639)
43 fatty acid$.tw. (185377)
44 (plant adj4 oil$).tw. (2449)
45 arginine.tw. (88608)
46 flavonoid$.tw. (32547)
47 carotenoid$.tw. (17021)
48 riboflavin$.tw. (9284)
49 pycnogenol$.tw. (345)
50 lutein$.tw. (36115)
51 lipoic acid$.tw. (3967)
52 exp Inositol/ (22263)
53 (Inositol or myoinositol).tw. (35152)
54 mesoinositol.tw. (36)
55 melatonin.tw. (21226)
56 n acetyl cysteine.tw. (3045)
57 docosahexaenoic acid.tw. (10078)
58 magnesium.tw. (51372)
59 nutritional supplement$.tw. (5235)
60 (diet$ adj3 supplement$).tw. (36417)
61 nutraceutical$.tw. (4403)
62 or/15-61 (1623704)
63 randomized controlled trial.pt. (452080)
64 controlled clinical trial.pt. (92108)
65 randomized.ab. (400977)
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66 placebo.tw. (190947)
67 clinical trials as topic.sh. (182333)
68 randomly.ab. (283901)
69 trial.ti. (176948)
70 (crossover or cross-over or cross over).tw. (75086)
71 or/63-70 (1155842)
72 (animals not (humans and animals)).sh. (4385913)
73 71 not 72 (1063162)
74 14 and 62 and 73 (559)
Appendix 4. Embase search strategy
Searched 1980 to 1 Febuary 2018
OVID platform
1 exp male infertility/ (36830)
2 (asthenozoospermia or oligospermia or azoospermia).tw. (8576)
3 Asthenospermia.tw. (404)
4 Teratospermia.tw. (196)
5 exp Spermatozoa/ (40046)
6 Sperm$.tw. (134402)
7 (male$ adj2 subfertil$).tw. (924)
8 (male$ adj2 infertil$).tw. (13888)
9 (subfertil$ adj2 men).tw. (607)
10 (infertil$ adj2 men).tw. (5561)
11 (male$ adj2 fertility).tw. (6397)
12 semen.tw. (31205)
13 oligoasthenoteratozoospermi$.tw. (501)
14 or/1-13 (168218)
15 vitamin$.tw. (224591)
16 exp Zinc/ (96319)
17 exp Selenium/ (33745)
18 (zinc or selenium).tw. (136357)
19 (Glutathione$ or folate).tw. (154128)
20 exp Ubiquinone/ (7428)
21 ubiquin$.tw. (8388)
22 coenzyme q10.tw. (4117)
23 exp Carnitine/ (13571)
24 (carnitine$ or carotenoid$).tw. (34331)
25 (astaxanthin$ or lycopene$).tw. (6806)
26 menevit.tw. (12)
27 multivitamin$.tw. (4547)
28 (betacarotene$ or beta carotene$).tw. (14287)
29 ascorbic acid.tw. (31008)
30 n-acetylcysteine.tw. (12585)
31 exp acetylcysteine/ (31271)
32 acetylcysteine.tw. (13657)
33 Acetyl cysteine.tw. (4153)
34 ethylcysteine.tw. (61)
35 alpha-tocopherol$.tw. (15603)
36 (fish adj2 oil$).tw. (12046)
37 omega$.tw. (44717)
38 fatty acid$.tw. (208396)
39 (plant adj4 oil$).tw. (3474)
40 arginine.tw. (95239)
41 flavonoid$.tw. (47169)
42 carotenoid$.tw. (18326)
43 riboflavin$.tw. (9563)
44 pycnogenol$.tw. (439)
45 lutein$.tw. (36273)
46 lipoic acid$.tw. (4844)
47 exp antioxidant/ (165170)
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48 free radical scavengers/ (20469)
49 (antioxidant$ or radical scavengers).tw. (209843)
50 exp vitamin/ or exp ascorbic acid/ or exp carotenoid/ or exp multivitamin/ or vitamin b group/ (560638)
51 exp edible oil/ or exp castor oil/ or exp lyprinol/ or exp olive oil/ or exp saLlower oil/ or exp essential fatty acid/ or exp arachidonic acid/
or exp linoleic acid/ or exp linolenic acid/ or exp gamma linolenic acid/ or exp unsaturated fatty acid/ or exp omega 6 fatty acid/ or exp
polyunsaturated fatty acid/ (170403)
52 exp fatty acid/ (499866)
53 exp vegetable oil/ (71261)
54 exp fish oil/ (15511)
55 exp cod liver oil/ (1108)
56 exp omega 3 fatty acid/ (26841)
57 exp inositol/ (10949)
58 docosahexaenoic acid.tw. (12438)
59 magnesium.tw. (57498)
60 (Inositol or myoinositol).tw. (38014)
61 mesoinositol.tw. (10)
62 melatonin.tw. (25584)
63 nutritional supplement$.tw. (7123)
64 nutraceutical$.tw. (5817)
65 or/15-64 (1906582)
66 Clinical Trial/ (963424)
67 Randomized Controlled Trial/ (481441)
68 exp randomization/ (76750)
69 Single Blind Procedure/ (30162)
70 Double Blind Procedure/ (142753)
71 Crossover Procedure/ (53922)
72 Placebo/ (303506)
73 Randomi?ed controlled trial$.tw. (170913)
74 Rct.tw. (26655)
75 random allocation.tw. (1715)
76 randomly allocated.tw. (28704)
77 allocated randomly.tw. (2277)
78 (allocated adj2 random).tw. (789)
79 Single blind$.tw. (20147)
80 Double blind$.tw. (177989)
81 ((treble or triple) adj blind$).tw. (733)
82 placebo$.tw. (259893)
83 prospective study/ (418782)
84 or/66-83 (1845002)
85 case study/ (51632)
86 case report.tw. (343900)
87 abstract report/ or letter/ (1015495)
88 or/85-87 (1402788)
89 84 not 88 (1798045)
90 14 and 65 and 89 (1401)
Appendix 5. CINAHL search strategy
Searched from 1961 to 1 February 2018
EBSCO platform
 
# Query Results
S43 S25 AND S42 100
S42 S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37
OR S38 OR S39 OR S40 OR S41
1,203,002
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S41 TX allocat* random* 8,211
S40 (MH "Quantitative Studies") 18,214
S39 (MH "Placebos") 10,641
S38 TX placebo* 49,628
S37 TX random* allocat* 8,211
S36 (MH "Random Assignment") 45,438
S35 TX randomi* control* trial* 142,613
S34 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) 13,112
S33 TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) 923,796
S32 TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) 291
S31 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 224
S30 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 224
S29 "or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )" 224
S28 TX clinic* n1 trial* 219,940
S27 PT Clinical trial 85,642
S26 (MH "Clinical Trials+") 233,936
S25 S20 AND S24 373
S24 S21 OR S22 OR S23 4,567
S23 TX sperm* 4,329
S22 (MH "Sperm Motility") OR (MH "Spermatozoa") OR (MH "Sperm Count") OR "sperm" 3,066
S21 "male infertility" 500
S20 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR
S14 OR S15 OR S16 OR S17 OR S18 OR S19
108,659
S19 TX docosahexaenoic acid 2,993
S18 TX magnesium 6,027
S17 TX acetyl cysteine 351
S16 TX melatonin 2,528
S15 TX chiro inositol 42
S14 TX myoinositol 85
  (Continued)
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S13 TX Inositol 839
S12 TX fatty acid 22,457
S11 TX omega 3 7,555
S10 TX Pentoxifylline 504
S9 TX Acetylcysteine 1,656
S8 TX menevit 3
S7 TX coenzyme q10 579
S6 TX Selenium 2,579
S5 TX Zinc 6,947
S4 TX carnitine 1,529
S3 TX vitamin* 45,611
S2 TX antioxidant* 22,539
S1 (MH "Antioxidants+") or (MH "Berries+") or (MH "Chlorophyll") or (MH "Flavonoids+") or
(MH "Lycopene") or (MH "Polyphenols+")
25,644
  (Continued)
 
Appendix 6. PsycINFO search strategy
Searched from 1806 to 1 Febuary 2018
OVID platform
1 exp Infertility/ (2007)
2 (asthenozoospermia or oligospermia or azoospermia).tw. (41)
3 exp Sperm/ (831)
4 Sperm$.tw. (2981)
5 (male$ adj2 subfertil$).tw. (8)
6 (male$ adj2 infertil$).tw. (202)
7 (subfertil$ adj2 men).tw. (1)
8 (infertil$ adj2 men).tw. (94)
9 (male$ adj2 fertility).tw. (143)
10 semen.tw. (439)
11 oligoasthenoteratozoospermi$.tw. (2)
12 Asthenospermia.tw. (2)
13 Teratospermia.tw. (0)
14 or/1-13 (5309)
15 vitamin$.tw. (6685)
16 exp Zinc/ (780)
17 exp Antioxidants/ (2458)
18 (zinc or selenium).tw. (2256)
19 (Glutathione$ or folate).tw. (3469)
20 ubiquin$.tw. (98)
21 coenzyme q10.tw. (195)
22 (carnitine$ or carotenoid$).tw. (745)
23 (astaxanthin$ or lycopene$).tw. (76)
24 menevit.tw. (0)
25 multivitamin$.tw. (229)
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26 (betacarotene$ or beta carotene$).tw. (139)
27 ascorbic acid.tw. (416)
28 n-acetylcysteine.tw. (347)
29 exp Cysteine/ (628)
30 acetylcysteine.tw. (357)
31 alpha-tocopherol$.tw. (219)
32 (fish adj2 oil$).tw. (278)
33 omega$.tw. (2433)
34 fatty acid$.tw. (4091)
35 (plant adj4 oil$).tw. (40)
36 l-arginine$.tw. (1068)
37 arginine$.tw. (2842)
38 flavonoid$.tw. (382)
39 carotenoid$.tw. (352)
40 riboflavin$.tw. (196)
41 pycnogenol$.tw. (13)
42 lutein$.tw. (1544)
43 lipoic acid$.tw. (175)
44 (antioxidant$ or radical scavengers).tw. (4920)
45 Inositol.tw. (1411)
46 myoinositol.tw. (130)
47 mesoinositol.tw. (0)
48 acetyl cysteine.tw. (146)
49 melatonin.tw. (4242)
50 or/15-49 (30905)
51 random.tw. (52089)
52 control.tw. (401965)
53 double-blind.tw. (21242)
54 clinical trials/ (10777)
55 placebo/ (5057)
56 exp Treatment/ (705267)
57 or/51-56 (1095872)
58 14 and 50 and 57 (34)
Appendix 7. 'The World Health Organization International Clinical Trials Registry Platform' search portal 
Searched 1 Febuary 2018
Web platform
1) Antioxidant* AND men
2) Vitamins* AND men
3) Antioxidant* AND male
4) Vitamin* AND male
5) Infertility AND men
6) Infertility AND male
Appendix 8. 'ClinicalTrials.gov' trials register
Searched 1 Febuary 2018
Web platform
1) Antioxidants (clinical condition: infertility)
2) Vitamins (clinical condition: infertility)
Appendix 9. OpenGrey
Searched 1 Febuary 2018
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Web platform
1) Antioxidant*
2) Vitamin*
3) Infertility AND Men
4) Antoxidant AND fertility
Appendix 10. ProQuest Dissertations & Theses database
Searched 1 Febuary 2018
Web platform
1) Antioxidants AND sperm AND (men OR male) AND (fertility or infertility) AND random*
2) Antoxidants AND sperm AND (men OR male) AND (fertility or infertility)
Appendix 11. Web of Science
Searched 1 Febuary 2018
Web platform
1) Antioxidants AND sperm AND male AND (fertility OR infertil*) limited by 'clinical trial'
W H A T ' S   N E W
 
Date Event Description
4 December 2018 New search has been performed Nineteen new studies were added in this update (Barekat 2016;
Blomberg Jensen 2018; Boonyarangkul 2015; Busetto 2018;
Cyrus 2015; Deng 2014; Ener 2016; Exposito 2016; Gamidov 2017;
Gopinath 2013; Haghighian 2015; Haje 2015; Martinez 2015;
Mehni 2014; Micic 2017; Pourmand 2014; Raigani 2014; Shar-
ifzadeh 2016; Sofikitis 2016). There is one study placed in await-
ing classification (Goswami 2015).
All pentoxifylline studies were excluded. Two previously included
studies were excluded for containing an ineligible study popula-
tion.
4 December 2018 New citation required and conclusions
have changed
Pentoxifylline was removed from the review due to the fact that
it is a prescription drug and not an 'over-the-counter' supple-
ment.
Progressive sperm motility was added as a secondary outcome;
this is an outcome with more clinical importance than total
sperm motility.
 
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 1, 2011
 
Date Event Description
10 February 2015 Amended Correction of some analysis graph labels.
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Date Event Description
28 November 2014 New citation required and conclusions
have changed
Comparisions were restructured into a more logical framework.
Clinical pregnancy rate data were used in this update rather than
the undefined pregnancy rate data of the original review as this
is more clinically meaningful when considering the evidence for
use of antioxidants.
28 November 2014 New search has been performed 14 new studies were added in this update (Attallah 2013, Azi-
zollahi 2013, Dimitriadis 2010, Eslamian 2013, Kumamoto 1988,
Martinez-Soto 2010, Morgante 2010, Nadjarzadeh 2011, Poveda
2013, Pryor 1978, Safarinejad 2011b, Safarinejad 2012, Sivkov
2011, Wang 2010). The search was updated in August 2014 and
six studies were placed in awaiting classification (Anarte 2013a;
Gopinath 2013; Iacono 2014; Nadjarzadeh 2014; Nashivochniko-
va 2014a; Nematollahi-Mahani 2014).
7 December 2011 Feedback has been incorporated Change of emphasis to conclusions, additional sensitivity analy-
sis performed, Risk of Bias, Summary of Findings Table and Dis-
cussion sections edited to increase this review's focus on clinical
outcomes of pregnancy and live birth.
3 May 2011 Amended 2.1 Analysis edited to fixed effect Peto. The conclusions remain
the same.
8 March 2011 Amended Changed summary of findings table to reflect quality of studies
21 December 2010 Amended Minor edits made - no changes to conclusions
4 May 2007 New citation required and major
changes
Substantive amendment
 
C O N T R I B U T I O N S   O F   A U T H O R S
RS: starting from the 2018 update: searched other sources, selected studies for inclusion, assessed quality, performed data extraction,
entered data, updated and renewed the whole background text and wrote the final 2018 update review. Also provided clinical expertise.
RM-P: selected studies for inclusion in the 2014 and 2018 update, assessed quality, performed data extraction and commented on the final
version of the update. In the 2014 update also assisted with background text updating and entered text into tables of characteristic.
AY: co-draQed the protocol and wrote the section concerning sperm DNA fragmentation for the background up to the 2014 update. Provided
technical advice on all versions.
MS: co-draQed the protocol and provided technical advice on semen parameters. Commented on all versions.
VJ: starting from the 2018 update: provided technical advice and commented on the final version of the update.
MGS: initiated, conceptualised and wrote the protocol, performed the searches in all versions. Up to and including the 2014 update:
selected studies for inclusion, assessed quality, performed data extraction, entered data and wrote the first review and the 2014 update.
Commented on the final versions of the 2018 update.
D E C L A R A T I O N S   O F   I N T E R E S T
The institution of first author Roos M Smits received an unrestricted grant for conducting the trial NCT03337360, to cover the salary of
the trial co-ordinator Roos M Smits. This trial (NCT03337360) started in April 2018. No data have been extracted from this study. The trial
NCT03337360 is submitted to 'Ongoing studies'. This matter was referred to Cochrane's Funding Arbiters who have confirmed that Dr Smits’
declared interest does not constitute a COI under the current policy.
The following authors have reported financial activities outside the submitted work:
• AY is a member of the advisory board of MSD. He is a stockholder of Queensland Fertility Group and is director of research and
development of that institution. The research foundation of Queensland Fertility Group has received research grants from Merck Serono,
MSD and the AGES Society (unrestricted grant December 2018; research proposal for pragmatic trial on surgery vs IVF). AY has received
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travel and conference expenses from Merck Serono (February 2018) and Ferring (January 2016 and January 2018). AY advises that none
of these companies manufacture or market any antioxidants.• MS has received travel and conference expenses from Merck Serono (July 2018), Finox (April 2017) and Ferring (January 2016).
VJ, MGS and RM-P have no conflicts to declare.
S O U R C E S   O F   S U P P O R T
Internal sources• Cochrane Gynaecology and Fertility Group, Other.
External sources• None, Other.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the 2011 full review, sperm outcomes of concentration and motility were added as these two sperm outcomes are thought to reflect the
oxidative process. A study by El-Taieb (El-Taieb 2009) states that "increased ROS generation and reduced antioxidant capacity is negatively
correlated with sperm concentration and motility in infertile men".
The comparisons 'antioxidant versus placebo' and 'antioxidants versus no treatment' were combined as the one comparison 'antioxidants
versus control', and then it was stated in the sensitivity analysis whether exclusion of those that failed to use placebo would have altered
the conclusions - as per statistical advice in the editorial comments.
Subgrouping and sensitivity analysis were performed on the outcomes of live birth and pregnancy in order to assess the potential of
overestimation of benefit and reporting bias.
Subgroup analysis was performed on studies that enrolled couples undergoing IVF/ICSI and a sensitivity analysis was performed on those
studies enrolling men undergoing IUI.
Sensitivity analysis was performed to consider whether conclusions were any diLerent if eligibility was restricted to those studies without
risk of bias.
A post hoc sensitivity analysis was conducted to examine the eLect of excluding from the analysis those studies which reported remarkably
low standard deviations as the review authors considered that these data were potentially erroneous.
In the 2014 update of the review 'pregnancy rate per couple' was redefined to be 'clinical pregnancy rate'. Stillbirth as an outcome was
removed; this will be reported as an adverse event, as reported by the studies. The outcome 'level of sperm DNA damage aQer treatment'
was reworded as 'level of sperm DNA fragmentation'.
In the 2018 update, we decided to remove pentoxifylline due to the fact that it is a prescription drug and not an 'over-the-counter' or
overall free available supplement. In the future, there will be a new Cochrane Review solely on this item. We added a new secondary
outcome: progressive sperm motility. In past versions of this review we already noticed that four studies only reported on progressive
sperm motility and not on total sperm motility. In this 2018 update, we noticed that eight more studies (out of the 17 new included) report
only on progressive sperm motility. We came to the conclusion that progressive sperm motility is the motility outcome with more clinical
importance.
Furthermore, in the 2018 update we clarified that this review is (as the title implies) solely for subfertile men; men with abnormal semen
parameters. In the previous updates it was said to include "men of a couple with male factor infertility or unexplained infertility". However,
male factor infertility has always been the main focus of the search and the review. Broadening the focus of the review to also unexplained
infertility would change the scope of the review. Therefore we changed the inclusion and exclusion criteria, which are now also more like
those in the review 'Antioxidants for female subfertility' (Showell 2017).
Other changes were made in regard with the 'Risk of bias' assessments of blinding: we decided to assess 'performance bias' and 'detection
bias' separately.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Abortion, Spontaneous  [epidemiology];  Antioxidants  [*therapeutic use];  DNA Damage;  DNA Fragmentation;  Gastrointestinal
Diseases  [chemically induced];  Infertility, Male  [*drug therapy]  [etiology];  Live Birth  [epidemiology];  Oxidative Stress  [*drug eLects]; 
Pregnancy Rate;  Randomized Controlled Trials as Topic;  Sperm Count;  Sperm Motility  [drug eLects];  Spermatozoa  [drug eLects]
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MeSH check words
Female; Humans; Male; Pregnancy
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